AU6621600A - Melanocortin-4 receptor binding compounds and methods of use thereof - Google Patents
Melanocortin-4 receptor binding compounds and methods of use thereof Download PDFInfo
- Publication number
- AU6621600A AU6621600A AU66216/00A AU6621600A AU6621600A AU 6621600 A AU6621600 A AU 6621600A AU 66216/00 A AU66216/00 A AU 66216/00A AU 6621600 A AU6621600 A AU 6621600A AU 6621600 A AU6621600 A AU 6621600A
- Authority
- AU
- Australia
- Prior art keywords
- phenyl
- tetrahydro
- methoxy
- pyrimidine
- benzylsulfanyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims description 418
- 238000000034 method Methods 0.000 title claims description 213
- 230000027455 binding Effects 0.000 title claims description 180
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 title description 249
- 102000001796 Melanocortin 4 receptors Human genes 0.000 title 1
- -1 amino, amidino, guanidino Chemical group 0.000 claims description 324
- 125000000217 alkyl group Chemical group 0.000 claims description 265
- 125000003118 aryl group Chemical group 0.000 claims description 143
- 125000003342 alkenyl group Chemical group 0.000 claims description 121
- 125000000623 heterocyclic group Chemical group 0.000 claims description 116
- 125000000304 alkynyl group Chemical group 0.000 claims description 108
- 125000003545 alkoxy group Chemical group 0.000 claims description 97
- 229910052736 halogen Inorganic materials 0.000 claims description 97
- 150000002367 halogens Chemical class 0.000 claims description 97
- 102100023724 Melanocortin receptor 4 Human genes 0.000 claims description 94
- 239000001257 hydrogen Substances 0.000 claims description 94
- 229910052739 hydrogen Inorganic materials 0.000 claims description 94
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 79
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 77
- 229910052799 carbon Inorganic materials 0.000 claims description 70
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 60
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 55
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 54
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 54
- 150000003839 salts Chemical class 0.000 claims description 53
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 52
- 241000124008 Mammalia Species 0.000 claims description 51
- 150000001721 carbon Chemical group 0.000 claims description 51
- 125000001424 substituent group Chemical group 0.000 claims description 50
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 46
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 46
- 125000001072 heteroaryl group Chemical group 0.000 claims description 45
- 239000008194 pharmaceutical composition Substances 0.000 claims description 45
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 43
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 43
- 125000002252 acyl group Chemical group 0.000 claims description 42
- 125000001624 naphthyl group Chemical group 0.000 claims description 42
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 40
- 229910052757 nitrogen Inorganic materials 0.000 claims description 40
- 125000004122 cyclic group Chemical group 0.000 claims description 38
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 37
- 229910052717 sulfur Inorganic materials 0.000 claims description 37
- 229910052760 oxygen Inorganic materials 0.000 claims description 35
- 239000001301 oxygen Substances 0.000 claims description 35
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 33
- 239000000460 chlorine Substances 0.000 claims description 32
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 31
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 31
- 239000011593 sulfur Chemical group 0.000 claims description 31
- 229910052801 chlorine Inorganic materials 0.000 claims description 30
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 30
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 29
- 229910052731 fluorine Inorganic materials 0.000 claims description 28
- 239000011737 fluorine Substances 0.000 claims description 28
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 27
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 27
- 229910052794 bromium Inorganic materials 0.000 claims description 27
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 26
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 26
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 25
- 238000006467 substitution reaction Methods 0.000 claims description 25
- 150000005347 biaryls Chemical group 0.000 claims description 24
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 22
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 22
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 20
- 125000004429 atom Chemical group 0.000 claims description 19
- 150000003568 thioethers Chemical class 0.000 claims description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 18
- 150000003573 thiols Chemical class 0.000 claims description 18
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 239000003937 drug carrier Substances 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- SBOJXQVPLKSXOG-UHFFFAOYSA-N o-amino-hydroxylamine Chemical class NON SBOJXQVPLKSXOG-UHFFFAOYSA-N 0.000 claims description 15
- 125000005647 linker group Chemical group 0.000 claims description 14
- 208000016261 weight loss Diseases 0.000 claims description 14
- 230000004580 weight loss Effects 0.000 claims description 14
- 206010006895 Cachexia Diseases 0.000 claims description 13
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 13
- KPPVNWGJXFMGAM-UUILKARUSA-N (e)-2-methyl-1-(6-methyl-3,4-dihydro-2h-quinolin-1-yl)but-2-en-1-one Chemical compound CC1=CC=C2N(C(=O)C(/C)=C/C)CCCC2=C1 KPPVNWGJXFMGAM-UUILKARUSA-N 0.000 claims description 12
- 229910014033 C-OH Inorganic materials 0.000 claims description 12
- 229910014570 C—OH Inorganic materials 0.000 claims description 12
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 12
- 125000003277 amino group Chemical group 0.000 claims description 12
- 125000002837 carbocyclic group Chemical group 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 12
- 125000002757 morpholinyl group Chemical group 0.000 claims description 11
- 125000003386 piperidinyl group Chemical group 0.000 claims description 11
- 125000004076 pyridyl group Chemical group 0.000 claims description 11
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 11
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical compound C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 claims description 10
- IIXSESNTPZDVOB-UHFFFAOYSA-N 2-[2-[(2,6-difluorophenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound FC1=CC=CC(F)=C1CSC1=CC=CC=C1C1=NCCCN1 IIXSESNTPZDVOB-UHFFFAOYSA-N 0.000 claims description 10
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 10
- 150000001412 amines Chemical class 0.000 claims description 9
- 125000004104 aryloxy group Chemical group 0.000 claims description 9
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 9
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 9
- 125000004434 sulfur atom Chemical group 0.000 claims description 9
- XWJXXXQFFDDHEK-UHFFFAOYSA-N 1-[[2-[(2-methoxynaphthalen-1-yl)methylsulfanyl]phenyl]methyl]pyrrolidin-3-amine Chemical compound COC1=CC=C2C=CC=CC2=C1CSC1=CC=CC=C1CN1CCC(N)C1 XWJXXXQFFDDHEK-UHFFFAOYSA-N 0.000 claims description 8
- QRDFGAHATXGIBR-UHFFFAOYSA-N 2-[2-[(2-methoxy-5-nitrophenyl)methoxy]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C([N+]([O-])=O)C=C1COC1=CC=CC=C1C1=NCCCN1 QRDFGAHATXGIBR-UHFFFAOYSA-N 0.000 claims description 8
- GLGIWLZTKPEBKS-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]-6-ethyl-1,4,5,6-tetrahydropyrimidine Chemical compound N1C(CC)CCN=C1C1=CC=CC=C1SCC1=CC(Br)=CC=C1OC GLGIWLZTKPEBKS-UHFFFAOYSA-N 0.000 claims description 8
- HMGGFEHSQUFZTI-UHFFFAOYSA-N 2-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methoxymethyl]pyrrolidine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1COCC1NCCC1 HMGGFEHSQUFZTI-UHFFFAOYSA-N 0.000 claims description 8
- VBUILYKEAPKRKE-UHFFFAOYSA-N 2-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1CC1=NCCCN1 VBUILYKEAPKRKE-UHFFFAOYSA-N 0.000 claims description 8
- OQQKRORCCALBOF-UHFFFAOYSA-N 3-(2-methylpiperidin-1-yl)-n-[[2-(2-naphthalen-1-ylethyl)phenyl]methyl]propan-1-amine Chemical compound CC1CCCCN1CCCNCC1=CC=CC=C1CCC1=CC=CC2=CC=CC=C12 OQQKRORCCALBOF-UHFFFAOYSA-N 0.000 claims description 8
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 8
- 239000000556 agonist Substances 0.000 claims description 8
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 8
- 125000002619 bicyclic group Chemical group 0.000 claims description 8
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 8
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 8
- DHMLFLUIIOQLOJ-UHFFFAOYSA-N 1,3-di(piperidin-1-yl)propan-2-yl n-(2-hexoxyphenyl)carbamate Chemical compound CCCCCCOC1=CC=CC=C1NC(=O)OC(CN1CCCCC1)CN1CCCCC1 DHMLFLUIIOQLOJ-UHFFFAOYSA-N 0.000 claims description 7
- VBXZSFNZVNDOPB-UHFFFAOYSA-N 1,4,5,6-tetrahydropyrimidine Chemical compound C1CNC=NC1 VBXZSFNZVNDOPB-UHFFFAOYSA-N 0.000 claims description 7
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 7
- 239000005557 antagonist Substances 0.000 claims description 7
- 230000019612 pigmentation Effects 0.000 claims description 7
- KWBJMDZAPHKDFB-UHFFFAOYSA-N 1-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methyl]piperidine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1CN1CCCCC1 KWBJMDZAPHKDFB-UHFFFAOYSA-N 0.000 claims description 6
- DYASGHCSJCHRAM-UHFFFAOYSA-N 1-[[3-fluoro-2-(2-naphthalen-1-ylethyl)phenyl]methyl]piperazine Chemical compound C=1C=CC2=CC=CC=C2C=1CCC=1C(F)=CC=CC=1CN1CCNCC1 DYASGHCSJCHRAM-UHFFFAOYSA-N 0.000 claims description 6
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 claims description 6
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims description 6
- ZCBPTFJSXQSXMK-UHFFFAOYSA-N [1-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-chlorophenyl]methyl]piperidin-2-yl]methanol Chemical compound COC1=CC=C(Br)C=C1CSC1=C(Cl)C=CC=C1CN1C(CO)CCCC1 ZCBPTFJSXQSXMK-UHFFFAOYSA-N 0.000 claims description 6
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 6
- XYZDDOTYDXXWPM-UHFFFAOYSA-N n-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methyl]-n-ethylethanamine Chemical compound CCN(CC)CC1=CC=CC=C1SCC1=CC(Br)=CC=C1OC XYZDDOTYDXXWPM-UHFFFAOYSA-N 0.000 claims description 6
- MRBFGEHILMYPTF-UHFFFAOYSA-N 1-(2-Pyrimidyl)piperazine Chemical compound C1CNCCN1C1=NC=CC=N1 MRBFGEHILMYPTF-UHFFFAOYSA-N 0.000 claims description 5
- ZACLFWISXHXZSS-UHFFFAOYSA-N 1-(6-bromo-2-chloroquinolin-4-yl)-3-[2-(diethylamino)ethyl]urea Chemical compound C1=C(Br)C=C2C(NC(=O)NCCN(CC)CC)=CC(Cl)=NC2=C1 ZACLFWISXHXZSS-UHFFFAOYSA-N 0.000 claims description 5
- BNMSJUIMZULLAS-UHFFFAOYSA-N 1-[5-(trifluoromethyl)pyridin-2-yl]piperazine Chemical compound N1=CC(C(F)(F)F)=CC=C1N1CCNCC1 BNMSJUIMZULLAS-UHFFFAOYSA-N 0.000 claims description 5
- GPPWPYMVKYICCM-UHFFFAOYSA-N 2-[2-(2-naphthalen-1-ylethyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1CCC1=CC=CC=C1C1=NCCCN1 GPPWPYMVKYICCM-UHFFFAOYSA-N 0.000 claims description 5
- WBJVPAABGFBMJQ-UHFFFAOYSA-N 2-piperazin-1-yl-4-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=CC=NC(N2CCNCC2)=N1 WBJVPAABGFBMJQ-UHFFFAOYSA-N 0.000 claims description 5
- QLTXFTSBONWMPM-UHFFFAOYSA-N 4,6-dimethyl-2-piperazin-1-ylpyrimidine Chemical compound CC1=CC(C)=NC(N2CCNCC2)=N1 QLTXFTSBONWMPM-UHFFFAOYSA-N 0.000 claims description 5
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 5
- 229940126661 MC4 antagonist Drugs 0.000 claims description 5
- 125000002393 azetidinyl group Chemical group 0.000 claims description 5
- 235000010290 biphenyl Nutrition 0.000 claims description 5
- 239000004305 biphenyl Substances 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 150000004985 diamines Chemical class 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 125000001041 indolyl group Chemical group 0.000 claims description 5
- GZRKXKUVVPSREJ-UHFFFAOYSA-N pyridinylpiperazine Chemical compound C1CNCCN1C1=CC=CC=N1 GZRKXKUVVPSREJ-UHFFFAOYSA-N 0.000 claims description 5
- GAZFMSFTOKVZQL-UHFFFAOYSA-N 1-(1-ethylpyrrolidin-2-yl)-n-(naphthalen-1-ylmethyl)-n-(naphthalen-2-ylmethyl)methanamine Chemical compound CCN1CCCC1CN(CC=1C2=CC=CC=C2C=CC=1)CC1=CC=C(C=CC=C2)C2=C1 GAZFMSFTOKVZQL-UHFFFAOYSA-N 0.000 claims description 4
- GIHQQJIHBAIGSO-UHFFFAOYSA-N 1-[2-(2-naphthalen-1-ylethyl)phenyl]ethane-1,2-diamine Chemical compound NCC(N)C1=CC=CC=C1CCC1=CC=CC2=CC=CC=C12 GIHQQJIHBAIGSO-UHFFFAOYSA-N 0.000 claims description 4
- ATZDPWOFOKHOFM-UHFFFAOYSA-N 1-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]-n,n-dimethylmethanamine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1CN(C)C ATZDPWOFOKHOFM-UHFFFAOYSA-N 0.000 claims description 4
- HIZHZFLGIHIACW-UHFFFAOYSA-N 1-[2-[2-[(2-chloro-6-fluorophenyl)methylsulfanyl]phenyl]-5,6-dihydro-4h-pyrimidin-1-yl]ethanone Chemical compound CC(=O)N1CCCN=C1C1=CC=CC=C1SCC1=C(F)C=CC=C1Cl HIZHZFLGIHIACW-UHFFFAOYSA-N 0.000 claims description 4
- RCAPUOMCNFOSTP-UHFFFAOYSA-N 1-[4-methoxy-3-[[2-(1,4,5,6-tetrahydropyrimidin-2-yl)phenyl]sulfanylmethyl]phenyl]ethanone Chemical compound COC1=CC=C(C(C)=O)C=C1CSC1=CC=CC=C1C1=NCCCN1 RCAPUOMCNFOSTP-UHFFFAOYSA-N 0.000 claims description 4
- UPUQOEPOWHSGPH-UHFFFAOYSA-N 1-[[2-(2-naphthalen-1-ylethyl)phenyl]methyl]piperazine Chemical compound C=1C=CC2=CC=CC=C2C=1CCC1=CC=CC=C1CN1CCNCC1 UPUQOEPOWHSGPH-UHFFFAOYSA-N 0.000 claims description 4
- UWBWBCKISPTABJ-UHFFFAOYSA-N 1-[[2-(2-naphthalen-1-ylethyl)phenyl]methyl]pyrrolidin-3-amine Chemical compound C1C(N)CCN1CC1=CC=CC=C1CCC1=CC=CC2=CC=CC=C12 UWBWBCKISPTABJ-UHFFFAOYSA-N 0.000 claims description 4
- BCQNKADIWADQCL-UHFFFAOYSA-N 1-[[2-(naphthalen-1-ylsulfanylmethyl)phenyl]methyl]piperazine Chemical compound C=1C=CC2=CC=CC=C2C=1SCC1=CC=CC=C1CN1CCNCC1 BCQNKADIWADQCL-UHFFFAOYSA-N 0.000 claims description 4
- IFCDMRMMCXRJEV-UHFFFAOYSA-N 1-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-chlorophenyl]methyl]pyrrolidin-3-ol Chemical compound COC1=CC=C(Br)C=C1CSC1=C(Cl)C=CC=C1CN1CC(O)CC1 IFCDMRMMCXRJEV-UHFFFAOYSA-N 0.000 claims description 4
- IILSKIZWMSVWAI-UHFFFAOYSA-N 1-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methyl]piperazine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1CN1CCNCC1 IILSKIZWMSVWAI-UHFFFAOYSA-N 0.000 claims description 4
- IKYPYTQRZDPPLI-UHFFFAOYSA-N 1-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methyl]pyrrolidin-3-amine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1CN1CC(N)CC1 IKYPYTQRZDPPLI-UHFFFAOYSA-N 0.000 claims description 4
- WOAQXXVCKUXXIM-UHFFFAOYSA-N 1-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methyl]pyrrolidin-3-ol Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1CN1CC(O)CC1 WOAQXXVCKUXXIM-UHFFFAOYSA-N 0.000 claims description 4
- JLYBRUBFGATRBM-UHFFFAOYSA-N 1-[[3-chloro-2-(naphthalen-1-ylsulfanylmethyl)phenyl]methyl]piperazine Chemical compound C=1C=CC2=CC=CC=C2C=1SCC=1C(Cl)=CC=CC=1CN1CCNCC1 JLYBRUBFGATRBM-UHFFFAOYSA-N 0.000 claims description 4
- WBODHADKZJNENR-UHFFFAOYSA-N 1-phenyl-3-piperazin-1-yl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile Chemical compound N#CC1=C2CCCCC2=C(C=2C=CC=CC=2)N=C1N1CCNCC1 WBODHADKZJNENR-UHFFFAOYSA-N 0.000 claims description 4
- LPFIAUCSSYOSJI-UHFFFAOYSA-N 2-(2-benzhydrylsulfanylphenyl)-1,4,5,6-tetrahydropyrimidine Chemical compound C1CCNC(C=2C(=CC=CC=2)SC(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 LPFIAUCSSYOSJI-UHFFFAOYSA-N 0.000 claims description 4
- SYACJNJDWOFLPR-UHFFFAOYSA-N 2-(2-benzylsulfanylphenyl)-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC=CC=1CSC1=CC=CC=C1C1=NCCCN1 SYACJNJDWOFLPR-UHFFFAOYSA-N 0.000 claims description 4
- VBGDTCBHSKWUHT-UHFFFAOYSA-N 2-(2-benzylsulfanylphenyl)-4,5-dihydro-1h-imidazole Chemical compound C=1C=CC=CC=1CSC1=CC=CC=C1C1=NCCN1 VBGDTCBHSKWUHT-UHFFFAOYSA-N 0.000 claims description 4
- AFKXHBOKRSLWGJ-UHFFFAOYSA-N 2-(2-pentadecylsulfanylphenyl)-1,4,5,6-tetrahydropyrimidine Chemical compound CCCCCCCCCCCCCCCSC1=CC=CC=C1C1=NCCCN1 AFKXHBOKRSLWGJ-UHFFFAOYSA-N 0.000 claims description 4
- ORVKGXPJZJAEEK-UHFFFAOYSA-N 2-(3-aminopropylamino)-6-[(5-bromo-2-methoxyphenyl)methylsulfanyl]benzonitrile Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC(NCCCN)=C1C#N ORVKGXPJZJAEEK-UHFFFAOYSA-N 0.000 claims description 4
- DJWODOBNDWFNTI-UHFFFAOYSA-N 2-(dimethylamino)ethyl n-[2-(naphthalen-1-ylmethylsulfanyl)phenyl]carbamate Chemical compound CN(C)CCOC(=O)NC1=CC=CC=C1SCC1=CC=CC2=CC=CC=C12 DJWODOBNDWFNTI-UHFFFAOYSA-N 0.000 claims description 4
- BPGGBTUYXDFQIR-UHFFFAOYSA-N 2-(naphthalen-1-ylmethylsulfanyl)-3-(1,4,5,6-tetrahydropyrimidin-2-yl)aniline Chemical compound C=1C=CC2=CC=CC=C2C=1CSC=1C(N)=CC=CC=1C1=NCCCN1 BPGGBTUYXDFQIR-UHFFFAOYSA-N 0.000 claims description 4
- KGUYGXACOPYBBV-UHFFFAOYSA-N 2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-(1,4,5,6-tetrahydropyrimidin-2-yl)pyrazine Chemical compound COC1=CC=C(Br)C=C1CSC1=NC=CN=C1C1=NCCCN1 KGUYGXACOPYBBV-UHFFFAOYSA-N 0.000 claims description 4
- SCCAFPIBEOBGTQ-UHFFFAOYSA-N 2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]benzenecarboximidamide Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1C(N)=N SCCAFPIBEOBGTQ-UHFFFAOYSA-N 0.000 claims description 4
- XOTXXSNBMHVICF-UHFFFAOYSA-N 2-[2-(1-benzothiophen-3-ylmethylsulfanyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1SC2=CC=CC=C2C=1CSC1=CC=CC=C1C1=NCCCN1 XOTXXSNBMHVICF-UHFFFAOYSA-N 0.000 claims description 4
- DLZFOGIKAJESJI-UHFFFAOYSA-N 2-[2-(1-naphthalen-1-ylethylsulfanyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1C(C)SC1=CC=CC=C1C1=NCCCN1 DLZFOGIKAJESJI-UHFFFAOYSA-N 0.000 claims description 4
- ACJPYKJBCKVDIV-UHFFFAOYSA-N 2-[2-(2-naphthalen-1-ylethyl)-3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1CCC=1C(C(F)(F)F)=CC=CC=1C1=NCCCN1 ACJPYKJBCKVDIV-UHFFFAOYSA-N 0.000 claims description 4
- RTLGWGUKVAYFGQ-UHFFFAOYSA-N 2-[2-(2-naphthalen-1-ylethyl)phenyl]ethanamine Chemical compound NCCC1=CC=CC=C1CCC1=CC=CC2=CC=CC=C12 RTLGWGUKVAYFGQ-UHFFFAOYSA-N 0.000 claims description 4
- HQKSAFODQJVAMY-UHFFFAOYSA-N 2-[2-(9h-fluoren-9-ylsulfanyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C1CCNC(C=2C(=CC=CC=2)SC2C3=CC=CC=C3C3=CC=CC=C32)=N1 HQKSAFODQJVAMY-UHFFFAOYSA-N 0.000 claims description 4
- HLXFXORVYDASPB-UHFFFAOYSA-N 2-[2-(cyclohexylmethylsulfanyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C1CCCCC1CSC1=CC=CC=C1C1=NCCCN1 HLXFXORVYDASPB-UHFFFAOYSA-N 0.000 claims description 4
- QDZMJIFWBKCDIU-UHFFFAOYSA-N 2-[2-(naphthalen-1-ylmethoxy)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1COC1=CC=CC=C1C1=NCCCN1 QDZMJIFWBKCDIU-UHFFFAOYSA-N 0.000 claims description 4
- WUXIBNPXDCPMEH-UHFFFAOYSA-N 2-[2-(naphthalen-1-ylmethylsulfanyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1CSC1=CC=CC=C1C1=NCCCN1 WUXIBNPXDCPMEH-UHFFFAOYSA-N 0.000 claims description 4
- UWVOBSJHFFRYJU-UHFFFAOYSA-N 2-[2-(naphthalen-1-yloxymethyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1OCC1=CC=CC=C1C1=NCCCN1 UWVOBSJHFFRYJU-UHFFFAOYSA-N 0.000 claims description 4
- FIZAQPWFWADZQW-UHFFFAOYSA-N 2-[2-(naphthalen-1-ylsulfanylmethyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1SCC1=CC=CC=C1C1=NCCCN1 FIZAQPWFWADZQW-UHFFFAOYSA-N 0.000 claims description 4
- VJKACOCRHHQFEQ-UHFFFAOYSA-N 2-[2-(naphthalen-1-ylsulfanylmethyl)phenyl]piperidine Chemical compound C=1C=CC2=CC=CC=C2C=1SCC1=CC=CC=C1C1CCCCN1 VJKACOCRHHQFEQ-UHFFFAOYSA-N 0.000 claims description 4
- ZLJUCWCUFIZEDW-UHFFFAOYSA-N 2-[2-[(2,5-dichlorophenyl)sulfanylmethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound ClC1=CC=C(Cl)C(SCC=2C(=CC=CC=2)C=2NCCCN=2)=C1 ZLJUCWCUFIZEDW-UHFFFAOYSA-N 0.000 claims description 4
- LTWCBBRXEBVHTH-UHFFFAOYSA-N 2-[2-[(2,5-dichlorothiophen-3-yl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound S1C(Cl)=CC(CSC=2C(=CC=CC=2)C=2NCCCN=2)=C1Cl LTWCBBRXEBVHTH-UHFFFAOYSA-N 0.000 claims description 4
- WWNCZFPVXCKTNW-UHFFFAOYSA-N 2-[2-[(2,5-dimethoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(OC)C(CSC=2C(=CC=CC=2)C=2NCCCN=2)=C1 WWNCZFPVXCKTNW-UHFFFAOYSA-N 0.000 claims description 4
- USWIGGWFARNAIT-UHFFFAOYSA-N 2-[2-[(2,5-dimethylphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound CC1=CC=C(C)C(CSC=2C(=CC=CC=2)C=2NCCCN=2)=C1 USWIGGWFARNAIT-UHFFFAOYSA-N 0.000 claims description 4
- HGTPFVATRKNXIH-UHFFFAOYSA-N 2-[2-[(2-bromophenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound BrC1=CC=CC=C1CSC1=CC=CC=C1C1=NCCCN1 HGTPFVATRKNXIH-UHFFFAOYSA-N 0.000 claims description 4
- KEDBEJDOVCGYMS-UHFFFAOYSA-N 2-[2-[(2-bromophenyl)sulfanylmethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound BrC1=CC=CC=C1SCC1=CC=CC=C1C1=NCCCN1 KEDBEJDOVCGYMS-UHFFFAOYSA-N 0.000 claims description 4
- HNKHRELQAZCOCP-UHFFFAOYSA-N 2-[2-[(2-chloro-6-fluorophenyl)methylsulfanyl]phenyl]-4,5-dihydro-1h-imidazole Chemical compound FC1=CC=CC(Cl)=C1CSC1=CC=CC=C1C1=NCCN1 HNKHRELQAZCOCP-UHFFFAOYSA-N 0.000 claims description 4
- XUNKOLSVSAKVHQ-UHFFFAOYSA-N 2-[2-[(2-chlorophenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound ClC1=CC=CC=C1CSC1=CC=CC=C1C1=NCCCN1 XUNKOLSVSAKVHQ-UHFFFAOYSA-N 0.000 claims description 4
- JCBIOHYTOHEEKN-UHFFFAOYSA-N 2-[2-[(2-chlorophenyl)sulfanylmethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound ClC1=CC=CC=C1SCC1=CC=CC=C1C1=NCCCN1 JCBIOHYTOHEEKN-UHFFFAOYSA-N 0.000 claims description 4
- SMTXSQTYIZFVIR-UHFFFAOYSA-N 2-[2-[(2-cyclopentyloxynaphthalen-1-yl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C1CCCC1OC=1C=CC2=CC=CC=C2C=1CSC1=CC=CC=C1C1=NCCCN1 SMTXSQTYIZFVIR-UHFFFAOYSA-N 0.000 claims description 4
- VKOWVQSIVDKTFD-UHFFFAOYSA-N 2-[2-[(2-cyclopentyloxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC=C(OC2CCCC2)C=1CSC1=CC=CC=C1C1=NCCCN1 VKOWVQSIVDKTFD-UHFFFAOYSA-N 0.000 claims description 4
- RLQOQTQCFAZGSR-UHFFFAOYSA-N 2-[2-[(2-ethoxynaphthalen-1-yl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound CCOC1=CC=C2C=CC=CC2=C1CSC1=CC=CC=C1C1=NCCCN1 RLQOQTQCFAZGSR-UHFFFAOYSA-N 0.000 claims description 4
- UEYAWOPDBOWKEK-UHFFFAOYSA-N 2-[2-[(2-fluorophenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound FC1=CC=CC=C1CSC1=CC=CC=C1C1=NCCCN1 UEYAWOPDBOWKEK-UHFFFAOYSA-N 0.000 claims description 4
- AMSWPHUXJQRFBP-UHFFFAOYSA-N 2-[2-[(2-iodophenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound IC1=CC=CC=C1CSC1=CC=CC=C1C1=NCCCN1 AMSWPHUXJQRFBP-UHFFFAOYSA-N 0.000 claims description 4
- JQMKHYYNAWZZBX-UHFFFAOYSA-N 2-[2-[(2-iodophenyl)methylsulfanyl]phenyl]-4,5-dihydro-1h-imidazole Chemical compound IC1=CC=CC=C1CSC1=CC=CC=C1C1=NCCN1 JQMKHYYNAWZZBX-UHFFFAOYSA-N 0.000 claims description 4
- KTWWZGRWSAZNFV-UHFFFAOYSA-N 2-[2-[(2-methoxy-5-nitrophenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C([N+]([O-])=O)C=C1CSC1=CC=CC=C1C1=NCCCN1 KTWWZGRWSAZNFV-UHFFFAOYSA-N 0.000 claims description 4
- XROZEKFUKUQTAT-UHFFFAOYSA-N 2-[2-[(2-methoxy-5-nitrophenyl)methylsulfanyl]phenyl]-4,5-dihydro-1h-imidazole Chemical compound COC1=CC=C([N+]([O-])=O)C=C1CSC1=CC=CC=C1C1=NCCN1 XROZEKFUKUQTAT-UHFFFAOYSA-N 0.000 claims description 4
- JLIDYMPVMLNLGY-UHFFFAOYSA-N 2-[2-[(2-methoxy-5-nitrophenyl)methylsulfanyl]pyridin-3-yl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C([N+]([O-])=O)C=C1CSC1=NC=CC=C1C1=NCCCN1 JLIDYMPVMLNLGY-UHFFFAOYSA-N 0.000 claims description 4
- CGDASKIJYYWJSM-UHFFFAOYSA-N 2-[2-[(2-methoxy-5-phenylphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(C=2C=CC=CC=2)C=C1CSC1=CC=CC=C1C1=NCCCN1 CGDASKIJYYWJSM-UHFFFAOYSA-N 0.000 claims description 4
- VUQUNQSDLBZMCT-UHFFFAOYSA-N 2-[2-[(2-methoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=CC=C1CSC1=CC=CC=C1C1=NCCCN1 VUQUNQSDLBZMCT-UHFFFAOYSA-N 0.000 claims description 4
- QRISVWPWDXQJMG-UHFFFAOYSA-N 2-[2-[(2-methoxyphenyl)sulfanylmethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=CC=C1SCC1=CC=CC=C1C1=NCCCN1 QRISVWPWDXQJMG-UHFFFAOYSA-N 0.000 claims description 4
- ZAZUDFGPICAKDI-UHFFFAOYSA-N 2-[2-[(2-methylnaphthalen-1-yl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound CC1=CC=C2C=CC=CC2=C1CSC1=CC=CC=C1C1=NCCCN1 ZAZUDFGPICAKDI-UHFFFAOYSA-N 0.000 claims description 4
- MFWSRNUATFFCLO-UHFFFAOYSA-N 2-[2-[(2-methylphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound CC1=CC=CC=C1CSC1=CC=CC=C1C1=NCCCN1 MFWSRNUATFFCLO-UHFFFAOYSA-N 0.000 claims description 4
- PHPOZVKYMNDMHX-UHFFFAOYSA-N 2-[2-[(2-phenylphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC=C(C=2C=CC=CC=2)C=1CSC1=CC=CC=C1C1=NCCCN1 PHPOZVKYMNDMHX-UHFFFAOYSA-N 0.000 claims description 4
- JURFLFGQSHDRQR-UHFFFAOYSA-N 2-[2-[(2-propan-2-yloxynaphthalen-1-yl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound CC(C)OC1=CC=C2C=CC=CC2=C1CSC1=CC=CC=C1C1=NCCCN1 JURFLFGQSHDRQR-UHFFFAOYSA-N 0.000 claims description 4
- MVFGKBOVQQMARR-UHFFFAOYSA-N 2-[2-[(2-propoxynaphthalen-1-yl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound CCCOC1=CC=C2C=CC=CC2=C1CSC1=CC=CC=C1C1=NCCCN1 MVFGKBOVQQMARR-UHFFFAOYSA-N 0.000 claims description 4
- YZQSLUVOBLBNMG-UHFFFAOYSA-N 2-[2-[(3,5-dimethoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC(OC)=CC(CSC=2C(=CC=CC=2)C=2NCCCN=2)=C1 YZQSLUVOBLBNMG-UHFFFAOYSA-N 0.000 claims description 4
- COTASPQXFNVYQO-UHFFFAOYSA-N 2-[2-[(3-bromophenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound BrC1=CC=CC(CSC=2C(=CC=CC=2)C=2NCCCN=2)=C1 COTASPQXFNVYQO-UHFFFAOYSA-N 0.000 claims description 4
- QCHPOPXUCRMGCY-UHFFFAOYSA-N 2-[2-[(3-chlorophenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound ClC1=CC=CC(CSC=2C(=CC=CC=2)C=2NCCCN=2)=C1 QCHPOPXUCRMGCY-UHFFFAOYSA-N 0.000 claims description 4
- GMDPNUDGOALJPG-UHFFFAOYSA-N 2-[2-[(3-iodophenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound IC1=CC=CC(CSC=2C(=CC=CC=2)C=2NCCCN=2)=C1 GMDPNUDGOALJPG-UHFFFAOYSA-N 0.000 claims description 4
- YQXGBUCFRQYHMD-UHFFFAOYSA-N 2-[2-[(3-methoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=CC(CSC=2C(=CC=CC=2)C=2NCCCN=2)=C1 YQXGBUCFRQYHMD-UHFFFAOYSA-N 0.000 claims description 4
- IHIDTXABSJSEDM-UHFFFAOYSA-N 2-[2-[(3-nitrophenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound [O-][N+](=O)C1=CC=CC(CSC=2C(=CC=CC=2)C=2NCCCN=2)=C1 IHIDTXABSJSEDM-UHFFFAOYSA-N 0.000 claims description 4
- OPPJDQNZBNINSH-UHFFFAOYSA-N 2-[2-[(3-phenylphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC(C=2C=CC=CC=2)=CC=1CSC1=CC=CC=C1C1=NCCCN1 OPPJDQNZBNINSH-UHFFFAOYSA-N 0.000 claims description 4
- KWBUUMUFWHBVGS-UHFFFAOYSA-N 2-[2-[(4-fluorophenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C1=CC(F)=CC=C1CSC1=CC=CC=C1C1=NCCCN1 KWBUUMUFWHBVGS-UHFFFAOYSA-N 0.000 claims description 4
- AWWMCYRTRDYSLP-UHFFFAOYSA-N 2-[2-[(4-methylnaphthalen-1-yl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C12=CC=CC=C2C(C)=CC=C1CSC1=CC=CC=C1C1=NCCCN1 AWWMCYRTRDYSLP-UHFFFAOYSA-N 0.000 claims description 4
- PUDQPIKMLRFZPN-UHFFFAOYSA-N 2-[2-[(5-bromo-2-cyclopentyloxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC=C(C=2NCCCN=2)C=1SCC1=CC(Br)=CC=C1OC1CCCC1 PUDQPIKMLRFZPN-UHFFFAOYSA-N 0.000 claims description 4
- GPSOQGAPPIJCEG-UHFFFAOYSA-N 2-[2-[(5-bromo-2-ethoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound CCOC1=CC=C(Br)C=C1CSC1=CC=CC=C1C1=NCCCN1 GPSOQGAPPIJCEG-UHFFFAOYSA-N 0.000 claims description 4
- PXBUAHNXIUFNNY-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methoxy]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1COC1=CC=CC=C1C1=NCCCN1 PXBUAHNXIUFNNY-UHFFFAOYSA-N 0.000 claims description 4
- CPJWCFKQCQUQLI-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methoxymethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1COCC1=CC=CC=C1C1=NCCCN1 CPJWCFKQCQUQLI-UHFFFAOYSA-N 0.000 claims description 4
- RTXJBQSGOVXPQR-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-fluorophenyl]-5,5-dimethyl-4,6-dihydro-1h-pyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=C(F)C=CC=C1C1=NCC(C)(C)CN1 RTXJBQSGOVXPQR-UHFFFAOYSA-N 0.000 claims description 4
- ZECWULPQHNOWRR-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-5-fluorophenyl]-4,5-dihydro-1h-imidazole Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=C(F)C=C1C1=NCCN1 ZECWULPQHNOWRR-UHFFFAOYSA-N 0.000 claims description 4
- VFXNWSNBKZPTTD-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]guanidine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1NC(N)=N VFXNWSNBKZPTTD-UHFFFAOYSA-N 0.000 claims description 4
- VJCWFTJNIJPWCW-UHFFFAOYSA-N 2-[2-[(5-bromo-2-propan-2-yloxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound CC(C)OC1=CC=C(Br)C=C1CSC1=CC=CC=C1C1=NCCCN1 VJCWFTJNIJPWCW-UHFFFAOYSA-N 0.000 claims description 4
- MUSSZQAYEUONGF-UHFFFAOYSA-N 2-[2-[(5-bromo-2-propoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound CCCOC1=CC=C(Br)C=C1CSC1=CC=CC=C1C1=NCCCN1 MUSSZQAYEUONGF-UHFFFAOYSA-N 0.000 claims description 4
- NHYCLGJOZNTBRB-UHFFFAOYSA-N 2-[2-[(5-ethynyl-2-methoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(C#C)C=C1CSC1=CC=CC=C1C1=NCCCN1 NHYCLGJOZNTBRB-UHFFFAOYSA-N 0.000 claims description 4
- FYSBRELZWWDOLV-UHFFFAOYSA-N 2-[2-[(6-bromo-2-methoxynaphthalen-1-yl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C2C=C(Br)C=CC2=C1CSC1=CC=CC=C1C1=NCCCN1 FYSBRELZWWDOLV-UHFFFAOYSA-N 0.000 claims description 4
- TYHWUSYRUAHMBB-UHFFFAOYSA-N 2-[2-[(6-fluoronaphthalen-1-yl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC(F)=CC=C2C=1CSC1=CC=CC=C1C1=NCCCN1 TYHWUSYRUAHMBB-UHFFFAOYSA-N 0.000 claims description 4
- UCANUPCLAHKJLU-UHFFFAOYSA-N 2-[2-[2-(2,3-dihydro-1,4-benzodioxin-5-yl)ethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC=2OCCOC=2C=1CCC1=CC=CC=C1C1=NCCCN1 UCANUPCLAHKJLU-UHFFFAOYSA-N 0.000 claims description 4
- GYJLBLSVLQVQOR-UHFFFAOYSA-N 2-[2-[2-(2-methoxynaphthalen-1-yl)ethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C2C=CC=CC2=C1CCC1=CC=CC=C1C1=NCCCN1 GYJLBLSVLQVQOR-UHFFFAOYSA-N 0.000 claims description 4
- DSRUBXVCPSJSAX-UHFFFAOYSA-N 2-[2-[2-(2-methylnaphthalen-1-yl)ethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound CC1=CC=C2C=CC=CC2=C1CCC1=CC=CC=C1C1=NCCCN1 DSRUBXVCPSJSAX-UHFFFAOYSA-N 0.000 claims description 4
- CCISHMCRIWHRTE-UHFFFAOYSA-N 2-[2-[[2,4-bis(trifluoromethyl)phenyl]methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC=C1CSC1=CC=CC=C1C1=NCCCN1 CCISHMCRIWHRTE-UHFFFAOYSA-N 0.000 claims description 4
- RBUZILJRVMVRED-UHFFFAOYSA-N 2-[2-[[3,5-bis(trifluoromethyl)phenyl]methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CSC=2C(=CC=CC=2)C=2NCCCN=2)=C1 RBUZILJRVMVRED-UHFFFAOYSA-N 0.000 claims description 4
- FSGARAUGNFHJCY-UHFFFAOYSA-N 2-[3-(naphthalen-1-ylsulfanylmethyl)thiophen-2-yl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1SCC=1C=CSC=1C1=NCCCN1 FSGARAUGNFHJCY-UHFFFAOYSA-N 0.000 claims description 4
- HUQNTTQVZYURMS-UHFFFAOYSA-N 2-[3-[(5-bromo-2-methoxyphenyl)methylsulfanyl]pyridin-2-yl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CN=C1C1=NCCCN1 HUQNTTQVZYURMS-UHFFFAOYSA-N 0.000 claims description 4
- XFWBPYOQWBEJDY-UHFFFAOYSA-N 2-[3-chloro-2-(2-naphthalen-1-ylethyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1CCC=1C(Cl)=CC=CC=1C1=NCCCN1 XFWBPYOQWBEJDY-UHFFFAOYSA-N 0.000 claims description 4
- VQPNUOOVVQVJAQ-UHFFFAOYSA-N 2-[3-fluoro-2-(2-naphthalen-1-ylethyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1CCC=1C(F)=CC=CC=1C1=NCCCN1 VQPNUOOVVQVJAQ-UHFFFAOYSA-N 0.000 claims description 4
- VSLAWUJINZENSD-UHFFFAOYSA-N 2-[3-fluoro-2-(naphthalen-1-ylmethylsulfanyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1CSC=1C(F)=CC=CC=1C1=NCCCN1 VSLAWUJINZENSD-UHFFFAOYSA-N 0.000 claims description 4
- WWQPTDNNDBFOLF-UHFFFAOYSA-N 2-[3-methoxy-2-(2-naphthalen-1-ylethyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1CCC=1C(OC)=CC=CC=1C1=NCCCN1 WWQPTDNNDBFOLF-UHFFFAOYSA-N 0.000 claims description 4
- REYLZFXVSGOFRG-UHFFFAOYSA-N 2-[4-(naphthalen-1-ylmethylsulfanyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1CSC(C=C1)=CC=C1C1=NCCCN1 REYLZFXVSGOFRG-UHFFFAOYSA-N 0.000 claims description 4
- ZDCKTYHRUDDTRR-UHFFFAOYSA-N 2-amino-2-[2-(2-naphthalen-1-ylethyl)phenyl]acetonitrile Chemical compound N#CC(N)C1=CC=CC=C1CCC1=CC=CC2=CC=CC=C12 ZDCKTYHRUDDTRR-UHFFFAOYSA-N 0.000 claims description 4
- SNXAPSQAOUWUBO-UHFFFAOYSA-N 3-(2-naphthalen-1-ylethyl)-2-(1,4,5,6-tetrahydropyrimidin-2-yl)aniline Chemical compound NC1=CC=CC(CCC=2C3=CC=CC=C3C=CC=2)=C1C1=NCCCN1 SNXAPSQAOUWUBO-UHFFFAOYSA-N 0.000 claims description 4
- QAAXFJDGBDRGRQ-UHFFFAOYSA-N 3-[4-(dimethylamino)phenyl]-1-[3-(dimethylamino)propyl]-1-(naphthalen-1-ylmethyl)thiourea Chemical compound C=1C=CC2=CC=CC=C2C=1CN(CCCN(C)C)C(=S)NC1=CC=C(N(C)C)C=C1 QAAXFJDGBDRGRQ-UHFFFAOYSA-N 0.000 claims description 4
- NFZJLBMRYVVSKF-UHFFFAOYSA-N 3-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methoxy]piperidine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1COC1CNCCC1 NFZJLBMRYVVSKF-UHFFFAOYSA-N 0.000 claims description 4
- KGMGBTYHOQWYMB-UHFFFAOYSA-N 3-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methoxy]pyrrolidine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1COC1CNCC1 KGMGBTYHOQWYMB-UHFFFAOYSA-N 0.000 claims description 4
- VRMGVFAVTFUVOZ-UHFFFAOYSA-N 3-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methylamino]-3-methylbutan-1-ol Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1CNC(C)(C)CCO VRMGVFAVTFUVOZ-UHFFFAOYSA-N 0.000 claims description 4
- YHFJHNVCVXVVEH-UHFFFAOYSA-N 3-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methylamino]propan-1-ol Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1CNCCCO YHFJHNVCVXVVEH-UHFFFAOYSA-N 0.000 claims description 4
- HLMAGOZCRZZHQE-UHFFFAOYSA-N 3-imidazol-1-yl-n-(naphthalen-1-ylmethyl)-n-(naphthalen-2-ylmethyl)propan-1-amine Chemical compound C=1C=C2C=CC=CC2=CC=1CN(CC=1C2=CC=CC=C2C=CC=1)CCCN1C=CN=C1 HLMAGOZCRZZHQE-UHFFFAOYSA-N 0.000 claims description 4
- RQCGBMCXRYEWNS-UHFFFAOYSA-N 4-[[2-(1,4,5,6-tetrahydropyrimidin-2-yl)phenyl]sulfanylmethyl]quinoline Chemical compound C=1C=NC2=CC=CC=C2C=1CSC1=CC=CC=C1C1=NCCCN1 RQCGBMCXRYEWNS-UHFFFAOYSA-N 0.000 claims description 4
- LCPGBTISTIGVED-UHFFFAOYSA-N 4-tert-butyl-n-(naphthalen-1-ylmethyl)-n-(2-piperidin-1-ylethyl)benzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)N(CC=1C2=CC=CC=C2C=CC=1)CCN1CCCCC1 LCPGBTISTIGVED-UHFFFAOYSA-N 0.000 claims description 4
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 claims description 4
- DBIZGVXQPFDTDA-UHFFFAOYSA-N [1-[[2-(2-naphthalen-1-ylethyl)phenyl]methyl]piperidin-2-yl]methanol Chemical compound OCC1CCCCN1CC1=CC=CC=C1CCC1=CC=CC2=CC=CC=C12 DBIZGVXQPFDTDA-UHFFFAOYSA-N 0.000 claims description 4
- HKCYUJLPMMMRCF-UHFFFAOYSA-N [1-[[2-(naphthalen-1-ylsulfanylmethyl)phenyl]methyl]piperidin-2-yl]methanol Chemical compound OCC1CCCCN1CC1=CC=CC=C1CSC1=CC=CC2=CC=CC=C12 HKCYUJLPMMMRCF-UHFFFAOYSA-N 0.000 claims description 4
- XGRRFBZSVWCCNA-UHFFFAOYSA-N [1-[[3-chloro-2-(naphthalen-1-ylsulfanylmethyl)phenyl]methyl]piperidin-2-yl]methanol Chemical compound OCC1CCCCN1CC1=CC=CC(Cl)=C1CSC1=CC=CC2=CC=CC=C12 XGRRFBZSVWCCNA-UHFFFAOYSA-N 0.000 claims description 4
- 125000005157 alkyl carboxy group Chemical group 0.000 claims description 4
- 125000004682 aminothiocarbonyl group Chemical group NC(=S)* 0.000 claims description 4
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 claims description 4
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- TWKUKZOQMKBOKB-UHFFFAOYSA-N methyl 1-(2-naphthalen-1-ylethyl)piperidine-2-carboxylate Chemical compound COC(=O)C1CCCCN1CCC1=CC=CC2=CC=CC=C12 TWKUKZOQMKBOKB-UHFFFAOYSA-N 0.000 claims description 4
- AZJXYSILXBMBDR-UHFFFAOYSA-N n,n-dimethyl-n'-(naphthalen-1-ylmethyl)-n'-(naphthalen-2-ylmethyl)propane-1,3-diamine Chemical compound C1=CC=C2C(CN(CC=3C=C4C=CC=CC4=CC=3)CCCN(C)C)=CC=CC2=C1 AZJXYSILXBMBDR-UHFFFAOYSA-N 0.000 claims description 4
- WHPBDZMNGAVUPV-UHFFFAOYSA-N n-[(3-bromophenyl)methyl]-1-(1-ethylpyrrolidin-2-yl)-n-(naphthalen-1-ylmethyl)methanamine Chemical compound CCN1CCCC1CN(CC=1C2=CC=CC=C2C=CC=1)CC1=CC=CC(Br)=C1 WHPBDZMNGAVUPV-UHFFFAOYSA-N 0.000 claims description 4
- SRNCFCZLRQCEOG-UHFFFAOYSA-N n-[(3-bromophenyl)methyl]-3-imidazol-1-yl-n-(naphthalen-1-ylmethyl)propan-1-amine Chemical compound BrC1=CC=CC(CN(CCCN2C=NC=C2)CC=2C3=CC=CC=C3C=CC=2)=C1 SRNCFCZLRQCEOG-UHFFFAOYSA-N 0.000 claims description 4
- ZHTYTQLZBHEOHT-UHFFFAOYSA-N n-[(5-bromo-2-methoxyphenyl)methyl]-2-(1,4,5,6-tetrahydropyrimidin-2-yl)aniline Chemical compound COC1=CC=C(Br)C=C1CNC1=CC=CC=C1C1=NCCCN1 ZHTYTQLZBHEOHT-UHFFFAOYSA-N 0.000 claims description 4
- IUUWYNSTWKOEJX-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-n-(naphthalen-1-ylmethyl)naphthalene-2-sulfonamide Chemical compound C1=CC=CC2=CC(S(=O)(=O)N(CC=3C4=CC=CC=C4C=CC=3)CCN(C)C)=CC=C21 IUUWYNSTWKOEJX-UHFFFAOYSA-N 0.000 claims description 4
- 229950000688 phenothiazine Drugs 0.000 claims description 4
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 4
- RGFBAGOHQXOXRY-UHFFFAOYSA-N 1,3-di(piperidin-1-yl)propan-2-yl n-[2-(naphthalen-1-ylmethylsulfanyl)phenyl]carbamate Chemical compound C=1C=CC=C(SCC=2C3=CC=CC=C3C=CC=2)C=1NC(=O)OC(CN1CCCCC1)CN1CCCCC1 RGFBAGOHQXOXRY-UHFFFAOYSA-N 0.000 claims description 3
- SHZPSAKOOSXLBB-UHFFFAOYSA-N 1-(naphthalen-1-ylmethyl)-3-(2-phenylethyl)-1-(2-piperidin-1-ylethyl)thiourea Chemical compound C1CCCCN1CCN(CC=1C2=CC=CC=C2C=CC=1)C(=S)NCCC1=CC=CC=C1 SHZPSAKOOSXLBB-UHFFFAOYSA-N 0.000 claims description 3
- OWTGZNSAINYLEJ-UHFFFAOYSA-N 1-[2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]-5,6-dihydro-4h-pyrimidin-1-yl]-2-phenylethanone Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1C1=NCCCN1C(=O)CC1=CC=CC=C1 OWTGZNSAINYLEJ-UHFFFAOYSA-N 0.000 claims description 3
- WODPAVGRLDMTGA-UHFFFAOYSA-N 1-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-chlorophenyl]methyl]-2-(methoxymethyl)pyrrolidine Chemical compound COCC1CCCN1CC1=CC=CC(Cl)=C1SCC1=CC(Br)=CC=C1OC WODPAVGRLDMTGA-UHFFFAOYSA-N 0.000 claims description 3
- JMUUYBCFUZIXOY-UHFFFAOYSA-N 1-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-chlorophenyl]methyl]azetidine Chemical compound COC1=CC=C(Br)C=C1CSC1=C(Cl)C=CC=C1CN1CCC1 JMUUYBCFUZIXOY-UHFFFAOYSA-N 0.000 claims description 3
- AWVJYNDPVRJZQI-UHFFFAOYSA-N 1-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-chlorophenyl]methyl]pyrrolidin-3-amine Chemical compound COC1=CC=C(Br)C=C1CSC1=C(Cl)C=CC=C1CN1CC(N)CC1 AWVJYNDPVRJZQI-UHFFFAOYSA-N 0.000 claims description 3
- HVDWCFNXMDSFSR-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl n-[2-(naphthalen-1-ylmethylsulfanyl)phenyl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NC1=CC=CC=C1SCC1=CC=CC2=CC=CC=C12 HVDWCFNXMDSFSR-UHFFFAOYSA-N 0.000 claims description 3
- WSXOKTKQMKXUKK-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl n-[2-[(2-methylnaphthalen-1-yl)methylsulfanyl]phenyl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NC1=CC=CC=C1SCC1=C2C=CC=CC2=CC=C1C WSXOKTKQMKXUKK-UHFFFAOYSA-N 0.000 claims description 3
- JSSURDODLIXQJB-UHFFFAOYSA-N 1-methyl-2-[2-(naphthalen-1-ylmethylsulfanyl)phenyl]-5,6-dihydro-4h-pyrimidine Chemical compound CN1CCCN=C1C1=CC=CC=C1SCC1=CC=CC2=CC=CC=C12 JSSURDODLIXQJB-UHFFFAOYSA-N 0.000 claims description 3
- OCDKDDRPKABOLN-UHFFFAOYSA-N 2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-piperazin-1-ylpyrazine Chemical group COC1=CC=C(Br)C=C1CSC1=NC=CN=C1N1CCNCC1 OCDKDDRPKABOLN-UHFFFAOYSA-N 0.000 claims description 3
- FWPVLIBLPJCPKP-UHFFFAOYSA-N 2-[2-(2,3-dihydro-1,4-benzodioxin-5-ylmethylsulfanyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC=2OCCOC=2C=1CSC1=CC=CC=C1C1=NCCCN1 FWPVLIBLPJCPKP-UHFFFAOYSA-N 0.000 claims description 3
- PTYYJYFKWLYTJJ-UHFFFAOYSA-N 2-[2-(naphthalen-1-ylsulfanylmethyl)phenyl]-4,5-dihydro-1h-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1SCC1=CC=CC=C1C1=NCCN1 PTYYJYFKWLYTJJ-UHFFFAOYSA-N 0.000 claims description 3
- GKFNKZYRWRRHJJ-UHFFFAOYSA-N 2-[2-(naphthalen-1-ylsulfanylmethyl)thiophen-3-yl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1SCC=1SC=CC=1C1=NCCCN1 GKFNKZYRWRRHJJ-UHFFFAOYSA-N 0.000 claims description 3
- SUSFCKRSJXFKFJ-UHFFFAOYSA-N 2-[2-[(2,5-dimethoxyphenyl)sulfanylmethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(OC)C(SCC=2C(=CC=CC=2)C=2NCCCN=2)=C1 SUSFCKRSJXFKFJ-UHFFFAOYSA-N 0.000 claims description 3
- KEFSOJHGKGLWGI-UHFFFAOYSA-N 2-[2-[(2,6-dimethoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=CC(OC)=C1CSC1=CC=CC=C1C1=NCCCN1 KEFSOJHGKGLWGI-UHFFFAOYSA-N 0.000 claims description 3
- FGRRSCLWFFIDDZ-UHFFFAOYSA-N 2-[2-[(2-bromo-5-methoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C(CSC=2C(=CC=CC=2)C=2NCCCN=2)=C1 FGRRSCLWFFIDDZ-UHFFFAOYSA-N 0.000 claims description 3
- PRRRRTXDJJLOLL-UHFFFAOYSA-N 2-[2-[(2-bromo-6-methoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=CC(Br)=C1CSC1=CC=CC=C1C1=NCCCN1 PRRRRTXDJJLOLL-UHFFFAOYSA-N 0.000 claims description 3
- IKNWNXHMEIPMHN-UHFFFAOYSA-N 2-[2-[(2-chloro-6-fluorophenyl)methylsulfanyl]phenyl]-3a,4,5,6,7,7a-hexahydro-1h-benzimidazole Chemical compound FC1=CC=CC(Cl)=C1CSC1=CC=CC=C1C(N1)=NC2C1CCCC2 IKNWNXHMEIPMHN-UHFFFAOYSA-N 0.000 claims description 3
- IZUJSZAYULSQCW-UHFFFAOYSA-N 2-[2-[(2-iodophenyl)methylsulfanyl]phenyl]-3a,4,5,6,7,7a-hexahydro-1h-benzimidazole Chemical compound IC1=CC=CC=C1CSC1=CC=CC=C1C(N1)=NC2C1CCCC2 IZUJSZAYULSQCW-UHFFFAOYSA-N 0.000 claims description 3
- KKWGREIGMAWSGA-UHFFFAOYSA-N 2-[2-[(2-methoxy-5-methylphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(C)C=C1CSC1=CC=CC=C1C1=NCCCN1 KKWGREIGMAWSGA-UHFFFAOYSA-N 0.000 claims description 3
- YSKONJARCLBXRG-UHFFFAOYSA-N 2-[2-[(2-methoxy-5-nitrophenyl)methylsulfanyl]phenyl]-3a,4,5,6,7,7a-hexahydro-1h-benzimidazole Chemical compound COC1=CC=C([N+]([O-])=O)C=C1CSC1=CC=CC=C1C(N1)=NC2C1CCCC2 YSKONJARCLBXRG-UHFFFAOYSA-N 0.000 claims description 3
- GMKOONYUECAQPJ-UHFFFAOYSA-N 2-[2-[(2-methoxy-5-thiophen-3-ylphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(C2=CSC=C2)C=C1CSC1=CC=CC=C1C1=NCCCN1 GMKOONYUECAQPJ-UHFFFAOYSA-N 0.000 claims description 3
- NUTDJMUUFLZXSZ-UHFFFAOYSA-N 2-[2-[(2-methoxynaphthalen-1-yl)sulfanylmethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C2C=CC=CC2=C1SCC1=CC=CC=C1C1=NCCCN1 NUTDJMUUFLZXSZ-UHFFFAOYSA-N 0.000 claims description 3
- LOPZEVFRRBDVPB-UHFFFAOYSA-N 2-[2-[(2-methylphenyl)sulfanylmethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound CC1=CC=CC=C1SCC1=CC=CC=C1C1=NCCCN1 LOPZEVFRRBDVPB-UHFFFAOYSA-N 0.000 claims description 3
- DRCKIXIPSQZHTF-UHFFFAOYSA-N 2-[2-[(4-phenylmethoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC=CC=1COC(C=C1)=CC=C1CSC1=CC=CC=C1C1=NCCCN1 DRCKIXIPSQZHTF-UHFFFAOYSA-N 0.000 claims description 3
- BHRKIYVQKAPXBH-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3,5-difluorophenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=C(F)C=C(F)C=C1C1=NCCCN1 BHRKIYVQKAPXBH-UHFFFAOYSA-N 0.000 claims description 3
- BVRSBCUMISUFPR-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-chlorophenyl]-1,4,5,6-tetrahydropyrimidin-5-ol Chemical compound COC1=CC=C(Br)C=C1CSC1=C(Cl)C=CC=C1C1=NCC(O)CN1 BVRSBCUMISUFPR-UHFFFAOYSA-N 0.000 claims description 3
- ORJVHEZQRTWNPN-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-chlorophenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=C(Cl)C=CC=C1C1=NCCCN1 ORJVHEZQRTWNPN-UHFFFAOYSA-N 0.000 claims description 3
- WHXSLNWBYOEZBI-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-fluoro-4-(trifluoromethyl)phenyl]-5,5-dimethyl-1,4-dihydroimidazole Chemical compound COC1=CC=C(Br)C=C1CSC1=C(F)C(C(F)(F)F)=CC=C1C1=NC(C)(C)CN1 WHXSLNWBYOEZBI-UHFFFAOYSA-N 0.000 claims description 3
- QMZMGFFTHMWJGO-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-fluoro-4-(trifluoromethyl)phenyl]-5,5-dimethyl-4,6-dihydro-1h-pyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=C(F)C(C(F)(F)F)=CC=C1C1=NCC(C)(C)CN1 QMZMGFFTHMWJGO-UHFFFAOYSA-N 0.000 claims description 3
- AKAKMYRPGCQWGD-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-5-fluorophenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=C(F)C=C1C1=NCCCN1 AKAKMYRPGCQWGD-UHFFFAOYSA-N 0.000 claims description 3
- LRARSJZZXIOEEO-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-5-methylphenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=C(C)C=C1C1=NCCCN1 LRARSJZZXIOEEO-UHFFFAOYSA-N 0.000 claims description 3
- WFGIAUVZRWXFIJ-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]-5,5-dimethyl-4,6-dihydro-1h-pyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1C1=NCC(C)(C)CN1 WFGIAUVZRWXFIJ-UHFFFAOYSA-N 0.000 claims description 3
- SMZVQYVSTZGACP-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanylmethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CSCC1=CC=CC=C1C1=NCCCN1 SMZVQYVSTZGACP-UHFFFAOYSA-N 0.000 claims description 3
- YOHMIPZLDKWENG-UHFFFAOYSA-N 2-[2-[(5-chloro-2-methoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Cl)C=C1CSC1=CC=CC=C1C1=NCCCN1 YOHMIPZLDKWENG-UHFFFAOYSA-N 0.000 claims description 3
- XAJUEBVKLILWRA-UHFFFAOYSA-N 2-[2-[(5-fluoro-2-methoxyphenyl)methylsulfanyl]phenyl]-4,5-dihydro-1h-imidazole Chemical compound COC1=CC=C(F)C=C1CSC1=CC=CC=C1C1=NCCN1 XAJUEBVKLILWRA-UHFFFAOYSA-N 0.000 claims description 3
- HJWLUEOYGAIIGV-UHFFFAOYSA-N 2-[2-[(5-iodo-2-methoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(I)C=C1CSC1=CC=CC=C1C1=NCCCN1 HJWLUEOYGAIIGV-UHFFFAOYSA-N 0.000 claims description 3
- XZTTZBZEQYPTEC-UHFFFAOYSA-N 2-[2-[(6-methoxy-2,3-dihydro-1,4-benzodioxin-5-yl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C2OCCOC2=C1CSC1=CC=CC=C1C1=NCCCN1 XZTTZBZEQYPTEC-UHFFFAOYSA-N 0.000 claims description 3
- XDMDMDPCJLVGGW-UHFFFAOYSA-N 2-[2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chlorophenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CCC1=C(Cl)C=CC=C1C1=NCCCN1 XDMDMDPCJLVGGW-UHFFFAOYSA-N 0.000 claims description 3
- GPVZZAYIPVQEAG-UHFFFAOYSA-N 2-[2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorophenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CCC1=C(F)C=CC=C1C1=NCCCN1 GPVZZAYIPVQEAG-UHFFFAOYSA-N 0.000 claims description 3
- QMKKPQXQBBNKQM-UHFFFAOYSA-N 2-[2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-methoxyphenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CCC1=C(OC)C=CC=C1C1=NCCCN1 QMKKPQXQBBNKQM-UHFFFAOYSA-N 0.000 claims description 3
- SNXCNGBBNPGLHD-UHFFFAOYSA-N 2-[3-[(2-methoxynaphthalen-1-yl)sulfanylmethyl]thiophen-2-yl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C2C=CC=CC2=C1SCC=1C=CSC=1C1=NCCCN1 SNXCNGBBNPGLHD-UHFFFAOYSA-N 0.000 claims description 3
- BTHAZOBIDZLSFQ-UHFFFAOYSA-N 2-[3-bromo-2-(naphthalen-1-ylsulfanylmethyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1SCC=1C(Br)=CC=CC=1C1=NCCCN1 BTHAZOBIDZLSFQ-UHFFFAOYSA-N 0.000 claims description 3
- JBPHWGGCJDJGDL-UHFFFAOYSA-N 2-[3-chloro-2-(naphthalen-1-ylsulfanylmethyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1SCC=1C(Cl)=CC=CC=1C1=NCCCN1 JBPHWGGCJDJGDL-UHFFFAOYSA-N 0.000 claims description 3
- WUPHVXHCTSWGPA-UHFFFAOYSA-N 2-[3-chloro-2-[(2-methoxynaphthalen-1-yl)sulfanylmethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C2C=CC=CC2=C1SCC1=C(Cl)C=CC=C1C1=NCCCN1 WUPHVXHCTSWGPA-UHFFFAOYSA-N 0.000 claims description 3
- XROBCDNMROGODT-UHFFFAOYSA-N 2-[3-fluoro-2-(naphthalen-1-ylsulfanylmethyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1SCC=1C(F)=CC=CC=1C1=NCCCN1 XROBCDNMROGODT-UHFFFAOYSA-N 0.000 claims description 3
- QQZLNBLGDXQLHB-UHFFFAOYSA-N 2-[5-bromo-2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=C(Br)C=C1C1=NCCCN1 QQZLNBLGDXQLHB-UHFFFAOYSA-N 0.000 claims description 3
- QVEWNZMMZGKMOK-UHFFFAOYSA-N 3-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-fluorophenyl]-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyridine Chemical compound COC1=CC=C(Br)C=C1CSC1=C(F)C=CC=C1C1=NCC2N1CCCC2 QVEWNZMMZGKMOK-UHFFFAOYSA-N 0.000 claims description 3
- MEAIANTWONFBMR-UHFFFAOYSA-N 5,5-dimethyl-2-[2-(2-naphthalen-1-ylethyl)phenyl]-1,4-dihydroimidazole Chemical compound N1C(C)(C)CN=C1C1=CC=CC=C1CCC1=CC=CC2=CC=CC=C12 MEAIANTWONFBMR-UHFFFAOYSA-N 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- IFWBHPFZSKBIIQ-UHFFFAOYSA-N [1-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1CN1C(CO)CCC1 IFWBHPFZSKBIIQ-UHFFFAOYSA-N 0.000 claims description 3
- JMVNFIOCAYFCIY-UHFFFAOYSA-N [2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methanamine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1CN JMVNFIOCAYFCIY-UHFFFAOYSA-N 0.000 claims description 3
- 125000005015 aryl alkynyl group Chemical group 0.000 claims description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 239000011630 iodine Substances 0.000 claims description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 3
- SLCAGYISQJNUGD-UHFFFAOYSA-N n-[[1-(2-naphthalen-1-ylethyl)pyrrolidin-2-yl]methyl]-1h-pyrrol-2-amine Chemical compound C=1C=CC2=CC=CC=C2C=1CCN1CCCC1CNC1=CC=CN1 SLCAGYISQJNUGD-UHFFFAOYSA-N 0.000 claims description 3
- VWLSDJQSNWMCNW-UHFFFAOYSA-N 2-[1-(2-naphthalen-1-ylethyl)pyrrol-2-yl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1CCN1C=CC=C1C1=NCCCN1 VWLSDJQSNWMCNW-UHFFFAOYSA-N 0.000 claims description 2
- LTKNAMJHFJKCLP-UHFFFAOYSA-N 2-[2-[(2-chloro-6-fluorophenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound FC1=CC=CC(Cl)=C1CSC1=CC=CC=C1C1=NCCCN1 LTKNAMJHFJKCLP-UHFFFAOYSA-N 0.000 claims description 2
- RGMPFJUALNCLIZ-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3,4-difluorophenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=C(F)C(F)=CC=C1C1=NCCCN1 RGMPFJUALNCLIZ-UHFFFAOYSA-N 0.000 claims description 2
- FOVOETZPEDCAOZ-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3,5-difluorophenyl]-5,5-dimethyl-1,4-dihydroimidazole Chemical compound COC1=CC=C(Br)C=C1CSC1=C(F)C=C(F)C=C1C1=NCC(C)(C)N1 FOVOETZPEDCAOZ-UHFFFAOYSA-N 0.000 claims description 2
- XDPJOQZPTYODRK-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-fluorophenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=C(F)C=CC=C1C1=NCCCN1 XDPJOQZPTYODRK-UHFFFAOYSA-N 0.000 claims description 2
- JYSMBTPEJSZMPQ-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]-4,5-dihydro-1h-imidazole Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1C1=NCCN1 JYSMBTPEJSZMPQ-UHFFFAOYSA-N 0.000 claims description 2
- NYPTVDKJISWLDP-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]-5,5-dimethyl-1,4-dihydroimidazole Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1C1=NCC(C)(C)N1 NYPTVDKJISWLDP-UHFFFAOYSA-N 0.000 claims description 2
- IGCCPAKERWHUNZ-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)sulfanylmethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1SCC1=CC=CC=C1C1=NCCCN1 IGCCPAKERWHUNZ-UHFFFAOYSA-N 0.000 claims description 2
- BQGMRZMJHCNXDE-UHFFFAOYSA-N 2-[2-[[2-methoxy-5-(4-methoxyphenyl)phenyl]methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C1=CC(OC)=CC=C1C1=CC=C(OC)C(CSC=2C(=CC=CC=2)C=2NCCCN=2)=C1 BQGMRZMJHCNXDE-UHFFFAOYSA-N 0.000 claims description 2
- OXYGFGRBQBBYLQ-UHFFFAOYSA-N 2-[2-[[2-methoxy-5-(trifluoromethyl)phenyl]methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(C(F)(F)F)C=C1CSC1=CC=CC=C1C1=NCCCN1 OXYGFGRBQBBYLQ-UHFFFAOYSA-N 0.000 claims description 2
- RVZPOOQPQZLVQC-UHFFFAOYSA-N 2-[2-[[5-(3-chloro-4-fluorophenyl)-2-methoxyphenyl]methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(C=2C=C(Cl)C(F)=CC=2)C=C1CSC1=CC=CC=C1C1=NCCCN1 RVZPOOQPQZLVQC-UHFFFAOYSA-N 0.000 claims description 2
- QGYCEPCCNPOGMR-UHFFFAOYSA-N 2-[3-fluoro-2-(naphthalen-1-ylsulfanylmethyl)phenyl]-5,5-dimethyl-1,4-dihydroimidazole Chemical compound N1C(C)(C)CN=C1C1=CC=CC(F)=C1CSC1=CC=CC2=CC=CC=C12 QGYCEPCCNPOGMR-UHFFFAOYSA-N 0.000 claims description 2
- QZTCPOQRAKEEBS-UHFFFAOYSA-N 2-[5-bromo-2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]-4,5-dihydro-1h-imidazole Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=C(Br)C=C1C1=NCCN1 QZTCPOQRAKEEBS-UHFFFAOYSA-N 0.000 claims description 2
- NPCMACUQHBFXEO-UHFFFAOYSA-N 3-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-fluorophenyl]-5,6,7,7a-tetrahydro-1h-pyrrolo[1,2-c]imidazole Chemical compound COC1=CC=C(Br)C=C1CSC1=C(F)C=CC=C1C1=NCC2N1CCC2 NPCMACUQHBFXEO-UHFFFAOYSA-N 0.000 claims description 2
- 101100441108 Arabidopsis thaliana CRR6 gene Proteins 0.000 claims description 2
- RECRHGNOHLGIHT-UHFFFAOYSA-N [1-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-chlorophenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound COC1=CC=C(Br)C=C1CSC1=C(Cl)C=CC=C1CN1C(CO)CCC1 RECRHGNOHLGIHT-UHFFFAOYSA-N 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- RHZAFXCZRSNAJI-UHFFFAOYSA-N ethyl 4-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-chlorophenyl]methylamino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NCC1=CC=CC(Cl)=C1SCC1=CC(Br)=CC=C1OC RHZAFXCZRSNAJI-UHFFFAOYSA-N 0.000 claims description 2
- 150000002460 imidazoles Chemical class 0.000 claims description 2
- QIJLUZAUEGPNIB-UHFFFAOYSA-N n'-[(5-bromo-2-methoxyphenyl)methyl]-n,n-dimethyl-n'-(naphthalen-1-ylmethyl)propane-1,3-diamine Chemical compound COC1=CC=C(Br)C=C1CN(CCCN(C)C)CC1=CC=CC2=CC=CC=C12 QIJLUZAUEGPNIB-UHFFFAOYSA-N 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 101710085775 Melanocortin receptor 4 Proteins 0.000 claims 93
- QCIYTUBLCHCWKF-UHFFFAOYSA-N 1-[3-[(5-bromo-2-methoxyphenyl)methylsulfanyl]pyrazin-2-yl]pyrrolidin-3-amine Chemical compound COC1=CC=C(Br)C=C1CSC1=NC=CN=C1N1CC(N)CC1 QCIYTUBLCHCWKF-UHFFFAOYSA-N 0.000 claims 2
- DWVZXZWVOVLLNB-UHFFFAOYSA-N 1-[3-[(5-bromo-2-methoxyphenyl)methylsulfanyl]quinoxalin-2-yl]pyrrolidin-3-amine Chemical compound COC1=CC=C(Br)C=C1CSC1=NC2=CC=CC=C2N=C1N1CC(N)CC1 DWVZXZWVOVLLNB-UHFFFAOYSA-N 0.000 claims 2
- NDPLIKQZAAIEAD-UHFFFAOYSA-N 1-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-chlorophenyl]methyl]piperazine Chemical compound COC1=CC=C(Br)C=C1CSC1=C(Cl)C=CC=C1CN1CCNCC1 NDPLIKQZAAIEAD-UHFFFAOYSA-N 0.000 claims 2
- SVPBPRSLWASWKI-UHFFFAOYSA-N 2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-piperazin-1-yl-6,7-dihydroquinoxaline Chemical compound COC1=CC=C(Br)C=C1CSC1=NC2=CCCC=C2N=C1N1CCNCC1 SVPBPRSLWASWKI-UHFFFAOYSA-N 0.000 claims 2
- OOYYKTSPPNPIOS-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-fluorophenyl]-5-methyl-4,5-dihydro-1h-imidazole Chemical compound COC1=CC=C(Br)C=C1CSC1=C(F)C=CC=C1C1=NC(C)CN1 OOYYKTSPPNPIOS-UHFFFAOYSA-N 0.000 claims 2
- LNPRXFXPBRCTGB-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]-5-methyl-4,5-dihydro-1h-imidazole Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1C1=NC(C)CN1 LNPRXFXPBRCTGB-UHFFFAOYSA-N 0.000 claims 2
- CXKQSXANCQVLRO-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)sulfanylmethyl]-3-fluorophenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1SCC1=C(F)C=CC=C1C1=NCCCN1 CXKQSXANCQVLRO-UHFFFAOYSA-N 0.000 claims 2
- FFFXXFREPCGSFR-UHFFFAOYSA-N 2-[2-[1-(5-bromo-2-methoxyphenyl)propan-2-yl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CC(C)C1=CC=CC=C1C1=NCCCN1 FFFXXFREPCGSFR-UHFFFAOYSA-N 0.000 claims 2
- LVWCZTLURLTYFL-UHFFFAOYSA-N 2-[2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CCC1=C(C=2NCCCN=2)C=CC=C1C(F)(F)F LVWCZTLURLTYFL-UHFFFAOYSA-N 0.000 claims 2
- WMSIKZDVBSROMD-UHFFFAOYSA-N 2-[2-[2-(5-bromo-2-methoxyphenyl)ethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CCC1=CC=CC=C1C1=NCCCN1 WMSIKZDVBSROMD-UHFFFAOYSA-N 0.000 claims 2
- CTHANELVHOFIDB-UHFFFAOYSA-N 2-[4-(naphthalen-1-ylsulfanylmethyl)thiophen-3-yl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1SCC1=CSC=C1C1=NCCCN1 CTHANELVHOFIDB-UHFFFAOYSA-N 0.000 claims 2
- IVLLVRGXVQYAEQ-UHFFFAOYSA-N 4-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methyl]morpholine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1CN1CCOCC1 IVLLVRGXVQYAEQ-UHFFFAOYSA-N 0.000 claims 2
- 101100439662 Arabidopsis thaliana CHR5 gene Proteins 0.000 claims 2
- SWVFZCLSKWSBEH-UHFFFAOYSA-N [1-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methyl]piperidin-2-yl]methanol Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1CN1C(CO)CCCC1 SWVFZCLSKWSBEH-UHFFFAOYSA-N 0.000 claims 2
- YXBXWTPGDOGXMJ-UHFFFAOYSA-N (2-hexoxyphenyl)carbamic acid Chemical compound CCCCCCOC1=CC=CC=C1NC(O)=O YXBXWTPGDOGXMJ-UHFFFAOYSA-N 0.000 claims 1
- OJJQCZAOHMHZLQ-UHFFFAOYSA-N 1-[2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]-5,6-dihydro-4h-pyrimidin-1-yl]-3-methylbutan-1-one Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1C1=NCCCN1C(=O)CC(C)C OJJQCZAOHMHZLQ-UHFFFAOYSA-N 0.000 claims 1
- FRFKCMNQNNNZNO-UHFFFAOYSA-N 1-[3-(trifluoromethyl)pyridin-2-yl]piperazine Chemical compound FC(F)(F)C1=CC=CN=C1N1CCNCC1 FRFKCMNQNNNZNO-UHFFFAOYSA-N 0.000 claims 1
- DHGHRXKJJOANFR-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-chlorophenyl]-5-methyl-4,5-dihydro-1h-imidazole Chemical compound COC1=CC=C(Br)C=C1CSC1=C(Cl)C=CC=C1C1=NC(C)CN1 DHGHRXKJJOANFR-UHFFFAOYSA-N 0.000 claims 1
- DIHXBZVYCWIMIW-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)sulfanylmethyl]-3-chlorophenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1SCC1=C(Cl)C=CC=C1C1=NCCCN1 DIHXBZVYCWIMIW-UHFFFAOYSA-N 0.000 claims 1
- NAPYCAWRLDPGFK-UHFFFAOYSA-N 2-[2-[[2-methoxy-5-(2-phenylethynyl)phenyl]methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(C#CC=2C=CC=CC=2)C=C1CSC1=CC=CC=C1C1=NCCCN1 NAPYCAWRLDPGFK-UHFFFAOYSA-N 0.000 claims 1
- IAHONBQOZYLKBE-UHFFFAOYSA-N 2-[4-bromo-2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC(Br)=CC=C1C1=NCCCN1 IAHONBQOZYLKBE-UHFFFAOYSA-N 0.000 claims 1
- YGHRJJRRZDOVPD-UHFFFAOYSA-N 3-methylbutanal Chemical compound CC(C)CC=O YGHRJJRRZDOVPD-UHFFFAOYSA-N 0.000 claims 1
- XWXDYXQSASHOQE-UHFFFAOYSA-N 4-methoxy-3-[[2-(1,4,5,6-tetrahydropyrimidin-2-yl)phenyl]sulfanylmethyl]benzonitrile Chemical compound COC1=CC=C(C#N)C=C1CSC1=CC=CC=C1C1=NCCCN1 XWXDYXQSASHOQE-UHFFFAOYSA-N 0.000 claims 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 1
- YNBADRVTZLEFNH-UHFFFAOYSA-N Methyl nicotinate Natural products COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 claims 1
- JMANUKZDKDKBJP-UHFFFAOYSA-N imidazo[1,5-a]pyridine Chemical compound C1=CC=CC2=CN=CN21 JMANUKZDKDKBJP-UHFFFAOYSA-N 0.000 claims 1
- PUFRITGIUCXJFV-UHFFFAOYSA-N n,n-dimethyl-n'-(2-naphthalen-1-ylethyl)-n'-(naphthalen-1-ylmethyl)ethane-1,2-diamine Chemical compound C1=CC=C2C(CN(CCC=3C4=CC=CC=C4C=CC=3)CCN(C)C)=CC=CC2=C1 PUFRITGIUCXJFV-UHFFFAOYSA-N 0.000 claims 1
- URCDELNWRSKOAA-UHFFFAOYSA-N n-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-chlorophenyl]methyl]-3-(2-methylpiperidin-1-yl)propan-1-amine Chemical compound COC1=CC=C(Br)C=C1CSC1=C(Cl)C=CC=C1CNCCCN1C(C)CCCC1 URCDELNWRSKOAA-UHFFFAOYSA-N 0.000 claims 1
- 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 description 247
- 210000004027 cell Anatomy 0.000 description 39
- 239000000203 mixture Substances 0.000 description 37
- 125000003282 alkyl amino group Chemical group 0.000 description 29
- 229910019142 PO4 Inorganic materials 0.000 description 26
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 26
- 239000010452 phosphate Substances 0.000 description 26
- 125000004442 acylamino group Chemical group 0.000 description 25
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 25
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 25
- 125000001769 aryl amino group Chemical group 0.000 description 25
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 25
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 25
- 125000004986 diarylamino group Chemical group 0.000 description 25
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 24
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 24
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 24
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 24
- 125000004414 alkyl thio group Chemical group 0.000 description 24
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 24
- 125000005110 aryl thio group Chemical group 0.000 description 24
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 description 24
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 24
- 150000007942 carboxylates Chemical class 0.000 description 24
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- 235000019000 fluorine Nutrition 0.000 description 23
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 23
- 239000000243 solution Substances 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- 125000002877 alkyl aryl group Chemical group 0.000 description 19
- 239000012528 membrane Substances 0.000 description 19
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 18
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 125000005842 heteroatom Chemical group 0.000 description 16
- 239000003446 ligand Substances 0.000 description 15
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 12
- 108010008364 Melanocortins Proteins 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- 102000004378 Melanocortin Receptors Human genes 0.000 description 10
- 108090000950 Melanocortin Receptors Proteins 0.000 description 10
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 10
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 10
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 9
- 125000005129 aryl carbonyl group Chemical group 0.000 description 9
- 239000011324 bead Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 150000002430 hydrocarbons Chemical group 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 102000030612 Melanocortin 5 receptor Human genes 0.000 description 8
- 108010088565 Melanocortin 5 receptor Proteins 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 108010021433 Type 3 Melanocortin Receptor Proteins 0.000 description 7
- 102000008318 Type 3 Melanocortin Receptor Human genes 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 125000000392 cycloalkenyl group Chemical group 0.000 description 7
- 239000002865 melanocortin Substances 0.000 description 7
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 101800000414 Corticotropin Proteins 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 5
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 5
- 229960000258 corticotropin Drugs 0.000 description 5
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 102100022455 Adrenocorticotropic hormone receptor Human genes 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 4
- 102400000739 Corticotropin Human genes 0.000 description 4
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 4
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000002723 alicyclic group Chemical group 0.000 description 4
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 4
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000006072 paste Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 235000010487 tragacanth Nutrition 0.000 description 4
- 239000000196 tragacanth Substances 0.000 description 4
- 229940116362 tragacanth Drugs 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 101710201349 Metallothionein B Proteins 0.000 description 3
- 101710094505 Metallothionein-2 Proteins 0.000 description 3
- 102100031347 Metallothionein-2 Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000005089 alkenylaminocarbonyl group Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 3
- 125000005125 aryl alkyl amino carbonyl group Chemical group 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- ZXTWLUSWTSOFIV-UHFFFAOYSA-N methyl 6-piperazin-1-yl-7-(trifluoromethyl)thieno[3,2-b]pyridine-3-carboxylate Chemical compound C=1N=C2C(C(=O)OC)=CSC2=C(C(F)(F)F)C=1N1CCNCC1 ZXTWLUSWTSOFIV-UHFFFAOYSA-N 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 125000004437 phosphorous atom Chemical group 0.000 description 3
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 3
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 150000003536 tetrazoles Chemical class 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 150000003852 triazoles Chemical class 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- WHNFPRLDDSXQCL-UHFFFAOYSA-N α-melanotropin Chemical compound C=1N=CNC=1CC(C(=O)NC(CC=1C=CC=CC=1)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)NC(CCCCN)C(=O)N1C(CCC1)C(=O)NC(C(C)C)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(NC(=O)C(CO)NC(C)=O)CC1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UHFFFAOYSA-N 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- LVGIUOZGDVZIMK-UHFFFAOYSA-N 1-sulfanylpyrrolidine Chemical compound SN1CCCC1 LVGIUOZGDVZIMK-UHFFFAOYSA-N 0.000 description 2
- YQQSRZSUGBETRS-UHFFFAOYSA-N 1h-pyridazine-6-thione Chemical compound SC1=CC=CN=N1 YQQSRZSUGBETRS-UHFFFAOYSA-N 0.000 description 2
- UFGOFMCEZLRIJD-UHFFFAOYSA-N 2-(2-naphthalen-1-ylethyl)benzonitrile Chemical compound N#CC1=CC=CC=C1CCC1=CC=CC2=CC=CC=C12 UFGOFMCEZLRIJD-UHFFFAOYSA-N 0.000 description 2
- QGXNHCXKWFNKCG-UHFFFAOYSA-N 2-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=CC=C1C#N QGXNHCXKWFNKCG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- VXYAUHIPEGXCOZ-UHFFFAOYSA-N 2-[(5-bromo-2-methoxyphenyl)sulfanylmethyl]benzonitrile Chemical compound COC1=CC=C(Br)C=C1SCC1=CC=CC=C1C#N VXYAUHIPEGXCOZ-UHFFFAOYSA-N 0.000 description 2
- ONZWKMMEAIYJPY-UHFFFAOYSA-N 2-[3-fluoro-2-(2-naphthalen-1-ylethyl)phenyl]-5,5-dimethyl-1,4-dihydroimidazole Chemical compound N1C(C)(C)CN=C1C1=CC=CC(F)=C1CCC1=CC=CC2=CC=CC=C12 ONZWKMMEAIYJPY-UHFFFAOYSA-N 0.000 description 2
- PEPBFCOIJRULGJ-UHFFFAOYSA-N 3h-1,2,3-benzodioxazole Chemical compound C1=CC=C2NOOC2=C1 PEPBFCOIJRULGJ-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- NVWMBFHESONALO-UHFFFAOYSA-N 5-bromo-2-methoxybenzenethiol Chemical compound COC1=CC=C(Br)C=C1S NVWMBFHESONALO-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 108010021430 Type 2 Melanocortin Receptor Proteins 0.000 description 2
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 238000013262 cAMP assay Methods 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229960002896 clonidine Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229960005016 naphazoline Drugs 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- RMVRSNDYEFQCLF-UHFFFAOYSA-N phenyl mercaptan Natural products SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 125000004426 substituted alkynyl group Chemical group 0.000 description 2
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000028016 temperature homeostasis Effects 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- NBOMNTLFRHMDEZ-UHFFFAOYSA-N thiosalicylic acid Chemical compound OC(=O)C1=CC=CC=C1S NBOMNTLFRHMDEZ-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960002312 tolazoline Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 108010072897 transcription factor Brn-2 Proteins 0.000 description 2
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- MCLUOLOIDQVZBQ-UHFFFAOYSA-N 1,4,5,6-tetrahydropyrimidine;hydrochloride Chemical compound Cl.C1CNC=NC1 MCLUOLOIDQVZBQ-UHFFFAOYSA-N 0.000 description 1
- XMWGTKZEDLCVIG-UHFFFAOYSA-N 1-(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1 XMWGTKZEDLCVIG-UHFFFAOYSA-N 0.000 description 1
- MJGOLNNLNQQIHR-UHFFFAOYSA-N 1-chloro-2-(chloromethyl)-3-fluorobenzene Chemical compound FC1=CC=CC(Cl)=C1CCl MJGOLNNLNQQIHR-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical class CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- 101150072531 10 gene Proteins 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- DUHDUYRXLGSMLQ-UHFFFAOYSA-N 2-(1,4,5,6-tetrahydropyrimidin-2-yl)benzenethiol Chemical compound SC1=CC=CC=C1C1=NCCCN1 DUHDUYRXLGSMLQ-UHFFFAOYSA-N 0.000 description 1
- YDPWBCYJZWQKDD-UHFFFAOYSA-N 2-(4,5-dihydro-1H-imidazol-2-yl)benzenethiol Chemical compound SC1=CC=CC=C1C1=NCCN1 YDPWBCYJZWQKDD-UHFFFAOYSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- 125000006304 2-iodophenyl group Chemical group [H]C1=C([H])C(I)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- VLRGXXKFHVJQOL-UHFFFAOYSA-N 3-chloropentane-2,4-dione Chemical compound CC(=O)C(Cl)C(C)=O VLRGXXKFHVJQOL-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000006305 3-iodophenyl group Chemical group [H]C1=C([H])C(I)=C([H])C(*)=C1[H] 0.000 description 1
- YWKSINPSASCIMZ-UHFFFAOYSA-N 4,5-dimethyl-4,5-dihydro-1h-imidazole Chemical compound CC1NC=NC1C YWKSINPSASCIMZ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 101710115814 Adrenocorticotropic hormone receptor Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010074311 Corticotropin Receptors Proteins 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101100129530 Homo sapiens MC4R gene Proteins 0.000 description 1
- 101000978418 Homo sapiens Melanocortin receptor 4 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000037490 Medically Unexplained Symptoms Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 101150048609 RR21 gene Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 description 1
- 102000008314 Type 1 Melanocortin Receptor Human genes 0.000 description 1
- 241000282458 Ursus sp. Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- RWRGOKPWZKWGMF-UHFFFAOYSA-N [2-(naphthalen-1-ylmethylsulfanyl)phenyl]carbamic acid Chemical compound OC(=O)NC1=CC=CC=C1SCC1=CC=CC2=CC=CC=C12 RWRGOKPWZKWGMF-UHFFFAOYSA-N 0.000 description 1
- IVUCMIHEFQUCKJ-UHFFFAOYSA-N [2-[(2-methylnaphthalen-1-yl)methylsulfanyl]phenyl]carbamic acid Chemical compound CC1=CC=C2C=CC=CC2=C1CSC1=CC=CC=C1NC(O)=O IVUCMIHEFQUCKJ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000005087 alkynylcarbonyl group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000005122 aminoalkylamino group Chemical group 0.000 description 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000005018 aryl alkenyl group Chemical group 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000005128 aryl amino alkyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000004799 bromophenyl group Chemical group 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000007585 cortical function Effects 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004802 cyanophenyl group Chemical group 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- JHAYEQICABJSTP-UHFFFAOYSA-N decoquinate Chemical group N1C=C(C(=O)OCC)C(=O)C2=C1C=C(OCC)C(OCCCCCCCCCC)=C2 JHAYEQICABJSTP-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006539 extracellular acidification Effects 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 125000006303 iodophenyl group Chemical group 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000011234 negative regulation of signal transduction Effects 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005071 nonynyl group Chemical group C(#CCCCCCCC)* 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 125000005004 perfluoroethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- DTUQWGWMVIHBKE-UHFFFAOYSA-N phenylacetaldehyde Chemical compound O=CCC1=CC=CC=C1 DTUQWGWMVIHBKE-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000000394 phosphonato group Chemical group [O-]P([O-])(*)=O 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000004673 propylcarbonyl group Chemical group 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- LTXJLQINBYSQFU-UHFFFAOYSA-N pyrimidin-5-ol Chemical compound OC1=CN=CN=C1 LTXJLQINBYSQFU-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000001300 stimulation of adenylate cyclase Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000005300 thiocarboxy group Chemical group C(=S)(O)* 0.000 description 1
- 229940103494 thiosalicylic acid Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
WO 01/10842 PCT/USOO/21327 -1 MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF 5 Background Melanocortins are known to have a broad array of physiological actions (Nakanishi, et al. Nature (1979) 278:423-427). Aside from their well known effects on adrenal cortical functions and on melanocytes, melanocortins have been shown to affect behavior, learning, memory, control of the cardiovascular system, analgesia, 10 thermoregulation, and the release of other neurohumoral agents including prolactin, luetinizing hormone, and biogenic amines (De Weid et al. Methods Achiev. Exp. Pathol. (1991) 15:167-199; De Weid et al. Physiol. Rev. (1982) 62:977-1059; Gruber, K.A. et al. Am. J. Physiol. (1989) 257:R681-R694; Murphy et al. Science (1980) 210:1247 1249; Murphy et al. Science (1983) 221:192-193; Ellerkmann, E. et al. Endocrinol. 15 (1992) 130:133-138; Versteeg, D.H.G. et al. Life Sci. (1986) 835-840). Peripherally, melanocortins have been identified to have immunomodulatory and neurotrophic properties, and to be involved in events surrounding partition (Cannon, J.G. et al. J. Immunol. (1986) 137:2232-2236; Gispen, W.H. Trends Pharm. Sci. (1992) 11:221-222; Wilson, J.F. Clin. Endocrinol. (1982) 17:233-242; Clark, D. et al. Nature (1978) 20 273:163-164; Silman, R.E. et al. Nature (1976) 260:716-718). Furthermore, melanocortins are present in a myriad of normal human tissues including the brain, ovary, lung, thyroid, liver, colon, small intestine and pancreas (Tatro, J.B. et al. Endocrinol. (1987) 121:1900-1907; Mountjoy, K.G. et al. Science (1992) 257:1248 1251; Chhajlani, V. et al., FEBSLett. (1992) 309:417-420; Gantz, L. et al., J Biol. 25 Chem. (1993) 268:8246-8250; Gantz, L. et al, J Biol. Chem. (1993) 268:15174-15179). Recent studies have described an unexpected diversity of subtypes of receptors for the melanocortin peptides and determined that they belong to the superfamily of seven transmembrane G-protein linked cell surface receptors (Mountjoy, K.G. et al., Science(1992), supra; Chhajlani, V. et al., FEBS Lett. (1992), supra). Five melanocortin 30 receptor subtypes have been cloned. The melanocortin-l (MC1) receptor is found in melanoma cells, where it has a role in mediating pigmentation. The melanocortin-2 receptor (MC2-R or ACTH receptor) is found in the adrenal glands where it mediates WO 01/10842 PCT/USOO/21327 -2 the effects of ACTH (adrenocorticotrophic hormone). The melanocortin-3 receptor (MC3-R) is primarily found in the central nervous system (CNS) (Gantz, L. et al., J. Biol. Chem. (1993) 268:8246-8250), but its physiological function is still unknown. The melanocortin-4 receptor (MC4-R) has been found in the brain, where it is widely 5 distributed in several areas, including the cortex, thalamus, hypothalamus, brain stem, and spinal cord (Gantz, L. et al. J. Biol. Chem. (1993) 268:15174-15179; Mountjoy, K.G. et al. Mol. Endocrinol. (1994) 8:1298-1308). MC4-R has recently been related to weight homeostasis. MC4-R "knock out" mice have been shown to develop obesity (Huszar et al. Cell (1997) 88:131-141). The feeding behavior leading to the obesity can 10 be inhibited by injection of MSH peptides (Vergoni et al. Neuropeptides (1986) 7:153 158; Vergoni et al. Eur. J. Pharmacol. (1990) 179:347-355; Fan et al. Nature (1997) 385:165-168). The melanocortin-5 receptor (MC5-R) has a wide peripheral distribution and is believed to participate in the regulation of the exocrine gland function (Chen et al. Cell (1997) 91:789-798). 15 Summary In one aspect, the invention pertains to a method for treating a melanocortin-4 receptor (MC4-R) associated state in a mammal. The method involves administering an effective amount of a MC4-R binding compound to a mammal, such that the MC4-R 20 associated state is treated. The MC4-R binding compound is of the formula (I): B-Z-E (I) wherein B is an anchor moiety, Z is a central moiety, E is a MC4-R interacting 25 moiety, and pharmaceutically acceptable salts, thereof. In a further embodiment, the MC4-R binding compound is of the formula (II): B-A-E (II) 30 wherein B is an anchor moiety, A is cyclic moiety, E is a MC4-R interacting moiety, and pharmaceutically acceptable salts, thereof.
WO 01/10842 PCT/USOO/21327 -3 In another embodiment, the invention pertains to another method for treating an MC4-R associated state in a mammal, by administering to a mammal an effective amount of a MC4-R binding compound of formula (III): 5 B-LI-A-L 2 -E (III) wherein B is an anchor moiety, L I and L 2 are linking moieties, A is a cyclic moiety, E is a MC4-R interacting moiety, and pharmaceutically acceptable salts thereof. The invention also pertains to treating MC4-R associated states with an MC4-R 10 binding compound of formula III, wherein B is substituted or unsubstituted biaryl, unsubstituted or substituted heterocyclic, or unsubstituted or substituted phenyl, wherein one or more of said substituents are halogens, alkyl, alkynyl, alkoxy, aryl, amino, cyano, or nitro; L, is a covalent bond, Ci-Cio branched or unbranched alkyl, wherein one or two of the carbons are optionally replaced with oxygen, sulfur or nitrogen atoms; L 2 is a 15 covalent bond, substituted or unsubstituted amino, ether, thioether, or alkyl; E is substituted or unsubstituted alkyl, amino, amidino, guanidino, heterocyclic, or aryl, wherein said substituents are amino, arylalkyl, aminoalkyl, alkyl, aryl, alkenyl, or alkynyl; and A is a substituted or unsubstituted phenyl, heteroaryl, cycloalkyl, or biaryl, and pharmaceutically acceptable salts thereof 20 In another embodiment, the invention pertains to a method for treating an MC4 R associated state in a mammal by administering an effective amount of a MC4-R binding compound to a mammal, such that the MC4-R associated state is treated. In this embodiment, the compound is of the formula (IV): N r s B-Lr-A-L2 N R (IV) 25 wherein B is substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl, or heteroaryl; A is aryl, heteroaryl, biaryl, cycloalkyl, heterocyclic, or cycloalkenyl; LI and L 2 are selected from the group consisting of a covalent bond, C,-C 6 branched or unbranched alkyl, wherein one or two of the carbons are optionally replaced with oxygen, sulfur or nitrogen atoms; r is a covalent bond, CH, CH 2 , CR', CR'R 2 , or H; t is WO 01/10842 PCT/USOO/21327 -4 CH, CH 2 , CR 3 , CR 3
R
4 , or H; s is CHR 5 , CR 5 , CR 5
R
6 or absent (e.g., leaving a non cyclic diamine); R is H, substituted or unsubstituted alkyl, arylalkyl, or heteroalkyl, and may optionally be linked to A, B, L 1 , or L 2 ; R', R2, R , R 4 , R', and R6 are each substituted or unsubstituted alkyl, alkenyl, halogen, thiol, or alkoxy, and may optionally 5 be linked to form a carbocyclic or heterocyclic ring. Pharmaceutically acceptable salts of the MC4-R binding compound are also included. The invention also pertains to methods for treating an MC4-R associated state in a mammal by administering an effective amount of a MC4-R binding compound of the formula (V): 10 A L3 ( i B- L 1 rI L 2 -E (V) wherein B is substituted or unsubstituted biaryl, unsubstituted or substituted heterocyclic, or unsubstituted or substituted phenyl, wherein one or more of said substituents are halogens, alkyl, alkynyl, alkoxy, aryl, amino, cyano, or nitro; LI is a 15 covalent bond, C 1 -Cjo branched or unbranched alkyl, wherein one or two of the carbons are optionally replaced with oxygen, sulfur or nitrogen atoms; L 2 is a covalent bond, substituted or unsubstituted amino, ether, thioether, or alkyl; E is substituted or unsubstituted alkyl, amino, amidino, guanidino, heterocyclic, or aryl, wherein said substituents are amino, arylalkyl, aminoalkyl, alkyl, aryl, alkenyl, or alkynyl; [ is a 20 covalent bond, a carbon atom, a nitrogen atom, heterocyclic, alkyl, cycloalkyl, or aryl;
L
3 is a covalent bond, C I-C 6 branched, unbranched or cyclic alkyl, wherein one, two or three of the carbons are optionally replaced with oxygen, sulfur or nitrogen atoms, carbonyl, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, or aminothiocarbonyl; and A is heterocyclic, aryl, alkoxy, amino, alkyl, alkenyl, alkynyl, 25 or hydrogen; and ) is 0, 1 or 2, and pharmaceutically acceptable salts thereof. In yet another embodiment, the invention also pertains to a method for treating an MC4-R associated state in a mammal by administering an effective amount of a MC4-R binding compound to a mammal, wherein the compound is an MC4-R antagonist, and is of the formula (VI): WO 01/10842 PCT/USOO/21327 -5 PI L2
P
4 L1 z 5 z1-z (VI) wherein P', P 2 , p 3 , p 4 , and P 5 are optionally substituted carbon, sulfur, or nitrogen, and 5 wherein one of P1, P 2 , p 3 , p 4 and P 5 may represent a covalent bond; Z1, Z 2 , Z 3 , Z 4 , and Z 5 are optionally substituted carbon or nitrogen; LI is a covalent bond, CI-C 10 branched or unbranched alkyl, wherein one or two of the carbons are optionally replaced with oxygen, sulfur or nitrogen atoms; L 2 is a covalent bond, substituted or unsubstituted amino, ether, thioether, or alkyl; and J is an unsubstituted or substituted nitrogen 10 containing heterocycle or a substituted or unsubstituted amino group, and pharmaceutically acceptable salts thereof. In another embodiment, the MC4-R binding compound is of formula (VII): p 2 -- p' 5 P2ps P Z5 z" 'zz (VII) wherein 15 z', Z 2 , Z 3 , Z 4 , and Z 5 are CH, N, or substituted carbon; and P1, P 2 p 3 . p 4 ., and P 5 are CH, N or substituted carbon. In another embodiment, the MC4-R binding compound is of formula (VIII): P2ps P1 p2- ' p 5 z. z1 z (VIII) wherein WO 01/10842 PCT/USOO/21327 -6 Z1, Z 2 , Z 3 , Z 4 , and Zs are CH, N, or substituted carbon; and pI, p2, p3, p 4 , and P 5 are CH, N or substituted carbon. The invention also pertains to MC4-R binding compound of the formula (IX): N s I I
P
2 N P 4 Gi z2-"' (IX) 5 wherein: p2 is CH, CF, CCl, CBr, C-alkyl, C-alkoxy, C-CN, C-OH, or CI;
P
3 is CH, CF, CCl, CBr, C-alkyl, C-alkoxy, C-CN, C-OH, or CI;
P
4 is CH, CCl, CBr, CF, C-alkyl, C-alkoxy, C-CN, C-OH, or CI;
G
1 and G 2 are each independently CH 2 , S, or 0; 10 r is a covalent bond or CH 2 ; t is CH 2 , CR 3 , or CR 3
R
4 ; s is CH 2 , CHRs or CRR6; R is hydrogen or alkyl; Z' is CH, or covalently linked to Z2 to form a naphthyl ring; 15 Z 2 is CH, C-(C=CH), CCl, CBr, CI, CF, or covalently linked to Z' to form a naphthyl ring;
Z
5 is CH, or C-OMe;
R
3 , R 4 , R', and R 6 are methyl, ethyl, hydroxyl, alkoxy, halogen, cyano, nitro, or amino, or pharmaceutically acceptable salts thereof. 20 The invention also features a pharmaceutical composition for the treatment of a MC4-R associated state in a mammal. The pharmaceutical compositions contain a pharmaceutically acceptable carrier and a MC4-R binding compound. The compounds are described herein in the context of the description of the method but it should be understood that the invention further pertains to pharmaceutical compositions containing 25 the compounds and the compounds per se. For example, pharmaceutical compositions of WO 01/10842 PCT/USOO/21327 -7the invention include a pharmaceutically acceptable carrier and an effective amount of at least one MC4-R binding compound of the formula (I): B-Z-E (I) 5 wherein B is an anchor moiety, Z is an central moiety, E is a MC4-R interacting moiety, and pharmaceutically acceptable salts thereof. Brief Description of the Drawings 10 Figures 1 a and lb are bar graphs showing the effects of MT II (a MC4-R agonist) on food intake in lean mice. Figure 2 is a graph depicting the effects of treating lean mice with Compound N and MT II on food intake over a six hour period. 15 Figure 3 is a graph depicting the effects of treating lean mice with Compound 0 and MT II on food intake over a six hour period. Detailed Description of the Invention 20 In one aspect, the invention pertains to a method for treating a melanocortin-4 receptor (MC4-R) associated state in a mammal. The method involves administering ar effective amount of a MC4-R binding compound to a mammal, such that the MC4-R associated state is treated. The MC4-R binding compound is of the formula (I): 25 B-Z-E (I) wherein B is an anchor moiety, Z is a central moiety, E is a MC4-R interacting moiety, and pharmaceutically acceptable salts thereof. The term "MC4-R" includes receptors for a-melanocyte stimulating hormone. 30 The MC4-R is usually found in the brain where it is widely distributed (Mountjoy et al. Mol. Endocrinol. (1994) 8:1298-1308). Melanocortins are peptide hormones that play an important role in regulating melanocyte pigmentation as well as memory and WO 01/10842 PCT/USOO/21327 -8 thermoregulation. They consist of various peptides, such as a-melanocyte stimulating hormone, that are cleaved from the polypeptide precursor prooptiomelanocortin (POMC). The effects of melanocortins are mediated via stimulation of adenylate cyclase via the activation of the melanocortin receptors. 5 The melancortin-4 receptor (MC4-R) is a G-protein coupled receptor (GPCR) expressed in brain tissue. The specific role of the MC4-R protein in vivo was investigated by engineering MC4-R "knock out" mice. The mice were unable to produce functional MC4-R protein, because the endogenous MC4-R gene coding sequence was deleted. 10 The knock-out mice were produced by using human MC4-r gene sequences to isolate and clone the murine MC4-r gene. A murine MC4-r targeting construct was then generated which was designed to delete the majority of the murine MC4-r coding sequence upon homologous recombination with the endogenous murine MC4-r gene. Embryonic stem (ES) cells containing the disrupted MC4-r gene were produced, isolated 15 and microinjected into murine blastocysts to yield mice chimeric for cells containing a disrupted MC4-r gene. Offspring of the chimeric mice resulting from germline transmission of the ES genome were obtained and animals heterozygous for the disrupted MC4-R were identified. To assess the role of MC4-R in vivo, the animals heterozygous for the MC4-r 20 disrupted gene were bred together, producing litters containing wild-type mice, mice heterozygous for the MC4-r mutation and mice homozygous for the MC4-R mutation. The weight gain of the animals was monitored regularly. Homozygous null MC4-R mutants showed an increase in weight compared to mice heterozygous for MC4-R deletion and wild type mice as early as 25 days of age. By 54-58 days of age, MC4-R 25 deficient mice exhibited, on average, a 55-70% greater weight relative to wild type mice, and an approximately 50% greater weight compared to mice heterozygous for the MC4-R deletion. The language "MC4-R associated states" includes those states, disorders, or diseases characterized by aberrant or undesirable activity or expression of MC4-Rs. It 30 also includes those states, disorders and diseases associated with MC4-R ligands (e.g., ax-melanocyte stimulating hormone). The language also includes prevention of states, disorders and diseases characterized by aberrant or undesirable activity of MC4-Rs or its WO 01/10842 PCT/USOO/21327 -9 ligands. Examples of MC4-R associated states include, but are not limited to, disorders involving pigmentation, weight homeostasis, e.g., weight loss or obesity. This can include the unhealthy decrease in body weight that can occur during an acute inflammatory response or that occurs in a cancer patient as a result of cachexia, 5 radiotherapy or chemotherapy, or to the undesirable decrease in body mass due to simulated or actual weightlessness, such as occurs during space travel. Other examples of unhealthy decreases occur in some patients during advance stages of illnesses such as AIDS. Physiologically, this may be a result from any one of a number of complex factors, such as loss of appetite and possibly abnormal catabolism. 10 This cachexia, may be slowed by MC4-R binding compounds. In a preferred embodiment of the invention, the weight loss is a result of old age, anorexia nervosa, or cachexia (e.g., cachexia associated with cancer or HIV). In one further embodiment, the MC4-R associated state is not weight loss. The term "mammal" includes organisms which express the MC4-R. Examples 15 of mammals include mice, rats, cows, sheep, pigs, goats, horses, bears, monkeys, dogs, cats and, preferably, humans. Transgenic organisms which express the MC4-R are also included in this definition. The language "MC4-R binding compound" includes those compounds which interact with the MC4-R resulting in modulation of the activity of the MC4-R. In an 20 embodiment, the MC4-R binding compounds are antagonists of the MC4-R. The term "antagonist" includes compounds which interact with the MC4-R and modulate, e.g., inhibit or decrease, the ability of a second compound, e.g., a-melanocyte stimulating hormone or another MC4-R ligand, to interact with the MC4-R. In another embodiment, the MC4-R binding compounds is an agonist of the MC4-R. The term 25 "agonists" includes compounds which interact with the MCR-4 and modulate, e.g., increase or stimulate, its activity and/or its ability to interact with a second compounds, e.g., a-melanocyte stimulaturing hormone. MC4-R binding compounds can be identified through both in vitro (e.g., cell and non-cell based) and in vivo methods. These methods are described in detail in Examples 30 2, 3, 4, and 5. The Scincillation Proximity Assay (SPA) is a non-cell based in vitro assay, described in Example 2. It can be used to identify compounds that interact with, e.g., WO 01/10842 PCT/USOO/21327 -10 bind to MC4-R. Such compounds may act as antagonists or agonists of MC4-R activity and may be used in the treatment of body weight disorders. One example of a qualitative measure of binding affinity of a MC4-R binding compound to MC4-R is its
IC
50 . Preferably, the MC4-R binding compound binds to the MC4-R with a binding 5 affinity, for example, of about 50pM or less, 20 pM or less, 10 pM or less, 5 pM or less, 2.5 pM or less, or 1 pM or less. In an advantageous embodiment, the IC 50 of a MC4-R binding compounds is about 0.5 pM or less,, about 0.3 pM or less, about 0.1 pM or less, about 0.08 pM or less, about 0.06 pM or less, about 0.05 pM or less, about 0.04 pM or less, or, preferably, about 0.03 pM or less. 10 In the SPA, isolated membranes are used to identify compounds that interact with MC4-R. For example, in a typical experiment using isolated membranes, 293 cells may be genetically engineered to express the MC4-R. Membranes are be harvested by standard techniques and used in an in vitro binding assay. I 25 1-labeled ligand (e.g., 125 labeled a-MSH, p-MSH, or ACTH) is bound to the membranes and assayed for specific 15 activity; specific binding is determined by comparison with binding assays performed in the presence of excess unlabelled ligand. To identify MC4-R binding compounds, membranes are incubated with labeled ligand in the presence or absence of test compound. Compounds that bind to the receptor and compete with labeled ligand for binding to the membranes-reduced the 20 signal compared to the vehicle control samples. Preferably, the screens are designed to identify compounds that antagonize the interaction between MC4-R and MC4-R ligands such as a-MSH, p-MSH and ACTH. In such screens, the MC4-R ligands are labeled and test compounds can be assayed for their ability to antagonize the binding of labeled ligand to MC4-R. 25 Cell based assay systems can also be used to identify MC4-R binding compounds. An example of a cell based assay system is the cAMP assay described in detail in Example 3. Cell based methods may use cells that endogenously express MC4 R for screening compounds which bind to MC4-R. Alternatively, cell lines, such as 293 cells, COS cells, CHO cells, fibroblasts, and the like, genetically engineered to express 30 the MC4-R can also be used for screening purposes. Preferably, host cells genetically engineered to express a functional receptor that responds to activation by melanocortin peptides can be used as an endpoint in the assay; e.g., as measured by a chemical, WO 01/10842 PCT/USOO/21327 -11 physiological, biological, or phenotypic change, induction of a host cell gene or a reporter gene, change in cAMP levels, adenylyl cyclase activity, host cell G protein activity, extracellular acidification rate, host cell kinase activity, proliferation, differentiation, etc. 5 To be useful in screening assays, the host cells expressing functional MC4-R should give a significant response to MC4-R ligand, preferably greater than 5-fold induction over background. Host cells should preferably possess a number of characteristics, depending on the readout, to maximize the inductive response by melanocortin peptides, for example, for detecting a strong induction of a CRE reporter 10 gene: (a) a low natural level of cAMP, (b) G proteins capable of interacting with the MC4-R, (c) a high level of adenylyl cyclase, (d) a high level of protein kinase A, (e) a low level of phosphodiesterases, and (f) a high level of cAMP response element binding protein would be advantageous. To increase response to melanocortin peptide, host cells could be engineered to express a greater amount of favorable factors or a lesser 15 amount of unfavorable factors. In addition, alternative pathways for induction of the CRE reporter could be eliminated to reduce basal levels. In using such cell systems, the cells expressing the melanocortin receptor are exposed to a test compound or to vehicle controls (e.g., placebos). After exposure, the cells can be assayed to measure the expression and/or activity of components of the 20 signal transduction pathway of the melanocortin receptor, or the activity of the signal transduction pathway itself can be assayed. For example, after exposure, cell lysates can be assayed for induction of cAMP. The ability of a test compound to increase levels of cAMP, above those levels seen with cells treated with a vehicle control, indicates that the test compound induces signal transduction mediated by the melanocortin receptor 25 expressed by the host cell. In screening for compounds that may act as antagonists of MC4-R, it is necessary to include ligands that activate the MC4-R, e.g., a-MSH, p-MSH or ACTH, to test for inhibition of signal transduction by the test compound as compared to vehicle controls. When it is desired to discriminate between the melanocortin receptors and to 30 identify compounds that selectively agonize or antagonize the MC4-R, the assays described above may be conducted using a panel of host cells, each genetically engineered to express one of the melanocortin receptors (MCl-R through MC5-R).
WO 01/10842 PCT/USOO/21327 -12 Expression of the human melanocortin receptors is preferred for drug discovery purposes. To this end, host cells can be genetically engineered to express any of the amino acid sequences shown for melanocortin receptors 1 through 5. The cloning and characterization of each receptor has been described: MCI-R and MC2-R (Mountjoy., 5 1992, Science 257: 1248-125 1; Chhajlani & Wikberg, 1992 FEBS Lett. 309: 417-420); MC3-R (Roselli-Rehfuss et al., 1993, Proc. Natl. Acad. Sci., USA 90: 8856-8860; Gantz et al., 1993, J. Biol. Chem. 268: 8246-8250); MC4-R (Gantz et al., 1993, J. Biol. Chem. 268: 15174-15179; Mountjoy et al., 1994, Mol. Endo. 8: 1298-1308); and MC5-R (Chhajlani et al., 1993, Biochem. Biophys. Res. Commun. 195: 866-873; Gantz et al., 10 1994, Biochem. Biophys. Res. Commun. 200; 1234-1220), each of which is incorporated by reference herein in its entirety. Thus, each of the foregoing sequences can be utilized to engineer a cell or cell line that expresses one of the melanocortin receptors for use in screening assays described herein. To identify compounds that specifically or selectively regulate MC4-R activity, the activation, or inhibition of MC4 15 R activation is compared to the effect of the test compound on the other melanocortin receptors. In certain embodiments, it may be advantageous to select compounds of the invention selective for MC4-R, or, alternatively, it may be useful to select compounds which interact with other receptors as well. In one further embodiment, the MC4-R binding compounds of the invention are 20 more selective for the MC4-R than at least one other MC receptors, for example, more than twice as selective, at least ten times as selective, at least twenty times as selective, at least fifty times as selective, or at least one hundred times as selective. In one further embodiment, the MC4-R binding compounds of the invention are more selective for the MC4-R than the MCl-R, for example, more than twice as 25 selective, at least ten times as selective, at least twenty times as selective, at least fifty times as selective, or at least one hundred times as selective. In one further embodiment, the MC4-R binding compounds of the invention are more selective for the MC4-R than the MC3-R, for example, more than twice as selective, at least ten times as selective, at least twenty times as selective, at least fifty 30 times as selective, or at least one hundred times as selective. In one further embodiment, the MC4-R binding compounds of the invention are more selective for the MC4-R than the MC5-R, for example, more than twice as WO 01/10842 PCT/USOO/21327 -13 selective, at least ten times as selective, at least twenty times as selective, at least fifty times as selective, or at least one hundred times as selective. In yet another further embodiment, the MC4-R binding compounds of the invention are more selective for the MC4-R receptor than at least one, two or three other 5 MC receptors (such as, for example, MC1-R, MC3-R, or MC5-R). In a further embodiment, the MC4-R binding compounds are more selective for the MC4-R than MCl-R, MC3-R, and MC5-R. In a further embodiment, the MC4-R binding compounds as at least ten times as selective, at least twenty times as selective, at least fifty times as selective, or at least one hundred times as selective for the MC4-R than the MCI-R, 10 MC3-R and the MC5-R. As stated above, in an embodiment, the MC4-R binding compound includes compounds of the formula (I): B-Z-E (I) wherein B is an anchor moiety, Z is a central moiety, E is a MC4-R interacting 15 moiety, and pharmaceutically acceptable salts thereof. The language "anchor moiety" ("B") includes moieties which interact with the MC4-R, which may, advantageously, result in the binding of the MC4-R binding compound to the MC4-R. Examples of anchor moieties include substituted or unsubstituted alkyl (e.g., branched, straight chain, or cyclic (e.g., cyclohexane, 20 cyclopentane)), alkenyl, alkynyl, aryl (e.g., substituted or unsubstituted phenyl, naphthyl, biphenyl, anthracenyl, fluorenyl, etc.), heterocyclic (e.g., thienyl, morpholinyl, piprazinyl, piperidinyl, etc.), and multicyclic (e.g., indolyl, benzothioenyl, etc.) moieties. Other examples of anchor moieties include carbonyl moieties, thiol groups, cyano groups, amino groups, and hydrogen atoms. 25 In a further embodiment, the anchor moiety ("B") includes substituted or unsubstituted carbocyclic aryl moieties, e.g., phenyl, naphthyl, etc. Examples of substituents include halogens (e.g., fluorine, chlorine, iodine, bromine, etc.), alkoxy (e.g., methoxy, ethoxy, isopropoxy, n-propyloxy, n-butyloxy, pentoxy, cyclopentoxy, arylalkyloxy, etc.) hydroxy, alkylcarbonyl, cyano, nitro, thiol, alkenyl, alkynyl (e.g., 30 ethynyl, etc.), alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, amino (including alkyl amino, dialkylamino, WO 01/10842 PCT/USOO/21327 -14 arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, trifluoromethyl, azido, heterocyclyl, alkylaryl, heteroaryl, alkyl (e.g., unsubstituted (e.g., methyl, ethyl, 5 propyl, butyl, hexyl, etc.) or substituted, e.g., halogen substituted, e.g., trifluoromethyl, trichloromethyl), aryl (e.g., substituted and unsubstituted phenyl, heteroaryl (e.g., thienyl, pyridinyl, etc.), arylalkyl, arylalkenyl, arylalkynyl, or combinations thereof. In yet another further embodiment, the anchor moiety substituent can be substituted itself with one or more halogen, nitro, alkyl, alkenyl, alkynyl, aryl or alkoxy groups, or 10 combinations thereof. In certain embodiments, the aryl moiety is fused to another ring which can be substituted or unsubstituted, carbocyclic or heterocyclic, aromatic or non aromatic. In a further embodiment, the anchor moiety is substituted with at least one halogen, alkoxy group, or alkyl (e.g., substituted or unsubstituted) group. Examples of 15 halogen substituted phenyl anchor moieties include o-iodophenyl, m-iodophenyl, o bromophenyl, m-bromophenyl, o-chlorophenyl, m-chlorophenyl, o-fluorophenyl, m fluorophenyl, p-fluorophenyl, m-nitrophenyl, or o-methoxy. The anchor moiety may also comprise more than one substituent, e.g. two halogens, e.g., two fluorines, a fluorine and a chlorine. Other examples of anchor moieties include 2-methoxy-5 20 bromophenyl, 2-methoxy-5-fluorophenyl, 2-methoxy-5-iodophenyl, 2-methoxy-5 fluorophenyl, 2-ethoxy-5-bromophenyl, 2-methoxy-6-bromophenyl, 3-methoxy-6 bromophenyl, 2-isopropyl-5-bromophenyl, 2-n-propyl-5-bromophenyl, and 2 cyclopentyloxy-5-bromophenyl. Other examples of anchor moieties include, but are not limited to, 2-methoxy-5 25 cyanophenyl, 2-chloro-5-chlorophenyl, 2-methoxy-6-methoxyphenyl, 2-methoxy-5 nitrophenyl, 2-methoxy-5-phenyl phenyl, 2-methoxy-5-3'-thiofuranyl phenyl, 2 methoxy-5-methylcarbonyl phenyl, 3,5-dimethyloxy phenyl, 2-methoxyphenyl, 2,5 dimethoxy phenyl, 2-fluoro-6-chlorophenyl, and 3-chloro-4-fluorophenyl. In another further embodiment, the anchor moiety includes substituted and 30 unsubstituted heterocycles. Examples of such heterocycles include, but are not limited to, furanyl, imidazolyl, benzothiophenyl, benzofuranyl, quinolinyl, isoquinolinyl, benzodiozanyl, benzoxazolyl, benzothiazolyl, methylenedioxyphenyl, WO 01/10842 PCT/USOO/21327 -15 ethylenedioxyphenyl, indolyl, thienyl, pyrimidyl, pyrazinyl, purinyl, deazapurinyl, morpholine, piprazine, piperidine, thiomorpholine, and thioazolidine. Examples of substituents include alkyl (e.g., substituted or unsubstituted, branched straight chain or cyclic, e.g., methyl, ethyl, propyl, butyl, pentyl, etc.), alkenyl, alkynyl, halogens (e.g., 5 fluorine, chlorine, bromine, iodine, etc.), hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, 10 arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, azido, heterocyclyl, alkylaryl, aryl and heteroaryl groups. In another further embodiment, the anchor moiety ("B") is a substituted or unsubstituted fused aryl or biaryl moiety. Biaryl moieties include moieties with two or 15 more aromatic rings, which may be fused or connected through one or more covalent bonds. Examples include biphenyl, fluorene, anthracenyl, benzoquinazolinyl, and naphthyl. Examples of substituents of biaryl moieties include alkyl (e.g., substituted and unsubstituted, branched or straight chain, methyl, ethyl, propyl, butyl, pentyl, etc.), alkoxy (e.g., methoxy, ethoxy, propoxy, butoxy, pentoxy, cyclopentoxy, etc.), alkenyl, 20 alkynyl, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, 25 sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, an aromatic heteroaromatic moiety, halogens (e.g., fluorine,. chlorine, bromine, iodine, etc.), combinations thereof and other groups which allow the MC4-R binding compound to perform its intended function. Biaryl moieties also include moieties which comprise one 30 or more heterocycles, such as, benzothiofuranyl, benzothienyl, quinolinyl, benzothiophenyl, benzofuranyl, isoquinolinyl, benzodiozanyl, benzoxazolyl, benzothiazolyl, methylenedioxyphenyl, ethylenedioxyphenyl, and indolyl. Examples of WO 01/10842 PCT/USOO/21327 -16 biaryl anchor moieties include naphthyl, 2-methoxynaphthyl, 2-methoxy-5-phenyl phenyl, 2-ethoxynaphthyl, 2-methoxy-5-thiofuranyl phenyl, 2-methyl naphthyl, 2-n propyl naphthyl, benxothiofuranyl, 2-phenyl phenyl, 2-methoxy-5-4'methoxy-phenyl phenyl; 2-methoxy-5-(3'-fluoro-4'-phenyl) phenyl phenyl; 2-cyclopentoxynaphthyl; 5 quinolinyl; and 2-methoxy-5-(3'-chloro-4'fluoro)phenyl phenyl. Furthermore, the anchor moiety can be multicyclic and comprise a combination of one or more aromatic, non-aromatic, heterocyclic, and heteroaryl rings, which can be fused, bridged, or linked together through covalent bonds. The multicyclic anchor moiety may also be substituted with substituents such as alkyl (e.g., substituted or 10 unsubstituted, branched straight chain or cyclic, e.g., methyl, ethyl, propyl, butyl, pentyl, etc.), alkenyl, alkynyl, halogens (e.g., fluorine, chlorine, bromine, iodine, etc.), hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl 15 amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, azido, heterocyclyl, alkylaryl, aryl and heteroaryl groups. 20 The term "central moiety" ("Z") includes moieties which covalently attach the anchor moiety to the MC4-R interacting moiety. Examples of central moieties include cyclic moieties, optionally substituted amines (e.g., tertiary amino, aminoalkylamino, dialkylaminoalkylamino, aminocarbonylamino, aminocarbonylamino; arylaminocarbonylamino groups; arylaminothiocarbonylamino), optionally substituted 25 alkyl groups (e.g., carbon atoms with substituted or unsubstituted alkyl, aryl (e.g., phenyl, naphthyl), heterocyclic moieties (e.g., morpholinyl, piprazinyl, etc.), and carbonyl groups, etc. Examples of substituents of the central moiety include, for example, alkyl (e.g., straight, branched or cyclic, substituted or unsubstituted, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl), alkenyl (ethenyl, 30 propenyl, butenyl, etc.), alkynyl (e.g., ethynyl, propynyl, etc.), halogen (e.g., chlorine, fluorine, iodine, bromine), hydroxyl, alkoxy (e.g., methoxy, ethoxy, trifluoromethoxy, trichloromethoxy, propoxy, butoxy, cyclopropoxy, etc.), alkylcarbonyloxy, WO 01/10842 PCT/USOO/21327 -17 arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, arylalkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, 5 arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, azido, heterocyclyl (e.g., morpholinyl, piprazinyl, etc.), arylalkyl, alkylaryl and aryl (e.g., substituted or unsubstituted phenyl (e.g., alkyl, halogen, alkoxy substituted), naphthyl, anthracene, etc.) and heteroaryl moieties. Furthermore, the 10 central moiety may further comprise one or more linking moieties. For example, the linking moieties may covalently link the cyclic moiety to the anchor moiety and/or the MC4-R interacting moiety. The term "central moiety" also includes moieties of the formula (XII): A L3 ( I3) (XII) 15 wherein 11 is a covalent bond, a carbon atom, a nitrogen atom, heterocyclic, alkyl, carbocyclic, or aryl;
L
3 is a covalent bond, C-C 6 branched, unbranched or cyclic alkyl(wherein one, two or three of the carbons are optionally replaced with oxygen, 20 sulfur or nitrogen atoms), carbonyl, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy,_or-aminothiocarbonyl moiety; A is substituted or unsubstituted heterocyclic, aryl, alkoxy, amino, alkyl, alkenyl, alkynyl, or hydrogen; and Xis 0, 1 or 2. 25 In a further embodiment, II is a carbon or nitrogen atom. In other embodiments, I is alkyl, carbocyclic, heterocyclic (e.g., piprazinyl, morphonlinyl, piperidinyl, etc.). In another further embodiment, A is heterocyclic (e.g., non-aromatic, e.g., substituted or unsubstituted, bridged, fused, or monocyclic, morpholinyl, piperidinyl, WO 01/10842 PCT/USOO/21327 -18 azetidinyl, piprazinyl, etc. or aromatic, e.g., pyridinyl, pyrimidinyl, pyrrolyl, etc.), aryl e.g., phenyl, naphthyl) or amino (e.g., substituted or unsubstituted, e.g., alkylamino, dialkyl amino, etc.). The language "cyclic moiety" includes heterocyclic and carbocyclic groups, such 5 as substituted or unsubstituted phenyl, heteroaryl, or biaryl moieties. Examples of cyclic moieties include those without aromaticity (e.g., cyclohexane, cyclopentane, etc.) and those with aromaticity, e.g. moieties that have at least one aromatic ring. Cyclic moieties may include one or more heteroatoms. Examples include phenyl, pyrrole, furan, thiophene, imidazole, benzoxazole, benzothiazole, triazole, tetrazole, pyrazole, 10 pyridine, pyrazine, pyridazine, pyrimidine, naphthyl, quinolyl, indolyl, and the like. The cyclic moiety can be substituted at one or more ring positions with such substituents such as, for example, alkyl (e.g., substituted or unsubstituted methyl, ethyl, propyl, butyl), alkenyl (ethenyl, propenyl, butenyl, etc.), alkynyl (e.g., ethynyl, propynyl, etc.), halogen (e.g., chlorine, fluorine, iodine, bromine), hydroxyl, alkoxy (e.g., methoxy, 15 ethoxy, trifluoromethoxy, trichloromethoxy, propoxy, butoxy, cyclopropoxy, etc.), aryloxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including 20 alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, azido, heterocyclyl, alkylaryl, and aryl (e.g., substituted or unsubstituted phenyl, naphthyl) and heteroaryl moieties. The cyclic moiety can also be fused or bridged with alicyclic or heterocyclic rings which are not 25 aromatic so as to form a polycycle (e.g., tetralin, or fluorene). In an embodiment, the cyclic moiety of the present invention is substituted or unsubstituted phenyl, heteroaryl, or biaryl. The language "cyclic moiety" also includes non-aromatic cyclic moieties, such as, substituted or unsubstituted cyclic alkanes, (e.g., cyclohexane, and cyclopentane), cyclic alkenes (e.g., cyclohexene), and substituted or 30 unsubstituted heterocycles (e.g., thiofuran, pyrimidine, pyrazine, pyrrole, imidazole, quinoxaline, etc.). The language "cyclic moiety" comprises not only the heterocyclic or carbocyclic moieties, but also may additionally include moieties which further comprise WO 01/10842 PCT/USOO/21327 -19 linking moieties, such as L, and L 2 which, for example, may link the anchor moiety to the carbocyclic or heterocyclic cyclic portion of the cyclic moiety. Furthermore, linking moieties may also link the heterocyclic or carbocyclic cyclic moiety to the MC4-R interacting moiety. Examples of cyclic moieties include unsubstituted phenyl, 5 halogenated phenyl (e.g., fluoro, bromo, chloro and iodo phenyl), alkyl substituted phenyl (e.g., methyl, ethyl, propyl, etc.),amino substituted phenyl, heteroaryls (e.g., thiofuran, pyridine, quinoxaline, pyrazine, pyrrole, etc.). The language "MC4-R interacting moiety" ("E") includes moieties which permit the MC4-R binding compound to perform its intended function, e.g., interact with the 10 MC4-R. Examples of MC4-R interacting moieties include substituted or unsubstituted alkyl (e.g., substituted with amino, cyano, nitro, hydroxy, etc.), aryl (e.g., phenyl, heteroaryl), amino (e.g., 3-aminopropylamino, dimethyl amino, diethyl amino), amidino, guanidino, carbocyclic and heterocyclic moieties. The language "MC4-R interacting moiety" is not intended to suggest that this moiety is the active pharmacophore of the 15 molecule, responsible for the pharmacological, binding or other properties of the MC4-R binding compound. In one embodiment, the MC4-R interacting moiety is cyclic, e.g., aryl, alkyl, biaryl, polycyclic, heteroaromatic, or heterocyclic. Examples of heterocyclic MC4-R interacting moieties include heterocycles which contain nitrogen atoms, such as, 20 substituted and unsubstituted pyridinyl, pyrrolyl, piprazinyl, imidoazopyridinyl, pyrolloimidazolyl, pyrrolyl, azetidinyl, azapanyl, pyrimidinyl, pyridinyl, morpholinyl, diazapanyl, and piperidinyl moieties. The MC4-R interacting moiety may be bicyclic, polycyclic, bridged or a fused ring system. Examples of fused and bridged heterocycles include: N R/ r N N N RN N NN N R NN
CN
WO 01/10842 PCT/USOO/21327 -20 The substituent R includes substituted and unsubstituted alkyl (e.g., methyl, ethyl, etc.), benzocarbonyl, alkylcarbonyl, arylalkylcarbonyl, and other groups which allow the MC4-R interacting moiety to perform its intended function. The MC4-R interacting moiety can be substituted with substituents such as, but 5 not limited to, halogens (e.g., fluorine, chlorine, bromine, iodine, etc.), alkyl (e.g., substituted or unsubstituted, branched straight chain or cyclic, e.g., methyl, ethyl, propyl, butyl, pentyl, etc.), alkenyl, alkynyl, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, 10 phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, aminoalkyl, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, azido, heterocyclyl, alkylaryl, aryl ,heteroaryl 15 moieties and combinations thereof. In another embodiment, the MC4-R interacting moiety is not cyclic, e.g., the MC4-R interacting moiety is alkyl, unsubstituted amino, alkylamino, dialkylamino, amidino, guanidino, etc. Examples of alkyl MC4-R interacting moieties include straight and branched chain alkyls such as n-butyl, n-pentyl, and n-hexyl. 20 In another embodiment, the MC4-R interacting moiety contains one or more nitrogen atoms, e.g., pyridinyl, pyrrolyl, pyrazinyl, imidazolyl, quinoxalinyl, or pyrimidinyl. In a further embodiment, the MC4-R interacting moiety is of the formula (XIII): N r s N R (XIII) 25 wherein r is a covalent bond, CH, CH 2 , CR', CR'R 2 , or H; t is CH, CH 2 , CR 3 , CR 3
R
4 , or H; s is CH, CH 2 , CHR 5 , CRR 6 , or absent; WO 01/10842 PCT/USOO/21327 -21 R is hydrogen, alkyl, alkenyl, arylalkyl, benzocarbonyl, arylalkylcarbonyl, alkylcarbonyl, optionally linked to A, B, L 1 , L 2 , R1, R2, R 3 , R 4 , R 5 , or R to form one or more rings; R', R2, R 3 , R 4 , R', and R 6 are each substituted or unsubstituted alkyl, 5 alkenyl, alkynyl, heterocyclic, halogen, thiol, hydroxyl, nitro, amino, cyano, or alkoxy, and may optionally be linked to form a carbocyclic or heterocyclic ring. The carbocyclic ring that is formed through the linkage of R, R', R 2 , R3, R 4 , R', or R6 may be bridged, fused, or spiro. In one embodiment, the MC4-R interacting moiety is represented by the formula 10 (XIV) below, when s is absent: NH
-NH
2 (XIV) For example, in another further embodiment, the MC4-R interacting moiety may be bicyclic, e.g., biheterocyclic, for example, quinoxalinyl. The language "linked to form a ring" refers to moieties covalently connected through a chain of atoms (e.g., 15 carbon atoms and/or heteroatoms). The chain of atoms can comprise any number of atoms, which allow the MC4-R binding moiety to perform its intended function. In a further embodiment, the chain of atoms is selected such that a ring with three, four, five, six, seven, or eight members are formed. The ring that can be formed may be spiro (e.g., connected through the same carbon atom), fused (connected through adjacent 20 carbon atoms), or bridged (e.g., connected through carbon atoms which are neither identical nor adjacent). In an embodiment, R and t are linked, e.g., to for a bicyclic moiety. Examples of bicyclic moieties include, but are not limited to, imidazopyridinyl, pyrolloimidazolyl, cyclopentaimidazolyl, pyridopyrimidinyl, etc. In a further embodiment R is H, alkyl, benzocarboxy, alkylcarboxy, or 25 arylalkylcarboxy. In another further embodiment, s is CR 5
R
6 and R 5 and R 6 are each methyl. In another further embodiment, r is a covalent bond, and at least one of t and s are CH 2 . In another, t, r, and s are each CH 2 . In another, r is a covalent bond, and t and s are linked through a 4 carbon chain. In another further embodiment, at least one R group is OH.
WO 01/10842 PCT/USOO/21327 -22 Examples of MC4-R interacting moieties include, but are not limited to, the following structures: N N NH2H N N N NH NNH2 NN H1 NN HN NH 2 N HN N OH N 2H 5 In another embodiment, the invention pertains to a method for treating an MC4 R associated state in a mammal, by administering an effective amount of a MC4-R binding compound to a mammal, such that the MC4-R associated state is treated. Examples of MC4-R binding compounds include compounds comprising the formula (II): 10 B-A-E (II) wherein: B is a anchor moiety; WO 01/10842 PCT/USOO/21327 -23 A is a cyclic moiety; and E is a MC4-R interacting moiety, and pharmaceutically acceptable salts thereof. The MC4-R binding compounds of formula (II), may further comprise linking 5 moieties, LI and L 2 . Such MC4-R binding compounds include compounds of the formula (III):
B-LI-A-L
2 -E (III) wherein B is an anchor moiety (as described above), L I and L 2 are linking moieties, A is a cyclic moiety (as described above), and E is a MC4-R interacting 10 moiety. Pharmaceutically acceptable salts of the MC4-R binding compound are also included. The language "linking moiety" includes moieties which link, preferably covalently, the MC4-R interacting moiety, the cyclic moiety, and the anchor moiety of the invention. Examples of linking moieties include covalent bonds, 1-10 atom chains 15 which may be branched or unbranched, substituted or unsubstituted alkyl, heterocyclic, alkenyl, or alkynyl. The chains may be substituted with 0-3 heteroatoms or other moieties which allow the MC4-R binding compound to perform its intended function. Examples of suitable heteroatoms include sulfur, oxygen, nitrogen, and phosphorous. The invention contemplates MC4-R binding compounds which comprises more than 20 two linking moieties. In an embodiment, LI is a chain of 1-10 atoms (e.g., such as carbon, nitrogen, oxygen, or sulfur atoms), e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 atoms. In an embodiment, LI is selected from the group consisting of a covalent bond, CI-C 6 , CI-C 5 , CI-C 4 , Ci-C 3 , Ci
C
2 , branched or unbranched alkyl, wherein one, two or three of the carbons are 25 optionally replaced with oxygen, sulfur or nitrogen atoms. In a further embodiment, LI is a thioether (e.g., -S-CH 2 -, S-CH(CH 3 )-, -CH 2
-S-CH
2 , -S-, or -S-CH-(C 6
H
5 )-.), an ether (e.g., -O-CH 2 or -CH 2 -0-CH 2 -), a sulfoxide, a sulfone, an amine (e.g., -NH-, -NH
CH
2 -, -NMe-CH 2 -, CH 2
-NH-CH
2 -, etc.) or alkyl (e.g., -CH 2
-CH
2 -, -CH 2 -, or -CH 2
-CH
2 CH 2 - ). In another embodiment, L I comprises a sulfonyl group. Furthermore, L, can be 30 substituted or unsubstituted (e.g., a hydrogen can be replaced by another moiety), such that the MC4-R binding compound is capable of performing its intended function, e.g., bind to or interact with the MC4-R. Examples of substituents include, but are not WO 01/10842 PCT/USOO/21327 -24 limited to, halogens (e.g., fluorine, chlorine, bromine, iodine, etc.), alkyl (e.g., substituted or unsubstituted, branched straight chain or cyclic, e.g., methyl, ethyl, propyl, butyl, pentyl, etc.), alkenyl, alkynyl, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, 5 alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, 10 trifluoromethyl, azido, heterocyclyl, alkylaryl, aryl heteroaryl moieties, or combinations thereof. In an embodiment, examples of L 2 include a covalent bond, a chain of 1-10 atoms (e.g., such as carbon, nitrogen, oxygen, or sulfur atoms), e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 atoms. In an embodiment, L 1 is selected from the group consisting of a covalent 15 bond, CI-C 6 , Ci-C 5 , C 1
-C
4 , Ci-C 3 , CI-C 2 , branched or unbranched alkyl, wherein one, two or three of the carbons are optionally replaced with oxygen, sulfur or nitrogen atoms.. In a further embodiment, L 2 is a covalent bond, -CH 2 - or -NH-. Furthermore,
L
2 may also comprise one or more carbonyl groups. For example, L 2 linkers include substituted urea groups (NH-C=O-NH), oxycarbonylamino groups (-O-C=O-NH), 20 thiocarboynl groups, etc. Furthermore, like LI, L 2 can be substituted with any substituent such that the MC4-R binding compound is capable of performing its intended function. Examples of substituents include, but are not limited to, halogens (e.g., fluorine, chlorine, bromine, iodine, etc.), alkyl (e.g., substituted or unsubstituted, branched straight chain or cyclic, 25 e.g., methyl, ethyl, propyl, butyl, pentyl, etc.), alkenyl, alkynyl, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including 30 alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, WO 01/10842 PCT/USOO/21327 -25 sulfonamido, nitro, trifluoromethyl, azido, heterocyclyl, alkylaryl, aryl and heteroaryl moieties. In a further embodiment, the MC4-R binding compound is of formula (III) (e.g.,
B-LI-A-L
2 -E), wherein B is substituted or unsubstituted biaryl (e.g., substituted or 5 unsubstituted biphenyl, naphthyl, fluorenyl), unsubstituted or substituted heteroaryl (e.g., thienyl, benzothienyl, furanyl, pyrazinyl, pyrrolyl, pyrrolidinyl, etc.), unsubstituted or substituted phenyl, wherein one or more of said substituents are selected from the group consisting of halogens (e.g., bromine, fluorine, chlorine, iodine, etc.), alkyl groups (e.g., branched, straight chain or cyclic, substituted or unsubstituted, methyl, ethyl, 10 propyl, butyl, etc.), alkoxy groups (e.g., substituted or unsubstituted alkoxy, e.g., methoxy, ethoxy, isopropoxy, n-propoxy, isobutoxy, n-butoxy, pentoxy, cyclopentoxy, methylenedioxy, ethylenedioxy, etc.), aryl groups (e.g., substituted or unsubstituted phenyl, heterocyclic groups), alkenyl, alkynyl, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, 15 alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, 20 trifluoromethyl, and azido; L, is a covalent bond, C 1
-C
10 branched or unbranched alkyl, wherein one or more of the carbons are optionally replaced with oxygen, sulfur or nitrogen atoms; A is a substituted or unsubstituted phenyl, heteroaryl (e.g., pyrrolyl, pyrazinyl, pyridinyl, etc.), or biaryl (e.g., naphthyl, quinoxalinyl, purinyl, etc.) wherein said 25 substituent is selected from the group consisting of halogens (e.g., bromine, fluorine, chlorine, iodine, etc.), alkyl groups (e.g., branched, straight chain or cyclic, substituted or unsubstituted, methyl, ethyl, propyl, butyl, etc.), alkoxy groups (e.g., substituted or unsubstituted alkoxy, e.g., methoxy, ethoxy, isopropoxy, n-propoxy, isobutoxy, n butoxy, pentoxy, cyclopentoxy, methylenedioxy, ethylenedioxy, etc.), aryl groups (e.g., 30 substituted or unsubstituted phenyl, heterocyclic groups), alkenyl, alkynyl, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, WO 01/10842 PCT/USOO/21327 -26 phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, 5 sulfonamido, nitro, trifluoromethyl, and azido;
L
2 is a covalent bond, a chain of 1-10 atoms (e.g., such as carbon, nitrogen, oxygen, or sulfur atoms), e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 atoms. In an embodiment, L I is selected from the group consisting of a covalent bond, CI-C 6 , Ci-Cs, Ci-C 4 , CI-C 3 , Ci
C
2 , branched or unbranched alkyl, wherein one, two or three of the carbons are 10 optionally replaced with oxygen, sulfur or nitrogen atoms, substituted or unsubstituted amino (e.g., -NH-, -NH-CH 2 ), ether, thioether, or alkyl (e.g., CI-C 1 o, -CH 2 -, -CH 2
-CH
2 -, or -CH 2
-CH
2
-CH
2 -, etc.); E is unsubstituted amino, unsubstituted and substituted alkylamino (e.g., 3 aminopropylamino), dialkylamino (e.g., dimethyl amino, diethyl amino), amidino, 15 guanidino, heterocyclic (e.g., substituted and unsubstituted piprazinyl, morpholinyl, piperidinyl, imidoazopyridinyl, pyrolloimidazolyl, pyridinyl, or pyrimidinyl) moieties, aryl (e.g., phenyl, heteroaromatic, e.g., substituted and unsubstituted pyrazinyl, imidazolyl, quinoxalinyl, or pyrimidinyl), wherein said substituents include, but are not limited to, amino (e.g., unsubstituted amino, alkylamino, dialkyl amino), aminoalkyl 20 (e.g., methylamino, ethylamino, propylamino, etc.), alkyl (e.g., branched and straight chain, substituted and unsubstituted (e.g., carboxy, hydroxy, halogen, amino, cyano, nitro, etc. substituted), methyl, ethyl, propyl, butyl, etc.), aryl (e.g., phenyl, heteroaromatic), alkenyl (e.g., branched or straight chain, substituted or unsubstituted), alkynyl, etc, and pharmaceutically acceptable salts thereof. 25 In another embodiment, the invention pertains to a method for treating an MC4 R associated state in a mammal by administering an effective amount of a MC4-R binding compound to a mammal, such that the MC4-R associated state is treated. In an embodiment, the compound is of the formula (IV): WO 01/10842 PCT/USOO/21327 -27 rs
B-LI-A-L
2 N' R (IV) wherein A is a substituted or unsubstituted phenyl, heteroaryl (e.g., pyrrolyl, pyrazinyl, pyridinyl, etc.), or biaryl (e.g., naphthyl, quinoxalinyl, purinyl, etc.) wherein said 5 substituent is selected from the group consisting of halogens (e.g., bromine, fluorine, chlorine, iodine, etc.), alkyl groups (e.g., branched, straight chain or cyclic, substituted or unsubstituted, methyl, ethyl, propyl, butyl, etc.), alkoxy groups (e.g., substituted or unsubstituted alkoxy, e.g., methoxy, ethoxy, isopropoxy, n-propoxy, isobutoxy, n butoxy, pentoxy, cyclopentoxy, methylenedioxy, ethylenedioxy, etc.), aryl groups (e.g., 10 substituted or unsubstituted phenyl, heterocyclic groups), alkenyl, alkynyl, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including 15 alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, and azido; B is substituted or unsubstituted biaryl (e.g., substituted or unsubstituted biphenyl, naphthyl, fluorenyl), unsubstituted or substituted heteroaryl (e.g., thienyl, 20 benzothienyl, furanyl, pyrazinyl, pyrrolyl, pyrrolidinyl, etc.), unsubstituted or substituted phenyl, wherein one or more of said substituents are-selected-from the group consisting of halogens (e.g., bromine, fluorine, chlorine, iodine, etc.), alkyl groups (e.g., branched, straight chain or cyclic, substituted or unsubstituted, methyl, ethyl, propyl, butyl, etc.), alkoxy groups (e.g., substituted or unsubstituted alkoxy, e.g., methoxy, ethoxy, 25 isopropoxy, n-propoxy, isobutoxy, n-butoxy, pentoxy, cyclopentoxy, methylenedioxy, ethylenedioxy, etc.), aryl groups (e.g., substituted or unsubstituted phenyl, heterocyclic groups), alkenyl, alkynyl, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, WO 01/10842 PCT/USOO/21327 -28 aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, 5 sulfamoyl, sulfonamido, nitro, trifluoromethyl, and azido; L, and L 2 are selected from the group consisting of a covalent bond, Ci
C
4 branched or unbranched, substituted or unsubstituted alkyl, wherein one or two of the carbons are optionally replaced with oxygen, sulfur or nitrogen atoms; r is a covalent bond, CH, CH 2 , CR', CR'R 2 , or H; 10 t is CH, CH 2 , CR 3 , CR 3
R
4 , or H; s is CHR 5 , CR 5 R6 or absent (e.g., leaving a non-cyclic diamine); R is H, substituted or unsubstituted alkyl, arylalkyl, or heteroalkyl, and may optionally be linked to A, B, LI, or L2; R', R2, R 3 , R!, Rs, and R6 are each substituted or unsubstituted alkyl, 15 halogen, thiol, alkoxy, and may be optionally linked to each other to form additional ring moieties, e.g., quinoxalinyl. Pharmaceutically acceptable salts of the MC4-R binding compounds are also included. In one further embodiment, A is substituted or unsubstituted phenyl. Examples of substituents include halogens (e.g., fluorine, chlorine, iodine, bromine), alkoxy, alkyl 20 (e.g., methyl, trifluoromethyl), and amino moieties. In other embodiments, A is heteroaromatic, (e.g., thienyl), or biaryl, (e.g., napthyl or quinoxalinyl). The invention also pertains to methods for treating an MC4-R associated state in a mammal comprising by administering an effective amount of a MC4-R binding compound of the formula (V): L3 25 B- L 1 H L 2 -E (V) B is substituted or unsubstituted biaryl, unsubstituted or substituted heterocyclic, or unsubstituted or substituted phenyl, wherein one or more of said substituents are halogens, alkyl, alkynyl, alkoxy, aryl, amino, cyano, or nitro; WO 01/10842 PCT/USOO/21327 -29 L 1 is a covalent bond, CI-C 10 branched or unbranched alkyl, wherein one or two of the carbons are optionally replaced with oxygen, sulfur or nitrogen atoms;
L
2 is a covalent bond, substituted or unsubstituted amino, ether, thioether, or alkyl; 5 E is substituted or unsubstituted alkyl, amino, amidino, guanidino, heterocyclic, or aryl, wherein said substituents are amino, arylalkyl, aminoalkyl, alkyl, aryl, alkenyl, or alkynyl; 17 is a covalent bond, a carbon atom, a nitrogen atom, heterocyclic, alkyl, carbocyclic, or aryl; 10 L 3 is a covalent bond, CI-C 6 branched, unbranched or cyclic alkyl (wherein one, two or three of the carbons are optionally replaced with oxygen, sulfur or nitrogen atoms), carbonyl, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, or an aminothiocarbonyl moiety; and A is substituted or unsubstituted heterocyclic, aryl, alkoxy, amino, alkyl, alkenyl, 15 alkynyl, or hydrogen; and ? is 0, 1 or 2, and pharmaceutically acceptable salts thereof. Examples of MC4-R binding compounds with this structure include, but are not limited to, compounds, wherein H is a carbon atom, L 3 is aminocarbonyloxy, A is substituted aryl, X is one, L I and L 2 are each CH 2 , and B and E are each pipridinyl. 20 Examples of substituents for A include but are not limited to, alkoxy (e.g., CI-Cio alkoxy, e.g., methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, nonoxy, and decoxy), cyano, halogens (e.g., fluorine, chlorine, bromine, iodine), alkyl (e.g., straight or branched chain, etc.), aryl, alkenyl, alkynyl, nitro, amino, or any other substituents which enables the MC4-R binding compound to perform its intended 25 function, e.g., treat an MC4-R associated state. Other examples of compounds of formula (V) include, but are not limited to, compounds wherein H, L 2 and L 3 together are a single covalent bond, E is alkyl, and B is substituted or unsubstituted heterocyclic. In other compounds of formula (V), H is a nitrogen atom, L 2 , Li and L 3 are each alkyl, E is substituted amino (e.g., alkyl 30 substituted), or heterocyclic (e.g., piprazinyl, piperidinyl, morpholinyl, etc.) and B and A are each aryl (e.g., phenyl, anthracenyl, biaryl, e.g., naphthyl).
WO 01/10842 PCT/USOO/21327 -30 In another further embodiment, the invention pertains to yet another method for treating an MC4-R associated state in a mammal by administering to a mammal an effective amount of a MC4-R binding compound of the formula(VI): p2 L P3
P
4 L YI z 2 z za (VI) 5 wherein P', P 2 , p 3 , and P 4 are optionally substituted carbon, sulfur, or nitrogen, and wherein one of Pl, P 2 ' p 3 , and p4 may represent a covalent bond; ZI, Z 2 , Z 3 , Z 4 , and Z 5 are optionally substituted carbon or nitrogen; L' is a covalent bond, CI-C 6 branched or unbranched alkyl, wherein one or two 10 of the carbons are optionally replaced with oxygen, sulfur or nitrogen atoms;
L
2 is a covalent bond, substituted or unsubstituted amino, ether, thioether, or alkyl; J is an unsubstituted or substituted nitrogen containing heterocycle or a substituted or unsubstituted amino group, and pharmaceutically acceptable salts thereof. 15 Examples of substituents of P 1 , P2, p3, p4, Z, Z 3 , Z 4 , and Z 5 include halogens (e.g., bromine, fluorine, chlorine, iodine, etc.), alkyl groups (e.g., branched, straight chain or cyclic, substituted or unsubstituted, methyl, ethyl, propyl, butyl, etc.), alkoxy groups (e.g., substituted or unsubstituted alkoxy, e.g., methoxy, ethoxy, isopropoxy, n propoxy, isobutoxy, n-butoxy, pentoxy, cyclopentoxy, methylenedioxy, ethylenedioxy, 20 etc.), aryl groups (e.g., substituted or unsubstituted phenyl, heterocyclic groups), alkenyl, alkynyl, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino 25 (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, and azido groups.
WO 01/10842 PCT/USOO/21327 -31 In a further embodiment, PI, P 2 p 3 , and P 4 are each substituted or unsubstituted carbon (e.g., CH). For example, P1 and p3 may be CH. In another further embodiment, P2 and p4 are each CH, CF, CCl, CBr, CI, CMe, C-OMe, or C-OCF 3 . In a third further embodiment, Z 3 and Z 4 are each CH. 5 In a fourth further embodiment, Z' is CH, or covalently linked to Z2 to form a naphthyl ring. Examples of Z 2 include CH, C-(C=CH), CCl, CBr, CI, and CF. Furthermore, Z 2 may be substituted with a chain of atoms which covalently links it to Z to form a naphthyl ring. Examples of Z 5 include, but are not limited to, CH and C-alkoxy. The term "C 10 alkoxy" includes carbon atoms covalently bound to an alkoxy group, as described below. Examples of alkoxy groups include methoxy, ethoxy, propoxy, butoxy, etc. In yet another further embodiment, L2 is a covalent bond. Examples of J include, but are not limited to, substituted or unsubstituted piprazinyl, imidoazopyridinyl, pyrolloimidazolyl, pyrrolyl, azetidinyl, azapanyl, 15 diazapanyl, pyrimidinyl, pyridinyl, morpholinyl, or piperidinyl. Furthermore, J may be a substituted or unsubstituted fused ring or bridged heterocycle. In a further embodiment, each of P', P 2 ' P 3 , and P4 are each optionally substituted carbon; Z1, Z 2 , Z 3 , Z 4 , and Z 5 are each also optionally substituted carbon (e.g., alkoxy substituted, halogen substituted or linked to form a ring); wherein Li is 20 either -S-CH 2 -, or CH 2
-CH
2 . In a further embodiment, L 2 is a covalent bond and J is a moiety of formula XIII, as described above. In another embodiment, the MC4-R binding compound is of formula (VII): z 5 I I (VII) wherein 25 ZI, Z2, Z 3 , Z 4 , and Z 5 are CH, N, or substituted carbon; and Pl, p2 p3, p4, and P5 are CH,N or substituted carbon.
WO 01/10842 PCT/USOO/21327 -32 Examples of substituents of Z1, Z 2 , Z 3 , Z 4 , Z 5 , P I, P2 , p 4 , and P 5 include halogens (e.g., bromine, fluorine, chlorine, iodine, etc.), alkyl groups (e.g., branched, straight chain or cyclic, substituted or unsubstituted, methyl, ethyl, propyl, butyl, etc.), alkoxy groups (e.g., substituted or unsubstituted alkoxy, e.g., methoxy, ethoxy, 5 isopropoxy, n-propoxy, isobutoxy, n-butoxy, pentoxy, cyclopentoxy, methylenedioxy, ethylenedioxy, etc.), aryl groups (e.g., substituted or unsubstituted phenyl, heterocyclic groups), alkenyl, alkynyl, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino 10 (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, and azido groups. In a further embodiment, pI, p2 p3, p 4 and P 5 are each substituted or 15 unsubstituted carbon (e.g., CH). For example, P1 and P 3 may be CH. In another further embodiment, P 2 and P 4 are each CH, CF, CCl, CBr, or CI. Furthermore, Pl, p2 p3, and
P
4 can be linked covalently to form a bicyclic ring. In a third further embodiment, Z 3 and Z 4 are each CH. In a fourth further embodiment, Z' is CH, or covalently linked to Z2 to form a 20 naphthyl ring. Examples of Z 2 include CH, C-(C=CH), CCl, CBr, CI, and CF. Furthermore, Z 2 may be substituted with a chain of atoms which covalently links it to Z' to form a naphthyl ring. In a further embodiment, P 5 is C-L 2 -J, wherein C is a carbon atom, L 2 is a linking moiety, e.g., a covalent bond, substituted or unsubstituted amino, ether, thioether, or 25 alkyl; and J is an unsubstituted or substituted nitrogen containing heterocycle or a substituted or unsubstituted amino group. In yet a further embodiment, L 2 is a covalent bond and J is a moiety of formula (XIII): r N rs R
(XIII)
WO 01/10842 PCT/USOO/21327 -33 wherein r is a covalent bond, CH, CH 2 , CR 1 , CR'R 2 , or H; t is CH, CH 2 , CR 3 , CR 3
R
4 , or H; s is CH, CH 2 ,alkenyl, CHR', CR 5
R
6 , or absent; 5 R is hydrogen, alkyl, alkenyl, arylalkyl, benzocarbonyl, arylalkylcarbonyl, alkylcarbonyl, optionally linked to A, B, Li, L 2 , R', R 2 , R 3 , R 4 , R 5 , or R6 to form one or more rings; and R', R2, R 3 , R 4 , R, and R 6 are each halogen, thiol, alkoxy, alkyl, alkenyl, alkynyl, heterocyclic, hydroxyl, nitro, amino, cyano, aryl, optionally linked to form a ring with 10 R, R', R2 R, R4, R', or R. In another embodiment, the MC4-R binding compound is of formula (VIII): p s z 2 z z za(ViII) wherein Z', Z2, Z', Z4, and Z 5 are CH, N, or substituted carbon; and 15 P 1 , P 2 , p 3 , p4, and P 5 are CH, N or substituted carbon. Examples of substituents of Z1, Z 2 , Z 3 , Z 4 , Z 5 , p 1 , p2 p 3 p 4 , and P 5 include halogens (e.g., bromine, fluorine, chlorine, iodine, etc.), alkyl groups (e.g., branched, straight chain or cyclic, substituted or unsubstituted, methyl, ethyl, propyl, butyl, etc.), alkoxy groups (e.g., substituted or unsubstituted alkoxy, e.g., methoxy, ethoxy, 20 isopropoxy, n-propoxy, isobutoxy, n-butoxy, pentoxy, cyclopentoxy, methylenedioxy, ethylenedioxy, etc.), aryl groups (e.g., substituted or unsubstituted phenyl, heterocyclic groups), alkenyl, alkynyl, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino 25 (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), WO 01/10842 PCT/USOO/21327 -34 amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, and azido groups. In a further embodiment, P', P 2 , P 3 , and P 4 are each substituted or unsubstituted carbon (e.g., CH). For example, P1 and P 3 may be CH. In another further embodiment, 5 P 2 and P 4 are each CH, CF, CCl, CBr, or CI. Furthermore, pI, p2 p 3 , and P 4 can be linked covalently to form a bicyclic ring. In a third further embodiment, Z 3 and Z 4 are each CH. In a fourth further embodiment, Z' is CH, or covalently linked to Z2 to form a naphthyl ring. Examples of Z 2 include CH, C-(C=CH), CCl, CBr, CI, and CF. 10 Furthermore, Z 2 may be substituted with a chain of atoms which covalently links it to Z' to form a naphthyl ring. In a further embodiment, P 5 is C-L 2 -J, wherein C is a carbon atom, L 2 is a linking moiety, e.g., a covalent bond, substituted or unsubstituted amino, ether, thioether, or alkyl; and J is an unsubstituted or substituted nitrogen containing heterocycle or a 15 substituted or unsubstituted amino group. In yet a further embodiment, L 2 is a covalent bond and J is a moiety of formula (XIII): R (XIII) wherein r is a covalent bond, CH, CH 2 , CR', CR'R 2 , or H; 20 t is CH, CH 2 , CR 3 , CR 3
R
4 , or H; s is CH, CH 2 , alkenyl, CHR 5 , CR 5
R
6 , or absent; R is hydrogen, alkyl, alkenyl, arylalkyl, benzocarbonyl, arylalkylcarbonyl, alkylcarbonyl, optionally linked to A, B, LI, L 2 , R', R2, R 3 , R 4 , R, or R6 to form one or more rings; and 25 R', R 2 , R 3 , R 4 , R', and R 6 are each halogen, thiol, alkoxy, alkyl, alkenyl, alkynyl, heterocyclic, aryl, hydroxyl, nitro, amino, cyano, optionally linked to form a ring with R, R', R2, R 3 , R 4 , R', or R6 WO 01/10842 PCT/USOO/21327 -35 In another embodiment, the invention pertains to MC4-R binding compounds of formulae VII and VIII. Examples of MC4-R binding compound of these formulae include, for example, compounds wherein P5 is a carbon covalently bonded to a moiety of formula XIII. In a further embodiment, the moiety of formula XIII is not 5 benzoimidazole. In another further embodiment, Z 3 is not ethoxy. In another embodiment, the invention pertains to both methods of using and MC4-R binding compounds of formula (IX): N s P2N t P G III G Z z z '(IX) wherein: 10 P 2 is CH, CF, CCl, CBr, C-alkyl, C-alkoxy, C-CN, C-OH, or CI;
P
3 is CH, CF, CCl, CBr, C-alkyl, C-alkoxy, C-CN, C-OH, or CI;
P
4 is CH, CCl, CBr, CF, C-alkyl, C-alkoxy, C-CN, C-OH, or CI; G' and G 2 are each independently CH 2 , S, or 0; r is a covalent bond or CH 2 ; 15 t is CH 2 , CR 3 , or CR 3
R
4 ; s is CH 2 , CHR 5 or CRR 6 ; R is hydrogen or alkyl; Z' is CH, or covalently linked to Z2 to form a naphthyl ring;
Z
2 is CH, C-(C-CH), CCl, CBr, CI, CF, or covalently linked to Z' to 20 form a naphthyl ring;
Z
5 is CH, or C-OMe;
R
3 , R 4 , R 5 , and R 6 are methyl, ethyl, hydroxyl, alkoxy, halogen, cyano, nitro, amino, or pharmaceutically acceptable salts thereof. The language "linked to form a naphthyl ring" includes moieties which join Z' 25 and Z 2 to form a naphthyl (fused) ring system. Examples of such Z' and Z 2 groups include, but are not limited to, -CH=CH-CH=CH-.
WO 01/10842 PCT/USOO/21327 -36 In a further embodiment, Z' is CH; Z 2 is CBr; and Z 5 is C-OMe. In another further embodiment, P 2 is CH. In another, P 4 is CCl or CF. G' and G 2 are each CH 2 . In another, G 1 and G 2 together are -CH 2
-CH
2 -, -CH 2 -0-, -O-CH 2 -, -CH 2 S- or -S-CH 2 -. In another, Z' and Z 2 are linked to form a naphthyl ring. 5 The invention pertains to MC4-R binding compound of the formula (VII): Z4 z zz (VII) wherein 10 Z', Z 2 , Z 3 , Z 4 , and Z 5 are CH, N, or substituted carbon; PI, P 2 ' P 3 , and P 4 are CH, N or substituted carbon; and
P
5 is C-L 2 -J, wherein L 2 is a covalent bond, alkyl (e.g., Ci-C 3 ), amino, ether, carbonyl, etc., and wherein J is a moiety of the formula (XIII): N r s R (XIII) 15 wherein r is a covalent bond, CH, CH 2 , CR', CR R2, or H; t is CH, CH 2 , CR 3 , CR 3
R
4 , or H; s is CH, CH 2 , CHR 5 , CR 5
R
6 , or absent; R is hydrogen, alkyl, alkenyl, arylalkyl, benzocarbonyl, 20 arylalkylcarbonyl, alkylcarbonyl, optionally linked to R', R 2, R , R, R', or R 6 to form one or more rings; and WO 01/10842 PCT/USOO/21327 -37 R', R 2 , R 3 , R4, R', and R 6 are each halogen, thiol, alkoxy, alkyl, alkenyl, alkynyl, heterocyclic, hydroxyl, nitro, amino, cyano,aryl, optionally linked to form a ring with R, R', R 2 , R, R 4 , R', or R 6 . 5 The invention also pertains to MC4-R binding compound of the formula (VIII): I z 5 z~ z za(VIII) wherein ZI, Z 2 , Z 3 , Z 4 , and Z 5 are CH, N, or substituted carbon; 10 P 1 , P 2 , p 3 , and P 4 are CH, N or substituted carbon; and
P
5 is C-L 2 -J, wherein L 2 is a covalent bond, alkyl (e.g., C-C 3 ), amino, ether, carbonyl, etc., and wherein J is a moiety of the formula (XIII): r N s }ILI R (XIII) wherein 15 r is a covalent bond, CH, CH 2 , CR', CR R2, or H; t is CH, CH 2 , CR 3 , CR 3
R
4 , or H; s is CH, CH 2 , CHR 5 , CRR 6 , or absent; R is hydrogen, alkyl, alkenyl, arylalkyl, benzocarbonyl, arylalkylcarbonyl, alkylcarbonyl, optionally linked to R', R 2 , R 3 , R 4 , R 5 , or R 6 to form 20 one or more rings; and R , R , R , Rs, and R 6 are each halogen, thiol, alkoxy, alkyl, alkenyl, alkynyl, heterocyclic, hydroxyl, nitro, amino, cyano,aryl, optionally linked to form a ring with R, R, R, R 3 , R 4 , R, or R6.
WO 01/10842 PCT/USOO/21327 -38 The invention also pertains to MC4-R binding compound of the formula (XV): I sz P3z z z z wherein 5 ZI, Z 2 , Z 3 , Z 4 , and Z 5 are CH, N, or substituted carbon; PI, P 2 p 3 , and P 4 are CH, N or substituted carbon; and
P
5 is C-L 2 -J, wherein L 2 is a covalent bond, alkyl (e.g., CI-C 3 ), amino, ether, carbonyl, etc., and wherein J is a moiety of the formula (XIII): r N s R (XIII) 10 wherein r is a covalent bond, CH, CH 2 , CR', CR'R 2 , or H; t is CH, CH 2 , CR, CR 3
R
4 , or H; s is CH, CH 2 , CHR 5 , CR 5
R
6 , or absent; R is hydrogen, alkyl, alkenyl, arylalkyl, benzocarbonyl, 15 arylalkylcarbonyl, alkylcarbonyl, optionally linked to R', R 2 , R3, R 4 , Ri, or R 6 to form one or more rings; and R', R2, R , R!, R', and R6 are each halogen, thiol, alkoxy, alkyl, alkenyl, alkynyl, heterocyclic, hydroxyl, nitro, amino, cyano,aryl, optionally linked to form a ring with R, R, R 2 , R 3 , R 4 , R 5 , or R 6 . 20 The invention also pertains to MC4-R binding compound of the formula (XVI): WO 01/10842 PCT/USOO/21327 -39 z 5 (XVI) wherein
Z
1 , Z 2 , Z 3 , Z 4 , and Z 5 are CH, N, or substituted carbon; P , P2, p3, and p4 are CH, N or substituted carbon; and 5 P 5 is C-L 2 -J, wherein L 2 is a covalent bond, alkyl (e.g., CI-C 3 ), amino,.ether, carbonyl, etc., and wherein J is a moiety of the formula (XIII): N 1.r s R (XIII) wherein r is a covalent bond, CH, CH 2 , CR , CR1R2, or H; 10 t is CH, CH 2 , CR 3 , CR 3
R
4 , or H; s is CH, CH 2 , CHR , CR 5
R
6 , or absent; R is hydrogen, alkyl, alkenyl, arylalkyl, benzocarbonyl, arylalkylcarbonyl, alkylcarbonyl, optionally linked to R1, R2, R3, R 4 , R 5 , or R 6 to form one or more rings; and 15 R', R 2 , R 3 , R 4 , R 5 , and R 6 are each halogen, thiol, alkoxy, alkyl, alkenyl, alkynyl, heterocyclic, hydroxyl, nitro, amino, cyano,aryl, optionally linked to form a ring with R, R', R2, R, R, R', or R. In a further embodiment, the invention includes compounds wherein P1, P 2 ' p 3 , and P 4 of any one of formulas VII, VIII, XV, or XVI are each substituted or 20 unsubstituted carbon. For example, in one embodiment, P1 is CH. In another example, at least one of P 2 , p 3 and P 4 is a substituted carbon. In a further embodiment, P2, p3 and
P
4 are selected from the group consisting of CH, CF, Cl, CBr, C-alkyl, C-alkyoxy, or CI.
WO 01/10842 PCT/USOO/21327 -40 In another embodiment, the compounds of formulae VII, VIII, XV, or XVI, include compounds wherein Z 3 and Z 4 are each CH. In another further embodiment of the formulae, Z' is CH. For example, in another further embodiment, Z' is covalently linked to Z2 to form a naphthyl ring. Z 2 is CH, C-(C=CH), CCl, CBr, CI, and CF. 5 In another further embodiment, the compounds of the invention include compounds of formulae VII, VIII, XV, or XVI, wherein L 2 is a covalent bond. Also included are compounds wherein R is H, alkyl, benzocarboxy, alkylcarboxy, or arylalkylcarboxy. In another further embodiment, the compounds of the invention include 10 compounds of formulae VII, VIII, XV, or XVI, wherein s is CR 5 R6 and R 5 and R 6 are each methyl. In another example r is a covalent bond. Alternatively, each of t, r and s may be CH 2 . In one further embodiment, the MC4-R binding compounds of the invention of formula VII do not include benzoimadazole as the moiety of formula XIII, when P', P2 15 P 3 , P 4 , ZI, Z 2 , Z 4 , Z 3 , and Z 5 are each CH. Furthermore, in another further embodiment, the compounds of the invention do not include compounds wherein the moiety of formula XIII is tetrahydropyrimidine, when P , P2, p3, p4, Z1, Z 2 , Z4, and Z5 are each CH and Z 3 is C-OEt or CH. In another further embodiment, the MC4-R binding compounds of the invention 20 of formula VIII, do not include compounds wherein the moeity of formula XIII is benzoimidazolyl. In another further embodiment, the MC4-R binding compounds of the invention of formula VIII, do not include compounds wherein P2 is not Cl, if P', p3, or
P
4 are CH. In another further embodiment, the MC4-R binding compounds of the invention of formula VIII, do not include compounds wherein P', p 2 , p 3 , p 4 , Z1, Z 2 , Z 4 , 25 Z 3 , and Z 5 are each CH, when the moiety of formula XIII is tetrahydropyrimidine. In another further embodiment, the compounds of formula VIII of the invention do not include compounds wherein the moiety of formula is 4,5-dihydro-1H-imidazole, when PI, P 2 , p 3 , and P 4 are each CH, and wherein one or two of Z1, Z 2 , or Z 3 is CCl, and the remaining Z groups are CH. In another further embodiments, the MC4-R binding 30 compounds of formula VIII of the invention, do not include compounds wherein the moiety of formula XIII is tetrahydropyrimidine, and when P', P 2 , p 3 , and P 4 are each CH, and Z 2 is CCl and the remaining Z groups are CH. In another further embodiments, WO 01/10842 PCT/USOO/21327 -41 the compounds of formula VIII of the invention, do not include compounds wherein when the moiety of formula XIII is tetrahydropyrimidine, and when P', P 2 , p 3 , and P 4 are each CH, and Z' and one of Z 4 or Z5 are CCl and the remaining Z groups are CH. In another further embodiment, the MC4-R binding compounds of the invention 5 do not include compounds of formula XV, wherein the moiety of formula VIII is not benzoimidazole if P', p 2 p 3 , p 4 are each CH, and wherein Z 2 is CMe and the remaining Z groups are CH. In another further embodiment, the MC4-R binding compounds of the invention do not include compounds of formula XVI, wherein the moiety of formula XVI, wherein 10 L 2 is not NH (e.g., amino), if P I, P2 p 3 p4, ZI, Z 2 , Z 4 , Z 3 , and Z 5 are each CH. In another embodiment, the MC4-R binding compounds of formula XVI of the invention do not include compounds wherein P groups are substituted to form a naphthyl ring. In another embodiment, the invention features a method for treating an MC4-R associated state in a mammal by administering an effective amount of a MC4-R binding 15 compound to a mammal. Compounds of formula (X) are also included in the invention. In this embodiment, the compound is of the formula (X): N > (CR 16R 16 Ar R R R (CH)e , / x-(CH)f R 1 4 RD R'2 (X) wherein Ar and Ar' are aromatic groups; 20 R" is-selected independently for each position capable of substitution from the group hydrogen, cyano, nitro, alkoxy, halogen, alkyl, amino, or aryloxy. R1 2 is selected for each position capable of substitution from the group consisting of hydrogen, halogen, alkoxy, acetylenic, nitro, aryl, alkyl, alkenyl, alkynyl, cyano, acyl, or carbonyl; 25 R 3 is hydrogen, alkenyl, alkynyl, aralkyl, nitro, cyano, alkyl (e.g., C 1
-C
10 alkyl, e.g., methyl, ethyl, etc.) acyl, carbonyl, or SO 2
CH
3 , and may optionally be linked to an R or an R16' group; WO 01/10842 PCT/USOO/21327 -42 R 1 6 and R 1' are each independently selected for each position capable of substitution from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heterocyclic, carbonyl, or acyl, and may optionally be connected through an alkyl chain to R1 3 or another Ri 6 or R 1' group, to form a fused or spiro ring system; 5 X is NR 7 , S, 0 or a covalent bond; R1 7 is hydrogen, alkyl, alkenyl, alkynyl, acyl, heterocyclic, or carbonyl; R1 4 and Ri 5 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, heteroaromatic, halogen, nitro, cyano, amino, or aryl, for each occurrence; 10 w is 0, 1, 2, 3, or 4; e is 0, 1, 2, or 3; f is 0, 1, 2, or 3, and pharmaceutically acceptable salts thereof. Examples of Ar groups include: R' - - 1 R" - N \11 N11R Rut R Iff R R R1 R1 N S N L wherein R 8 is acyl, alkyl or hydrogen. 15 In a further embodiment, Ar is, , or R WO 01/10842 PCT/USOO/21327 -43 R" is selected independently for each aromatic position capable of substitution. Exemplary R" groups include, but are not limited to, hydrogen, halogen (e.g., fluorine, chlorine, or bromine), alkyl, amino, and benzyloxy. Examples of Ar' groups include: /1 ).R 12 S R 1R RN R1-- R1 5 wherein R' 9 is hydrogen, alkyl, acyl, aryl, alkenyl, or alkynyl. In a further embodiment, each R group is selected independently from the group consisting of hydrogen, alkoxy, halogen (e.g., fluorine, bromine, chlorine, or iodine), and cyano. Examples of alkoxy groups include CI-C 10 alkoxy, such as, methoxy, ethoxy, n-propoxy, i-propoxy, and cyclopentoxy. 10 Examples of X include covalent bond, S, 0 and NR17. Examples of R' 7 include hydrogen, alkyl (e.g., Ci-Cio alkyl, e.g., methyl), or acyl. Examples of Ri 6 and R 1' include alkyl and hydrogen. Each R1 6 and Ri1' group is selected independently for each occurrence. In a further embodiment, at least one of R 1 or R16' are at least once hydrogen. In another embodiment, at least one of R1 6 or Ri1' 15 are at least once Ci-Cjo alkyl, e.g., methyl or ethyl. In yet another further embodiment, R1 4 and R1 5 are each independently hydrogen, alkyl (e.g., CI-CIo, e.g., methyl) or phenyl for each occurrence. In yet another further embodiment, R1 3 is hydrogen, acyl, alkyl (e.g., C 1 -C1O alkyl, e.g., methyl, ethyl, etc.) acyl, carboxy, or SO 2
CH
3 . Examples of acyl group 20 include, but are not limited to, optionally substituted Ci-Cioalkyl acyl (e.g., i propylcarbonyl and benzylcarbonyl). In yet another further embodiment, w is 2 or 3. In yet another further embodiment, e is 0 or 1. In yet another further embodiment, f is 0 or 1. In another embodiment, the invention features a method for treating an MC4-R 25 associated state in a mammal by administering an effective amount of a MC4-R binding compound to a mammal. In this embodiment, the compound is of the formula (XI): WO 01/10842 PCT/USOO/21327 -44 RH 2 2 RR21 N R R ~(H2)vR (CH)e, / / ~X-(CH), R 1 4 ArD' R 1 RM .RC(XI) wherein Ar and Ar' are aromatic groups, as described above; R" is selected independently for each position capable of substitution 5 from the group hydrogen, halogen, alkyl, amino, cyano, or aryloxy. R1 2 is selected for each position capable of substitution from the group consisting of hydrogen, halogen, alkoxy, acetylenic, nitro, aryl, alkyl, alkenyl, alkynyl, cyano, acyl, or carbonyl; X is NR", S, 0 or a covalent bond; 10 R1 7 is hydrogen, alkyl, acyl, heterocyclic, or carbonyl; R1 4 and R1 5 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, or aryl, for each occurrence;
R
20 and R21 are each independently selected from the group consisting of substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, hydrogen, or carbonyl, and may 15 optionally be linked to form a heterocycle (e.g., morphonlinyl, piperazinyl, piperidinyl, etc.); v is 0, 1, 2, 3, 4, 5, or 6; e is 0, 1, 2, or 3; f is 0, 1, 2, or 3, and pharmaceutically acceptable salts thereof. 20 Examples of Ar, Ar', R 11 , R' 2 , R14, R" and X moieties include those described for formula (X). Other examples of MC4-R binding compounds include compounds of the formula (XVIII): WO 01/10842 PCT/USOO/21327 -45
(CR
1 8 R'6'). R' Ar\ !1 R15 (CH), x C / X-(CHhf R14 Ar' R 1 2 (XVIII) wherein Ar and Ar' are aromatic groups; R" is selected independently for each position capable of substitution 5 from the group hydrogen, cyano, alkoxy, nitro, halogen, alkyl, amino, or aryloxy; R1 2 is selected for each position capable of substitution from the group consisting of hydrogen, halogen, alkoxy, acetylenic, nitro, aryl, alkyl, alkenyl, alkynyl, cyano, acyl, or carbonyl; R1 3 is hydrogen, alkenyl, alkynyl, aralkyl, nitro, cyano, alkyl, acyl, 10 carbonyl, or SO 2
CH
3 , and may optionally be linked to an R or an R1 6 ' group; R1 6 and R16' are each independently selected for each position capable of substitution from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, hydroxyl, cyano, aryl, heterocyclic, carbonyl, or acyl, and may optionally be connected through an alkyl chain to R 3 or another Ri 6 or R16' group, to form a fused-or spiro ring system; 15 X is NR 17 , S, 0 or a covalent bond;
R
7 is hydrogen, alkyl, or carbonyl; R1 4 and R 5 are each independently hydrogen, halogen, or alkyl; w is 1, 2, 3, or 4; e is 0 or 1; 20 f is 0 or 1, wherein both e and f are not both 0 if X is a covalent bond, and pharmaceutically acceptable salts thereof. Examples of Ar, Ar', R", R1 2 , R14, R" 1, Ri 6 and R16' and X moieties include those described for formula (X). Other examples of MC4-R binding compounds include compounds of the 25 formulae: WO 01/10842 PCT/USOO/21327 -46 NH-S33 NHiN ~ Ni N N NH- 0 N02 N02 N eNHN N N -NN '1NO NH N S A'- S 'I A s -l N- N" NA' N BBr N N ~ "a -N s' 0ii F BrrB rB BA NOr WO 01/10842 PCT/USOO/21327 -47 NN , N I'~ A' , -NH I I0 N" N I N' IN I ~'HN IS NN -s s 'N N wI F ia~ a s , A N Brr
N
7 N-"-) SS I . N ON s IFN AF F
I
WO 01/10842 PCT/USOO/21327 -48 N:- N-"' N I I 6 H H H OF SOMe0 C1 Br Br Br N N OH OCH3 Br Br The invention also includes MC4-R binding compounds such as: 2-[2-(4-benzyloxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-iodo-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 5 2-[2-(2-methoxy-5-nitro-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(naphthalen-1 -ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(3-chloro-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2,5-dimethoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(3-bromo-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 10 2-[2-(2-iodo-benzylsulfanyl)-phenyl]-4,5-dihydro-1 H-imidazole; 2-[2-(2-methoxy-5-nitro-benzylsulfanyl)-phenyl]-4,5-dihydro-1H-imidazole; 2-[2-(2-methoxy-5-nitro-benzyloxy)-phenyl]-1,4,5,6-tetrahydropyrimidine; 2-[2-(2-bromo-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(3-iodo-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 15 2-[2-(2-methoxy-5-nitro-benzylsulfanyl)-phenyl]-3a,4,5,6,7,7a-hexahydro-1H benzoimidazole; 2-{2-[2-(2-methoxy-naphthalen-1-yl)-ethyl]-phenyl}-1,4,5,6-tetrahydropyrimidine; 2-[2-(5-bromo-2-methoxy-benzylsulfanyl)-phenyl]-1,4,5,6,-tetrahydropyrimidine; 2-{2-[2-(2-methyl-naphthalen-1 -yl)-ethyl]-phenyl}-1,4,5,6-tetrahydropyrimidine; 20 2-{2-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yl) -ethyl]-phenyl} -1,4,5,6 tetrahydropyrimidine; 2-[2-(2-methoxy-napthalen-1-ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydropyrimidine; 2-(2-Benzylsulfanyl-phenyl)-1,4,5,6-tetrahydro-pyrimidine; WO 01/10842 PCT/USOO/21327 -49 2-(2-Pentadecylsulfanyl-phenyl)- 1,4,5,6-tetrahydro-pyrimidine; 2-(2-Cyclohexylmethylsulfanyl-phenyl)-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Methyl-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(3 -Nitro-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 5 2- [2-(3,5 -Dimethoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(4-Fluoro-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Chloro-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Fluoro-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2,4-Bis-trifluoromethyl-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 10 2-[2-(3-Methoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(3,5-Bis-trifluoromethyl-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Methoxy-5-nitro-benzyloxy)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Chloro-6-fluoro-benzylsulfanyl)-phenyl]-4,5-dihydro- 1 H-imidazole; 2-(2-Benzylsulfanyl-phenyl)-4,5-dihydro- 1 H-imidazole; 15 2-[2-(2,6-Difluoro-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(Naphthalen- 1 -ylmethoxy)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Methyl-naphthalen- 1 -ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 1- {2-[2-(2-Chloro-6-fluoro-benzylsulfanyl)-phenyl]-5,6-dihydro-4H-pyrimidin- 1-yl} ethanone; 20 2-[2-(2-Chloro-6-fluoro-benzylsulfanyl)-phenyl]-3a,4,5,6,7,7a-hexahydro- 1 H benzoimidazole; 2-[2-(2-Iodo-benzylsulfanyl)-phenyl]-3a,4,5,6,7,7a-hexahydro-1H-benzoimidazole; 2-[2-(2,5-Dimethyl-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 4-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-yl)-phenylsulfanylmethyl]-quinoline; 25 2-[2-(2-Methoxy-5-nitro-benzylsulfanyl)-pyridin-3-yl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Methoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Cyclopentyloxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2,3-Dihydro-benzo[1,4]dioxin-5-ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro pyrimidine; 30 2-[2-(6-Methoxy-2,3-dihydro-benzo[1,4]dioxin-5-ylmethylsulfanyl)-phenyl]-1,4,5,6 tetrahydro-pyrimidine; 2-[2-(5-fluoro-2-methoxy-benzylsulfanyl)-phenyl]-4,5-dihydro-IH-imidazole; WO 01/10842 PCT/USOO/21327 -50 1 -Methyl-2-[2-(naphthalen- 1 -ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-4,5-dihydro- 1 H-imidazole; 2-[2-(5-Bromo-2-methoxy-benzyloxy)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(Naphthalen- 1 -yloxymethyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 5 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-5,5 -dimethyl- 1,4,5,6-tetrahydro pyrimidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-5,5-dimethyl-4,5-dihydro- 1 H imidazole; 2-[2-(2,6-Dimethoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 10 2-[2-(2-Bromo-6-methoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[5-Bromo-2-(5-bromo-2-methoxy-benzylsulfanyl)-phenyl]-4,5-dihydro-1H-imidazole; 2-[5-Bromo-2-(5-bromo-2-methoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro pyrimidine; 2-[4-Bromo-2-(5-bromo-2-methoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro 15 pyrimidine; 2-[2-(2-Bromo-5-methoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-5-methyl-phenyl]-1,4,5,6-tetrahydro pyrimidine; 2-[2-(Biphenyl-3-ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 20 2-[2-(5-Chloro-2-methoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Methoxy-5-thiophen-3-yl-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro pyrimidine; 2-[2-(Biphenyl-2-ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Iodo-2-methoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 25 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-5-fluoro-phenyl]-1,4,5,6-tetrahydro pyrimidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-fluoro-phenyl]-1,4,5,6-tetrahydro pyrimidine; 2-[2-(4,4'-Dimethoxy-biphenyl-3-ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro 30 pyrimidine; 2-[2-(9H-Fluoren-9-ylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; WO 01/10842 PCT/USOO/21327 -51 2-[2-(3'-Chloro-4'-fluoro-4-methoxy-biphenyl-3-ylmethylsulfanyl)-phenyl]-1,4,5,6 tetrahydro-pyrimidine; 2-[2-(1 -Naphthalen- 1 -yl-ethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-5-fluoro-phenyl]-4,5-dihydro- 1 H-imidazole; 5 2-(2-Benzhydrylsulfanyl-phenyl)- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2'-Fluoro-4"-methoxy- [1,1 ';4', 1 "]terphenyl-3"-ylmethylsulfanyl)-phenyl]- 1,4,5,6 tetrahydro-pyrimidine; 2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzamidine; 2-[4-(Naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 10 2-[2-(5-Ethynyl-2-methoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Bromo-2-cyclopentyloxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro pyrimidine; 2-[2-(5-Bromo-2-ethoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 15 2-[2-(5-Bromo-2-propoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; [2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-diethyl-amine; 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-piperazine; C- {4-[3-(5-Bromo-2-methoxy-benzylsulfanyl)-quinoxalin-2-yl]-morpholin- 2 -yl} methylamine; 20 2-[2-(2-Methoxy-5-methyl-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Bromo-2-methoxy-benzyloxymethyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; [2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-dimethyl-amine; 2-[2-(5-Bromo-2-isopropoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Ethoxy-naphthalen-1-ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 25 2-[2-(2-Propoxy-naphthalen-1-ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 4-Methoxy-3-[2-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-phenysulfanylmethyl] benzonitrile; 1- {4-Methoxy-3-[2-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-phenylsulfanylmethyl]-phenyl} ethanone; 30 2-[2-(Naphthalen-1-ylsulfanylmethyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-piperidine; WO 01/10842 PCT/USOO/21327 -52 C- {4-[2-(2-Methoxy-naphthalen- 1 -ylmethylsulfanyl)-benzyl]-morpholin- 2 -yl} methylamine; 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-pyrrolidin- 3 -ylamine; 1-[2-(2-Methoxy-naphthalen- 1 -ylmethylsulfanyl)-benzyl]-pyrrolidin-3-ylamine; 5 3-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-fluoro-phenyl]-1,5,6,7,8,8a-hexahydro imidazo[1,5-a]pyridine; 3-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-fluoro-phenyl]-5,6,7,7a-tetrahydro- 1 H pyrrolo[1,2-c]imidazole; 2-[2-(Benzo[b]thiophen-3-ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 10 2-[3-Fluoro-2-(naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-(Naphthalen- 1 -ylmethylsulfanyl)-3-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-phenylamine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-phenyl]-1,4,5,6-tetrahydro pyrimidine; 2-[2-(2-Methoxy-phenylsulfanylmethyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 15 1- {2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-5,6-dihydro-4H-pyrimidin--yl} 3 -methyl-butan- 1-one; 1- {2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-5,6-dihydro-4H-pyrimidin- 1-yl} 2-phenyl-ethanone; 2-[3-(5-Bromo-2-methoxy-benzylsulfanyl)-pyridin-2-yl]-1,4,5,6-tetrahydro-pyrimidine; 20 N-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-guanidine; 2-[2-(2-Isopropoxy-naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro pyrimidine; 2-[2-(2-Cyclopentyloxy-naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro pyrimidine; 25 (5-Bromo-2-methoxy-benzyl)-[2-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-phenyl]-amine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanylmethyl)-phenyl]-1,4,5,6-tetrahydro pyrimidine; 2-[2-(2-Methoxy-naphthalen-1-ylsulfanylmethyl)-phenyl]-1,4,5,6-tetrahydro pyrimidine; 30 2-[3-(5-Bromo-2-methoxy-benzylsulfanyl)-pyrazin- 2 -yl]-1,4,5,6-tetrahydro-pyrimidine; 2-[3-Chloro-2-(naphthalen-1-ylsulfanylmethyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; WO 01/10842 PCT/USOO/21327 -53 2-[2-(6-Bromo-2-methoxy-naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1 ,4,5,6-tetrahydro pyrimidine; 2- [3-Chloro-2-(2-methoxy-naphthalen- 1 -ylsulfanylmethyl)-phenyl] -1,4,5 ,6-tetrahydro pyrimidine; 5 2- [2-(5-Bromo-2-methoxy-phenylsulfanylmethyl)-phenyl]- 1,4,5 ,6-tetrahydro pyrimidine; 2-[2-(5 -Bromol-2-methoxy-phenylsulfanylmethyl)-3-chloro-phelyl]- 1,4,5 ,6-tetrahydro pyrimidine; 2-[ 1-(2-Naphthalen- 1 -yl-ethyl)- 1 H-pyrrol-2-yl] -1,4,5 ,6-tetrahydro-pyrimidine; 10 (5-Bromo-2-methoxy-benzyl)-methyl-[2-(1 ,4,5,6-tetrahydro-pyrimidin-2-yl)-pheflyl] amine; 2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzylamile; 2-[2-(2-Chloro-phenylsulfanylmethyl)-phenyl]- 1,4,5 ,6-tetrahydro-pyrimidine; 2-[2-(2-Bromo-phenylsulfanylmethyl)-phenyl]- 1,4,5 ,6-tetrahydro-pyrimidine; 15 2-(2-o-Tolylsulfanylmethyl-phenyl)- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2,5-Dichloro-phenylsulfanylmethyl)-phenyl]- 1,4,5 ,6-tetrahydro-pyrimidine; 2-(3-Amino-propylamino)-6-(5 -bromo-2-methoxy-benzylsulfanyl)-benzonitrile; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]- 1,4,5,6-tetrahydro-pyrimidine; [2-(5-Bromo-2-methoxy-benzysulfany)-benzy]-diethy1-amine; 20 4-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-morpholile; 3'-(5-Bromo-2-methoxy-benzylsulfanyl)-3 ,4,5 ,6-tetrahydro-2H-[1 ,2']bipyrazinyl; 2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-piperazifl- 1 -yl-6,7-dihydro-quinoxaline; 1 -[2-(5 -Bromo-2-methoxy-benzylsulfanyl)-benzyl]-pipeidile; C- {4-[2-(2-Methoxy-naphthalen- 1 -ylmethylsulfanyl)-benzyl]-morpholin-2-yl} 25 methylamine; 1 -[3-(5-Bromo-2-methoxy-benzylsulfanyl)-pyrazin-2-y]-pyrrolidifl-3-ylamile; 1 -[3-(5-Bromo-2-methoxy-benzylsulfany1)-quinoxalin-2-y1]-pyrrolidifl-3-ylamile; 1 -[2-(2-Methoxy-naphthalen- 1 -ylmethylsulfanyl)-benzyl]-pyrrolidin-3-ylamine; C- {4-[3-(5 -Bromo-2-methoxy-benzylsulfanyl)-pyrazin-2-y]-morpholil- 3 -yl} 30 methylamine; 1 -13-Fluoro-2-(2-naphthalen- 1 -yl-ethyl)-benzyl]-piperazine; 1 -[2-(5-Bromo-2-methoxy-benzysufany)-3-choro-benl~y]-azetidile; WO 01/10842 PCT/USOO/21327 -54 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-pyrrolidin- 3 -ol; [2-(Naphthalen-1-ylmethylsulfanyl)-phenyl]-carbamic acid 1-aza-bicyclo[2.2.2]oct-3-yl ester; [2-(2-Methyl-naphthalen-1-ylmethylsulfanyl)-phenyl]-carbamic acid 1-aza 5 bicyclo[2.2.2]oct-3-yl ester; [2-(2-Methyl-naphthalen-1-ylmethylsulfanyl)-phenyl]-carbamic acid 2-piperidin-1-yl ethyl ester; {1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-pyrrolidin- 2 -yl} methanol; 10 4-tert-Butyl-N-naphthalen- 1 -ylmethyl-N-(2-piperidin- 1 -yl-ethyl)-benzamide; N,N-Dimethyl-N'-naphthalen-2-ylmethyl-N'-naphthalen-1-ylmethyl-propane-1,3 diamine; N-(5-Bromo-2-methoxy-benzyl)-N',N'-dimethyl-N-naphthalen- 1 -ylmethyl-propane- 1,3 diamine; 15 1 -Naphthalen- 1 -ylmethyl-3 -phenethyl- 1 -(2-piperidin- 1 -yl-ethyl)-thiourea; 3-(4-Dimethylamino-phenyl)- 1 -(3 -dimethylamino-propyl)- 1 -naphthalen- 1 -ylmethyl thiourea; 4-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzylamino]-piperidine-1 carboxylic acid ethyl ester; 20 2-[2-(2-Naphthalen- 1 -yl-ethyl)-phenyl]-ethylamine; Naphthalene-2-sulfonic acid (2-dimethylamino-ethyl)-naphthalen-1-ylmethyl-amide; 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-2-methoxymethyl pyrrolidine; (2-Hexyloxy-phenyl)-carbamic acid 2-piperidin- 1-yl-1 -piperidin- 1 -ylmethyl-ethyl ester; 25 3-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyloxy]-pyrrolidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyloxymethyl]-pyrrolidine; 2-[2-(Naphthalen- 1 -ylsulfanylmethyl)-phenyl]-piperidine; 3 -[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzylamino]-propan- 1 -ol; 3-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzylamino]-3-methyl-butan- 1 -ol; 30 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-pyrrolidin- 3 -ol; {1 -[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-pyrrolidin- 2 -yl} -methanol; {1 -[2-(Naphthalen- 1 -ylsulfanylmethyl)-benzyl]-piperidin-2-yl} -methanol; WO 01/10842 PCT/USOO/21327 -55 2-[2-(Naphthalen- 1 -ylsulfanylmethyl)-pyrrolidin- 1 -yl]-ethyl-N-pyrrolidine; N-pyrrolyl-[I1-(2-naphthalen-1 -yl-ethyl)-pyrrolidin-2-ylmethyl]-amine; 1-(2-Naphthalen- 1 -yl-ethyl)-piperidine-2-carboxylic acid methyl ester; (3-Bromo-benzyl)-(1 -ethyl-pyrrolidin-2-ylmethyl)-naphthalen- 1 -ylmethyl-amine; 5 3-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyloxy]-piperidine; (5-Bromo-2-methoxy-benzyl)-(1 -ethyl-pyrrolidin-2-ylmethyl)-naphthalen- 1 -ylmethyl amine; (1 -Ethyl-pyrrolidin-2-ylmethyl)-naphthalen-2-ylmethyl-naphthalen- 1 -ylmethyl-amine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyloxymethyl]-pyrrolidine; 10 (3-Bromo-benzyl)-(3 -imidazol- 1 -yl-propyl)-naphthalen- 1 -ylmethyl-amine; (3-Imidazol- 1 -yl-propyl)-naphthalen-2-ylmethyl-naphthalen- 1 -ylmethyl-amine; [2-(Naphthalen1-ylmethylsulfanyl)-phenyl]-carbamic acid 2-piperidin-1-yl-l-piperidin 1 -ylmethyl-ethyl ester; [2-(Naphthalen-1-ylmethylsulfanyl)-phenyl]-carbamic acid 2-dimethylamino-ethyl ester; 15 1-[2-(Naphthalen-1-ylsulfanylmethyl)-benzyl]-piperazine; [3-(2-Methyl-piperidin-1-yl)-propyl]-[2-(naphthalen-1-ylsulfanylmethyl)-benzyl] amine; 1-[3-Chloro-2-(naphthalen-1-ylsulfanylmethyl)-benzyl]-piperazine; N,N-Dimethyl-N'-(2-naphthalen- 1 -yl-ethyl)-N'-naphthalen- 1 -ylmethyl-ethane- 1,2 20 diamine; { 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-piperidin-2-yl} -methanol; 1-[2-(2-Naphthalen- 1 -yl-ethyl)-benzyl]-piperazine; [3-(2-Methyl-piperidin- 1 -yl)-propyl]- [2-(2-naphthalen- 1 -yl-ethyl)-benzyl]-amine; 1-[3-Fluoro-2-(2-naphthalen- 1 -yl-ethyl)-benzyl]-piperazine; 25 { 1 -[3 -Chloro-2-(naphthalen- 1 -ylsulfanylmethyl)-benzyl]-piperidin-2-yl} -methanol; {1 -[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-piperidin-2-yl} -methanol; {1 -[2-(2-Naphthalen- 1 -yl-ethyl)-benzyl]-piperidin-2-yl} -methanol; [3 -(2-Methyl-piperidin- 1 -yl)-propyl]-[2-(2-naphthalen- 1 -yl-ethyl)-benzyl]-amine; 1-[2-(2-Naphthalen- 1 -yl-ethyl)-benzyl]-pyrrolidin-3 -ylamine; 30 1 -Phenyl-3-piperazin- 1-yl-5,6,7,8-tetrahydro-isoquinoline-4-carbonitrile; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-6-ethyl-1,4,5,6-tetrahydro pyrimidine; WO 01/10842 PCT/USOO/21327 -56 2-[2-(4-Methoxy-biphenyl-3 -ylmethylsulfanyl)-phenyl]- 1,4,5 ,6-tetrahydro-pyrimidine; 2-[2-(2-Methoxy-5-phenylethynyl-benzylsulfanyl)-pheflyl]- 1,4,5 ,6-tetrahydro pyrimidine; 2-[2-(2-Naphthalen- 1 -yl-ethyl)-phenyl]- 1 ,4,5,6-tetrahydro-pyrimidine; 5 2- [3 -(2-Methoxy-naphthalen- I -ylsulfanylmethyl)-thiophen-2-yl]- 1,4,5 ,6-tetrahydro pyrimidine; 2-[2-(2,5 -Dimethoxy-phenylsulfanylmethyl)-phenyl]- 1,4,5 ,6-tetrahydro-pyrimidine; 2-[2-(4-Methyl-naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5 ,6-tetrahydro-pyrimidine; 2-[2-(5 -Bromo-2-methoxy-benzylsulfanyl)-3-fluoro-pheny1]-4,4-dimethy1-4,5-dihydro 10 1 H-imidazole; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3 -fluoro-phenyl]-5 ,5-dimethyl- 1,4,5,6 tetrahydro-pyrimidine; 2-[3 -(Naphthalen- 1 -ylsulfanylmethyl)-thiophen-2-yl]- 1,4,5 ,6-tetrahydro-pyrimidine; 2- {2-I2(5-Bromo-2-methoxy-pheny1)-ethy1]-pheny1) - -1,4,5,6-tetrahydro-pyrimidine; 15 2-[3-Chloro-2-(2-naphthalen- 1 -yl-ethyl)-phenyl]- 1 ,4,5,6-tetrahydro-pyrimidine; 2- {2-[2-(5-Bromo-2-methoxy-phenyl)-ethyl]-3-fluoro-phenyl } 1,4,5 ,6-tetrahydro pyrimidine; 2-[2-(5-Bromo-2-methoxy-phenylsulfanylmethyl)-3-fluoro-phell- 1,4,5 ,6-tetrahydro pyrimidine; 20 2-[2-(Naphthalen- 1 -ylsulfanylmethyl)-phenyl]-4,5-dihydro- 1 11-imidazole; 2-[3-Fluoro-2-(naphthalen- 1 -ylsulfanylmethyl)-phenyl]- 1,4,5 ,6-tetrahydro-pyrimidine; 2-[3-Bromo-2-(naphthalen- 1 -ylsulfanylmethyl)-phenyl]- 1,4,5 ,6-tetrahydro-pyrimidine; 2- {2-[2-(5-Bromo-2-methoxy-phenyl)-ethyl]-3-chloro-pheflyl - -1,4,5 ,6-tetrahydro pyrimidine; 25 2-[2-(2-Methoxy-5-trifluoromethyl-benzylsulfanyl)-phelyl] -1 ,4,5,6-tetrahydro pyrimidine; 2-[4-(Naphthalen- 1 -ylsulfanylmethyl)-thiophen-3 -yl]-l ,4,5,6-tetrahydro-pyrimidine; 2-[2-(Naphthalen- 1 -ylsulfanylmethyl)-thiophen-3-yl]- 1,4,5 ,6-tetrahydro-pyrimidine; 2-{2[-5Boo2mtox-hnl-ty]3trfurmty hnl-1,4,5,6 30 tetrahydro-pyrimidine; 2-[2-(2-Naphthalen- 1-yl-ethyl)-3-trifluoromethyl-phenyl]- 1,4,5 ,6-tetrahydro-pyrimidine; 2-[2-(6-Fluoro-naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1 ,4,5,6-tetrahydro-pyrimidine; WO 01/10842 PCT/USOO/21327 -57 (1 -[2-(5-Bromo-2-methoxy-benzylsulfany1)-benzy1]-piperidin-2-y} -methanl; 2- [3-Fluoro-2-(2-naphthalen- 1 -yl-ethyl)-phenyl]- 1,4,5 ,6-tetrahydro-pyrimidine; [2-(5-Bromo-2-methoxy-benzylsulfanyl)-3 -chloro-benzyl]-[3-(2-methyl-piperidin- Il-yl) propylil-amine; 5 1 -[2-(5-Bromo-2-methoxy-benzylsulfany1)-3-chloro-benzy]-pyrrolidifl-3-ylamile; 1 -[2-(5-Bromo-2-methoxy-benzysulfany1)-3-chloro-benzy11-piperazifle; 5,5 -Dimethyl-2- [2-(2-naphthalen- I -yl-ethyl)-phenyl] -4,5 -dihydro- 1 H-imidazole; 2-[3-Fluoro-2-(2-naphthalen- 1 -yl-ethyl)-phenyl] -5 ,5-dimethyl-4,5-dihydro- 1 H imidazole; 10 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3 ,5-difluoro-phenyl]- 1 ,4,5,6-tetrahydro pyrimidine; 2- [2-(5-Bromo-2-methoxy-benzylsulfanyl)-3 ,5-difluoro-phenyl]-5 ,5 -dimethyl-4,5 dihydro- 1 H-imidazole; 3-(2-Naphthalen- 1 -yl-ethyl)-2-( 1,4,5 ,6-tetrahydro-pyrimidin-2-yl)-phenylamine; 15 Amino- [2-(2-naphthalen- 1 -yl-ethyl)-phenyl]-acetonitrile; 1- [2-(2-Naphthalen- 1 -yl-ethyl)-phenyl] -ethane- 1 ,2-diamine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-pheny1]-4-methy1-4,5-dihydro- 1 H imidlazole; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-fluoro-phefl-4-methy1-4,5-dihydro- 1 H 20 imidazole; 2-[2-(5-Bromo-2-methoxy-benzylsulfany1)-3-chloro-pheny1]-4-methy1-4,5-dihydro- 1 H imidazole; 2-12-(5-Bromo-2-methoxy-benzylsulfanyl)-3 ,4-difluoro-phenyl]- 1,4,5 ,6-tetrahydro pyrimidine; 25 2-[3-Fluoro-2-(naphthalen- 1 -ylsulfanylmethyl)-phenyl]-5,5-dimethyl-4,5-dihydro- 1 H imidazole; 2- {2-[2-(5-Bromo-2-methoxy-phenyl)- 1 -methyl-ethylj-phenyl) } 1,4,5 ,6-tetrahydro pyrimidine; 2-[2-(5-Bromo-2-methoxy benzyl sulfanyl)-3 -fluoro-4-trifluoromethyl-phenyl]-4,4 30 dimethyl-4,5-dihydro- 1H-imidazole; 2-[2-(5-Bromo-2-methoxy-benzyl sulfanyl)-3-fluoro-4-trifluoromethyl-phenyl]-5 ,5 dimethyl-1I,4,5,6-tetrahydro-pyrimidine; WO 01/10842 PCT/USOO/21327 -58 2-[3-Methoxy-2-(2-naphthalen- 1 -yl-ethyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-phenyl]-1,4,5,6-tetrahydro pyrimidin-5-ol; 2-{2-[2-(5-Bromo-2-methoxy-phenyl)-ethyl]-3-methoxy-phenyl}-1,4,5,6-tetrahydro 5 pyrimidine; 2-[2-(5 -Bromo-2-methoxy-benzylsulfanyl)-phenyl]-6-ethyl- 1,4,5,6-tetrahydro pyrimidine, and pharmaceutically acceptable salts thereof. Other compounds of the invention are shown in Table 4. In one further embodiment, the methods of the invention do not include methods 10 wherein 2-[2-(2,5-dichlorothiophen-3-ylmethylsulfanyl)-phenyl]-1, 4, 5, 6 tetrahydropyrimidine (Compound A); 2[2-(2-chloro- 6-fluoro-benzylsulfanyl)-phenyl] 1, 4, 5, 6-tetrahydropyrimidine (Compound B); 1-(6-bromo-2-chloro-quinolin-4-yl)- 3 (2-diethylaminoethyl)-urea (Compound AN); 2-[2-(2,6-difluorobenzylsulfanyl)-phenyl] 1, 4, 5, 6-tetrahydropyrimidine (Compound AO); 1-(4-hydroxy-1, 3, 5-trimethyl 15 piperadin-4-yl)-ethanone (Compound AR); 4,6-dimethyl-2-piperazin-1-yl-pyrimidine (Compound FP); 2-piperazin-1-yl-pyrimidine (Compound FR); 1-pyridin-2-yl piperazine (Compound FS); 2-piperazin- 1 -yl-4-trifluoromethyl pyrimidine (Compound FT); 6-piperazin-1-yl-7-trifluoromethyl-thieno[3,2-b]pyridine-3-carboxylic acid methyl ester (Compound FU); 5-bromo-2-piperazin-1-yl)-pyrimidine (Compound FV); 1-(3 20 trifluoromethyl-pyridin-2-yl)-piperazine (Compound FW); 1-(5-trifluoromethyl-pyridin 2-yl)-piperazine (Compound FX); piperazine (Compound KY); or (2-Hexyloxy-phenyl) carbamic acid 2-piperidin- 1 -yl- 1 -piperidin- 1 -ylmethyl-ethyl ester (Compound OQ) are used as MC4-R binding compounds. In another further embodiment, the compounds claimed as MC4-R binding compounds do not include those listed above. 25 In another embodiment, the methods of the invention do not include methods wherein 2-naphthalen-1-ylmethyl-4,5-dihydro-1H-imidazole (NAPHAZOLINE; Compound AS); 10-[2-(1-methyl-piperadin-2-yl)-ethyl]-2-methylsulfanyl-1OH phenothiazine (THORADIAZINE; THIODIAZINE; Compound AP); (2,6-dichloro phenyl)-imidazolidin-2-ylidene-amine (CLONIDINE; Compound AY); or 2-benzyl-4,5 30 dihydro-1H-imidazole (TOLAZOLINE; Compound AZ) are used as MC4-R binding compounds. In another further embodiment, the invention pertain to compounds other than those listed above as MC4-R binding compounds.
WO 01/10842 PCT/USOO/21327 -59 In another further embodiment, the methods of the invention do not include 5-(4 chloro-phenyl)-2,5-dihydro-3H-imidazo[2,1-a]-isoindol-5-ol (MASPINDOL; Compound DT) as an MC4-R binding compound. In one embodiment, the compounds of the invention include MC4-R binding compounds other than MASPINDOL. 5 The term "alkyl" includes saturated aliphatic groups, including straight-chain alkyl groups (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc.), branched-chain alkyl groups (isopropyl, tert-butyl, isobutyl, etc.), cycloalkyl (alicyclic) groups (cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. The term alkyl 10 further includes alkyl groups, which can further include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone. In an embodiment, a straight chain or branched chain alkyl has 10 or fewer carbon atoms in its backbone (e.g., Ci-Cio for straight chain, C 3 -CIo for branched chain), and more preferably 6 or fewer. Likewise, preferred cycloalkyls have from 4-7 carbon atoms in 15 their ring structure, and more preferably have 5 or 6 carbons in the ring structure. Moreover, the term alkyl includes both "unsubstituted alkyls" and "substituted alkyls", the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, 20 arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, 25 arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonarmido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Cycloalkyls can be further substituted, e.g., with the substituents described above. An "alkylaryl" or an "aralkyl" moiety is an alkyl 30 substituted with an aryl (e.g., phenylmethyl (benzyl)). The term "alkyl" also includes the side chains of natural and unnatural amino acids. Examples of halogenated alkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, WO 01/10842 PCT/USOO/21327 -60 dichloromethyl, trichloromethyl, perfluoromethyl, perchloromethyl, perfluoroethyl, perchloroethyl, etc. The term "aryl" includes groups, including 5- and 6-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, 5 phenyl, pyrrole, furan, thiophene, thiazole, isothiaozole, imidazole, triazole, tetrazole, pyrazole, oxazole, isooxazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like. Furthermore, the term "aryl" includes multicyclic aryl groups, e.g., tricyclic, bicyclic, e.g., naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, 10 napthridine, indole, benzofuran, purine, benzofuran, deazapurine, or indolizine. Those aryl groups having heteroatoms in the ring structure may also be referred to as "aryl heterocycles", "heterocycles," "heteroaryls" or "heteroaromatics". The aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, 15 alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino 20 (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Aryl groups can also be fused or bridged with alicyclic or heterocyclic rings which are not aromatic so as to form a polycycle (e.g., 25 tetralin). The term "alkenyl" includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double bond. For example, the term "alkenyl" includes straight-chain alkenyl groups (e.g., 30 ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, etc.), branched-chain alkenyl groups, cycloalkenyl (alicyclic) groups (cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl), alkyl or alkenyl substituted WO 01/10842 PCT/USOO/21327 -61 cycloalkenyl groups, and cycloalkyl or cycloalkenyl substituted alkenyl groups. The term alkenyl further includes alkenyl groups which include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight chain or branched chain alkenyl group has 6 or fewer 5 carbon atoms in its backbone (e.g., C 2
-C
6 for straight chain, C 3
-C
6 for branched chain). Likewise, cycloalkenyl groups may have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure. The term C 2
-C
6 includes alkenyl groups containing 2 to 6 carbon atoms. Moreover, the term alkenyl includes both "unsubstituted alkenyls" and 10 "substituted alkenyls", the latter of which refers to alkenyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, 15 alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, 20 nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. The term "alkynyl" includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond. 25 For example, the term "alkynyl" includes straight-chain alkynyl groups (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, etc.), branched-chain alkynyl groups, and cycloalkyl or cycloalkenyl substituted alkynyl groups. The term alkynyl further includes alkynyl groups which include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon 30 backbone. In certain embodiments, a straight chain or branched chain alkynyl group has 6 or fewer carbon atoms in its backbone (e.g., C 2
-C
6 for straight chain, C 3
-C
6 for WO 01/10842 PCT/USOO/21327 -62 branched chain). The term C 2
-C
6 includes alkynyl groups containing 2 to 6 carbon atoms. Moreover, the term alkynyl includes both "unsubstituted alkynyls" and "substituted alkynyls", the latter of which refers to alkynyl moieties having substituents 5 replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, 10 phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or 15 heteroaromatic moiety. Unless the number of carbons is otherwise specified, "lower alkyl" as used herein means an alkyl group, as defined above, but having from one to five carbon atoms in its backbone structure. "Lower alkenyl" and "lower alkynyl" have chain lengths of, for example, 2-5 carbon atoms. 20 The term "acyl" includes compounds and moieties which contain the acyl radical
(CH
3 CO-) or a carbonyl group. The term "substituted acyl" includes acyl groups where one or more of the hydrogen atoms are replaced by for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, 25 aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, 30 sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
WO 01/10842 PCT/USOO/21327 -63 The term "acylamino" includes moieties wherein an acyl moiety is bonded to an amino group. For example, the term includes alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido groups. The term "aroyl" includes compounds and moieties with an aryl or 5 heteroaromatic moiety bound to a carbonyl group. Examples of aroyl groups include phenylcarboxy, naphthyl carboxy, etc. The terms "alkoxyalkyl", "alkylaminoalkyl" and "thioalkoxyalkyl" include alkyl groups, as described above, which further include oxygen, nitrogen or sulfur atoms replacing one or more carbons of the hydrocarbon backbone, e.g., oxygen, nitrogen or 10 sulfur atoms. The term "alkoxy" includes substituted and unsubstituted alkyl, alkenyl, and alkynyl groups covalently linked to an oxygen atom. Examples of alkoxy groups include methoxy, ethoxy, isopropyloxy, propoxy, butoxy, and pentoxy groups and may include cyclic groups such as cyclopentoxy. Examples of substituted alkoxy groups 15 include halogenated alkoxy groups. The alkoxy groups can be substituted with groups such as alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino 20 (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moieties. Examples of halogen substituted 25 alkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy, etc. The term "amine" or "amino" includes compounds where a nitrogen atom is covalently bonded to at least one carbon or heteroatom. The term "alkyl amino" includes groups and compounds wherein the nitrogen is bound to at least one additional 30 alkyl group. The term "dialkyl amino" includes groups wherein the nitrogen atom is bound to at least two additional alkyl groups. The term "arylamino" and "diarylamino" include groups wherein the nitrogen is bound to at least one or two aryl groups, WO 01/10842 PCT/USOO/21327 -64 respectively. The term "alkylarylamino," "alkylaminoaryl" or "arylaminoalkyl" refers to an amino group which is bound to at least one alkyl group and at least one aryl group. The term "alkaminoalkyl" refers to an alkyl, alkenyl, or alkynyl group bound to a nitrogen atom which is also bound to an alkyl group. 5 The term "amide" or "aminocarboxy" includes compounds or moieties which contain a nitrogen atom which is bound to the carbon of a carbonyl or a thiocarbonyl group. The term includes "alkaminocarboxy" groups which include alkyl, alkenyl, or alkynyl groups bound to an amino group bound to a carboxy group. It includes arylaminocarboxy groups which include aryl or heteroaryl moieties bound to an amino 10 group which is bound to the carbon of a carbonyl or thiocarbonyl group. The terms "alkylaminocarboxy," "alkenylaminocarboxy," "alkynylaminocarboxy," and "arylaminocarboxy" include moieties wherein alkyl, alkenyl, alkynyl and aryl moieties, respectively, are bound to a nitrogen atom which is in turn bound to the carbon of a carbonyl group. 15 The term "carbonyl" or "carboxy" includes compounds and moieties which contain a carbon connected with a double bond to an oxygen atom, and tautomeric forms thereof. Examples of moieties which contain a carbonyl include aldehydes, ketones, carboxylic acids, amides, esters, anhydrides, etc. The term "carboxy moiety" or "carbonyl moiety" refers to groups such as "alkylcarbonyl" groups wherein an alkyl 20 group is covalently bound to a carbonyl group, "alkenylcarbonyl" groups wherein an alkenyl group is covalently bound to a carbonyl group, "alkynylcarbonyl" groups wherein an alkynyl group is covalently bound to a carbonyl group, "arylcarbonyl" groups wherein an aryl group is covalently attached to the carbonyl group. Furthermore, the term also refers to groups wherein one or more heteroatoms are covalently bonded to 25 the carbonyl moiety. For example, the term includes moieties such as, for example, aminocarbonyl moieties, (wherein a nitrogen atom is bound to the carbon of the carbonyl group, e.g., an amide), aminocarbonyloxy moieties, wherein an oxygen and a nitrogen atom are both bond to the carbon of the carbonyl group (e.g., also referred to as a carbamatee"). Furthermore, aminocarbonylamino groups (e.g., ureas) are also include 30 as well as other combinations of carbonyl groups bound to heteroatoms (e.g., nitrogen, oxygen, sulfur, etc. as well as carbon atoms). Furthermore, the heteroatom can be WO 01/10842 PCT/USOO/21327 -65 further substituted with one or more alkyl, alkenyl, alkynyl, aryl, aralkyl, acyl, etc. moieties. The term "thiocarbonyl" or "thiocarboxy" includes compounds and moieties which contain a carbon connected with a double bond to a sulfur atom. The term 5 "thiocarbonyl moiety" includes moieties which are analogous to carbonyl moieties. For example, "thiocarbonyl" moieties include aminothiocarbonyl, wherein an amino group is bound to the carbon atom of the thiocarbonyl group, furthermore other thiocarbonyl moieties include, oxythiocarbonyls (oxygen bound to the carbon atom), aminothiocarbonylamino groups, etc. 10 The term "ether" includes compounds or moieties which contain an oxygen bonded to two different carbon atoms or heteroatoms. For example, the term includes "alkoxyalkyl" which refers to an alkyl, alkenyl, or alkynyl group covalently bonded to an oxygen atom which is covalently bonded to another alkyl group. The term "ester" includes compounds and moieties which contain a carbon or a 15 heteroatom bound to an oxygen atom which is bonded to the carbon of a carbonyl group. The term "ester" includes alkoxycarboxy groups such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentoxycarbonyl, etc. The alkyl, alkenyl, or alkynyl groups are as defined above. The term "thioether" includes compounds and moieties which contain a sulfur 20 atom bonded to two different carbon or hetero atoms. Examples of thioethers include, but are not limited to alkthioalkyls, alkthioalkenyls, and alkthioalkynyls. The term "alkthioalkyls" include compounds with an alkyl, alkenyl, or alkynyl group bonded to a sulfur atom which is bonded to an alkyl group. Similarly, the term "alkthioalkenyls" and alkthioalkynyls" refer to compounds or moieties wherein an alkyl, alkenyl, or 25 alkynyl group is bonded to a sulfur atom which is covalently bonded to an alkynyl group. The term "hydroxy" or "hydroxyl" includes groups with an -OH or -0. The term "halogen" includes fluorine, bromine, chlorine, iodine, etc. The term "perhalogenated" generally refers to a moiety wherein all hydrogens are replaced by 30 halogen atoms. The terms "polycyclyl" or "polycyclic radical" include moieties with two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) WO 01/10842 PCT/USOO/21327 -66 in which two or more carbons are common to two adjoining rings, e.g., the rings are "fused rings". Rings that are joined through non-adjacent atoms are termed "bridged" rings. Each of the rings of the polycycle can be substituted with such substituents as described above, as for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, 5 alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, alkylaminoacarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including 10 alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkyl, alkylaryl, or an aromatic or heteroaromatic moiety. The term "heteroatom" includes atoms of any element other than carbon or 15 hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur and phosphorus. The term "heterocycle" or "heterocyclic" includes saturated, unsaturated, aromatic ("heteroaryls" or "heteroaromatic") and polycyclic rings which contain one or more heteroatoms. Examples of heterocycles include, for example, benzodioxazole, benzofuran, benzoimidazole, benzothiazole, benzothiophene, benzoxazole, deazapurine, 20 furan, indole, indolizine, imidazole, isooxazole, isoquinoline, isothiaozole, methylenedioxyphenyl, napthridine, oxazole, purine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinoline, tetrazole, thiazole, thiophene, and triazole. Other heterocycles include morpholine, piprazine, piperidine, thiomorpholine, and thioazolidine. The heterocycles may be substituted or unsubstituted. Examples of 25 substituents include, for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, alkylaminoacarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino 30 (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, WO 01/10842 PCT/USOO/21327 -67 sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkyl, alkylaryl, or an aromatic or heteroaromatic moiety. It will be noted that the structure of some of the compounds of this invention includes asymmetric carbon atoms. It is to be understood accordingly that the isomers 5 arising from such asymmetry (e.g., all enantiomers and diastereomers) are included within the scope of this invention, unless indicated otherwise. Such isomers can be obtained in substantially pure form by classical separation techniques and by stereochemically controlled synthesis. Furthermore, the structures and other compounds and moieties discussed in this application also include all tautomers thereof. 10 In a further embodiment, the compound is an antagonist of the MC4-R. In another embodiment, the compound is an agonist of the MC4-R. Compounds which are agonists of MC4-R can be identified using the cAMP assay given in Example 5. The term "administering" includes routes of administration which allow the MC4-R binding compound to perform its intended function, e.g. interacting with MC4 15 Rs and/or treating a MC4-R associated state. Examples of routes of administration which can be used include parental injection (e.g., subcutaneous, intravenous, and intramuscular), intraperitoneal injection, oral, inhalation, and transdermal. The injection can be bolus injections or can be continuous infusion. Depending on the route of administration, the MC4-R binding compound can be coated with or disposed in a 20 selected material to protect it from natural conditions which may detrimentally effect its ability to perform its intended function. The MC4-R binding compound can be administered alone or with a pharmaceutically acceptable carrier. Further, the MC4-R binding compound can be administered as a mixture of MC4-R binding compounds, which also can be coadministered with a pharmaceutically acceptable carrier. The 25 MC4-R binding compound can be administered prior to the onset of a MC4-R associated state, or after the onset of a MC4-R associated state. The MC4-R binding compound also can be administered as a prodrug which is converted to another form in vivo. In one embodiment of the invention, the invention includes methods of treating an MC4-R associated state by administering the MC4-R binding compound of the 30 invention in combination with art recognized compounds, e.g., therapeutic agents. For example, a patient suffering from cachexia resulting from HIV, may be treated using both the MC4-R binding compounds of the invention in combination with art recognized WO 01/10842 PCT/USOO/21327 -68 compounds for treating the cachexia or HIV itself. The term "combination with" includes both simultaneous administration as well as administration of the MC4-R binding compound before the art recognized compound or after the compound. The period between administrations of the MC4-R binding compound and the other agent 5 may be any length of time which allows the compositions to perform their intended function, e.g., the interval may be between few minutes, an hour, more than one hour, etc. In addition, the MC4-R binding compounds may also be administered in combination with other MC4-R binding compounds of the invention. The invention also features a pharmaceutical composition for the treatment of a 10 MC4-R associated state in a mammal. The pharmaceutical composition includes a pharmaceutically acceptable carrier and an effective amount of an MC4-R binding compound of the formula (I): B-Z-E (I) wherein B is an anchor moiety, Z is a central moiety, and E is a MC4-R interacting 15 moiety. In other embodiments, the pharmaceutical compositions of the invention include MC4-R binding compounds of formulae II, III, IV, V, VI, VII, VIII, IX, X, and/or XI. Pharmaceutical compositions comprising pharmaceutically acceptable salts of at least one MC4-R binding compound are also included. The language "effective amount" of the compound is that amount necessary or 20 sufficient to treat or prevent a MC4-R associated state, e.g. prevent the various morphological and somatic symptoms of a MC4-R associated state. The effective amount can vary depending on such factors as the size and weight of the subject, the type of illness, or the particular MC4-R binding compound. For example, the choice of the MC4-R binding compound can affect what constitutes an "effective amount". One 25 of ordinary skill in the art would be able to study the aforementioned factors and make the determination regarding the effective amount of the MC4-R binding compound without undue experimentation. An in vivo assay as described in Example 4 below or an assay similar thereto (e.g., differing in choice of cell line or type of illness) also can be used to determine an "effective amount" of a MC4-R binding compound. The ordinarily 30 skilled artisan would select an appropriate amount of a MC4-R binding compound for use in the aforementioned in vivo assay. Advantageously, the effective amount is WO 01/10842 PCT/USOO/21327 -69 effective to treat a disorder associated with pigmentation or weight loss, e.g., weight loss is a result of anorexia nervosa, old age, cancer cachexia, or HIV cachexia. The regimen of administration can affect what constitutes an effective amount. The MC4-R binding compound can be administered to the subject either prior to or after 5 the onset of a MC4-R associated state. Further, several divided dosages, as well as staggered dosages, can be administered daily or sequentially, or the dose can be continuously infused, or can be a bolus injection. Further, the dosages of the MC4-R binding compound(s) can be proportionally increased or decreased as indicated by the exigencies of the therapeutic or prophylactic situation. 10 The term "treated," "treating" or "treatment" includes the diminishment or alleviation of at least one symptom associated or caused by the state, disorder or disease being treated. For example, treatment can be diminishment of one or several symptoms of a disorder or complete eradication of a disorder. The language "pharmaceutical composition" includes preparations suitable for 15 administration to mammals, e.g., humans. When the compounds of the present invention are administered as pharmaceuticals to mammals, e.g., humans, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier. 20 The phrase "pharmaceutically acceptable carrier" is art recognized and includes a pharmaceutically acceptable material, composition or vehicle, suitable for administering compounds of the present invention to mammals. The carriers include liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agent from one organ, or portion of the body, to another organ, 25 or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, 30 ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene WO 01/10842 PCT/USOO/21327 -70 glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible 5 substances employed in pharmaceutical formulations. Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions. 10 Examples of pharmaceutically acceptable antioxidants include: water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, ca-tocopherol, and the like; and metal chelating agents, such as citric acid, 15 ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like. Formulations of the present invention include those suitable for oral, nasal, topical, transdermal, buccal, sublingual, rectal, vaginal and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be 20 prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 per cent 25 to about 70 per cent, most preferably from about 10 per cent to about 30 per cent. Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present 30 invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
WO 01/10842 PCT/USOO/21327 -71 Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an 5 elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient. A compound of the present invention may also be administered as a bolus, electuary or paste. 10 In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as, for example, 15 carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; solution retarding agents, such as paraffin; absorption accelerators, such as quaternary ammonium compounds; wetting agents, such as, for example, cetyl alcohol and glycerol 20 monostearate; absorbents, such as kaolin and bentonite clay; lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules 25 using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like. A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, 30 disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be WO 01/10842 PCT/USOO/21327 -72 made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be 5 scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be sterilized 10 by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain 15 portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients. Liquid dosage forms for oral administration of the compounds of the invention 20 include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluent commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3 25 butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert dilutents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, 30 perfuming and preservative agents. Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and WO 01/10842 PCT/USOO/21327 -73 sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar agar and tragacanth, and mixtures thereof. Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by 5 mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound. 10 Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate. Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, 15 patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required. The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, 20 paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof. Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain 25 customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane. Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can 30 also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active compound in a polymer matrix or gel.
WO 01/10842 PCT/USOO/21327 -74 Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this invention. Pharmaceutical compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with 5 one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents. 10 Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating 15 materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal 20 agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin. 25 In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. 30 Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
WO 01/10842 PCT/USOO/21327 -75 Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable 5 polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue. The preparations of the present invention may be given orally, parenterally, topically, or rectally. They are of course given by forms suitable for each administration 10 route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administration is preferred. The phrases "parenteral administration" and "administered parenterally" as used 15 herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion. 20 The phrases "systemic administration," "administered systemically," "peripheral administration" and "administered peripherally" as used herein mean the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration. 25 These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually. Regardless of the route of administration selected, the compounds of the present 30 invention, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.
WO 01/10842 PCT/USOO/21327 -76 Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. 5 The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular 10 compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts. A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the 15 invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. In general, a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic 20 effect. Such an effective dose will generally depend upon the factors described above. Generally, intravenous and subcutaneous doses of the compounds of this invention for a patient, when used for the indicated analgesic effects, will range from about 0.0001 to about 100 mg per kilogram of body weight per day, more preferably from about 0.01 to about 50 mg per kg per day, and still more preferably from about 1.0 to about 100 mg 25 per kg per day. An effective amount is that amount treats an MC4-R associated state. If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. While it is possible for a compound of the present invention to be administered 30 alone, it is preferable to administer the compound as a pharmaceutical composition. As set out above, certain embodiments of the present compounds can contain a basic functional group, such as amino or alkylamino, and are, thus, capable of forming WO 01/10842 PCT/USOO/21327 -77 pharmaceutically acceptable salts with pharmaceutically acceptable acids. The term "pharmaceutically acceptable salts" is art recognized and includes relatively non-toxic, inorganic and organic acid addition salts of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds 5 of the invention, or by separately reacting a purified compound of the invention in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, 10 napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like. (See, e.g., Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci. 66:1-19). In other cases, the compounds of the present invention may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases. The term "pharmaceutically acceptable 15 salts" in these instances includes relatively non-toxic, inorganic and organic base addition salts of compounds of the present invention. These salts can likewise be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form with a suitable base, such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal 20 cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary or tertiary amine. Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like. Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine 25 and the like. The term "pharmaceutically acceptable esters" refers to the relatively non-toxic, esterified products of the compounds of the present invention. These esters can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a 30 suitable esterifying agent. Carboxylic acids can be converted into esters via treatment with an alcohol in the presence of a catalyst. Hydroxyls can be converted into esters via treatment with an esterifying agent such as alkanoyl halides. The term also includes WO 01/10842 PCT/USOO/21327 -78 lower hydrocarbon groups capable of being solvated under physiological conditions, e.g., alkyl esters, methyl, ethyl and propyl esters. (See, for example, Berge et al., supra.) A preferred ester group is an acetomethoxy ester group. Preferably, the amount of the MC4-R binding compound is effective to treat a pigmentation or weight loss 5 disorder, e.g., weight loss associated with anorexia nervosa, old age, cachexia, HIV or cancer. The invention also pertains to packaged MC4-R binding compounds. The packaged MC4-R binding compounds include, an MC4-R binding compound (e.g., of formulae I, II, III, IV, V, VI, VII, VIII, IX, X, and/or XI), a container, and directions for 10 using said MC4-R binding compound to treat an MC4-R associated state, e.g., weight loss, etc. Examples of MC4-R binding compounds for inclusion in pharmaceutical compositions include, for example, 2-[2-(4-benzyloxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 15 2-[2-(2-iodo-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-methoxy-5-nitro-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(naphthalen-1 -ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(3-chloro-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2,5-dimethoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 20 2-[2-(3-bromo-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-iodo-benzylsulfanyl)-phenyl]-4,5-dihydro- 1 H-imidazole; 2-[2-(2methoxy-5-nitro-benzylsulfanyl)-phenyl]-4,5-dihydro- 1 H-imidazole; 2-[2-(2-methoxy-5-nitro-benzyloxy)-phenyl]-1,4,5,6-tetrahydropyrimidine; 2-[2-(2-bromo-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 25 2-[2-(3-iodo-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-methoxy-5-nitro-benzylsulfanyl)-phenyl]-3a,4,5,6,7,7a-hexahydro-1H benzoimidazole; 2-{2-[2-(2-methoxy-naphthalen-1-yl)-ethyl]-phenyl}-1,4,5,6-tetrahydropyrimidine; 2-[2-(5-bromo-2-methoxy-benzylsulfanyl)-phenyl]-1,4,5,6,-tetrahydropyrimidine; 30 2-{2-[2-(2-methyl-naphthalen-1-yl)-ethyl]-phenyl}-1,4,5,6-tetrahydropyrimidine; 2-{2-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yl) -ethyl]-phenyl} -1,4,5,6 tetrahydropyrimidine; WO 01/10842 PCT/USOO/21327 -79 2-[2-(2-methoxy-napthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydropyrimidine; 2-(2-Benzylsulfanyl-phenyl)-1,4,5,6-tetrahydro-pyrimidine; 2-(2-Pentadecylsulfanyl-phenyl)- 1,4,5,6-tetrahydro-pyrimidine; 2-(2-Cyclohexylmethylsulfanyl-phenyl)-1,4,5,6-tetrahydro-pyrimidine; 5 2-[2-(2-Methyl-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2- [2-(3 -Nitro-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(3,5 -Dimethoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2- [2-(4-Fluoro-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Chloro-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 10 2-[2-(2-Fluoro-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2,4-Bis-trifluoromethyl-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(3-Methoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(3,5-Bis-trifluoromethyl-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Methoxy-5-nitro-benzyloxy)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 15 2-[2-(2-Chloro-6-fluoro-benzylsulfanyl)-phenyl]-4,5-dihydro- 1 H-imidazole; 2-(2-Benzylsulfanyl-phenyl)-4,5-dihydro- 1 H-imidazole; 2-[2-(2,6-Difluoro-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(Naphthalen- 1 -ylmethoxy)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Methyl-naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 20 1- {2-[2-(2-Chloro-6-fluoro-benzylsulfanyl)-phenyl]-5,6-dihydro-4H-pyrimidin-1 -yl} ethanone; 2-[2-(2-Chloro-6-fluoro-benzylsulfanyl)-phenyl]-3a,4,5,6,7,7a-hexahydro-1
H
benzoimidazole; 2-[2-(2-Iodo-benzylsulfanyl)-phenyl]-3a,4,5,6,7,7a-hexahydro-1H-benzoimidazole; 25 2-[2-(2,5-Dimethyl-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 4-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-yl)-phenylsulfanylmethyl]-quinoline; 2-[2-(2-Methoxy-5-nitro-benzylsulfanyl)-pyridin-3-yl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Methoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Cyclopentyloxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 30 2-[2-(2,3-Dihydro-benzo[1,4]dioxin-5-ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro pyrimidine; WO 01/10842 PCT/USOO/21327 -80 2-[2-(6-Methoxy-2,3-dihydro-benzo[ 1,4]dioxin-5-ylmethylsulfanyl)-pheflyl]- 1,4,5,6 tetrahydro-pyrimidine; 2- [2-(5-fluoro-2-methoxy-benzylsulfanyl)-phefl]-4,5-dihydro- 1 H-imidazole; 1 -Methyl-2-112-(naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1 ,4,5,6-tetrahydro-pyrimidine; 5 2-[2-(5 -Bromo-2-methoxy-benzylsulfany1)-pheny1]-4,5-dihydro- 1H-imidazole; 2-[2-(5-Bromo-2-methoxy-benzyloxy)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2- [2-(Naphthalen- 1 -yloxymethyl)-phenyl]- 1,4,5 ,6-tetrahydro-pyrimidine; 2-[2-(5 -Bromo-2-methoxy-benzylsulfanyl)-phenyll-5 ,5 -dimethyl- 1,4,5,6-tetrahydro pyrimidine; 10 2-2(-rm--ehx-ezlufnl-hnl-,-iehl45dhdo 1 H imidazole; 2-II2-(2,6-Dimethoxy-benzylsulfany1)-phel]- 1,4,5 ,6-tetrahydro-pyrimidine; 2- [2-(2-Bromo-6-methoxy-benzylsulfanyl)-pheflyl]- 1,4,5 ,6-tetrahydro-pyrimidine; 2-5Boo2(5boo2mthx-e1 ufay)pey]-,-iyr-H-imidazole; 15 2-[5-Bromo-2-(5-bromo-2-methoxy-belzylsulfaflyl)-phefllF1 ,4,5,6-tetrahydro pyrimidine; 2-[4-Bromo-2-(5-bromo-2-methoxy-benzysufany)-phelylI- 1,4,5 ,6-tetrahydro pyrimidine; 2-[I2-(2-Bromo-5-methoxy-benzylsulfany1)-phel- 1 ,4,5,6-tetrahydro-pyrimidine; 20 2-[2-(5-Bromo-2-methoxy-benzysulfany)-5-methy-phel]l- 1,4,5 ,6-tetrahydro pyrimidine; 2-[2-(Biphenyl-3 -ylmethylsulfanyl)-phenyl] -1,4,5 ,6-tetrahydro-pyrimidine; 2-[2-(5-Chloro-2-methoxy-benzylsulfanyl)-pheflyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Methoxy-5-thiophen-3-yl-benzylsulfalyl)-pheflyl]- 1,4,5,6-tetrahydro 25 pyrimidine; 2-[2-(Biphenyl-2-ylmethylsulfanyl)-phenyl]- 1,4,5 ,6-tetrahydro-pyrimidine; 2-[2-(5-lodo-2-methoxy-benzylsulfanyl)-phelyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-5-fluoro-phell- 1 ,4,5,6-tetrahydro pyrimidine; 30 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-fluoro-phelyl]-l ,4,5,6-tetrahydro pyrimidine; WO 01/10842 PCT/USOO/21327 -81 2-[2-(4,4'-Dimethoxy-biphenyl-3-ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro pyrimidine; 2-[2-(9H-Fluoren-9-ylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(3'-Chloro-4'-fluoro-4-methoxy-biphenyl-3-ylmethylsulfanyl)-phenyl]-1,4,5,6 5 tetrahydro-pyrimidine; 2-[2-(1 -Naphthalen- 1 -yl-ethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-5-fluoro-phenyl]-4,5-dihydro- 1 H-imidazole; 2-(2-Benzhydrylsulfanyl-phenyl)- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2'-Fluoro-4"-methoxy-[ 1,1';4', 1 "]terphenyl-3 "-ylmethylsulfanyl)-phenyl]- 1,4,5,6 10 tetrahydro-pyrimidine; 2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzamidine; 2-[4-(Naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5 -Ethynyl-2-methoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-1,4,5,6-tetrahydro-pyrimidine; 15 2-[2-(5-Bromo-2-cyclopentyloxy-benzylsulfanyl)-phenyl] -1,4,5,6-tetrahydro pyrimidine; 2-[2-(5-Bromo-2-ethoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Bromo-2-propoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; [2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-diethyl-amine; 20 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-piperazine; C- {4-[3-(5-Bromo-2-methoxy-benzylsulfanyl)-quinoxalin-2-yl]-morpholin-2-yl methylamine; 2-[2-(2-Methoxy-5-methyl-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Bromo-2-methoxy-benzyloxymethyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 25 [2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-dimethyl-amine; 2-[2-(5-Bromo-2-isopropoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Ethoxy-naphthalen-1-ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Propoxy-naphthalen-1-ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 4-Methoxy-3-[2-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-phenylsulfanylmethyl] 30 benzonitrile; 1- {4-Methoxy-3- [2-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-phenylsulfanylmethyl]-phenyl} ethanone; WO 01/10842 PCT/USOO/21327 -82 2-[2-(Naphthalen- 1 -ylsulfanylmethyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-piperidine; C- {4-[2-(2-Methoxy-naphthalen- 1 -ylmethylsulfanyl)-benzyl]-morpholin- 2 -yl} methylamine; 5 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-pyrrolidin-3-ylamine; 1-[2-(2-Methoxy-naphthalen- 1 -ylmethylsulfanyl)-benzyl]-pyrrolidin-3-ylamine; 3-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-fluoro-phenyl]- 1,5,6,7,8 ,8a-hexahydro imidazo[1,5-a]pyridine; 3-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-fluoro-phenyl]-5,6,7,7a-tetrahydro- 1 H 10 pyrrolo[1,2-c]imidazole; 2-[2-(Benzo[b]thiophen-3-ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[3-Fluoro-2-(naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-(Naphthalen- 1 -ylmethylsulfanyl)-3 -(1,4,5,6-tetrahydro-pyrimidin-2-yl)-phenylamine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-phenyl]- 1,4,5,6-tetrahydro 15 pyrimidine; 2-[2-(2-Methoxy-phenylsulfanylmethyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 1-{2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-5,6-dihydro-4H-pyrimidin-yl } 3-methyl-butan- 1-one; 1-{2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-5,6-dihydro-4H-pyrimidin- 1-yl} 20 2-phenyl-ethanone; 2-[3-(5-Bromo-2-methoxy-benzylsulfanyl)-pyridin-2-yl]- 1,4,5,6-tetrahydro-pyrimidine; N-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-guanidine; 2-[2-(2-Isopropoxy-naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro pyrimidine; 25 2-[2-(2-Cyclopentyloxy-naphthalen- 1 -ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro pyrimidine; (5-Bromo-2-methoxy-benzyl)-[2-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-phenyl]-amine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanylmethyl)-phenyl]-1,4,5,6-tetrahydro pyrimidine; 30 2-[2-(2-Methoxy-naphthalen-1 -ylsulfanylmethyl)-phenyl]- 1,4,5,6-tetrahydro pyrimidine; 2-[3-(5-Bromo-2-methoxy-benzylsulfanyl)-pyrazin- 2 -yl]-1,4,5,6-tetrahydro-pyrimidine; WO 01/10842 PCT/USOO/21327 -83 2-[3 -Chloro-2.-(naphthalen- 1 -ylsulfanylmethyl)-phenyl]- 1,4,5 ,6-tetrahydro-pyrimidine; 2-[2-(6-Bromo-2-methoxy-naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1 ,4,5,6-tetrahydro pyrimidine; 2- [3-Chloro-2-(2-methoxy-naphthalen- 1 -ylsulfanylmethyl)-phenyl] -1,4,5 ,6-tetrahydro 5 pyrimidine; 2- [2-(5-Bromo-2-methoxy-phenylsulfanylmethyl)-phenyll- 1,4,5 ,6-tetrahydro pyrimidine; 2-[2-(5-Bromo-2-methoxy-phenylsulfanylmethyl)-3-chloro-phelyl]- 1 ,4,5,6-tetrahydro pyrimidine; 10 2-[ 1-(2-Naphthalen- 1 -yl-ethyl)- I H-pyrrol-2-yl]-l ,4,5 ,6-tetrahydro-pyrimidine; (5-Bromo-2-methoxy-benzyl)-methyl-[2-( 1,4,5 ,6-tetrahydro-pyrimidin-2-yl)-phenyl] amine; 2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzylamine; 2-[2-(2-Chloro-phenylsulfanylmethyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 15 2-[2-(2-Bromo-phenylsulfanylmethyl)-phenyl] -1,4,5 ,6-tetrahydro-pyrimidine; 2-(2-o-Tolylsulfanylmethyl-phenyl)- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2,5-Dichloro-phenylsulfanylmethyl)-phenyl]- 1,4,5 ,6-tetrahydro-pyrimidine; 2-(3 -Amino-propylamino)-6-(5 -bromo-2-methoxy-benzylsulfanyl)-benzonitrile; 2-[2-(5 -Bromo-2-methoxy-benzylsulfanyl)-benzyl] -1,4,5 ,6-tetrahydro-pyrimidine; 20 [2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-diethyl-amfile; 4-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyll-morpholine; 3t-(5-Bromo..2.methoxy-benzylsulfanlyl)-3 ,4,5 ,6-tetrahydro-2H- [1 ,2']bipyrazinyl; 2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-piperazifl-l-yl-6,7-dihydro-quinoxaline; 1 -[2-(5-Bromo-2-methoxy-benzylsulfany1)-benzy1]-piperidile; 25 C- {4-[2-(2-Methoxy-naphthalen- 1-ylmethylsulfanyl)-benzyl]-morpholin-2-yl } methylamine; 1 -[3-(5-Bromo-2-methoxy-benzylsulfany1)-pyrazin-2-yl]-pyrroidil-3-ylamile; 1 -[3-(5-Bromo-2-methoxy-benzysufany)-quinoxain-2-y]-pyrrolidifl-3-ylamilC 1- [2-(2-Methoxy-naphthalen- 1-ylmethylsulfanyl)-benzyl]-pyrrolidin-3 -ylamine; 30 C- {4-[3-(5-Bromo-2-methoxy-benzylsulfany1)-pyrazin-2-y]-morpholin-3-yl
}
methylamine; I -[3-Fluoro-2-(2-naphthalen- 1 -yl-ethyl)-benzyl]-piperazine; WO 01/10842 PCT/USOO/21327 -84 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-azetidine; 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-pyrrolidin- 3 -ol; [2-(Naphthalen-1-ylmethylsulfanyl)-phenyl]-carbamic acid I-aza-bicyclo[2.2.2]oct-3-yl ester; 5 [2-(2-Methyl-naphthalen-1-ylmethylsulfanyl)-phenyl]-carbamic acid 1 -aza bicyclo[2.2.2]oct-3-yl ester; [2-(2-Methyl-naphthalen- 1 -ylmethylsulfanyl)-phenyl)-carbamic acid 2-piperidin- 1-yl ethyl ester; {1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-pyrrolidin-2-yl} 10 methanol; 4-tert-Butyl-N-naphthalen- 1 -ylmethyl-N-(2-piperidin- 1 -yl-ethyl)-benzamide; N,N-Dimethyl-N'-naphthalen-2-ylmethyl-N'-naphthalen- 1 -ylmethyl-propane- 1,3 diamine; N-(5-Bromo-2-methoxy-benzyl)-N',N'-dimethyl-N-naphthalen-1-ylmethyl-propane-1,3 15 diamine; 1 -Naphthalen- 1 -ylmethyl-3 -phenethyl- 1 -(2-piperidin- 1 -yl-ethyl)-thiourea; 3-(4-Dimethylamino-phenyl)- 1 -(3-dimethylamino-propyl)- 1 -naphthalen- 1 -ylmethyl thiourea; 4- [2-(5 -Bromo-2-methoxy-benzylsulfanyl)-3 -chloro-benzylamino]-piperidine- 1 20 carboxylic acid ethyl ester; 2-[2-(2-Naphthalen- 1 -yl-ethyl)-phenyl]-ethylamine; Naphthalene-2-sulfonic acid (2-dimethylamino-ethyl)-naphthalen-1-ylmethyl-amide; 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl)-2-methoxymethyl pyrrolidine; 25 (2-Hexyloxy-phenyl)-carbamic acid 2-piperidin- 1-yl-1 -piperidin- 1 -ylmethyl-ethyl ester; 3-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyloxy]-pyrrolidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyloxymethyl]-pyrrolidine; 2-[2-(Naphthalen- 1 -ylsulfanylmethyl)-phenyl]-piperidine; 3-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzylamino]-propan-1-ol; 30 3-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzylamino]-3-methyl-butan- 1 -ol; 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-pyrrolidin-3-ol; {1 -[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-pyrrolidin-2-yl}I-methanol; WO 01/10842 PCT/USOO/21327 -85 {1 -[2-(Naphthalen-1 -ylsulfanylmethyl)-benzyl]-piperidin-2-yl} -methanol; 2-[2-(Naphthalen- 1 -ylsulfanylmethyl)-pyrrolidin-I -yl]-ethyl-N-pyrrolidine; N-pyrrolyl-[1 -(2-naphthalen- 1 -yl-ethyl)-pyrrolidin-2-ylmethyl]-amine; 1-(2-Naphthalen- 1 -yl-ethyl)-piperidine-2-carboxylic acid methyl ester; 5 (3-Bromo-benzyl)-(1 -ethyl-pyrrolidin-2-ylmethyl)-naphthalen- 1 -ylmethyl-amine; 3-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyloxy]-piperidine; (5-Bromo-2-methoxy-benzyl)-(1 -ethyl-pyrrolidin-2-ylmethyl)-naphthalen- 1 -ylmethyl amine; (1 -Ethyl-pyrrolidin-2-ylmethyl)-naphthalen-2-ylmethyl-naphthalen- 1 -ylmethyl-amine; 10 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyloxymethyl]-pyrrolidine; (3-Bromo-benzyl)-(3-imidazol-1-yl-propyl)-naphthalen-1-ylmethyl-amine; (3-Imidazol- I -yl-propyl)-naphthalen-2-ylmethyl-naphthalen- 1 -ylmethyl-amine; [2-(Naphthalenl-ylmethylsulfanyl)-phenyl]-carbamic acid 2-piperidin-1-yl-l-piperidin 1-ylmethyl-ethyl ester; 15 [2-(Naphthalen-1-ylmethylsulfanyl)-phenyl]-carbamic acid 2-dimethylamino-ethyl ester; 1-[2-(Naphthalen- 1 -ylsulfanylmethyl)-benzyl]-piperazine; [3-(2-Methyl-piperidin- 1 -yl)-propyl]-[2-(naphthalen- 1 -ylsulfanylmethyl)-benzyl] amine; 1-[3-Chloro-2-(naphthalen- 1 -ylsulfanylmethyl)-benzyl]-piperazine; 20 NN-Dimethyl-N'-(2-naphthalen- 1 -yl-ethyl)-N'-naphthalen- 1 -ylmethyl-ethane- 1,2 diamine; { I -[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-piperidin-2-yl}-methanol; 1-[2-(2-Naphthalen-1-yl-ethyl)-benzyl]-piperazine; [3-(2-Methyl-piperidin- 1 -yl)-propyl]-[2-(2-naphthalen- 1 -yl-ethyl)-benzyl]-amine; 25 1-[3-Fluoro-2-(2-naphthalen-1-yl-ethyl)-benzyl]-piperazine; {1 -[3-Chloro-2-(naphthalen- 1 -ylsulfanylmethyl)-benzyl] -piperidin-2-yl} -methanol; {I -[2-(5-Bromo-2-methoxy-benzylsulfany)-3-chloro-benzyl]-piperidin-2-yl}-methanol; (1 -[2-(2-Naphthalen- 1 -yl-ethyl)-benzyl]-piperidin-2-yl} -methanol; [3 -(2-Methyl-piperidin- 1 -yl)-propyl]-[2-(2-naphthalen- 1 -yl-ethyl)-benzyl]-amine; 30 1-[2-(2-Naphthalen-1-yl-ethyl)-benzyl]-pyrrolidin-3-ylamine; 1 -Phenyl-3-piperazin- 1 -yl-5,6,7,8-tetrahydro-isoquinoline-4-carbonitrile; WO 01/10842 PCT/USOO/21327 -86 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-6-ethyl- 1,4,5,6-tetrahydro pyrimidine; 2-[2-(4-Methoxy-biphenyl-3 -ylmethylsulfanyl)-phenyl]- 1,4,5 ,6-tetrahydro-pyrimidine; 2-[2-(2-Methoxy-5-phenylethynyl-benzylsulfanyl)-phenyl]- 1,4,5 ,6-tetrahydro 5 pyrimidine; 2-[2-(2-Naphthalen- 1 -yl-ethyl)-phenyl]- 1,4,5 ,6-tetrahydro-pyrimidine; 2-[3 -(2-Methoxy-naphthalen- 1 -ylsulfanylmethyl)-thiophen-2-yl]- 1,4,5 ,6-tetrahydro pyrimidine; 2-[I2-(2,5-Dimethoxy-phenylsulfanylmethy1)-pheny]- 1 ,4,5,6-tetrahydro-pyrimidine; 10 2-[2-(4-Methyl-naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5 ,6-tetrahydro-pyrimidine; 2-2(-rm--ehx-ezlufnl--fur-hnl-,-iehl45dhdo 1 H-imidazole; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3 -fluoro-phenyl]-5 ,5-dimethyl- 1,4,5,6 tetrahydro-pyrimidine; 15 2-[3 -(Naphthalen- I -ylsulfanylmethyl)-thiophen-2-yl]- 1,4,5 ,6-tetrahydro-pyrimidine; 2-f{ 2- [2-(5-Bromo-2-methoxy-phenyl)-ethyl]-phenyl }-1 ,4,5,6-tetrahydro-pyrimidine; 2-[3 -Chloro-2-(2-naphthalen- 1-yl-ethyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2- {2- [2-(5-Bromo-2-methoxy-phenyl)-ethyll-3 -fluoro-phenyl }-1,4,5 ,6-tetrahydro pyrimidine; 20 2-[2-(5 -Bromo-2-methoxy-phenylsulfanylmethyl)-3-fluoro-pheflyl] -1,4,5 ,6-tetrahydro pyrimidine; 2- [2-(Naphthalen- 1-ylsulfanylmethyl)-phenyl]-4,5-dihydro- 1H-imidazole; 24[3-Fluoro-2-(naphthalen- 1-ylsulfanylmethyl)-phenyl]- 1,4,5 ,6-tetrahydro-pyrimidine; 2-13-Bromo-2-(naphthalen- 1-ylsulfanylmethyl)-phenyl]- 1,4,5 ,6-tetrahydro-pyrimidine; 25 2- {2-[2-(5-Bromo-2-methoxy-phenyl)-ethyl]-3-chloro-phenyl }-1 ,4,5,6-tetrahydro pyrimidine; 2-[2-(2-Methoxy-5-trifluoromethyl-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro pyrimidine; 2-[4-(Naphthalen- 1-ylsulfanylmethyl)-thiophen-3 -yl]-l ,4,5,6-tetrahydro-pyrimidine; 30 2-[2-(Naphthalen- 1-ylsulfanylmethyl)-thiophen-3 -yl]-l ,4,5,6-tetrahydro-pyrimidine; 2- {2-12-(5-Bromo-2-methoxy-phenyl)-ethyl]-3 -trifluoromethyl-phenyl} -1,4,5,6 tetrahydro-pyrimidine; WO 01/10842 PCT/USOO/21327 -87 2-[2-(2-Naphthalen- 1 -yl-ethyl)-3-trifluoromethyl-phenyl]- 1 ,4,5,6-tetrahydro-pyrimidine; 2-[2-(6-Fluoro-naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5 ,6-tetrahydro-pyrimidine; (I1 -[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-piperidil-2-y1 } -methanol; 2-[3 -Fluoro-2-(2-naphthalen- 1 -yl-ethyl)-phenyl] - 1,4,5 ,6-tetrahydro-pyrimidine; 5 [2-(5-Bromo-2-methoxy-benzylsulfanyl)-3 -chloro-benzyl] -13-(2-methyl-piperidin- l -yl) propyl]-amine; 1 -[2-(5 -Bromo-2-methoxy-benzylsulfanyl)-3 -chloro-benzyl]-pyrrolidin-3 -ylamine; 1 -[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-piperazile; 5 ,5-Dimethyl-2-[2-(2-naphthalen- 1 -yl-ethyl)-phenyl]-4,5-dihydro- 1 1--imidazole; 10 2-[3 -Fluoro-2-(2-naphthalen- 1 -yl-ethyl)-phenyl]-5,5-dimethyl-4,5-dihydro- 1 H imidazole; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3 ,5-difluoro-phenyl]- 1,4,5,6-tetrahydro pyrimidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3 ,5-difluoro-phenyl]-5 ,5-dimethyl-4,5 15 dihydro- 1 H-imidazole; 3-(2-Naphthalen- 1 -yl-ethyl)-2-( 1,4,5 ,6-tetrahydro-pyrimidin-2-yl)-phenylamine; Amino- [2-(2-naphthalen- 1 -yl-ethyl)-phenyl]-acetonitrile; 1- [2-(2-Naphthalen- 1 -yl-ethyl)-phenyl] -ethane- 1 ,2-diamine; 2- [2-(5 -Bromo-2-methoxy-benzylsulfanyl)-phenyl] -4-methyl-4,5 -dihydro- 1 H 20 imidazole; 2-[2-(5-Bromo-2-methoxy-benzylsulfany1)-3-fluoro-phefl-4-methyl-4,5-dihydro 1 H imidazole; 2-[2-(5-Bromo-2-methoxy-benzylsulfany1)-3-chloro-phefl]-4-methy[-4,5-dihydro- 1 H imidazole; 25 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3 ,4-difluoro-phenyl]- 1,4,5 ,6-tetrahydro pyrimidine; 2-[3-Fluoro-2-(naphthalen- 1 -ylsulfanylmethyl)-phenyl]-5 ,5-dimethyl-4,5-dihydro- I H imidazole; 2- {2-[2-(5-Bromo-2-methoxy-phenyl)- 1 -methyl-ethyl]-phenyl - -1,4,5 ,6-tetrahydro 30 pyrimidine; 2-[2-(5-Bromo-2-methoxy benzyl sulfanyl)-3 -fluoro-4-trifluoromethyl-phenyl]-4,4 dimethyl-4,5-dihydro- IH-imidazole; WO 01/10842 PCT/USOO/21327 -88 2-[2-(5-Bromo-2-methoxy-benzyl sulfanyl)-3-fluoro-4-trifluoromethyl-phenyl]-5,5 dimethyl- 1,4,5,6-tetrahydro-pyrimidine; 2-[3-Methoxy-2-(2-naphthalen- I -yl-ethyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5 -Bromo-2-methoxy-benzylsulfanyl)-3-chloro-phenyl]- 1,4,5,6-tetrahydro 5 pyrimidin-5-ol; 2-{2-[2-(5-Bromo-2-methoxy-phenyl)-ethyl]-3-methoxy-phenyl}-1,4,5,6-tetrahydro pyrimidine; 2-[2-(5 -Bromo-2-methoxy-benzylsulfanyl)-phenyl]-6-ethyl- 1,4,5,6-tetrahydro pyrimidine, and pharmaceutically acceptable salts thereof. Also included are 10 compositions containing the compounds listed in Table 4. In a further embodiment, the pharmaceutical compositions of the invention include compositions wherein the MC4-R binding compound is not 5-(4-chloro-phenyl) 2,5-dihydro-3H-imidazo[2, 1 -a]-isoindol-5-ol (MASPINDOL; Compound DT). In another embodiment, the pharmaceutical compositions of the invention 15 include compositions wherein the MC4-R binding compound is not 2-naphthalen- 1 ylmethyl-4,5-dihydro- I H-imidazole (NAPHAZOLINE; Compound AS); 10-[2-( 1 methyl-piperadin-2-yl)-ethyl]-2-methylsulfanyl- 1 OH-phenothiazine (THORADIAZINE; THIODIAZINE; Compound AP); (2,6-dichloro-phenyl)-imidazolidin-2-ylidene-amine (CLONIDINE; Compound AY); or 2-benzyl-4,5-dihydro-1H-imidazole 20 (TOLAZOLINE; Compound AZ). In another further embodiment, the pharmaceutical compositions of the invention includes compositions wherein the MC4-R binding compound is not 2-[2-(2,5 dichlorothiophen-3-ylmethylsulfanyl)-phenyl]-1, 4, 5, 6- tetrahydropyrimidine (Compound A); 2[2-(2-chloro- 6-fluoro-benzylsulfanyl)-phenyl]-1, 4, 5, 6 25 tetrahydropyrimidine (Compound B); 1-(6-bromo-2-chloro-quinolin-4-yl)-3-(2 diethylaminoethyl)-urea (Compound AN); 2-[2-(2,6-difluorobenzylsulfanyl)-phenyl]-1, 4, 5, 6-tetrahydropyrimidine (Compound AO); 1-(4-hydroxy-1, 3, 5-trimethyl-piperadin 4-yl)-ethanone (Compound AR); 4,6-dimethyl-2-piperazin- 1 -yl-pyrimidine (Compound FP); 2-piperazin- 1 -yl-pyrimidine (Compound FR); 1 -pyridin-2-yl-piperazine 30 (Compound FS); 2-piperazin-1-yl-4-trifluoromethyl pyrimidine (Compound FT); 6 piperazin-1-yl-7-trifluoromethyl-thieno[3,2-b]pyridine-3-carboxylic acid methyl ester (Compound FU); 5-bromo-2-piperazin- 1 -yl)-pyrimidine (Compound FV); 1-(3- WO 01/10842 PCT/USOO/21327 -89 trifluoromethyl-pyridin-2-yl)-piperazine (Compound FW); 1-(5-trifluoromethyl-pyridin 2-yl)-piperazine (Compound FX); piperazine (Compound KY); or (2-Hexyloxy-phenyl) carbamic acid 2-piperidin-1-yl-1-piperidin-1-ylmethyl-ethyl ester (Compound OQ). 5 The compounds of the present invention can be synthesized using standard methods of chemical synthesis and/or can be synthesized using schemes described herein. Synthesis of specific compounds is discussed in detail in the Example sections below. Examples of syntheses of several classes of compounds of the invention are outlined in the schemes below. Scheme 1 depicts a method of synthesizing 10 thiomethylene compound of the invention. 0 OH | reflux in 1,2-dichlorobenzene + q YH YHH I X N N HX H MeOH 22-60 *C YH -R Y =0 or S; q= bond, CH 2 , fused-cyclohexane. R various alkyl, cycloalkyl, aryl or heteroaryl X 1, Br or CI Scheme 1 2-hydroxy or 2-mercapto benzoic acid is heated with the diamine in refluxing 1,2-dichlorobenzene to form the corresponding heterocyclic compound. The desired 15 thioether or ether is formed by treating the thiol or alcohol with a corresponding halogenated compound. Scheme 2 depicts a general preparation of ethanyl-linked compounds of the invention.
WO 01/10842 PCT/USOO/21327 -90 CN CN 1) LDA[rHF -78 *C 2) Ar-\ x Ar 1,3-diaminopropane, H 2 S N Ar Scheme 2 Scheme 2 shows a method of synthesizing ethanyl linked compounds by treating a-tolunitrile with a lithium base in THF at -78 *C. A halogenated alkylaryl compound 5 is then added to form the ethanyl linkage. To form the heterocycle, hydrogen sulfide gas is bubbled through a solution of the nitrile and 1,3 diaminopropane. After formation, the product can then be obtained and purified using standard techniques. Scheme 3 depicts a method of preparing methylenethio linked compounds of the invention. 10 CN Ar-SH CN Br K 2
CO
3 /DMF S Ar 1,3-diaminopropane, H 2 S N H Scheme 3 As depicted in Scheme 3, the methylenethio compounds of the invention can be prepared by adding anhydrous K 2 C0 3 to a thiophenol compound (Ar-SH) in DMF. The solution is then stirred and bromomethyl-benzonitrile is subsequently added. The 15 thioether is then converted to the heterocyclic compound by bubbling hydrogen sulfide through a solution of the thioether and 1,3 diaminopropane. After formation, the product can then be obtained and purified using standard techniques.
WO 01/10842 PCT/USOO/21327 -91 The invention is further illustrated by the following examples which in no way should be construed as being further limiting. The contents of all references, pending patent applications and published patent applications, cited throughout this application are hereby incorporated by reference. It should be understood that the animal models 5 used throughout the examples are accepted animal models and that the demonstration of efficacy in these animal models is predictive of efficacy in humans. EXEMPLIFICATION OF THE INVENTION: 10 EXAMPLE 1: Synthesis of Compounds B, HO, and IZ Synthesis of Compound B 2-(4,5-Dihydro-1H-imidazol-2-yl)-benzenethiol. To a suspension of 20.0 g (0.112 mol) of thiosalicylic acid in 200 mL of 1,2-dichlorobenzene was added 21.6 mL (0.323 mol) 15 of ethylenediamine. The mixture was refluxed under nitrogen for 4 h then cooled to ca. 60 oC and 50 mL of methanol was added. The solution was allowed to stand at 22 OC over night and the resulting yellow crystalline solid collected and washed with ether to give 10.6 g of pure product. 2-[2-(2-Chloro-6-fluoro-benzylsulfanyl)-phenyll- 1,4,5,6-tetrahydro-pyrimidine; 20 hydrochloride (Compound B). To a solution of 750 mg (3.90 mmol) of 2-(1,4,5,6 Tetrahydro-pyrimidin-2-yl)-benzenethiol was added 1.04 g (5.81 mmol) of 1 -Chloro-2 chloromethyl-3-fluoro-benzene. The solution was stirred overnight at 22 oC and 2-3 mL of ether was added to induce crystallization. The crystals were collected and washed with ether to give 1.34 g of product. 25 NMR Data for Compound B 'H NMR (300 MHz, CD 3 0D) 8 2.01-2.09 (2H, in), 3.49 (4H, br t, J = 5.8 Hz), 4.28 (2H, s), 7.01-7.07 (1H, in), 7.22-7.33 (2H, in), 7.48 (2H, in), 7.56-7.64 (1H, m), 7.75 (1H, d, J= 7.8 Hz) 30 Synthesis of Compound HO: WO 01/10842 PCT/USOO/21327 -92 N H Compound HO CN CNN CN 1,~ THF + N + n-BuLi + HMPA + H ~'-78*C Scheme 4 5 2-(2-Naphthalen-1-yl-ethyl)-benzonitrile. A solution of 1.26 mL (911 mg, 9.00 mmol) of diisopropylamine in 50 mL of THF (tetrahydrofuran) was cooled to -78 *C under nitrogen and 5.6 mL (9.0 mmol) of n-butyllithium, 1.6 M in hexanes, was added via syringe. The mixture was stirred at -78 "C for 1 hour and a solution of 353 mg (3.00 10 mmol) of a-tolunitrile in 10 mL of THF was added. The solution was stirred at -78 *C for one additional hour and a solution of 1.57 mL (9.00 mmol) of HMPA and 583 mg (3.30 mmol) of 1-chloromethylnaphthalene in 10 mL of THF was added dropwise. After stirring for one additional hour at -78*C, the reaction was quenched with water and extracted with Et 2 0 (diethyl ether) (2x30 mL). The organic layer was washed with 15 aqueous 1 N HCl (30mL), water (3x3OmL), brine (30mL) and dried (Na 2
SO
4 ). The solvent was evaporated to give 735 mg of crude product which was used directly in the next step. N CNN N H2N N H N---NH2 H + SH 2 Scheme 5 20 2-[2-(2-Naphthalen-1-yl-ethyl)-phenyll-1,4,5,6-tetrahydro-pyrimidine (Compound IQ). Hydrogen sulfide gas was bubbled through a solution of 735 mg of crude 2-(2 Naphthalen-1-yl-ethyl)-benzonitrile in 5 mL of 1,3-diaminopropane for 5 minutes, as WO 01/10842 PCT/USOO/21327 -93 depicted in Scheme 3. The reaction was capped and heated to 80 "C for 72 hours. The reaction mixture was then diluted with 5 mL of water and extracted with ethyl acetate (2xOmL). The organic extracts were washed with water (3xOmL), brine (2xOmL), dried (Na 2
SO
4 ) and the solvent was evaporated. The residue was purified on silica gel 5 (eluting with 90:10:1:1 of dichloromethane/methanol/water/formic acid) to afford 310 mg of the formate salt of the product as a colorless oil. NMR Data for Compound HO: 'H NMR (300 MHz, CDCl 3 ) 8 1.35-1.50 (2H, m), 2.80-2.95 (4H, m), 3.03 (2H, t, J= 10 6.8), 3.30 (2H, t, J= 6.8), 6.77 (1H, d, J = 6.9), 7.03-7.30 (3H, m), 7.30-7.57 (4H, m), 7.67 (1H, d, J = 8.1), 7.80-7.90 (1H, m), 7.94-8.03 (1H, m), 8.06 (2H, brs, formate salt). Synthesis of Compound IZ: N S N H0 S, Br 15 Compound IZ CN + Br ON + KCO, DMF 0 Br Scheme 6 2-(5-Bromo-2-methoxy-phenylsulfanylmethyl)-benzonitrile. As depicted in Scheme 4 above, to a solution of 104 mg (0.470 mmol) of 2-methoxy-5-bromo-thiophenol in 5 mL 20 of DMF was added 162 mg (1.18 mmol) of anhydrous to a solution of 104 mg (0.470 mmol) of 2-methoxy-5-bromo-thiophenol in 5 mL of DMF was added 162 mg (1.18 mmol) of anhydrous K 2
CO
3 . The solution was stirred for 15 minutes at 22 "C and 103 mg (0.520 mmol) of 2-bromomethyl-benzonitrile was added. The reaction was capped and heated to 40 *C for 12 hours. The mixture was subsequently diluted with 5 mL of WO 01/10842 PCT/USOO/21327 -94 water and extracted with ethyl acetate (2x 1 OmL). The organic extracts were washed with water (3xlOmL), brine (2xlOmL), and dried (Na 2
SO
4 ). The solvent was evaporated and the product was purified on silica gel (eluting with 9:1 of hexane/ethyl acetate) to afford 102 mg of the product as a colorless oil. N C o + SH 2 S S 5 Br Br Scheme 7 2-[2-(5-Bromo-2-methoxy-phenylsulfanylmethyl)-phenyll-1,4,5,6-tetrahydro pyrimidine. (Compound DV) Compound DV was obtained from 2-(5-Bromo-2 methoxy-phenylsulfanylmethyl)-benzonitrile, 1,3-propanediamine and hydrogen sulfide 10 in 73% yield by a procedure analogous to that used for the preparation of 2-[2-(2 Naphthalen- I -yl-ethyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine described above. Following chromatography, the material was converted to the hydrochloride salt and recrystallized from methanol/ether. 15 NMR Data for Compound IZ H NMR (300 MHz, DMSO-d 6 ) 6 1.95-2.10 (2H, m), 3.45-3.55 (4H, m), 3.86 (3H, s), 4.40 (2H, s), 6.97-7.04 (1H, m), 7.36-7.65 (6H, m), 10.03 (2H, s, hydrochloride salt). The compounds given in Table 1, were made using procedures similar to that 20 used for Compound B. The ES-LRMS values each had a relative intensity of 100.
WO 01/10842 PCT/USOO/21327 -95 Table 1: Physical Data of Selected MC4-R Binding Compounds ID Molecular Formula Exact ES- Melt Mass LRMS Point Name (free found ("C) Base) (M+H) I 2-[2-(4-Benzyloxy-benzylsulfanyl)-phenyl]- C 2 4
H
2 4
N
2 0S 388.16 389.6 178 1,4,5,6-tetrahydro-pyrimidine; hydrochloride HCI 179 M 2-[2-(2-Iodo-benzylsulfanyl)-phenyl]- C 1 7
HI
7
N
2 S 408.02 409 207 1,4,5,6-tetrahydro-pyrimidine; HCI 209 hydrochloride N 2-[2-(2-Methoxy-5-nitro-benzylsulfanyl)- C 18
H
19
N
3 0 3 S 357.11 358.1 239 phenyl]- 1,4,5,6-tetrahydro-pyrimidine; HBr 241 hydrobromide 0 2-[2-(Naphthalen-1-ylmethylsulfanyl)-
C
21
H
20
N
2 S 332.13 333.1 207 phenyll- 1,4,5,6-tetrahydro-pyrimidine; HCI 208 hydrochloride Q 2-[2-(3-Chloro-benzylsulfanyl)-phenyl]-
C
17
H
1 7 ClN 2 S 316.08 317 224 1,4,5,6-tetrahydro-pyrimidine; HBr 225.5 hydrobromide AI 2-[2-(2,5-Dimethoxy-benzylsulfanyl)-
C
19
H
2 2
N
2 0 2 S 342.14 343.2 201 phenyl]- 1,4,5,6-tetrahydro-pyrimidine; HCI 202 hydrochloride Z 2-[2-(3-Bromo-benzylsulfanyl)-phenyl]-
C
17
H
17 BrN 2 S 360.03 361 210 1,4,5,6-tetrahydro-pyrimidine; HBr 211 hydrobromide B 2-[2-(2-Chloro-6-fluoro-benzylsulfanyl)-
C
17
H
16
CIFN
2 S 334.07 335 232 phenyl]- 1,4,5,6-tetrahydro-pyrimidine; HCI 233 hydrochloride AE 2-[2-(2-Iodo-benzylsulfanyl)-phenyl]-4,5- Cl 1 HisIN 2 S 394 394.9 184 dihydro-1H-imidazole; hydrochloride HCI 185 AF 2-[2-(2-Methoxy-5-nitro-benzylsulfanyl)-
C
17
HI
7
N
3 0 3 343.1 344.1 253 phenyl]-4,5-dihydro-1H-imidazole; HBr 254 hydrobromide Y 2-[2-(2-Methoxy-5-nitro-benzyloxy)- CIgH 19
N
3 0 4 341.14 342.1 220 phenyl]-1,4,5,6-tetrahydro-pyrimidine; HCl 221 hydrochloride AA 2-[2-(2-Bromo-benzylsulfanyl)-phenyl]-
C
17
H
17 BrN 2 S 360.03 361.0 177 1,4,5,6-tetrahydro-pyrimidine; HBr (rel. 179 hydrobromide int.= 96 P 2-[2-(3-Iodo-benzylsulfanyl)-phenyl]-
C
1 7
H
17
IN
2 S 408.02 409 183 1,4,5,6-tetrahydro-pyrimidine; HBr 185 hydrobromide AG 2-[2-(2-Methoxy-5-nitro-benzylsulfanyl)-
C
2 1
H
23
N
3 0 3 S 397.15 398.1 >240 phenyl]-3a,4,5,6,7,7a-hexahydro-1H- HBr benzoimidazole; hydrobromide AL 2-[2-(2-Methoxy-napthalen-1- C 22
H
22
N
2 0S 362.1 363 ylmethylsulfanyl)-phenyl]-1,4,5,6- HCI tetrahydropyrinidine; hydrochloride Am 2-[2-(5-bromo-2-methoxy-benzylsulfanyl)- C 18 HIBrN 2 OS 390 390.9 phenyl]- 1,4,5,6-tetrahydropyrimidine; HCl hydrochloride | | WO 01/10842 PCT/USOO/21327 -96 Example 2: Scincillation Proximity Assay (SPA) High-Throughput Receptor Binding Screening for MC4-R Binding Compounds A. Preparation of Membranes from MC4-R Cells 5 A crude preparation of plasma membranes, of sufficient purity for use in the scincillation proximity assay (SPA), was prepared using the following protocol (Maeda et al. (1983) Biochem. Biophys. Acta 731:115-120). MC4-R cells were stable recombinant K293 cells overexpressing the MC4-R. The cells were routinely cultured and passaged in a growth medium composed of 10 DMEM base medium: 10% fetal bovine serum (FBS), IX Glutamine, and 0.5 mg/ml G418. Terminal cultures (i.e., those which will be processed to produce plasma membranes) were grown in identical media, with the exception that the media contained 0.2 mg/ml G418. At 4*C, harvested cells were pelleted and immediately washed with 25 mL of 15 PBS. The washed cells were resuspended in two volumes of STM buffer (0.25 M sucrose, 5 mM Tris, 1 mM MgCl 2 , pH 7.5), containing Boehringer CompleteTM protease inhibitors. Cell breakage was accomplished using a Dounce homogenizer. After 20-30 strokes, nuclei and unbroken cells were pelleted by centrifugation at 1100 rpm for 5 minutes. The supernatant was saved and the pellet was resuspended in 1 volume of 20 STM/protease inhibitors, and then a further lysis step was carried out by the Dounce homogenizer (10-20 strokes). This material was then combined with the first supernatant. 11.25 mL of the homogenate was gently layered on top of 27.25 mL f 42% (w/w) sucrose (5 mM Tris, 1 mM MgCl 2 , pH 7.5). After spinning at 28,000 rpm (ultracentrifuge, SW-28 rotor) for 90 minutes, membranes were collected at the interface 25 with a transfer pipette. The membrane suspension obtained from the sucrose interface was collected and diluted with 5 mM Tris and 1 mM MgCl 2 . Membranes were collected by a further round of centrifugation at 33,000 rpm for 30 minutes (SW-41 Ti rotor). The pellet of membranes was subsequently resuspended in a small (0.5 mL) volume of STM, using a 30 2 mL Dounce homogenizer, and immediately frozen. The resulting membranes were stable to both freeze-thaw cycles and temperatures around 4*C for at least 6 hours.
WO 01/10842 PCT/USOO/21327 -97 B. High-throughput screen A scincillation proximity assay (SPA) format ligand binding assay was used. The membranes from the MC4-R mammalian cells (K293 expressing MC4-R) were bound to wheat germ agglutinin (WGA) coated SPA beads. The membrane coated SPA 5 beads were added to screening plates, which contained the test compounds pre-dissolved in 30pL of 10% DMSO. After pre-equilibration of the receptor coated beads with the test compounds (1 hour), 2nM of radioactive ligand ([12 I]NDP-X-MSH) was added. Since the binding of the radioactive ligand to the receptor causes the scincillation of the beads, blockage of the binding of the radioactive ligand by a small molecule causes a 10 reduction in scincillation. 1. Pre-Binding of the MC4R Membranes to the WGA-SPA beads The membranes were mixed with the SPA beads to make a 2X stock of membrane and beads. 15 For a twenty plate batch of screening plates, the components were mixed in proportions given in Table 2. The membranes and beads were stirred with a magnetic stir bar at room temperature for 1-2 hours to allow binding. Table 2 20 Component Volume Final Concentration in Assay 4 mg/ml WGA-SPA Beads 14.4 mL 25 pg/well MC4R crude plasma membranes 600 pL' 5 ptg/well SPA Binding Buffer 100 mL N/A the exact amount of membranes used varies with the quality of the membrane preparation and must be checked for each new batch. 2. Binding Assay The following assay was performed with automation using a Titertec MultiDrop 25 with plate stacker. 30 pL of 10% DMSO was added per well to the dried compound film in an OptiPlate. Then, 5piL of cold NDP-a-MSH was added to the control wells.
WO 01/10842 PCT/USOO/21327 -98 Subsequently, 50d per well of 2X membranes and beads were added and pre equilibrated with the compounds for 1 hour. Binding was initiated by adding 20ptL of radioactive ligand (a 20 nM solution of
[
25 1I]-NDP-c-MSH) to each test well. The plates were incubated overnight at room 5 temperature and read the following morning. The reagents and amounts are summarized below in Table 3. Table 3 Volume (pL) Reagent Max (100%) Min (0%) 50% Test 20% DMSO 30 30 30 30 2X membranes + beads 60 0 60 60 2nM [1 25 1]-NDP-c-MSH in 20 20 20 20 binding buffer NDP-a-MSH (5pM in H20) 5 0 0 0 NDP-a-MSH (20 nM in H20) 0 0 5 0 Test Compound* 0 0 0 5p.M Test compound stock diluted in BuOH 1:10, 25 [LL dried in assay plate in hood prior to addition of assay buffer. Well contained 0.5 nmol of each test compound (20/well) in 2.5 pLL 100% DMSO. 10 Potency of inhibitors was quantified with respect to positive (100% inhibition) and negative (no inhibitor; 0% inhibition) controls. The following formula was used: % Inhibition = {1-[cpm-(positive control)]/[(negative control)-(positive control)]} * 100% 15 Results from the SPA, are summarized in Table 4. In Table 4, * indicates good inhibition of the MC4-R, ** indicates very good inhibition of the MC4-R, and *** indicates exemplary inhibition of the MC4-R. Compounds which were found to be not active as MC4-R binding compounds, 20 using the SPA assay described herein, are depicted in Table 5. In an embodiment, the present invention pertains to the compounds and methods described herein provided that the compound is not selected from the group consisting of those depicted in Table 5.
WO 01/10842 PCT/USOO/21327 -99 Table 4 Mol NHMIAME m MC4-R ID CHEMICAL Weight Structure (Tot) 2-[2-(2,5-Dichlore ci s C1 thiophen-3- s A ylmethylsulfanyl)- 393.7877 ** phenyl]-1,4,S,6- NH tetrahydro- H pyrimidine; HCI N 2-[2-(2-Chloro-6- N fluoro B benylsulfanyl)- 415.7566 NF F phenyl}-1,4,5,6- N tetrahydro pyrimidine; HCI 2-(2- D Benz-ylsulfanyl D phenyl)-1,4,5,6- 363.3214 s * tetrahydro pyrimidine; HBr 2-(2 Pentadecylsulfan E yl-phenyl)-1,4,5., 483.6 * tetrahydro pyrimidine: HBr N 2-(2- "-"H Cyclohexylmethyl F sulfanyl-phenyl)- 369.369 * 1,4,5,6-tetrahydrK pyrnmidine: HBr 2-[2-(2-Methyl- N-4 benzylsulfanyl)- S G phenyli-1,4,5,6- 377.3483 tetrahydro pyrimidine; HBr 2-[2-(3-Nitro benzylsulfanyl) H phenyIl-1.4.s,- 408.319 tetrahydro pyrimidine; HBr 2-[2-(4-Benzyloxy benzylsulfanyl) phenyl]-1.4.,56- 424.9934 tetrahydro pyrmidine; HCI SUBSTITUTE SHEET (RULE6) WO 01/10842 PCT/USOO/21327 -100 2-[2-(2-Iodo- 2 benzylsulfanyl). M phenyl)-l.4,5.6- 444.7659 * tetrahydro pydmidine; HCI 2-[2.(2-Methoxy-E-N nitro- s N benzylsulfanyl)- 4 83 5 p enyl]-1,4,5,6 tetrahydro-\ pyrimidine; H~r 2-[2-(Naphthalen N 1 0 ylmethylsultanyl). 368.9293 phenyl]-1 .4,5,6 tetrahydro pynmidine: HCI 2-[2-(3-Iodo- -, N benzylsulfanyl)- S jp phenyl]-1,4,5,6- 489.2179 * tetrahydro pynmidine; HBr eN 2-[2-(3-Chloro- benzylsulfanyl). s Q phenyl]-1,4,5,6- 397.7662 tetrahydro-, pyrimidine 2-[2-(3.5 Dimethoxy-N R benzylsulfanyl)- 3 89 2* phenyll-1,4,5,6 tetrahydro pyrimidine: HCI benzylsulfanyl)- /s S phenyl]-1,4,5,6- 381.3119 tetrahydro pynmidine; HBr . 2-(2.(2-Chloro- N benzylsulfanyl) T phenyl]-1,4,5,6- 397.7662 T tetrahydro-K* pynmidine c H-e 2-[2-(2-Fluorobenzylsulfanyl)- \ U phenylj.1,4,5,6- 381 .3119 K* tetrahydro pyrimidine: HBr ' 2-[2-(2 .4-Bis trifluoromethyl-N v benzylsulfanyl)- 499.3179 F _ phenyl]-1,4,5,6-\ / tetrahydro- 2 pyrimidine; HBr WO 01/10842 PCT/USOO/21327 -101 2-[2-(3-Methoxy benzylsulfanyl)- s W phenyli-1,4,s,r- 348.8957* tetrahydro pyrmidine: HCI 2-[2-(3,5-Bis trifluoromethyl- s x b"nzylsulfanyl ) 454.8659 * phenyl]-1,4,5,6 tetrahydro pyrmidine: HCI F-. F F 2-{2-(2-Methoxy-4 nitro-benzyloxy)- o .* Y phenyl]-1,4.5,6- 377.8267 I i tetrahydro pyrimidine; HCI HN 7,,, / 2-[2-(3-Bromo- N benzylsulfanyl)- s Z phenyli-1,4,5.6- 442.2175 ** tetrahydro pyrimidine; HBr 2-[2-(2-Bromo benzylsulfanyl)- ' AA phenyl]-1,4,5,6- 442.2175 tetrahydro pyrimidine Br, 2-[2-(2-Chloro-6 fluoro AB benzylsulfanyl)- 357.2777 F phenyl]-4,5 dihydro-1H- -_ imidazole cl 2-(2- r N Benzylsulfanyl- N AC phenyl)-4,5- 304.8425 * dihydro-1H- s imidazole; HC/ 2-(2-(2-todo benzylsulfanyl)- N AE phenyli-4,5- 430.7391 ** dihydro-1H imidazole; HCI 2-[2-(2-Methoxy- NH nitro- 0:, N AF benzylsulfanyl)- 424.3184 / M\\ phenyl]-4,5 dihydro-1H imidazole; HBr o 2-[2-(2-Methoxynitro benzylsulfanyl) AG 3a,",5phf - 478.41 hexahydro-1H benzoimidazole; HBr SUBSTITUTE SHEET (RULE26) WO 01/10842 PCT/USOO/21327 -102 2-[2-(Naphthalen 1-ylmethoxy) AH phenyI]-1,4,5,S- 362.4327 C o AH tetrahydro-' pydmidine; FormateK? _ 2-[2-(2,5- \N Dimethoxy Al benzylsutfanl) 37.2 O ,* Al phenyl]-1,4.5.6)- 378,92 -0\ tetrahydro pynrnidine; HCI o 2-[2-(2-Methyl naphthalen-1- , S AJ ytmetkrylsulfanyl)- 3646 AJ phenyl].1,4,5,6-34.92 H tetrahydro- 'N pyrimidine\.= 1-{2-[2-(2-Chloro-N 6-fluoro- ~ ' benzylsulfanyl)-I AK phenyJ-5,6- 376.8819 F dihydro-4H- F pydmidifl-yI) ethanone 2-[2-(2-Methoxy naphthalen-1 AL ylmethylsulfanyl)- 398.9556 "'s phenyl]-1,4,5,6 tetrahydro pyrimidine; HCI 2-(2-(5-Bromo-2 methoxy AM benzylsulfanyl)- 427.7917 . phenyl]-1 .4,5,6 tetrahydro pyrimidine; HCI - B, 1-(6-Brorno-2-0 chloro-quinolin-4 AN yI)-3-(2- 399.7179 K"' * diethylamino ethyl)-urea N 2-[2-(2,6-Difluoro benzylsulfanyl)- N F AO phenyl]-1,4,5.6- 480.2143 H* tetrahydro- pynimidine; HBr)F 1O-[2-(1-Methyl piperidin-2-yi) AP ethyl]-2- K~ AP methylsutfanyt- 407.0429 1OH- N S phenothiazine; I HCI N "N """ 4-(3,5-Bis trifluoromethyl phenyl)-1,4,6,7 tetrahydro- H AQ imidazo[4,5- 507.5465* c]pyridine-5 carbothioic acid r (3-diethylamino ____________propyl)-amide _______ _________________ SUBSTITUTE SHET (HULE26) WO 01/10842 PCT/USOO/21327 -103 1-(4-Hydroxy-\ AR 1,3,5-trimethy- 185.2664 " "* * pipeddin-4-yi) ethanone 2-Naphthalen-1 AS ylmethyl-4 's- 246.7386* imidazole: HOI 1 .(3-Diethylaminc propyl)-3-{1-[5-(2 methyl-5 trifuOromethyl-2 H AT pyrazol-3-y)- 552.7096 thiophenG.2 sulfonyl] pyrrolidin-3-yi) thliourea N-(2-Cyclopropyl 3-(1,1, 3, 3-$ tetramethyl AU butylamino)- 342.4846* imidazo]1 .2 alpyridin-8-yll acetamide (2-Isopropyt- HC F imidazo(1,2- cFi cFi AV alpyddin-3-yl) 342.4846 H (1.1,3,3- c tetramethyl-butyl)N F amine N b imidazo[1,2- C, c AW a]pyddin-3-yl)- 287.4485 HN- c AW (1,1,3.3-C, tetramethyl-butyl) cU, amine N AX ,21W-y 4-y-hy 505.6509 (2.6-Dichloro- H AY iiaoii- 266.5561\ / * HCI C H 2-BenzyI4,5 AZ ditrydro-lH- 160.2188 N imidlazole 1-(4-Phenyl-5' trifluoromethyl 3,4,5,6-tetrahydm * BA 1 21pny-1- 489.5843 ylmethyl)-3-(2 piperidifl-1-yI ethyl)-urea0 SUBSTITUTE SHEET (R L2) WO 01/10842 PCT/USOO/21327 -104 Methylsulfanyl BR phenyl).1,4 5,.6- 334.2216 ' tetrahydro-H pynmidine N 2-(1.4,5,6 BZ Tetrahydro- 1224 ~ BZ pyrimidin-2-yI)- 1224 benzenethiol 2-[2-(4-Nitro benzylsulfanyl) BD Pheny,]-1,4,5,6- 408.319/ * tetrahydro pydmidine 2-{3--[2-(1 .4,5.6 Tetrahydro BE pyrimidin-2-yI) 6 98 S~ BE phenylsulfany) 40.94 propyr}-isoindole- N- 1,3-dione; HBr e 2-[2-(3-Phenyl propylsultanyl)- N BE phenyl]-1, 4,5 '6- 391.3752 tetrahydro pyinidine; HBr \ Trifluoromethyl BG benzylsulfanyl)- 4139 BG phenyl]-1,4,5,6- 43.39 tetrahydro pynmidine; H~r 4-Piperazin-1-yI-2 RH tluoromethyl- 281.2806 * quinolineF F NH BI benzamnidine; HC 201.6116 0 2 N N Rj 4-Carbamirndoy- 163.1791 >- ' NH 2-Phenyl-4,5-H RK dihydro-lH 146.1919N imidazol C SUBSTITUTE SHIEET (RLA WO 01/10842 PCT/USOO/21327 -105 Ben y sulfanyl BL phenyl)-1,4,5,6- 282.4094* tetrahydro pyrimidine 2-[2-(4-tert-flutyl benzylsulfanyl). BM phenyl]-1.4,5,6- 419.4289 tetrahydro pyrimidine; HBr 2,2-Diphenyl-4.(2 (1.4.5,6 BN tetrahydro- 492.4827 pyrimidin-2-yi) phenylsulfanyl) butyronitrile; HBr 6 benZylsulfanyl) BO phenyl]-l .,6- 346.9232* tetrahydro pyrimidine; HCI l 3-[2-(1 .4,5,6. Tetrahydro BQ pydmidin-2-yi)- 3 83 1 phenylsulfanylm)e3 8.3 hylJ-benzonitrile; HBr 2-[2-(4-Bromo benzylsulfanyl) BR phenyll-1,4,5,6- 442.2175 tetrahydro pyrimidine; HBr benzylsulfanyl)-N BS phenyl]- , 4,5.6- 432.2109 * tetrahydro pynmidine; HBr 8 2-(2-(Naphthalen. 2- \s N BT ylme thylsulfanyl)- 413.3813 phenyl]-1 .4,5.6 tetrahydro pyrimidine; HBr 2-[2-(4-Fluoro benzylsulfanyt) BU phenyl].1,4,5,6- 381.3119 * tetrahydro pyimdne; HBr 2-(2(Bipheriy-4 4 ymethy sulfany N BV phenyl] 14,56- 394.9672/\ tetrahydr0 pynrndine; HCl SUBSTITUTE SHEET1 (RUE2) WO 01/10842 PCT/USOO/21327 -106 HN 2-[2-(2,4-Bis- N trifluoromethyl BW benzylsulfanyl)- 499.3179 * pheny]-1,4.5,6 tetrahydro- F pyrimidine; H~r F - F F F HN 2-[2-(1,4.5,6- / Tetrahydro- N BX pyrimidin-2-yi)- 388.3312 * phenylsulfanylme hyl]-benzonitrile; HBr N c 4-[2-(1,4,5,6 Tetrahydro BY pyndmdin-2-y')- 388.3312 phenylsulfanylme ' hyl]-benzonitrile; HBrc N H~HN 2-[2-(4-Methoxy benzylsulfanyt) BZ phenyl]-1,4,5.6- 348.8957 * tetrahydro pyrimidine; HCI /0 NH CA Benzamidine: HC 156.614 e NH 2 F NH 3,5-Bis- F NH2 CB trifluoromethyl- 292.6105 F benzamidine; HC FY F F 2-(2 Benzylsulfanyl CC phenyl)-4,5- 304.8425 dihydro-1H imidazole; HCI (2-Butoxy-phenyl: carbamic acid 2 CD pipendin-1-yI-- 463.6221 N O .. *4 piperidin-l ylmethyl-ethyl ester; Formate (2-Pentyloxy phenyl)-carbamic CE ayid,2-pipe"din-1 477.649 N ylmethyl-ethyl ester Formate N 2-(2-Bromo CF dheydr-4,H- 261.5479 N imidazole; HCI SUBSTITUTE SHEET (RULE6) WO 01/10842 PCT/USOO/21327 -107 4-Phenyl-2 CJ Piperazin-1-yi-6-P 330.4326 N tolyl-pyrimidine N-Benzyb-N-(3 chloro-benzyl) CK N',N'-dime t hyl- 302.846 CK ethane-1 .2 diamine N-Benzyl-N-(4 brmo-benzyl) CL N',N'-dimethy- 347.2981 ethane-1 .2 diamine N- Benzyl-N-(3, 4 dictiloro-benzyl) CM N',N-dimethyl- 337.2916N * ethane-1,2 diamine 7-Chloro-4,8 Co dirnethyi.2- 365.8208 I.KN* quinoline; Oxalat 7-Chloro-4,8 CP dimethyl-2- 275.7808* quinolineI 7-Chioro-4,8 dimethyI-2- ' CQ piperazin-1-y-3180 quinoline; .8 0 " N"eN Formate CS 2.7-Dichloo'8 2.06 I~ cs dimethyl-qOuinolin,- 226104 2-(2. Benzylsulfanyl phenyl) CT 3a.4,5,6,7,7a- 358.9342 benzoimidazoheaydoeHo t HCI 2-12(2-Chloo-6 fluoro benzylsulfany)-2 CU phenyl] 41364 hexahydra-lH benzoimidazole, HC cl SUBSTITUTE SET (RULE26) WO 01/10842 PCT/USOO/21327 -108 2-[2-(2-Iodo benzylsulfanyl)- ' phenyl]. CV 3a,4,5,6.7,7a- 484.8307V hexahydro-lHbenzoimidazole; HCI 1-Phenyl-3- J piperazin-1-yi CY 5,6,7,8-tetrahydrc 3 18.42 16 O rXA* isoquinoline-4 carbonitrile 2-[2-(Pyridin-3 ylmethylsulfanyl)-I CZ phenyl].1,4,5,6- 283.3972* tetrahydro pynmidine 1-Pyridin-3 ylmethyl-2-[2 (pyddin-3 DA ylmethylsulfanyi)- 374.5096 phenyl]-1 4,5,6 tetrahydro pydmidine 2-12-(2-Ethoxy- N: ethylsulfanyl) DR phenyll-1,4,5 '6- 345.3037 H * tetrahydro- s pyrimidine; HBr L_.o 2-[2-(2,5-Dimethy N benzylsulfanyl) DC phenyl]-1.4.5.6- 346.9232 S* tetrahydro pynimidine; HCI 2-[2/(2/ Benzenesulfonyl DD methyl-* DD benzylsulfanyl)- 517.5108 phenyl].1,4,5,6 tetrahydro pyrimidine; HBr 4-[2-(1,4.56 Tetrahydro- N NH DE pyrirnidin-2-yt)- 414.3691 s~ I* hyl]-quinoline; HBr I 2-[2-(2-Methoxy-E 11M nitro- ~N O * DF benzylsulfanyl)- 439.3331 DF pynidin-3-yi] 1.4,5 6-tetrahydm K pyrimidine; lBr 2-[2-(2-Methoxy benzylsulfanyl) DG phenyl] 1,4,56- 348.8957 N-'NS t < tet-ahydro- I pynmidine; HCI SUBSTITUTE SHEET1 f(LE6 WO 01/10842 PCT/USOO/21327 -109 2-[2-(2 Cyciopentyloxy- M benzylsultanyl). ~ I~. 0 .1) * DH phenyl]-1 .4,5,6 tetrohydro- lol pyrimidine; HBr N 2-Biphenyl-2-y DI 1,4.5.6-tetrahydr 282346 DI pyrimidine; 8.36 H 2-[2-(2,3 Dimethoxy DJ benzylsulfanl) 42. 4* DJ phenyl]-1,4,5,6)- 42.7 i i's tetrahydro- 1 0 pynmidine: HBr 2.[2-(2,3-Dihydr benzo[1 ,4jdioxin- NH 5. DK ylmethylsulfanyl)- 421 .3581 I's O->. * phenyl].1,4,5,6 tetrahydro pynmidine; H~r 2-[2-(6-Methoxy 2,3-dihydro- ""j benzo[1 ,4]dioxin- H DL ylmethylsulfanyl)- 4134 s phenyl].1,4,5 6- 1 , tetrahydro-. \ r pyrimidine 2-[2-(5-fluoro-2-I methoxy DM benzylsulfanyl)- 411 .3381 _ o phenyl]-4,5 dihydro-1H imidazole; HCI 1-Methyl-2-[2- N' (naphthalen--'' ylmethylsulfanyl)-I DN phenytj.1.4,5,6- 392.5262 ~ 's -* tetrahydro pynimidine; formate 1-Methyl.2.[2 (naphthalen-l ylmethllysulfanyI). 3.49 DO phenylj-4,5- 32.63 a dihydro-1 H imidazole IN~ 2.(2-(S-Bromo-2 methoxy. " DP benzylsulfanyl)- 413.7649 (1"s phenyl).4,5 dihydro-1H imnidazole: HCI 2-[2.(S-Bromo-2- ' methoxy DQ benzyloxy)- 411.7251 C <.7! phenylj.1 .4.5,6 tetahydro pyimdne; HCI SU STiI T E SHEET (RULEM) WO 01/10842 PCT/USOO/21327 -1 10 2.[2.(Naphthalen.N~N 1.yloxymethyl) DR phenyl3-1,4,5,6- 3 64 27 * tetrahydro pyrimidine DS 2-(2-Phenoxy- 8 .7 5 DS tetrahydro'- 2 87 5 pydmidine; HCI 5-(4-Chloro- N' phenyl)-2,5- ? N DT dihydro-3H- 284.7448 ..o* imidazo[2.1 ajisoindol-5-o 2-[2-(2-Methoxy phenoxymethyl) DU phenyl]-1,4,5,6- 332.8291* tetrahydro- N pyrimidine: HCI 2-[2-(2.6 Dimethoxy DV phenoxymethyl)- 326.3954 phenyl]-1 .4,5.6 tetrahydro pydmidine 2-[2-(5-Bromo-2. methoxy benzylsultanyl)- r DW phenyl]-5,5- 419.3855 o-, dimethyl-1.4,5,6 tetrahydro pyrimidine 2-[2-(2-Methoxy- ' phenoxy)-phenyl] oH DX 1,4,5,6-tetrahydrc 328.3722o* pynmidine; Fomate 2-[2-(5-Bromo-2- A methoxy DY phenyl]-5.5- 405.3586 dimettiyl-4,5 dihydro-lH imidazole 2-[2-(5-Bromo-2-I methoxy benzylsulfanyl)-5F DZ trifluoromethyl- 459.33 * phenyl]-1.4,5,6 tetrahydro pynro dine N 2-[2-2,6- 1 D methoxy- N EA benzylsulfany 37 92 EA pheny)-,4,5,6- 7 .2 ' tetrahydro pynmdne; HC J SUBSTITUTE SHEET1 f(UE2) WO 01/10842 PCT/USOO/21327 2.(2-(5-Bromo-2 benzylsulfanl) 419.385 EB phenyl]-6-ethyl- 4 93 5 1 .4,5,8-tetrahydr pyrimidine methoxy- 3 42 6 EC benzylsulfanyI)- 3 42 6 benzonitrile 2-(2-(2-Bromo-6 methoxy- 7 benzylsulfanyl)- 472.12437 C ls 0 ED phenyll-1.4,5,6 tetrahydro pyrimidine; HBr 2-[5-Bromo-2-(5 bromo-2-methoxyN EF benylu]tany- 502.2309 dihydro-H- K imidazole; Formate 9-Benzylidene EJ 1,2,3,9-tetrahydrc 306.3685 4,9a-diaza fluorene; Format 2-[2-(Biphenyl-3- c N EK yoy-henylj4 314.3868 * dihydro-1 H imidazole 2-f2-(4-Chloro EL phenoxy)-phenyl] 272.73380 4.5-dihydro-lH imidazole 2-[5-Bromo-2-(5 bromo-2-methox benzylsulfanyl). I EM phenylj-1,4,5,6- 516.2578 tetrahydro pynmidine; Formate 2-(2-(Naphthalen 2.yloxy)-phenyll-N EN 4.5-dihydro-lH- 334.3789 * imidazole; Formate o 2-[4-Bromo-2-(5 bromo-2-methoxyrr EQ benzylsulfanyl)- 47 .2 8 7 s.-~o G EO phenyl].1,4,5,e- 7 .2 7 tetrahydro pynmidine SUBSTITUTE SHEET (RDE6 WO 01/10842 PCT/USOO/21327 -112 2-{2-(2-Bromo-5 methoxy EP " "be"zylsulfan ' 42 phenylj-1,4.5,6 tetrahydro pyrimidine; HBr 2-[2-(5-Bromo-2 methoxy EQ benzysulfanyl)-5 405.3586 methyl-phenyl] 1,4,5,6-tetrahydrc pyrimidine 2-[2-(Naphthalen' N 1-yloxy)-phenyl} ER 4 ,5-dihydro-lH- 334.3789 imidazole; format N 2-[2-(Naphthalen NH I-yloxy)-phenyl] ES 1,4,5,6-tetrahydr< 348.4058 0 * pynmidine; Format 2-[2-(Biphenyl-3 ylmethylsulfanyl) ET phenyl]-1,4,5,6- 439.4192 tetrahydro- e, pyrimidine; HBr 2-[2-(Naphthalen. N 2-yloxy)-phenylj- H EU 1,4,5,6-tetrahydr 348.4058 * pyrimidine; 0 Format I k 2-[2-(5-Bromo-2 methoxy EV phenylmethanes 407.3311 M * Ifinyl)-phenyl] 1, 4,5,6-tetrahydrt pyrimidine 2-[2-(5-Chloro-2 methoxy EW benzylsulfanyl)- 383.3404 * phenyl-1,4,5,6 tetrahydro pyrimidine; HCl 2-[2-(2-Mathoxy-' thiophen-3-yl benzylsultanyl)-43 .01 EX phenyl]-1,4,5,6- 4 1 2 tetrahydro pyrimidine; HCI 2-[2-(Biphenyl-2 ylmethylsulfanyl) EY phenyl]-1,4,5,6- 404.5372 ** EY tetrahydro pyrimidine; Format SUBSTITUTE SHEET (RULE261 WO 01/10842 PCT/USOO/21327 2-[2-(54odo-2. methoxy benzylsulfany)- a 0 EZ phenylj-1,4,5.6- 484.3622 tetrahydro pyrimidine;0 2-[2-(5.Bromo-2- Fl j bnmethoxy F bezylsulfanyl)- 4 932 2 NJ FA fluoro-phenyl]- 4 93 2 1 4,5,6-tetrahydrc pyrimidine 2-(2-(5-Bromo-2 methoxy EB benzylsulfanyl)-3-4 93 2 fluoro-phenyl] 1, 4,5,6-tetrahydrc pyrimidine Dimethoxy biphenyl-3-K FC ylmethylsulfanyl). 499.4717 12* phenyl].1.4 5,6 terahydro pynimidine; HBr 2-[2-(9H-Fluoren- HN 7 9-yisulfanyt) FD phenyl]-1,45,6- 437.4033 Ns* tetrahydro pyrimidine; HBr 2-[2-(3'-Chloro-4 fluoro-4-methoxy D biphnyl3-0 bipehenslnyl FE yrehtufy)-486.9987 j * phenylj-1 .4,5,5 tetrahydro pynmidine; ~ Formate Naphthalen-1-yi-N FE ethylsultanyl)- 382.9562 N phenyl]-1,4,5,6-I tetrahydro pynimidine; HCI 2-[2-(4-Methoxy- N.L ylmethylsulfanyl) FG phenyl]-l.
4 .,B-& 434.5634 tetrahydro- pyrimidine; Formate 2-[2-(5-Bromo-2- N methoxy- F, N benzylsulfanyl)- 5N' FH ttuoro-phenylj.4,E 441 .3253 dihydro-1 H imidazole; Formate 2-2 Benzhydrylsulan M Fl l'pheny ' 404 537 F etrahydro- 4 45 7 pyrmdne; Form~ate SUBSTITUTE SHEET (RILE) WO 01/10842 PCT/USOO/21327 -114 2-(3-Amino- c propylamino)-6-( . FJ bromo-2-metho 4 * benzylsulfanyl)- 452.3764 benzonitrle; Formate 2-[2-(2'-Fluoro-4" methoxy [1,1';4',1"]terpher yI- 3
"
FK ylmethylsulfanyl)- 528.6517 phenyl]-1,4,5,6 tetrahydro pynmidine; formate 2-[2-(2-Methoxy- N phenylethynyl benzylsulfanyl)- \ s FL phenyl]-1,4,5,6- 458.5854 ** tetrahydro- C. pyrmidine; Formate 2-[3-(Naphthalen. N 1 ylmethylsulfanyl) FM phenyl]-1,4,5,6- 378.4993 * tetrahydro- s pyrimidine; Formate 4-Methoxy-N-{4 methyl-2-(1,4,5,6. tetrahydro- a H FN pyrimidin-2-yl)- 369.4248 phenyl] benzamide: Formate NH 2-(5-Bromo-2-NH methoxy-s FO benzylsultany)- 397.297 ** benzamidine; formate H 4,6-Dimethyl-2- CN) FP piperazin-1-y- 192.264 N* pyrmidine 8-Isopropyl-3,3- N dimethyl-6 piperazin-1-yi-3,4 FQ dihydro-1H- 314.4308 pyrano[3,4 c]pyridine-5 carbonitrile H (N FR 2-Piperazin-1-y*- 164.2102 N * pyrimidine N N H N FS 1-Pyridin-2-y . 163.2224 N* piperazine SUBSTITUTE SHEET (A E2R WO 01/10842 PCT/USOO/21327 2-Piperazin-1-yi- FC N K NH FT tnfluoromethyl- 232.2085'3NN) FT pyrimidineIN 0 5-Piperazin-1-yi-7 N ( trifluoromethyl FU thieno[3,2- 345.3454 S* b]pyridine-3- CF, carboxylic acid methyl ester 5-Bromo-2- N N. FV piperazin-1-yi- 243.1063 fI _y NN~ pyieraine B EX Trifluoromethyl- 231 .2207 * pyridin-2-y) piperazine FY tahdrot- 26.38 -1iH FX pyidin-2-y)- 2 12 0 peyraine FZ penyl--14,56- N7.93 ~ ~ - ~ * tetrahydro-H FY pyriridine;y) 6538 2.2(Ehynyl .2-n me4(Nthy- . GA betzylsufanyl)- 3297 FZ phenylI 378.4936 tetrahydro pyrimidine;HI 2-[2-(5-Bromoy-2 methoxy GB benzylsultany)- 4188 ~ .* GA benyl(.1,4,5,6- 3297 tetrahydro pyrimidine; HCI 2-[2-(5-tB utyl .1 2methoxyCs GC benzylsulfanyl)-4503 p enzyl 1 414858 tetrahydro pyrimidine; HCI SIIR~I~iIT ~ (~ii F WO 01/10842 PCT/USOO/21327 2.(2-(5-Bnomo-2- j cyclopentyloxy-,D benzylsulfanyl) GD phenylj-1,4,5,6- 491 .4534 tetrahydro pyrimidine: Fomiate 2-(2-(5-Bromo-2 ethoxy GE benzylsulfanyl)- 4 18 8 GE phenylj-1,4,5,6- 4 18 8 tetrahydro pynimidine; HI-I 2.(2-(5-Bnomc, propoxy GE benzylsulfanyl)- 455.8455 GF phenyl]-1,4, 5,6- 5 .8 5 tetrahydro pynimidine; HCI [2-(5-Bromo-2 roethoxy GG benzylsulfanyl)- 430.8357 K._oTIs o' * amine; HCI 4-[2-(5-Bromo-2 m ethoxy GH benzyfsulfanyl)- 444.8192 iS.* benzyl] morpholine; HCI 1-12-(5-Bromo-2 methoxy I I**zlulay) 4 74 4 benzyl] piperazine; Oxalate (1-[2-(5-Bromo-2-H e methoxy- l benzylsulfanyl) GK benzyl]-pyrrolidin 507.4918 3-yf)-carbamic acid tert-butyl ester 3'-(5-Bromo-2- N N GL methoxy- ~N benzylsultanyl)- 395.3232s GL 3,4 ,5,6-tetrahydr 2H [1,2']bipyrazinyl C-(4-[3-(5-Bromc 2-methoxy benzylsultanyl) GM quinoxalin-2-yi]- 548.3308 morpholin-2-yt) methylamine; ) 2HCIr 2-(5-Bnomo-2-N N m ethoxy GN benzylsulfanyl)-3 491.4131 cl piperazin-1-yl quinoxaline; Foriate _ WO 01/10842 PCT/USOO/21327 -117 2-[2-(2-Methoxy.E. methyl GO benIzylsulfanyl)- 362.9226 IS o phenyll-1 .4,5,6 tetrahydro pyrmidine; HCI 2-[2-(5-Bromo-2 methoxy- m GP bezyloxymethyl) 425.752 0~ GP phenyl]-1,4,5,6 tetrahydro pynimidine; HCI 0, 2-{2-(5-(3.3 Dimethyl-but-1 ynyl)-2-methoxy GQ benzylsulfanylj- 429.0252 * phenyl)-1,4.5,6 tetrahydro pyrimidine; HCI 3-Benzylidene-2-I GR (2-methylamino-27 .5 8,-* GR ethyl)-2,3-dihydrc2 83 8 isoindol-1-one 2-[2-(2 Naphthalen-1-yl- Cl GS ethylsulfanyl)- 346.4962* phenylj-1 4,5,6 tetrahydro pynimidine [2-(5.Bromo-2 GU benzylsulfanyl)- 402.7819 benzyl]-dimethyl. amine; HCIK 2.(2.(5-Bmomo-2 isopropoxy GV benzylsulfanyl)- 455.8455 K phenyl).1 .4,5,6 tetrahydro pydmidine; HCI 2-[2-(2-Ethoxy naphthalen-l GW ylmethylsulfany)- 412.9824 C I , phenyl].1 .4,5,6 tetrahydro pynmidine; HCI 2-[2-(2-Propoxy naphthalen-1 GX ylmethylsulfanyl). 427.0093 JV phenyl]-1,4,5.6 tetrahydro pyrimidine; HCI 4-Methoxy-3-42 (1,45,6 tetrahydro- + GY pynimidin-2-yi) 373.9055 phenylsulfanylme hyl]-benzonitrite; HCI AIRTITiITF RET(PiiF WO 01/10842 PCT/USOO/21327 -11 8 1-{4-Methoxy-3-[2N (1,4,5,6 tetrahydro GZ pyrimidin-2-yI)- 400.503 ** phenylsulfanylme hyl]-phenyl} ethanone: Formate (1-[2-(2-Methoxy naphthalen-1 ylmethylsulfanyl)- * HA benzyl]-pyrrolidin 478.6556 3-yt}-carbamic acid tert-butyl ester 2-(2-(NaphthalenN 1- N HB ylsulfanylmethyl)- 368.9293 phenyl]-i.4.5.6 tetrahydro pyrimidine; HCI N' 2-(2-Phenethyl phenyl)-1,4,5.6- HN HC te t rahydro- 310.4003 * pyrimidine; Forrate 1-[2-(5-Bromo-2 methoxy HD benzylsulfanyl)- 452.4167 ** benzyl] piperidine; Formate {4-[2-(2-Methoxy naphthalen-1 ylmethylsulfany|) HE benzyl]-morpholir 508.6819 2-ylmethy} carbamic acid ter butyl ester C-{4-[2-(2 Methoxy naphthaten-1 HF ylmethylsulfanyl)- 481.486 Kr'* benzyt]-morpholir 2-yl} methylamine; 2HCI 1-[2-(5-Bromo-2 methoxy HG benzylsulfanyl)- 480.2959 ** benzyl].pyrrolidin. 3-yamine; 2HCI 2-{2-(Naphthalen. NH 1-_I HH ytmethylsultanyly- 316.4265 " * phenyl]-1H imidazole 2-[2-(1-Benzyl-1F N imidazol-2- H HI ylmethylsultanyl)~ 362.4986 S * phenyl]-1,4,5,6 tetrahydro pyrimidine N SUBSTITUTE SHEET (RULE26) WO 01/10842 PCT/USOO/21327 -1 19 1-[3-(5-Bromo-2- NN methoxy HJ benzylsulfany 468.2446 * HJ pyrazin-2-yJ- 6 .24 pyrrolidin-3 ylamine; 2HCI 1-[3-(5-Bromo-2 methoxy benzytsulfanyl)- 5834 HK quinoxain 2yl- 518.3045* pyrrolidin-3 ylamine; 2HCI 1-[2-(2-Methoxy naphthalen-1 HL ylmethylsulfanyo- 414.9983 ** benzyl]-pyrrolidin 3-ylamine; HCI 1-(5-Bromo-2- N O HM methoxy-benzyl)- 360.2938 * 2-phenyl piperidine Nr 9-Benzyl-2,3,9.1C tetrahydro-1 H H N 4,9,10a-triaza- 323.3991 N* phenanthrene; Formate N 2-[2-(2- i} Naphthalen-1-yl- NH HO ethyl)-phe 360.4602 pyrimidine; Formate 3-[2-(5-Bromo-2 methoxy benzylsulfanyl)-3. HP fluoro-phenyl]- 485.847 1,5,6,7,8,8a hexahydro imidazo[1,5 alpyridine; HCI 3-[2-(5-Bromo-2- N, methoxy benzylsulfanyl)-3- N fluoro-phenyl] HQ 5,6,7,7- 481.3901 tetrahydro- 1H pyrrolo[1,2 c]imidazote; Formate 2-[2 (Benzo[b]thiophe NH th-3 HR ylmethylsulfanyl)- 419.4094 phenyl]-1,4,5,6 tetrahydro pyrimidine; HBr 2-[3-Fluoro-2 (naphthalen-1 ylmethylsulfanyl) HS phenyl]-1,4,5,6- 396.4897 $ tetrahydro pyrimidine; Format SV) SUBSTITUTE SEET ULE26) WO 01/10842 PCT/USOO/21327 -120 2-(Naphthalen.1 ylmethylsulfanyt)- N , 3-(1,4,5 , HT tetrahydro- 393.514 $ I * pydmidin.2-yI)-y phenylamnine; Formate 2-[2-(5-Bromo-2 methoxy HU banzyisulfanyl)- 41.06 HU chloro-phenylj.47.86 1 .4,5,6-tetrahydr N pydmidine C-{4-[3-(5-Bromo o 2-methoxy-(N benzylsulfanyl) HV pyrazin-2-yI]- 471 .3795 N cl morpholin-2-y} niethylamnine: Fomiate Benzyl-methyl-[2 (1,4,5,6- 1N1 HW tetrahydro- 3241* HW pydmidin-2-yl). 2.1 N phenyll-amine;N Forroate NH phenylsulfanylme HX hyl).phenylj- 348.8957 o 1 ,4,5,6-tetrahydrc pyrimidine; HCI N16 1-{2-[2-(S-Bromo 2-metiroxy benzylsulfanyl)-9 HY dihydro-4H- 47.49 pyinidjn-l-y}-3- L ) methyl-butan-1. ' one 2-[2-(5-Bromo-2 methoxy HZ benzylsulfanyl)-'-%# * phenyl]-5,6- 5546 HZ dihydro-4H- 5546 0-e pydmidine-l-/ carbonylic acid benzyl 1-{2-[2(5-Bnomo 2-methoxy benzylsuffanyt)-,- IA phenyl]-5,O- 509.4668 \ dihydro-4H phenyl-ethanone 2-[2-(S-BromD-2 Smethoxybenzylsulfanyl)- / lB phenyll-l- 469.4234-_ _* methanesuo onyt- s' 14,56-a tahydr pyn i dine 2-(5-Bromo-2 2 ic methoxy 324.2413S benzylsulfanyl) phenylam ine l SUBSTITUTE SHEET1 (RUL26 WO 01/10842 PCT/USOO/21327 2-o-Tolyi-1,4,5,6 ID t e t rahydro- 174.2456 N pyrimidine 2-[3.(S.Bromo-2 methoxy I E benzylsulfanyl)- 392.31 95 K 'C1 pyddin-2-yI]. 1 ,4,5,6-tetrahydrc pyrimidiney 5-[2-(5-Bromo-2- A N methoxy- c r i IF benzytsulfanyl)- 392.2762 0 IFphenyl] [1 ,3,4]oxadiazol-2 _ K ylamlifl* 2-(5-Bromo-2 methoxy IJ benzylsulfanyl)- 367.2664* benzoic acid hydrazide N IK benzylsulfanyl)- 3 62 1 phenyl]-guanidine 2-12-(2 Isopropoxy-J naphthaten.-[ IL ylmethylsulfanyt)-43 .7 3 S* IL phenyl]-1 .4,5,6- 4 65 9 tetrahydro pyrimidine; Formate 2-(2.(2. I Cyclopentyloxy naphthalen-l-I I M ylmethylsulfany)- 453.0472 o *o phenyl]-1 .4,5,6 tetrahydro-J pynmidine; HCI (5-Bromo-2 methoxy-benzyl) IN [2-((1,4 -5,6- 374.2804K tetrahydro pyrimidin-2-yi) phenyt i-amine 2-[2-(S-Bromo-2 methoxy 10 hyt)-phenylj- 451.3886 I ,4,5,6-tetrahydrc pyrimidine; Forrate 2-[2-(2-Methoxy naphthalen-l IP ylouifanylmethyl)- 398.9556 o phenytj-1 .4,5.6 tetrahnydro pynmidine: HCI SUBSTITUTE SHEET (RDE6 WO 01/10842 PCT/USOO/21327 -122 2-[3-(5-Bromo-2- ,L IQ bezlsufany)- 393.3073 NS ~ * IQ ain-2-yi] 1 .4,5,6-tetrahydrc pyrimidine 2-[3-Chloro-2- I (naphthalen-l- N M4 IR ylsulfanylmethyl)- 403.374 phenylj-1,4,5,6-N tatrahydro- a -" pynmidine; HCI 2-[2-(B-Brbmo-2 methoxy- N7r~o naphthalen-l-[ is ylmetriylsulfanyl)- 477.8516 phenyt]-1,4,5,6 tetrahydro pynmidine; H~l 9-(5-Bromo-2 methoxy-benzyl). N'' 2,3 '9,10- I I IT tetrahydr-lH. 432.3214 ~ N 4,9,10a-triaza phenanthrene; Formate 2-[3-Chloro-2-(2 methoxy- '<> naphthalen-l lU ylsulfanylrnethyl)- 396.9403 phenyl]-1,4.5,6- a s tetrahydro- N"~ o pynmidine 2-[2-(2,7 Dimethoxy naphttlalen-1 IV ylmethylsulfanyl)- 438.5518o-N phenyl]-1 .4,5,6 tetrahydro pynmidine; -,j Formiate/ 1W 2-Piperazin-1-y- 27 .55HSO N ethylamidle 7-Methoxy-3-(4 rxntro-peny)-2 364.404 o" x quinoline 4-Methyl-2- N " IY piperazin-1-yi- 227.3092 * quinoline ),'N N 2-[2-(5-Bromo-2. 21 methoxy N" 0 iz phenylsulfanylme 427.7917 X 14,6ttayrhyl)-phenyl]- s pynmidine; HCI SUBSTITUTE SHEET (RDE6 WO 01/10842 PCT/USOO/21327 -123 2-[2-(5 Bromo-2 ethoxy phenylsulfarrylme o JA hyl)-3-chloro. 462.2365 phenyll-1 .4,5.6 tetrahydro pyrimidine: HCI 3-(5-Bromo-2. methoxy- N. e benzylsulf'anyl)-2- s JR (1,4,5,6- 442.3794 tetrahydro pyrimidin.2-yl) quinoline Naphthalen-1.y ic ethyl)-1H-pyrrol-2 303.407 <* yll-l .4,5,6 tetrahydro pyrimidine (5-Bromo-2 methoxy-benzyl)- -~NH JD methyl.[2-(1,4,5, 3 83 73E* JD totrahydro- 8 .3 7 pyrimidin-2-yi)-N phenyl).anmine , (2-(5.Bromo-2 methoxy- s 0 JE benzytsutfanyl)- 338.2682* phenyl]-methyl. . amine 2-(5-Bromo-2- .1 JE methoxy- 37.22* JF benzylsulf anyt)- 347 8 benzylamine; HCl A 2-12-(2-Chloro phenylsultanylmeI JK hyl)-phenylj. 353.3142 * 1 ,4,5,6-tetrahydrc pyrimidine; HCI 2-[2-(2-Bronmo phenylsulfanylme JL hyl)_phenyl]- '397.7655 e I .4,5,r.tetrahydr4 pyrimidine; HCI l N 2-(2-o- N 0 Tolyisulfanylmeth JM yi phenyl) 1,4,56 332.8963 * tetrahydro pynmidine; HCI 2-[2-(2,5-Dichlorc phenylsulfanylme JN hyl)-phenyti- 387.7589 ~ > 14,56_etrahydr pynadine; HClY SUBSTITUTE SHEET1 f(LE6 WO 01/10842 PCT/USOO/21327 -124 2-[3-(3-Chloro- N be nzylsulfanyl)-5-M methyl-isotihiazol- S , N J0 4-yll-l.4,5.6- 383.927 N s tetrahydro pyrimidine; ... C Formate N-(4-Methyl- * SP quinazolin-2-yi)- 237.691 guanidine; HCI N-(l-Methyl j benzo[flquinazoli 2 77 0 <~-N n -3-yl)-guartidjne, 287750 HOI 2-[3-(2.Methoxy naphthalen-l yisulfanylmethyl) JR thiophen-2-ylj- 414.5537 S\ 0o* 1,4,5,6-tetrahydrc pynmidine: 2-[2-(2.5 Dimethoxy jS phenylsulfanylme 34 .6 hyl)-phenyl]- 3 2.6 1 .4,5,6-tetrahydrc pydmidine ynaphthalen-l JT ymethylsulfanyl). 382.9562 phenyl-1 .4,5,'6 tetrahydro pynimidine; HCI 2-[2-(5-Bromo-2. m ethoxy benzy'sulfanyl)-3 JU fluoro-phenyl]- 4 ,4 459.8091 dinmethyl.4,5 dihydro-1 H imidazole: HCI 2-[2-(S-Bromo-2 methoxy benzylsulfanyl)-3- ~ , JV fluoro-phenyli-5,E 473.836 dimethyl-1,4,5,6 tetrahydro pyuimidine; HCII Methyl- N naphthalen-1.yl.[, - N (1.4.5,6 JW tetrahydro- 375.4748 -N pyrimidin-2-yi)- N benzyl]-amine; Fomiate tetrahydro- 18 .2 03 I ix pyrimidin-2-yl). 8 .6 3N phenyl]-amine i' ~m U ' Coalf~H WO 01/10842 PCT/USOO/21327 -125 2-(5-Bromo-2 Methoxy- "I'o benzytsulfanyl).3-4 33 7 oo. tetrahydro pydmidin-2-yi) quinoxaline 2-[3-(Naphthalen I > ylsulfanylmethyl) JZ thiophen-2-y'J- 384.5274 1 ,4.5,6-tetrahydrc pyrimidine: / Foanate Naphthalen-l-yt. N ethoxy)-pyndin KA y]1,145 377.4474 pydmidine; Forrate 2.{2.(2.(5.BromoA 2-methoxy-I KB phenyl).ethyl]. 373.2926 CI phenyl, 4,5.6 tetrahydro pyrimidine 10.(5-Bromo-2 methoxy-phenyl).
NN
9-methyl-2,3,9,IC v KC tetrahydr-I H- 432.3214 I'' I 4,9,l0a-triaza phenanthrefle; Formate Er OH 2-Morpholin-4 KD ymethyl- 245.2811 ~~ quinazolin-4-o N,N-Dimethyl.N' (4-phenyl K E quinazolin-2-yi)- 292.3838* ethane-1 .2 diamine 4-Phenyl-2 K F piperazin-1-yi- 290.3679 quinazoline N' 2-[3-Chloro--(2- " N ' I naphthalen- 1-yt. KG ethyt)-phenylj. 385.3349 1. 4,5,6-tetrahydrc pyrimidine; HCI 2-f2-[2-(5-BromoN 2-methoxy KH phenyt)-ethyl].3- 42 .7 3 ) ol KH fluoro-pheny}. 42N43 1 .4,5,6-tetrahydrc pyrimidine; HCI om mBOTITI ITC OLICW 10 Ca WO 01/10842 PCT/USOO/21327 -126 1.(2-Naphthaterv-N 1-yi-ethyl)-8- ' (1,4.5.&- H KI tetrahydro- 377.4474 N e-_ pyrimidin-2-yI).1H 0 pyridin-2-one; Formate 2.[2.(5-Bromo-2 methoxy phenylsulfanylme oI KJ hyl)- 3-fluoro- 445.7822 phenylj-1 .4.5,6-F a tetrahydro pynmidine; HCI 2-[2-(Naphthalen -. 1 KK ylsulfanylmethyl)- 3 49 2 KK phenyll-4,5- 349 2 dihydro-1H imidazote; HCI N 2.[3-Fluoro-2 (naphthalen-1. " HN" KL yisulfnylmethyl)- 386.9197 tetrahydro- F S pynmidine; HOI 2-[3-Bromo-2 (naphthalen-1. KM yslalmtyl)- 447.8253 pheflyl]-1 .4,5,6-K. tetrahydro- Dr s I, pyrimidine; HCI 2-{2-[2-(S-Bromo-D 2-methoxy- I KN phenyl)-ethyl]-3. 4 1 74*-0 KN chloro-phenyl)- 44 .17 1,4,5,6-tetrahydr pynmidine; HCI 6-Benzylsulfanyl-N 5-(1,.4,5,'6 tetrahydro-H KO pynmidin-2-yI)- 374.492 N * imidazo[2,1 bithiazole; Formiate 2.(3.(S.Bromo-2- N ) methoxy-N phenylsulfanyl). KP propyl].1,4,5,6- 389.3177 ON.* tetrahydro pynmidine; Formate 2-(2.(2-Methoxy-EJ. trifuoromethyt. KQ benzylsultanyl)- 380.4339 s F phenyl]-1 .4,5.6- , F tetrahydro-F pyrimidine lIIy ' 9-Methyl-0 naph halen-1yi 2,3,9,0 K R tetrahydro-1 H- 373.459 4,9,0atraza. phenanthrene; Fomiate SUBSTITUTE SHEET1 f(UE2) WO 01/10842 PCT/USOO/21327 -127 7-Chloro-4.8- . N KS dimethyl-lH- 207.6592 IKO * quinotin-2-one C 7-Chloro-4-methy I KT 2.piperazin-1-yi- 261 .754 c KT quinoline 4,8-Dimethyl-2- N N KU piperazin-1-yI- 241.3361 0 quiflolifle 2-[4-(Naphthalen N KV ylonylehyl)- 374.9574 1,4. .- etayd pyrimidineH I" 2-[2-(Naphthalen- N 1- 1-MIl KW ylsulfanylmethyl)-379 4 \S KW thiophen-3-yi]- 37s97 1 ,4,5,6-tetrahydrc pynmidine; HCI 6-(2-Methoxy. phenyl)-3.4- . N OM KX dihydro-2H- 336.3948 .* pyrimido[2.1-I ajisoquinoline; Formate H KY Piperazine 86.1369 ( N N 2-[2-(4.Fluoro- I naphthalen-1. S KZ ylmethylsulfanyl)- hnl-,. 431 .3717 tetrahydro pyrirnidine; HBr 7-Ethyl-4-methyl-I LA 2-piperazin-1-yi- 255.363 N N"> * quinoline O LB 2-piperazin-1-yI. 255.363 :N NN quinoline O SUBSTITUTE SHEET (RUME2) WO 01/10842 PCT/USOO/21327 -128 MeO 5,8-Dimethoxy-4- -. LC pimethyl-2- 287.3618 -* P.iern--y- N , N ' quinoline OMe KN 2.{2-[2-(5-Bromo 2-methoxy phenyl)-ethyl)-3 tntWluoromethyl- 440.90 LD phenyF(-1,4,5,6- 44 .9 9 F tetrahydro pynmidine: Parent ethyl)-3 LE tnuoromethyl- 418.8884 phenyl3-1,4,5,6- F2 tetrahydro- F' 'F pyn midine: Nd i 2-[4-Benzyloxy-2 u (5-bromo-2 methoxy- LE ezys ltay)- 543.4858 phenyl].1 4,5.6 tetrahydro pyrimidine; Formate (3-(5-Bromo-2 methoxy- benzylsulfanyl) LG quinoxalin-2-yi]-(Z 533.4937 5N' Oj pyrrolidin-1-yi- '. propyl)-amifle; tOr~ate Naphthalen-1- N (1,4,5,6 LH trahydro- 361 .448 '~r pyrimidin-2-yi)-L phenyl]-amine; ql Fomate [3-(5-Bromo-2 methoxy- ' benzylsulfanyl). Ll quinoxalin-2-yl].[2 LI (1-methyl- 53c93 x " x , pyrrotidin-2-yl) ethylj-arnine; Fomate [3-(5-Bromo-2 methoxy benzylsulfanyl)-c x a * q uinoxalin-2-y.(I 56 .547 U (2-methyl- -'5 15 7 pipendin-1-yl) propyll-amine; a Formate [3.(S-Bromo-2 methoxy- N N benzylsulfanyl)- l lX o UK quinoxalin-2-yi3. 519.4669 piperidin ylmethl-amine;6 Formate 2-D [,4]Bipipendinyl l'yl3-(5-b omo-2 UM methexy- 573.5585 LM benzylsulanyl) quinoxaline; Formate SUBSTITUTE SMEET (RIJLE26) WO 01/10842 PCT/USOO/21327 -129 N N1.[3-(5-Bromo-2 I ( methoxy- ~N~ o,' LN benzytsultanyt- 5 62 3 LN quinoxalin-2ylJ- 50 .2 3 propane-1,3 diamine; 2HCI 2- I I 1,4J]ipipeddinyl- ~I5 1'-yI-3.(5-bromo-2* LO methoxy- 581.577 benzylsulfanyl)-N S quinoxatine; Formna ta 2-(5-Bromo-2 mthoxy- N ' 0 bezylsulfanyl)-3 LP [4-(3.eorpholin.4 61 .99 N piperazin-1.yl]. quifloxalifle; Formate 4-[2-(5-Bromo-2 mthoxy benzylsulfanyl) LQ benzylamino]- 539494 pipeddine-1 carboxytic acid ethyl eter: Formate 1.[2-(Na phthalen. 1R- 34.54 LR ylmethytsultanyl)- 3 75 4 benzyl3-piperidin ) 2-f4-[2-(5-Bromo fKN-N 2-methoxy- 1 §N. benzylsulfany) 53 4 7 LS benzyl]-piperazin- 0 1-yi)-pyrimidine; Formeate 2-[2-(6-Fluoro naphthalen-1 LT ytme thytsuttanyt). 431.3717 ~ ph nyll-1,.,6 tetrahydro pyrimidine; HBr 0 1-{4-[2.(S-Bromo LU benzylsutfanyt). 495.441 8 * benzyll-piperazin 1-yll-ethanone; Formate Bromo-2-methox LV bezlutnt. 541.5108* benzyt].piperazin 1.yt)-ethoxy) ethanol; Formnate 2{(4 [2-5-Bromo 2 niB hoxy benzy xx fanyl) LW benzy]piperazin 552.537 1 0 1yt)-N-ispropy acetamide; Formate SUBSTITUTE SHEET (RULE26) WO 01/10842 PCT/USOO/21327 -130 {1-(2-(5-Bromo-2. methoxy ix benzylsulfanyl)- 482.443 LX benzyl]-pipeddin 2-yI)-methanol; Fomiate 1-(2.(5-Bromo-2-J methoxy benzylsulfanyl) LY benzyl)-2-(N- 521.523 ci2,* pyrrolo)methyl pyrrolidine; Formate methoxy- -. *~ LZ benzylsulfanyl)- 53 .4 90 LZ benzyl] Fofrnate Br 1-[2-(5-Bromo-2 methoxy- (N benzylsulfanyl)- N.. MA benzyl]-4- 549.5768 cyctoheptyl piperazine: Formate Br 3-{2-[2.(1 .4,5,6 Tetrahydro MB pyrimidin-2-yi)- 349.437 .. * phenyl)-ethyl-H indote N'-(3-(S-Bromo-2 methoxy benzylsulfanyt) Mc quinoxalin-2.yI]. 521.4827 Kk N,N-diethyl ethane-1,2 diamine; Formatl N'-[3-(5-Bromo-2 methoxy benzylsulfanyl)-I MD quinoxalin-2-yj- 507.4559 K N,N-dimethyl propane-1,3 diamine; Formatl 2-(-Bromo-2 methoxy ME benzylsulfanyt)-. 505.44* [1 ,4]diazepan-1-y quinoxaline; Formate IN' N-(4-Bromo benzyl).N',N' ME dimethyl-N- 397.358 * naphttlaten-l- ' ylmetthy-ethane 1,2-diamine 3'-(5-Bromo-2 benzylsulfanyl)-4 MG (3-Morpholin-4-y 568.5396 propyl)-3,4,5,6 tetrahydro-2H [1 ,2'bipyrazinyl; Formate SUBSTITUTE SHEET1 (RUL26 WO 01/10842 PCT/USOO/21327 {3-[3'-(5-Bromo-2 methoxy benzylsulfanyl) MH 2,3 ,5,6t e t rahydr 52 .5 2 [1 ,2]bipyrazmnyl-4 dimethyl-amine;/ _ Formate N-(3-Bromo benzyl)-N-(5 mi brmo-2-methoxy 456.2204 N* MI benzyl)-N',N' dimethyl-ethane- 0N 1 .2-diamine N-(1-Benzyl pipefidin-4-yi)-2 MJ (naphthalen-1. 466.6471 1-~ ylmethylsulfanyl)-l benzamide N,N-Dimethyl-N' naphthalen-2- . MK ylmethyl-N'- 368.5218* naphthalen-l ylmethyl-ethane 1,2-diamine 8-Methyl-3-[2 (naphtthalen-1 M L yisulfanylmethyl)- 435.5915 phenyl]-8-aza bicyclo[3.2.ljoct t n-3-o1 Formate 1-Methyl-4-[2 (naphthalen-1 M M ylsulfanylmethyl)- 409.5536* phenyij-pipeddin 4-oi; Formate s. 3-[2-(Naphthalen *XI MN ysulanyme.,a) 421 .5646 I* bi'yclo[2 2 2]oct I n-3_oI; Formate l'-[3-(5-Bromo-2 ' MO0 benzyltsulfanyl)- 477.4686 (>X * (1.4'bipipeidinyl (3-(5-Bromo-2 methoxy- N3 MP enzylsulfanyl)- 437.4039 ( X* pyrazin-2-yi]-[2.(1 OS metsyl-pyrrolidin 2-yi)-ethyl]-amine [3-(5-Bromo-2 methoxy MO benzylsulfany- 46 .5 6 ,* pyrazin-2-ytH3-(2 methyl-piperidin-I yi)-propyl}-amine WO 01/10842 PCT/USOO/21327 -132 N-(3-Chloro-N benzyl).N.(2- 1 MR methoxy-benzyl)- 33.71N MR ,N-dimethyl- 332873 0 ethane-1 .2- 1~ diamine N-(3-Bromo benzyl)-N',N' MS dimethyl-N-(4-3172 methyl-benzyl). ethane-1,2 diamine N-(3-Bromo MT dimethyl-N- 39.8* MT naphthalen-2- 9.5 ylmethyl-ethane 1,2-diamine N-(3-Bromo benzyl)-N' N'-0C MU dimethyl-N-(4-36.2 Mu methyl-benzyl)-36.2 ethane-1,2 diamine N-Benzyl-N-(2 methoxy-benzyl)- . MV N'N-dimethyl- 298.428 I * ethane-1,2- ~ diamine e N-Benzyl-N-(2 chloro-benzyl)- C M W N',N'-dimetttyl- 302.8468 \N N. ethane-1,2- I diamine N-Benzyl-N,N'- I dimetliyl-N MX naphthalen-l- 318.4619 N ylmethyl-ethane 1 .2-dianirne N-(5-Bromo-2. c* methoxy-benzyl) MY naphthen-l~- 427.3843* ylmethyl-ethane-I 1.2-diamine N/ B-Methyl-3-[2- X/ (naphthalen- 31542 C(* MZ phenyl].8.aza- 37.56 bicycio[3.2.1]oct- s f \ 2-enep 1 Ethyl 3-12 N (naphthtaten 1 I NA ylsulfanylmethyl) 423.5805 * phenyl] p penidin S 3-al; Formeate WO 01/10842 PCT/USOO/21327 -133 1-Methyl-4-[2 NB (naphthalen-1- * NB ylsulfanytmethyl)- 391 .5384 phenyI].1,2,3,6 pynidine; Formate 2-Phenyl cyriopropanerar NC oyic acid (2- 3 25 0 NC dimethylamino- 37 .5 0 ethyI)-naphthalen 1-ylmethyl-amde, N-AnthacenU9 N-Anthrac-N9N dlmethyl-N ND namthyle-- 418.5817* ylmethyt-ethane 1,2-diamine N,N-Oimethyl. N',N'-bis-/ NE naphthalen-1- 368.5218 r ,'~ ylmethyl-ethane 1 .2-diamine ~ N-(2-Methoxy- N naphthalen-l ylmethyl)-N', N' NE dimethyl-N- 398.5481* naphthalen-1 ylmethyl-ethano- r 1 2-diamine 1-(2-(5-Bromo-2 methoxy NG benzylsulfanyl)-3 440.8315 L. chloro-benzyl] pipendine N' 2 -(3-Fluoro-2-(2 naphthalen-1-yi NH ethyl)-phenyl]- 368.8806 1 ,4,5,6-tetrahydrc - F pyrimidine; HCI 3-(3,4-Dichloro phenyl)-l-(2- C(-I dimethylamino NI ethyl).1- 416.3496 naphthalen-l ylmethyl-urea 3-(3.5-Dichloro phenyl)-1-(2 dimethylamino- " NJ ,ethyl)-l- 416.3496 nphthalen-l ylmethyl-urea Dimethylamino ethyl)-l N K naphthalen-1- 415.4584 ylmethyl-3-(2 trifluoromethyl- phenyl)-urea SUBSTITUTE SHEET (~LE426 WO 01/10842 PCT/USOO/21327 -134 NL Dimethylarino- 0* A NL methoxy-phenyl)- 3746 1-naphthaten-1 ylmethyl-urea Dimethylamino- C 5 ethyl)-1- 3 55 3 NM naphthalen-1- 375513 phenethyl-urea Dimethylamiris NN ethyl)-l- 313.443* naphthalen-1 ylmethyl-3-propyl.. urea 1-(2 Dimethylamino- .IL* NO ettiyl)-3-(4- NO methoxy-benzyl). 391.5133 < 1-naphthalen-l ylmethyl-urea 3-(3-Cyano phenyl)-l-(2 NP dimethylamino- 372.4699 * ethyl)- 1 naphthalen-1 ylmethyl-urea 3-(2,r.Dicthtoro pyridin-4-yi)-l-(2 NQ dimethylamino- 417.3374H ethyl)-1 naphthalen-l ylmethyl-urea [2-(Naphthalen-2 0o ylrnethylsulfanyl)- N NR phenyll-carbamic 466.6056 acid 2-piperidifl yl-ethyl ester formnate (2-(Naphthalen-2 ylmethylsulfanyl) phenyl]-carbamic NS acid1-aza- 464.5897* 3-yI ester; formate [2-(5-Bromo-2-o methoxy NT benzylsulfanyl)- 525.468 NU phenyl]-carbamic 5 34 2 acid -aza-ii~ yorrnay ee SU(5BSTIUTESHET ( WO 01/10842 PCT/USOO/21327 -135 [2-(5-B3romc-2 methoxy benzylsulfanyl)-3 NV hloro-benzy-3 5 48 5 piperidin-1-yi) propyl]-amine; 2)-Id 1.[2-(5.Bromo-2 NW e-ttloxy NW bencylsultanyl)-3 514.7407 chloro-benzyl] piperazine; 2HCI 1.[2-(5-Bromo-2 rnethoxy NX enzylsulfanyl)-3 4 883 NX chloro-benzylj- 48 .3 pyrrolidin-3-ol; Formate {1-[2-(5-Bromo-2 me'thoxy beazylsulfanyl)-3 NY chloro-benzylj- 502.8609 -s* pyrrolidin-2-y} methanol; Formate 1-[2-(5-Bromo-2- a methoxy NZ benzylsulfanyl)-3 4 88 77. NZ chloro-benzylF 5 .8 7 azetidine; Formate 1-(2-(5-Bromo-2 methoxy OA benzylsultanyl)-3 488.834 * chloro-benzylFpyfrolidin-3-oI;0 Formate [2-(Naphthalen-1. ylmethytsulfanyl) phenylj-carbamic OB and 1-aza- 464.5897 N bicycto[2.2.2]oct 3 -yl ester; Formate naphtlialen-1 ylmethylsulfanyl) oc phenyt]-carbamic 478.6166 * acid 1-aza- sN bicyclo[2.2.2]oct 3-yl ester, Formate naphthalen-1 ylmethylsuitanyl) OD phenyll-carbamic 480.6325 NO* acid 2-pipeddin-1 yl-ethyl eater; Formate {1-(2-(5-Bromo-2 methoxy- \ o benzyisulfanyl)-3 OE chioro-benzyll- 502.8609 pyrrolidmn-2-yl)-0 _I methanol; Formate SU BSITUTE SHEET (RJLEZ) WO 01/10842 PCT/USOO/21327 -136 ylmetttyl OF naphthalen-1- 4856 OF ylmethyl-(2- 4856 piperidin-1.yI ethyl)-amino 4-tert-Butyl-N- O naphthalern-* OG ylmethyl-N-(2- 428.6177 pipeddin-1-yi ethyl).benzamide0 N,N-Dimethyi.N.
naphthalen-2 OH naIhhaloiel 382.5487* 1 .3-diamine ' N-(5-Bromo-2-U methoy-benzyl) 01 N,xdimethlN 441411 K_ 01 naphthalen-1- 44.41 ylrnethyl-propaneo 1 .3-diamine C0 1-N aphthaten.ylmethyl-3 phenethyl-1-(2- 4815 Oj pipeddin-1-yl- 46.15 ethyl)-thiourea; HCI Dimethylamino-r phenyl)-I-(3 OK dimethylamino-4508 r OK propyl)-1- 4508 naphthalen-l- U. ytmethyl-thiourea HCI 4-[2-(5-Bromo-2 methoxy benzylsulfanyl)-3 chioro OL benzytamino]- 573.9397 OL piperidine-1. * carboxylic ad o ethyl ester; Formnate 1-[2-(5-Bromo-2 metlhoxy OM benzylsulfanyl)- 54.40 OM chloro-benzyl]- 5470 pyrrolidin-3 ylamine; 2HCI 2-[2-(2 ON Naphthalen 1 Yl1 311.8535 all ethylam nn HCI Nephthalene-2- N sultonic acid (2- f ) 00 dimetiylamino- 418.5597 *bS 1y m e hy am del SUBSTITUTE SHEET (RILE) WO 01/10842 PCT/USOO/21327 -137 1.[2.(5-Bromo-2- 0 methoxy- 1 benzylsuttanyl)-3. c..yN~ OP chloro-benzylj- 516.8877 methoxymethyl. pyrrolidine; Formats (2-Hexyloxy phenyl)-carbamic QQ acl-pipefdn- 491.6758 * ylrnethyl-ethyl ester; Fominate0 3-(2-(5-Bromo-2 methoxy OR benzylsulfanyl)- 444.8192 '* benzyloxyj pyrrolidine; HCI 3-[2-(5-Bromo-2 ODS benzylsulfanyl)- 444.8192 ~* benzyloxy] pyrrolidine; HCI 2-(2-(5-Bromo OT methoxy- * OT benzylsultanyl)- 458.8461 benzyloxymethyl] pynolidine; HCI 2-[2-(Naphttialen. OU ylsulfanylmethyl)- 369.9574 ' 9 ,* phenyl] piperidine; HCI l 3.(2-(S-Bromo-2 nmethoxy OV benzylsultanyl)- 396.3482 * benzylamino] propan-1-ol 3-[2-(5-Bromo-2. methoxy OW benzylsulfanyt)- 424.402 .~-* benzylaminoJ.3- 4, methyl-butan-l-oI 1-[2-(5-Bromo-2 methoxy OX benzylsulfanyl). 408.35920* benzyl]-pyrro idin -p 1-[2-(5-B3romo-. OY benzyisulfafyl)- 408.3592 NA '* benzyll-pyrrolidin. 3-ol SUBSTITUTE SHEET (RULE26) WO 01/10842 PCT/USOO/21327 -138 (I-(2-(5-Bromo-2 methoxy- . OZ benzylsulfanyt)- 422.3861 * benzylj-pyrrolidin S 2-yi}-mettianol {1-[2-(5-Bromo-2 methoxy PA benzylsulfanyl)- 422.3861 I* benzyl]-pynrolidin 2-yl)-methanol {1.[2-(NaphthaletN 1 PB yisulfanylmethyl) 423.5805, 2-yl}-methanol; Formate 2-[2-(Naphthalen ylsulfanylmethyl). PC pyrrolidin-l-yll- 386.5628 * ethyl-N pyrrolidine;I Formate N-pyrrolyt-[l-(2-/ PD naphthalen-1-yi-30468"* PD ethyl)-pyrrolidin-2 3846 ylmethyl]-amine -0 1.(2-Naphthalen- 011 PE pipeddine-2- 297.31972* carboxylic acid 'N N methyl esterJ (3-Bromo-benzyl) (1-ethyl-pyrrolidin * PF 2-ylmethyl)- 4742 naphthalen-l- 4742 ylmethyl-amine N 3-12-(5-Bromo-2- 0 . methoxy- I s ~ PG benzylsulfanyl)- 458.8461 KN* benzyloxy] piperidine; HO (5- Bromo-2 methoxy-benzyl) P (1ethyl-pyrrolidin4649* P 12-ylmethyl)- 46.9 naphthalen-l-I ytmethyl-amine (1- Ettiyl-pyrrolidin 2-ylmethyl) P1 naphthalen-2-40586 N<I naphthalen 1 s ylmethyl-amine a SUBSTITUTE SHEET (RLA WO 01/10842 PCT/USOO/21327 -139 2-[2-(5-Bromo-2 methoxy- * Pi benzytsulfanY,)- 458.8461 tbenzyloxymethyl] pyrrolidine: HCI (3-Bromo-benzyl) (3-imidazol-1-yI. PK propyl)- 434.3788 naphthalen-1 ylrnethyl-amifle (3-lmidazol-1-yi-J propyl)- PL naphthalen-2- 4 55 2 ylrflmethyl- 4 55 2 naphthalen-1 ylmethyl-amine (2-(Naphthalenl ylmethylsulfanyl)- o phenyl]-carbamicj PM acid 2-piperidin-I 563.7657 o K yl-1-piperidin-1 ytmethyl-ethyl ester Formate (2-(Naphthalen-. ylmethylsulfanyl) phenyl].carbamic' PN d 2~an- 426.5408 K ethyl ester Formate 1.[2-(Naphthalen.N p 0 yisulfanylmethyl). 9 .42S* benzyll- 39 54 piperazine; Formate [3-(2-Methyl piperidin-1-yl) propyl]-[2- ' pp (naphthalen-1- 464.6764 $ * yisulfanytmethyl) benzyl]-amine; Formate 14[3-Chloro-2 (naphthalen-1- c PQ ylsulfanylmethyl)- 419.4168 a** benzyl] piperazine; HCI 1.[3-Fluoro-2-(2 PR nahhln1y-384.9234 prazie;C PS m]pieidn 458.0253 a* SUBSTAThIEOSHEET (RUt 2) WO 01/10842 PCT/USOO/21327 -140 N,N-Dimethyl-N'- IN' (2-naphthalen yi-ettlyl)-N' PT naphthalen-1- 428.5787* ytmethyl-ethane ,2-diamine:C& 2 Formate {1-(2-(5-Bromo-2 roethoxy- C. benzylsulfanyl)- 4 0.57 PU chloro-benzylj- 4 08 7 piperidin-2-yi) methanol {1-[2-(2. Naphthalen-1-yi ethyl)benzy~- 4 55 1 Pv methanol; pieii-k'l- 4 55 1 Fornmate Naphthalen-1-yl PW ethyl)-benzyl]. 376.5029* piperazrfle; Formate [3-(2-Methyl- N piperidin-1-yl)- c ~ propyll-[2-(2- 4 66 7 PX naphthaten-1-yl- 4 66 7 ethyl)-benzyl] amine; Fornmate 1-[2-(2. Naphthalen-1-yi PY ethyl)-benzyl]- 376.5029 pyrrotidin-3 ylamine; Fonmate 5, 5-Dimethyl-2-[2 N (2-naphttiaten-l- H PZ yl-ethyl)-phenyl]- .. 4,5-dihydro-1 H imidlazoleI 2.(3-Fluoro-2-(2- / N naphthalen-1-y- N QA ethyl)-phenyl]-5,5.A dihydro-1 H- F imidazole 2-[2-(5-Bromo-2- F II methoxy- - H M benzylsulfanyl)- ~ Q B 3,5-difluoro- F phenyl-1456 tetrahydro pyrimidine 2-[2-(5-Bromo-2-N methoxy- F, N/\ benzylsulfanyl)- I H ~ 35-difluoro- s OM. * QC Phenyl]-5,5- F dimethyt-4,5 d ihydro-1H-1 imidazole e SUBSTITUTE ShilEET (AW PERI WO 01/10842 PCT/USOO/21327 3-(2-Naphthalen 1.yI-ethyl)-2- N OD (1,4,5,6- -* QD tetrahydro pydmidin-2-yi) phenylamine Amino-[2-(2 QE naphthaten-1-yl-N NH* QE ethyl)-phenyl] acetonitrie. Naphthalen-1-yi. QE ethyl).phenylj-N NH ethane-1,2- C diamine I 2-[2-(5-Bromo-2-N methoxy- Nl QG benzytsulfanyl)- - * QG phenyll-4-methyl. 4,5-dihydro-lH.N imidazoler 2-[2-(S-Brmmo-2-N enmethoxy-" bzylsulfanyl)-3 H QH fluoro-phenyl)-4 QH mathyl-4,5- N dihydro-klH imidazole 2-(2-(5-Bromo-2-N methoxy benzylsulfanyl)-3 H Q I chloro-ptrenyl]-4-S rnethyl-4,5- N, dihydro-1H-I imidazole 2-[2-(5-Bromo-2 methoxy- O benzylsultanyl)- q H QJ 3,4-difluoro F S OMe phenyl].1,4,5,B.. F tetrahydro pyrimidine 2-[3-Fluoro-2- HN (naphthalen-l ylsulfanytmethyl)-N N QK phenyl]-5.5- I .* dimethyl-4,5 dihydro-1H- F S N imidazole 2-{2-(2-(5-BromoN 2-methoxy- N QL phenyl)-1 methyl- l QL ethyl] pheny) 1,4,5.6-tetrahyd N pynrndrre 22-5 B HH-2 nrethoxy b-nyl Sn fanyl)-3f on,4 SUBSTITUTE SHEET1 f(LE6 WO 01/10842 PCT/USOO/21327 -142 2-f2-(5Bron-2 nmethomy-benzyl Q N t~iiuomthaphn* 5,5-diNethyI-1,4.5.6 tetrahyd-pyrinmidine 2.E3-Methoxy-2-(2 naphthalen-1-y- N QO ethyl)-phenyl) 1,4,5,6-tetrahydrcOF pydmidine OH 2-[2-(5-Bromo-2- I metlioxy- H Qp benz Isulfan 1)-3 - s o 1,4,-tetrahydr pynm'din-5o 2-{2-(2-(5-Bromo 2-methoxy- H phenyl)-ethyl]-3- - o QQ methoxy-phenyl)- o N 1,4,56-tetahyd I pyrimidine SUBSTITUTE SHEET1 (RUE2) WO 01/10842 PCT/USOO/21327 143 TABLE 5 Salt Molecular Structure Salt Molecular Structure Weight [_________ _______jWeightII co Parent 347.5242 O Parent 466.6471 Parent 331.9091 s Parent 508.7277 t N Parent 333.4453 F Parent 377.3244 0 F) N N NH N Parent 365.4626 C Parent 378.5383 sO I Parent 646.0503 Parent 406.5921 : N I N Formate 513.4192 Parent 348.4882 N Formate 533.4937 Parent 404.5762 Formate 595.5646 s - Parent 312.4552 N -N0 HCI 525.9799 Parent 348.4882 N SUBSTITUTE SHEET (RULE26 WO 01/10842 PCT/USOO/21327 144 Formate 530.4901 Parent 328.4546 N Formate 599.6367 Parent 372.3079 ' N)N OL N Formate 579.5194 Parent 377.3244 Formate 590.5457 Parent 337.2916 N Cl Formate 568.4987 N S Parent 458.6678 0 N -L Formate 535.5096 as Parent 353.5078 0 Parent 561.5456 Parent 362.4717 KN N N N N Formate 559.5316 s. o- Formate 468.5781 a NN Formate 534.4815 Formate 527.4406 0~ N Format 507.4559 NXS O, Formate 468.5781 2 SUBSTITUTE SHEET (RULE261 WO 01/10842 PCT/USOO/21327 145 NH, Formate 493.429 Formate 502.8609 s r<-7 Parent 591.6153 * Formate 516.8877 NN N N Formate 483.4339 Parent 321.2376 N Parent 178.2774 Parent 454.6122 NH Parent 426.1942 N Parent 513.4747 0 Parent 392.2957 Parent N32.2769 7 l 0 \ ... ... Parent 649.6519 Parent 467.449 - Br Parnte 426.56426 Parent 53.477 . SUBSTIUTE SEET (UL '-6 WO 01/10842 PCT/USOO/21327 146 N Parent 377.3244 N HCI 451.0753 CN% IN Parent 298.4283 HCI 418.0454N IN Parent 404.5762 HCI 443.0552 N NN Parent 447.6446 (x2..HCI 442.024 Parent 402.5603 \ Parent 508.4765 /D Parent 549.5346 Parent 508.4765 Formate 581.5377 jf\.J Parent 522.5034 Format 443.3691 N S Parent 522.5034 N HN N N Formate 485.4497 " s Parent 522.5034 N N Formate 523.4986 INS Parent 428.5524 N SUBSTITUTE SHEET (RULE26) WO 01/10842 PCT/USOO/21327 147 Formate 457.396 s Parent 374.528 0:o \ B,
/N
M 0 N Formate 529.4595 Parent 387.5029 CK N*N N Formate 338.4082 "*Parent 294.4399 \ 0>0 Formate 336.3924 N Oc HI 472.873 Parent 293.4118 Formate 467.388 0 I N Parent 336.4003 Parent 278.3538 Parent 318.4619 N Parent 282.4289 N N N Parent 454.4283 Parent 378.4742 ) ON Parent 357.4552 Parent 406.528 SUBSTITUTE SKEET (ULE26) WO 01/10842 PCT/USOO/21327 148 Parent 386.4903 F Parent 464.4051 N N' \N/ Parent 393.5096 Parent 296.4558 C < Ni KN i Parent 364.4473 N Formate 443.3855 N Formate 400.5463 N Parent 336.5206 Formate 400.5897 ' Parent 343.4717 ccNH Parent 430.5902 Deterined SNH Not Not Determined Determined 61 C, NH Not Not N Determined Determined 0 0_NH= Not - Not \NN Determined Determined I Not Not Determined Determined O MiOTAT Ir E oreporr-o-"iP ag -,Pf4Nv WO 01/10842 PCT/USOO/21327 149 0 Not Not Determined Determined Determined NoPtf nrGc7 n O 200%.ftA, WO 01/10842 PCT/USOO/21327 -150 Example 3: cAMP Assay for MC4-R Antagonist Activity Method MC4 Receptors are expressed in stably transfected K293 cells. The cells 5 are incubated in DMEM base medium (10% FBS, IX glutamine, and 0.4 mg/ml G418) at 37"C, in an atmosphere of 6.0% CO 2 and 90% relative humidity. Two days before the experiment, the cells are trypsinized and 200 pl of the cell suspension (138,000 cells/ml) is deposited into 96-well Costar cell culture plates. The test compounds are then dissolved in DMSO creating a 30mM stock 10 solution, which is subsequently diluted to 180, 650, 20, 6.6, 2.2 pM in OPTI-MEM (GIBCO-BRL) media with 50 pM IBMX (isobutylmethylxanthine, Sigma) minutes before the experiment. The media is then thoroughly removed from the cell culture plates through a 12-channel straight manifold. 90 pl of OPTI-MEM media with 50 pM IBMX 15 is added to each well (McHale et al. FEBS Letters 345 (1994) 147-150). The plate is then placed in an incubator set at 37 'C, 6.0% CO 2 and 90% relative humidity. After 15 minutes of incubation, 90 pl of the test compound solutions (or a control solution of OPTI-MEM and IBMX) are added and the plates are incubated for another 10 minutes. 20 pl of the ligand MSH solution in OPTI-MEM is then added. The cell plates are 20 incubated for an additional hour at 37 *C. After the incubation, the media mixture is removed by 12-channel straight manifold. 60 pl of 70% ethanol is added to each well. The plates are then placed on a shaker for 30 minutes to extract the cAMP. The amount of cAMP is detected by the cyclic AMP [121] Biotrak SPA screening assay system (Amersham). 25 The system involves adding 50 pl of IX assay buffer into each well of an OptiPlate-96 (Packard). 50 pl of the tracer solution (cAMP-I 25 1) is added into each well. 5 pl of the cAMP extract is added into the mixture, followed by the addition of cAMP antiserum and 50 pl of SPA PVT-antibody binding beads. The plates are then covered with TopSeal-A (Parkard) and incubated at room temperature for up to fifteen hours before 30 being analyzed using a TOPCOUNT machine.
WO 01/10842 PCT/USOO/21327 -151 Example 4: In Vivo Assay for MC4-R Antagonist Activity The following in vivo assay was used to test the effects of MC4-R antagonists on mice. Male lean C57BL/6J mice were individually housed in macrolon cages (22 5 2C*; 12:12 h light/dark cycle with lights off at 6 pm). Tap water and mouse chow diet were given ad libitum. Mice were stereotaxically implanted with a chronic guide cannula aimed to the third ventricle (intracerabroventricular) one week prior to testing. It had been previously determined that food deprived lean mice which had been injected with 0.1 nmol of MT II (a MC4-R agonist) prior to refeeding showed decreased 10 feeding response within 1 hour of injection (Figure 1). In previous experiments using peptidic MC4-R antagonists, it has been shown that the decreased feeding response of MT II treated food-deprived mice can be reversed by the intracerabroventricular injection of MC4-R antagonists. In this experiment, food deprived lean mice were injected 15 intracerabroventricularly with either Compound N or Compound 0, at a dose of 15 nmol prior to injection of MT II at the dose of 0.05 nmol. The results of the experiment are shown in Figures 2 and 3. Figure 2 shows that administration of 15 nmol of Compound N partially reverses the effect of the administration of the MC4-R agonist, MT II. Figure 3 shows that administration of 20 Compound 0 did not significantly effect the food intake of mice treated with MT II. Example 5: cAMP Assay for MC Receptor Agonist Activity (cAMP Assay) The cAMP assay identifies compounds which have agonist activity against MC receptors. It is used to identify the selectivity of agonist which selectively 25 antagonize receptors of interest. The following method is outlined for MC4-R, but corresponding procedures were used for the other MC receptors, MC 1 -R, MC3-R, and MC5-R. Method MC4 Receptors are expressed in stably transfected HEK293 cells. The cells are 30 incubated in DMEM base medium (10% FBS, IX glutamine, and 0.4 mg/ml G418) at 37'C, in an atmosphere of 6.0% CO 2 and 90% relative humidity. Two days before the experiment, the cells are trypsinized and 200 pl of the cell suspension (138,000 cells/ml) is deposited into 96-well Costar cell culture plates.
WO 01/10842 PCT/USOO/21327 -152 The test compounds are then dissolved in DMSO creating a 30mM stock solution, which is subsequently diluted to 180, 650, 20, 6.6, 2.2 PM in OPTI-MEM (GIBCO-BRL) media with 50 pM IBMX (isobutylmethylxanthine, Sigma) minutes before the experiment. 5 The media is then thoroughly removed from the cell culture plates through a 12 channel straight manifold. 90 pl of OPTI-MEM media with 50 pM IBMX is added to each well (McHale et al. FEBS Letters 345 (1994) 147-150). The plate is then placed in an incubator set at 37 *C, 6.0% CO 2 and 90% relative humidity. After 15 minutes of incubation, 90 il of the test compound solutions (or a control solution of OPTI-MEM 10 and IBMX) are added and the plates are incubated for another 10 minutes. 20 pl of the ligand MSH solution in OPTI-MEM is then added. The cell plates are incubated for an additional hour at 37 'C. After the incubation, the media mixture is removed by 12-channel straight manifold. 60 ptl of 70% ethanol is added to each well. The plates are then placed on a 15 shaker for 30 minutes to extract the cAMP. The amount of cAMP is detected by the cyclic AMP [125 I] Biotrak SPA screening assay system (Amersham). The system involves adding 50 pl of 1X assay buffer into each well of an OptiPlate-96 (Packard). 50 pl of the tracer solution (cAMP- 251) is added into each well. 5 pl of the cAMP extract is added into the mixture, followed by the addition of cAMP antiserum and 50 pl 20 of SPA PVT-antibody binding beads. The plates are then covered with TopSeal-A (Packard) and incubated at room temperature for up to fifteen hours before being analyzed using a TOPCOUNT machine. Compounds 0, N, AG, AL, and AM were found to be at least 100 fold more selective for MC4-R than MCl-R, MC3-R and MC5-R. 25 INCORPORATION BY REFERENCE The entire contents of all references and patents cited herein are hereby incorporated by reference. The entire contents of U.S. Patent 5,908,609 and all its references also expressly incorporated herein. EQUIVALENTS 30 Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments and methods described herein. Such equivalents are intended to be encompassed by the WO 01/10842 PCT/USOO/21327 -153 scope of the following claims.
Claims (221)
1. A method for treating a MC4-R associated state in a mammal comprising administering an effective amount of a MC4-R binding compound to a mammal, such 5 that the MC4-R associated state is treated, wherein said compound is of the formula (I): B-Z-E (I) wherein B is an anchor moiety; Z is a central moiety; and 10 E is a MC4-R interacting moiety.
2. A method for treating an MC4-R associated state in a mammal comprising administering an effective amount of a MC4-R binding compound to a mammal, such that the MC4-R associated state is treated, wherein said compound is of the formula 15 (III): B-LI-A-L 2 -E (III) wherein: B is an anchor moiety; L, and L 2 are linking moieties; 20 A is a cyclic moiety; and E is a MC4-R interacting moiety.
3. A method for treating an MC4-R associated state in a mammal comprising administering an effective amount of a MC4-R binding compound to said mammal, such 25 that the MC4-R associated state is treated, wherein said compound is an MC4-R antagonist, and is of the formula (III): B-L 1 -A-L 2 -E (III) wherein B is substituted or unsubstituted biaryl, unsubstituted or substituted heterocyclic, 30 or unsubstituted or substituted phenyl, wherein one or more of said substituents are halogens, alkyl, alkynyl, alkoxy, aryl, amino, cyano, or nitro; L I is a covalent bond, CI-C 6 branched or unbranched alkyl, wherein one or two of the carbons are optionally replaced with oxygen, sulfur or nitrogen atoms; WO 01/10842 PCT/USOO/21327 -155 L 2 is a covalent bond, substituted or unsubstituted amino, ether, thioether, or alkyl; E is substituted or unsubstituted alkyl, amino, amidino, guanidino, heterocyclic, or aryl, wherein said substituents are amino, arylalkyl, aminoalkyl, alkyl, aryl, alkenyl, 5 or alkynyl; and A is a substituted or unsubstituted phenyl, heteroaryl, cycloalkyl, or biaryl, and pharmaceutically acceptable salts thereof.
4. The method of any one of claims 1-3, wherein said compound binds to the MC4 10 R with an IC 50 of about 5 ptM or less.
5. The method of claim 4, wherein said compound binds to the MC4-R with an IC 50 of about I pM or less. 15
6. The method of claim 5, wherein said compound binds to the MC4-R with an IC 50 of about 0.5 piM or less.
7. The method of claim 6, wherein said compound binds to the MC4-R with an IC 50 of about 0.1 pM or less. 20
8. The method of claim 7, wherein said compound binds to the MC4-R with an IC 50 of about 0.05 ptM or less.
9. The method of claim 8, wherein said compound binds to the MC4-R with an IC 50 25 of about 0.03 ptM or less.
10. The method of any one of claims 1-9, wherein said compound is an antagonist of the MC4-R. 30
11. The method of any one of claims 1-9, wherein said compound is an agonist of the MC4-R. WO 01/10842 PCT/USOO/21327 -156
12. The method of any one of claims 1-11, wherein said effective amount is effective to treat a disorder associated with pigmentation or weight loss.
13. The method of claim 12, wherein said effective amount is effective to treat a 5 disorder associated with weight loss.
14. The method of claim 13, wherein said weight loss is a result of anorexia nervosa, old age, cancer cachexia, HIV cachexia, or weightlessness. 10
15. The method of any one of claims 1-14, wherein said mammal is a human.
16. The method of any one of claims 1-15, wherein B is substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, or heterocyclic. 15
17. The method of claim 16, wherein B is aryl.
18. The method of claim 17, wherein B is carbocyclic.
19. The method of claim 18, wherein B is phenyl. 20
20. The method of claim 19, wherein B is substituted with at least one substituent, wherein each substituent is independently selected from the group consisting of halogens, alkoxy, hydroxy, alkylcarbonyl, cyano, nitro, thiol, alkyl, alkenyl, alkynyl, aryl, arylalkynyl, or arylalkyl. 25
21. The method of claim 20, wherein B is substituted with at least one halogen.
22. The method of claim 20, wherein B is substituted with at least one alkoxy group. 30
23. The method of claim 20, wherein B is substituted with at least one alkyl group.
24. The method of claim 16, wherein B comprises more than one aromatic ring. WO 01/10842 PCT/USOO/21327 -157
25. The method of claim 24, wherein B is substituted or unsubstituted naphthyl, fluorene, anthracene, or biphenyl.
26. The method of claim 25, wherein B is substituted or unsubstituted naphthyl. 5
27. The method of claim 25, wherein B is substituted with one or more substituents selected from the group consisting of halogens, alkoxy, hydroxy, alkylcarbonyl, cyano, nitro, thiol, alkyl, alkenyl, alkynyl, aryl, arylalkynyl, or arylalkyl. 10
28. The method of claim 16, wherein B comprises a heterocycle.
29. The method of claim 27, wherein B is substituted or unsubstituted furanyl, imidazolyl, benzothiophenyl, benzofuranyl, quinolinyl, isoquinolinyl, benzodiozanyl, benzoxazolyl, benzothiazolyl, methylenedioxyphenyl, ethylenedioxyphenyl, piperidinyl, 15 indolyl, thienyl, pyrimidyl, pyrazinyl, purinyl, or deazapurinyl.
30. The method of any one of claims 2-29, wherein L, is a covalent bond or a substituted or unsubstituted chain of one to six atoms. 20
31. The method of claim 30, wherein said chain comprises a carbon atom and at least one other atom selected from the group consisting of carbon, sulfur, oxygen, or nitrogen.
32. The method of claim 31, wherein said chain comprises a sulfur atom. 25
33. The method of claim 31, wherein said chain comprises an oxygen atom.
34. The method of claim 31, wherein said chain comprises two carbon atoms.
35. The method of any one of claims 2-34, wherein A is substituted or unsubstituted 30 phenyl, heteroaryl, or bicyclic.
36. The method of claim 35, wherein A is unsubstituted phenyl. WO 01/10842 PCT/USOO/21327 -158
37. The method of claim 36, wherein A is substituted phenyl.
38. The method of claim 37, wherein A is substituted with one or more substituents selected from the group consisting chlorine, fluorine, bromine, iodine, amino, cyano, 5 alkoxy, or alkyl.
39. The method of claim 38, wherein A is substituted with chlorine.
40. The method of claim 38, wherein A is substituted with fluorine. 10
41. The method of claim 38, wherein said alkyl group is methyl or trifluoromethyl.
42. The method of claim 35, wherein A is heteroaryl and selected from the group consisting of pyrimidyl, pyrazinyl, thienyl, pyrrolyl, imidazolyl, or quinoxalinyl. 15
43. The method of any one of claims 2-42, wherein L 2 is selected from the group consisting of a covalent bond, a carbonyl moiety, a thiocarbonyl moiety or C I-C 6 branched or unbranched alkyl, wherein one, two or three of the carbons are optionally replaced with oxygen, sulfur or nitrogen atoms. 20
44. The method of claim 43, wherein L 2 is a covalent bond.
45. The method of any one of claims 1-42, wherein E is a substituted or unsubstituted amino group, alkyl, cyano, guanidino, amidino, or a heterocyclic moiety. 25
46. The method of claim 45, wherein E is dialkylamino.
47. The method of claim 45, wherein E is heterocyclic. 30
48. The method of claim 47, wherein E contains a nitrogen atom. WO 01/10842 PCT/USOO/21327 -159
49. The method of claim 48, wherein E is substituted or unsubstituted piprazinyl, imidoazopyridinyl, pyrolloimidazolyl, pyrrolyl, azetidinyl, azapanyl, diazapanyl, pyrimidinyl, pyridinyl, morpholinyl, or piperidinyl. 5
50. The method of claim 47, wherein E is multicyclic.
51. The method of claim 50, wherein E is a bridged or fused ring.
52. The method of claim 47, wherein E is of the formula (XIII): N s R 10 (XIII) wherein r is a covalent bond, CH, CH 2 , CR', CR'R 2 , or H; t is CH, CH 2 , CR, CR 3 R 4 , or H; s is CH, CH 2 ,alkenyl, CHR 5 , CRR 6 , or absent; 15 R is hydrogen, alkyl, alkenyl, arylalkyl, benzocarbonyl, 1 2 3 4 5 arylalkylcarbonyl, alkylcarbonyl, optionally linked to A, B, Li, L 2 , R1, R , R , R4, R or R6 to form a ring; and R1, R2, R , R4, R5, and R 6 are each halogen, thiol, alkoxy, alkyl, alkenyl, alkynyl, heterocyclic, aryl, hydroxyl, nitro, amino, cyano, optionally linked to form a 20 ring with R, R', R2, R3, R4, R', or R 6 .
53. The method of claim 52, wherein each of r, s and t are CH 2 .
54. The method of claim 52, wherein R is H, alkyl, benzocarboxy, alkylcarboxy, or 25 arylalkylcarboxy.
55. The method of claim 52, wherein r is a covalent bond. WO 01/10842 PCT/USOO/21327 -160
56. A method for treating an MC4-R associated state in a mammal comprising administering an effective amount of a MC4-R binding compound to said mammal, such that the MC4-R associated state is treated, wherein said compound is an MC4-R antagonist, and is of the formula (V): 5 (IX L3 B-- I L 2 -E (V) B is substituted or unsubstituted biaryl, unsubstituted or substituted heterocyclic, or unsubstituted or substituted phenyl, wherein one or more of said substituents are halogens, alkyl, alkynyl, alkoxy, aryl, amino, cyano, or nitro; 10 L I is a covalent bond, CI-C 6 branched or unbranched alkyl, wherein one or two of the carbons are optionally replaced with oxygen, sulfur or nitrogen atoms; L 2 is a covalent bond, substituted or unsubstituted amino, ether, thioether, or alkyl; E is substituted or unsubstituted alkyl, amino, amidino, guanidino, heterocyclic, 15 or aryl, wherein said substituents are amino, arylalkyl, aminoalkyl, alkyl, aryl, alkenyl, or alkynyl; H is a covalent bond, a carbon atom, a nitrogen atom, heterocyclic, alkyl, cycloalkyl, or aryl; L 3 is a covalent bond, C I-C 6 branched, unbranched or cyclic alkyl, wherein one, 20 two or three of the carbons are optionally replaced with oxygen, sulfur or nitrogen atoms, carbonyl, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, or aminothiocarbonyl; and A is heterocyclic, aryl, alkoxy, amino, alkyl, alkenyl, alkynyl, or hydrogen; and k is 0, 1 or 2, and pharmaceutically acceptable salts thereof. 25
57. The method of claim 56, wherein Ul is a carbon or nitrogen atom.
58. The method of any one of claims 56-57, wherein L 3 is aminocarbonyloxy. WO 01/10842 PCT/USOO/21327 -161
59. The method of any one of claims 56-58, wherein A is substituted or unsubstituted aryl.
60. The method of claim 59, wherein A is substituted with alkoxy, cyano, halogens, 5 alkyl, aryl, alkenyl, alkynyl, nitro, or an amino group.
61. The method of any one of claims 56-60, wherein k is one.
62. The method of any one of claims 56-61, wherein Li and L 2 are each CH 2 . 10
63. The method of any one of claim 56-61, wherein B is heterocyclic.
64. The method of any one of claim 56-63, wherein E is heterocyclic or substituted amino. 15
65. The method of claim 56, wherein 1-, L 2 and L 3 together are a single covalent bond.
66. A method for treating an MC4-R associated state in a mammal comprising 20 administering an effective amount of a MC4-R binding compound to a mammal, such that the MC4-R associated state is treated, wherein said compound is an MC4-R antagonist, and is of the formula (VI): P L2 P4 (L1 sZ5 P 5 3 z Iz z (VI) wherein 25 P 2 , P2 p 3 p 4 , and P 5 are optionally substituted carbon, sulfur, or nitrogen, and wherein one of pI, p2 p3 p 4 and P 5 may represent a covalent bond; Z I, Z2, Z3, Z4 , and Z5 are optionally substituted carbon or nitrogen; WO 01/10842 PCT/USOO/21327 -162 L' is a covalent bond, CI-C 6 branched or unbranched alkyl, wherein one or two of the carbons are optionally replaced with oxygen, sulfur or nitrogen atoms; L 2 is a covalent bond, substituted or unsubstituted amino, ether, thioether, or alkyl; 5 L 2 is a covalent bond, substituted or unsubstituted amino, ether, thioether, or alkyl; and J is an unsubstituted or substituted nitrogen containing heterocycle or a substituted or unsubstituted amino group, and pharmaceutically acceptable salts thereof. 10
67. The method of claim 66, wherein P , P2 p3, p4 , and P 5 are each substituted or unsubstituted carbon.
68. The method of claim 67, wherein P' and P 3 are CH. 15
69. The method of any one of claims 66, 67, or 68 wherein P 2 and P 4 are each CH, CF, CCl, CBr, or CI.
70. The method of any one of claims 66-69, wherein Z 3 and Z 4 are each CH. 20
71. The method of any one claims 66-70, wherein Z' is CH, or covalently linked to Z2 to form a naphthyl ring;
72. The method of any one of claims 66-70, wherein Z 2 is CH, C-(C=CH), CCl, CBr, CI, CF, or covalently linked to Z' to form a naphthyl ring; 25
73. The method of any one of claims 66-72, wherein Z 5 is CH or C-alkoxy.
74. The method of any one of claims 66-73, wherein L2 is a covalent bond. 30
75. The method of any one of claims 66-74, wherein J is substituted or unsubstituted piprazinyl, imidoazopyridinyl, pyrolloimidazolyl, pyrrolyl, azetidinyl, azapanyl, diazapanyl, pyrimidinyl, pyridinyl, morpholinyl, or piperidinyl. WO 01/10842 PCT/USOO/21327 -163
76. The method of claim 66, wherein J is a substituted or unsubstituted fused ring or bridged heterocycle.
77. The method of claim 66, wherein said MC4-R binding compound is of the 5 formula (IX): N s P2 N P G G Z izNz2 (IX) wherein: p2 is CH, CF, CCl, Clr, C-alkyl, C-alkoxy, C-CN, C-OH, or CI; P3 is CH, CF, CCl, CBr, C-alkyl, C-alkoxy, C-CN, C-OH, or CI; 10 P4 is CH, CC, Clr, CF, C-alkyl, C-alkoxy, C-CN, C-OH, or CI; G' and G2 are each independently CH 2 , S, or 0; r is a covalent bond or CH 2 ; t is CH 2 , CR3, or CR 3R; s is CH 2 ,CHR5 or CR 5 R 6 ; 15 R is hydrogen or alkyl; Z' is CH, or covalently linked to Z2 to form a naphthyl ring; Z2 is CH, C-(C=CH), CCl, CBr, CI, CF, or covalently linked to Z' to form a naphthyl ring; Z 5 is CH, or C-OMe; 20 R 3 , R 4 , R 5 , and R 6 are methyl or ethyl, or pharmaceutically acceptable salts thereof.
78. The method of claim 77, wherein ZI is CH, Z 2 is CBr and Z 5 is C-OMe. 25
79. The method of claim 77 or 78, wherein P 2 is CH. WO 01/10842 PCT/USOO/21327 -164
80. The method of any one of claims 77-79, wherein P 4 is CCl or CF.
81. The method of any one of claims 77-80, wherein G' and G 2 are each CH 2 . 5
82. The method of any one of claims 77-80, wherein G' and G 2 together are -CH 2 -S or -S-CH 2 -.
83. The method of any one of claims 73-82, wherein Z and Z2 are linked to form a naphthyl ring. 10
84. The method of claim 2, wherein said compound is selected from the group consisting of: NH O NN s NHO S -~C, -~S Oe NB 2 NB 2 N N N N N NH N NH N- NH N S - S -P- S1 -- S, B r CI S X 'S < GI0 0 0< Br -<NS , N '-S avis Br WO 01/10842 PCT/USOO/21327 -165 NN NN (I X B, NNH"NH K J BBr N I N "I N Br Br N") ~"" N"""" 'N~ I"H'N H" S 0N B'ra ~ 'NN"-) N - "N - " " I1 NH' NH B s 07 N 'NN NH NH N""N NJ N7 ~) 0"" 'N Br Br WO 01/10842 PCT/USOO/21327 -166 N NH N HN NHN N C - S 0- 7 01 S F Br Br N N N HN F Oe F : S F B B r Br r SBr N N \N F 7 N NK Br Br W" ~NN NII 7 N N N N NI H ANAF S OMe 0 S 0F Br Br Br N OH N IND 'N N N N - N H N KN1 0 OCHr 3 I" K Br Br
85. The method of claim 2, wherein said compound is selected from the group consisting of: 2-[2-(4-benzyloxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-iodo-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 5 2-[2-(2-methoxy-5-nitro-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(naphthalen-1 -ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(3-chloro-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2,5-dimethoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; WO 01/10842 PCT/USOO/21327 -167 2-[2-(3 -bromo-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-iodo-benzylsulfanyl)-phenyl]-4,5-dihydro- 1 H-imidazole; 2-[2-(2-methoxy-5-nitro-benzylsulfanyl)-phenyl]-4,5-dihydro- 1 H-imidazole; 2- [2-(2-methoxy-5-nitro-benzyloxy)-phenyl]- 1,4,5,6-tetrahydropyrimidine; 5 2- [2-(2-bromo-benzylsulfanyl)-phenyl] -1,4,5,6-tetrahydro-pyrimidine; 2-[2-(3-iodo-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-methoxy-5-nitro-benzylsulfanyl)-phenyl]-3a,4,5,6,7,7a-hexahydro- I H benzoimidazole; 2- {2-[2-(2-methoxy-naphthalen- 1 -yl)-ethyl]-phenyl} -1,4,5,6-tetrahydropyrimidine; 10 2-[2-(5-bromo-2-methoxy-benzylsulfanyl)-phenyl]- 1,4,5,6,-tetrahydropyrimidine; 2- {2-[2-(2-methyl-naphthalen- 1 -yl)-ethyl]-phenyl } -1,4,5,6-tetrahydropyrimidine; 2-{2-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yl) -ethyl]-phenyl }-1,4,5,6 tetrahydropyrimidine; 2-[2-(2-methoxy-napthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydropyrimidine; 15 2-(2-Benzylsulfanyl-phenyl)- 1,4,5,6-tetrahydro-pyrimidine; 2-(2-Pentadecylsulfanyl-phenyl)- 1,4,5,6-tetrahydro-pyrimidine; 2-(2-Cyclohexylmethylsulfanyl-phenyl)- 1,4,5,6-tetrahydro-pyrimidine; 2- [2-(2-Methyl-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2- [2-(3 -Nitro-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 20 2- [2-(3,5 -Dimethoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2- [2-(4-Fluoro-benzylsulfanyl)-phenyl] -1,4,5,6-tetrahydro-pyrimidine; 2- [2-(2-Chloro-benzylsulfanyl)-phenyl] -1,4,5,6-tetrahydro-pyrimidine; 2- [2-(2-Fluoro-benzylsulfanyl)-phenyl] -1,4,5,6-tetrahydro-pyrimidine; 2- [2-(2,4-Bis-trifluoromethyl-benzylsulfanyl)-phenyl] -1,4,5,6-tetrahydro-pyrimidine; 25 2- [2-(3 -Methoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(3,5 -Bis-trifluoromethyl-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Methoxy-5-nitro-benzyloxy)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Chloro-6-fluoro-benzylsulfanyl)-phenyl]-4,5-dihydro- 1 H-imidazole; 2-(2-Benzylsulfanyl-phenyl)-4,5-dihydro- 1 H-imidazole; 30 2-[2-(2,6-Difluoro-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(Naphthalen- 1 -ylmethoxy)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Methyl-naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; WO 01/10842 PCT/USOO/21327 -168 1- {2-[2-(2-Chloro-6-fluoro-benzylsulfanyl)-phenyl]-5,6-dihydro-4H-pyrimidin- 1-yl} ethanone; 2-[2-(2-Chloro-6-fluoro-benzylsulfanyl)-phenyl]-3a,4,5,6,7,7a-hexahydro- 1 H benzoimidazole; 5 2-[2-(2-Iodo-benzylsulfanyl)-phenyl]-3a,4,5,6,7,7a-hexahydro-1H-benzoimidazole; 2- [2-(2,5 -Dimethyl-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 4-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-yl)-phenylsulfanylmethyl]-quinoline; 2- [2-(2-Methoxy-5 -nitro-benzylsulfanyl)-pyridin-3 -yl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Methoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 10 2-[2-(2-Cyclopentyloxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2,3-Dihydro-benzo[1,4]dioxin-5-ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro pyrimidine; 2-[2-(6-Methoxy-2,3-dihydro-benzo [1,4]dioxin-5-ylmethylsulfanyl)-phenyl]- 1,4,5,6 tetrahydro-pyrimidine; 15 2-[2-(5-fluoro-2-methoxy-benzylsulfanyl)-phenyl]-4,5-dihydro- 1 H-imidazole; 1 -Methyl-2-[2-(naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5 -Bromo-2-methoxy-benzylsulfanyl)-phenyl]-4,5-dihydro- I H-imidazole; 2-[2-(5 -Bromo-2-methoxy-benzyloxy)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(Naphthalen- 1 -yloxymethyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 20 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-5,5-dimethyl- 1,4,5,6-tetrahydro pyrimidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-5,5-dimethyl-4,5-dihydro- I H imidazole; 2-[2-(2,6-Dimethoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 25 2-[2-(2-Bromo-6-methoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[5-Bromo-2-(5-bromo-2-methoxy-benzylsulfanyl)-phenyl]-4,5-dihydro- 1 H-imidazole; 2-[5-Bromo-2-(5-bromo-2-methoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro pyrimidine; 2-[4-Bromo-2-(5-bromo-2-methoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro 30 pyrimidine; 2-[2-(2-Bromo-5-methoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-5-methyl-phenyl]-1,4,5,6-tetrahydro pyrimidine; WO 01/10842 PCT/USOO/21327 -169 2-[2-(Biphenyl-3 -ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Chloro-2-methoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Methoxy-5-thiophen-3-yl-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro pyrimidine; 5 2-[2-(Biphenyl-2-ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2- [2-(5 -Iodo-2-methoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5 -Bromo-2-methoxy-benzylsulfanyl)-5 -fluoro-phenyl]- 1,4,5,6-tetrahydro pyrimidine; 2- [2-(5 -Bromo-2-methoxy-benzylsulfanyl)-3 -fluoro-phenyl]- 1,4,5,6-tetrahydro 10 pyrimidine; 2-[2-(4,4'-Dimethoxy-biphenyl-3-ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro pyrimidine; 2-[2-(9H-Fluoren-9-ylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(3'-Chloro-4'-fluoro-4-methoxy-biphenyl-3-ylmethylsulfanyl)-phenyl]-1,4,5,6 15 tetrahydro-pyrimidine; 2-[2-(1 -Naphthalen- 1 -yl-ethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-5-fluoro-phenyl]-4,5-dihydro- 1 H-imidazole; 2-(2-Benzhydrylsulfanyl-phenyl)- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2'-Fluoro-4"-methoxy- [1,1';4', 1 "]terphenyl-3 "-ylmethylsulfanyl)-phenyl] -1,4,5,6 20 tetrahydro-pyrimidine; 2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzamidine; 2-[4-(Naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Ethynyl-2-methoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]- 1,4,5,6-tetrahydro-pyrimidine; 25 2-[2-(5-Bromo-2-cyclopentyloxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro pyrimidine; 2-[2-(5-Bromo-2-ethoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Bromo-2-propoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; [2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-diethyl-amine; 30 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-piperazine; C- {4-[3-(5-Bromo-2-methoxy-benzylsulfanyl)-quinoxalin-2-yl]-morpholin-2-yl} methylamine; 2-[2-(2-Methoxy-5-methyl-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; WO 01/10842 PCT/USOO/21327 -170 2-[2-(5-Bromo-2-methoxy-benzyloxymethyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; [2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-dimethyl-amine; 2-[2-(5-Bromo-2-isopropoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Ethoxy-naphthalen- I -ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 5 2-[2-(2-Propoxy-naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 4-Methoxy-3-[2-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-phenylsulfanylmethyl] benzonitrile; 1- {4-Methoxy-3-[2-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-phenylsulfanylmethyl]-phenyl} ethanone; 10 2-[2-(Naphthalen- 1 -ylsulfanylmethyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-piperidine; C- {4-[2-(2-Methoxy-naphthalen- 1 -ylmethylsulfanyl)-benzyl]-morpholin-2-yl} methylamine; 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-pyrrolidin-3-ylamine; 15 1-[2-(2-Methoxy-naphthalen- 1 -ylmethylsulfanyl)-benzyl]-pyrrolidin-3-ylamine; 3- [2-(5 -Bromo-2-methoxy-benzylsulfanyl)-3 -fluoro-phenyl]- 1,5,6,7,8,8a-hexahydro imidazo[1,5-a]pyridine; 3-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-fluoro-phenyl]-5,6,7,7a-tetrahydro- 1 H pyrrolo[ 1,2-c]imidazole; 20 2- [2-(Benzo [b]thiophen-3 -ylmethylsulfanyl)-phenyl] -1,4,5,6-tetrahydro-pyrimidine; 2-[3-Fluoro-2-(naphthalen- I -ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-(Naphthalen- 1 -ylmethylsulfanyl)-3-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-phenylamine; 2- [2-(5-Bromo-2-methoxy-benzylsulfanyl)-3 -chloro-phenyl] -1,4,5,6-tetrahydro pyrimidine; 25 2-[2-(2-Methoxy-phenylsulfanylmethyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 1- {2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-5,6-dihydro-4H-pyrimidin- l-yl} 3-methyl-butan- 1-one; 1- {2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-5,6-dihydro-4H-pyrimidin- 1-yl} 2-phenyl-ethanone; 30 2-[3-(5-Bromo-2-methoxy-benzylsulfanyl)-pyridin-2-yl]- 1,4,5,6-tetrahydro-pyrimidine; N-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-guanidine; 2-[2-(2-Isopropoxy-naphthalen- 1 -ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro pyrimidine; WO 01/10842 PCT/USOO/21327 -171 2-[2-(2-Cyclopentyloxy-naphthalen- 1 -ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro pyrimidine; (5-Bromo-2-methoxy-benzyl)-[2-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-phenyl]-amine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanylmethyl)-phenyl]- 1,4,5,6-tetrahydro 5 pyrimidine; 2-[2-(2-Methoxy-naphthalen- 1 -ylsulfanylmethyl)-phenyl]- 1,4,5,6-tetrahydro pyrimidine; 2-[3-(5-Bromo-2-methoxy-benzylsulfanyl)-pyrazin-2-yl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[3-Chloro-2-(naphthalen- 1 -ylsulfanylmethyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 10 2-[2-(6-Bromo-2-methoxy-naphthalen- 1 -ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro pyrimidine; 2-[3-Chloro-2-(2-methoxy-naphthalen-I -ylsulfanylmethyl)-phenyl]-1,4,5,6-tetrahydro pyrimidine; 2-[2-(5-Bromo-2-methoxy-phenylsulfanylmethyl)-phenyl]-1,4,5,6-tetrahydro 15 pyrimidine; 2-[2-(5-Bromo-2-methoxy-phenylsulfanylmethyl)-3-chloro-phenyl]-1,4,5,6-tetrahydro pyrimidine; 2-[1-(2-Naphthalen-I -yl-ethyl)-1H-pyrrol-2-yl]-1,4,5,6-tetrahydro-pyrimidine; (5-Bromo-2-methoxy-benzyl)-methyl-[2-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-phenyl] 20 amine; 2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzylamine; 2-[2-(2-Chloro-phenylsulfanylmethyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Bromo-phenylsulfanylmethyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-(2-o-Tolylsulfanylmethyl-phenyl)- 1,4,5,6-tetrahydro-pyrimidine; 25 2- [2-(2,5 -Dichloro-phenylsulfanylmethyl)-phenyl] -1,4,5,6-tetrahydro-pyrimidine; 2-(3-Amino-propylamino)-6-(5-bromo-2-methoxy-benzylsulfanyl)-benzonitrile; 2- [2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]- 1,4,5,6-tetrahydro-pyrimidine; [2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-diethyl-amine; 4-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-morpholine; 30 3'-(5 -Bromo-2-methoxy-benzylsulfanyl)-3,4,5,6-tetrahydro-2H-[ 1,2']bipyrazinyl; 2-(5-Bromo-2-methoxy-benzylsulfanyl)-3 -piperazin- 1 -yl-6,7-dihydro-quinoxaline; 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-piperidine; WO 01/10842 PCT/USOO/21327 -172 C- {4-[2-(2-Methoxy-naphthalen- 1 -ylmethylsulfanyl)-benzyl]-morpholin-2-yl} methylamine; 1-[3-(5-Bromo-2-methoxy-benzylsulfanyl)-pyrazin-2-yl]-pyrrolidin-3-ylamine; 1-[3-(5-Bromo-2-methoxy-benzylsulfanyl)-quinoxalin-2-yl]-pyrrolidin-3-ylamine; 5 1-[2-(2-Methoxy-naphthalen- 1 -ylmethylsulfanyl)-benzyl]-pyrrolidin-3-ylamine; C- {4-[3-(5-Bromo-2-methoxy-benzylsulfanyl)-pyrazin-2-yl]-morpholin-3-yl} methylamine; 1-[3-Fluoro-2-(2-naphthalen- 1 -yl-ethyl)-benzyl]-piperazine; 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-azetidine; 10 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-pyrrolidin-3-ol; [2-(Naphthalen-1-ylmethylsulfanyl)-phenyl]-carbamic acid 1-aza-bicyclo[2.2.2]oct-3-yl ester; [2-(2-Methyl-naphthalen-1-ylmethylsulfanyl)-phenyl]-carbamic acid 1-aza bicyclo[2.2.2]oct-3-yl ester; 15 [2-(2-Methyl-naphthalen- 1 -ylmethylsulfanyl)-phenyl]-carbamic acid 2-piperidin- 1-yl ethyl ester; { 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-pyrrolidin-2-yl} methanol; 4-tert-Butyl-N-naphthalen- 1 -ylmethyl-N-(2-piperidin- 1 -yl-ethyl)-benzamide; 20 N,N-Dimethyl-N'-naphthalen-2-ylmethyl-N'-naphthalen- 1 -ylmethyl-propane- 1,3 diamine; N-(5-Bromo-2-methoxy-benzyl)-N',N'-dimethyl-N-naphthalen- 1 -ylmethyl-propane- 1,3 diamine; 1 -Naphthalen- 1 -ylmethyl-3 -phenethyl- 1 -(2-piperidin- 1 -yl-ethyl)-thiourea; 25 3 -(4-Dimethylamino-phenyl)- 1 -(3 -dimethylamino-propyl)- 1 -naphthalen- 1 -ylmethyl thiourea; 4- [2-(5-Bromo-2-methoxy-benzylsulfanyl)-3 -chloro-benzylamino]-piperidine- 1 carboxylic acid ethyl ester; 2- [2-(2-Naphthalen- 1 -yl-ethyl)-phenyl] -ethylamine; 30 Naphthalene-2-sulfonic acid (2-dimethylamino-ethyl)-naphthalen- 1 -ylmethyl-amide; 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-2-methoxymethyl pyrrolidine; (2-Hexyloxy-phenyl)-carbamic acid 2-piperidin- 1-yl-1 -piperidin- I -ylmethyl-ethyl ester; WO 01/10842 PCT/USOO/21327 -173 3-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyloxy]-pyrrolidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyloxymethyl]-pyrrolidine; 2-[2-(Naphthalen- 1 -ylsulfanylmethyl)-phenyl]-piperidine; 3-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzylamino]-propan- 1 -ol; 5 3-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzylamino]-3-methyl-butan- 1 -ol; 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-pyrrolidin-3-ol; { 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-pyrrolidin-2-yl} -methanol; { 1-[2-(Naphthalen- 1 -ylsulfanylmethyl)-benzyl]-piperidin-2-yl } -methanol; 2-[2-(Naphthalen- 1 -ylsulfanylmethyl)-pyrrolidin- 1 -yl]-ethyl-N-pyrrolidine; 10 N-pyrrolyl- [1 -(2-naphthalen- 1 -yl-ethyl)-pyrrolidin-2-ylmethyl]-amine; 1-(2-Naphthalen- 1 -yl-ethyl)-piperidine-2-carboxylic acid methyl ester; (3-Bromo-benzyl)-(1 -ethyl-pyrrolidin-2-ylmethyl)-naphthalen- 1 -ylmethyl-amine; 3-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyloxy]-piperidine; (5-Bromo-2-methoxy-benzyl)-(1 -ethyl-pyrrolidin-2-ylmethyl)-naphthalen- 1 -ylmethyl 15 amine; (1 -Ethyl-pyrrolidin-2-ylmethyl)-naphthalen-2-ylmethyl-naphthalen- 1 -ylmethyl-amine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyloxymethyl]-pyrrolidine; (3 -Bromo-benzyl)-(3 -imidazol- 1 -yl-propyl)-naphthalen- I -ylmethyl-amine; (3-Imidazol- 1 -yl-propyl)-naphthalen-2-ylmethyl-naphthalen- 1 -ylmethyl-amine; 20 [2-(Naphthalen1-ylmethylsulfanyl)-phenyl]-carbamic acid 2-piperidin-1-yl-l-piperidin 1 -ylmethyl-ethyl ester; [2-(Naphthalen-1-ylmethylsulfanyl)-phenyl]-carbamic acid 2-dimethylamino-ethyl ester; 1-[2-(Naphthalen- 1 -ylsulfanylmethyl)-benzyl]-piperazine; [3-(2-Methyl-piperidin- 1 -yl)-propyl]-[2-(naphthalen- 1 -ylsulfanylmethyl)-benzyl] 25 amine; 1-[3-Chloro-2-(naphthalen- 1 -ylsulfanylmethyl)-benzyl]-piperazine; N,N-Dimethyl-N'-(2-naphthalen- 1 -yl-ethyl)-N'-naphthalen- 1 -ylmethyl-ethane- 1,2 diamine; { 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-piperidin-2-yl} -methanol; 30 1-[2-(2-Naphthalen- 1 -yl-ethyl)-benzyl]-piperazine; [3-(2-Methyl-piperidin-1 -yl)-propyl]-[2-(2-naphthalen- 1 -yl-ethyl)-benzyl]-amine; 1-[3-Fluoro-2-(2-naphthalen- 1 -yl-ethyl)-benzyl]-piperazine; {1-[3-Chloro-2-(naphthalen- 1 -ylsulfanylmethyl)-benzyl]-piperidin-2-yl } -methanol; WO 01/10842 PCT/USOO/21327 -174 {1 -[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-piperidin-2-yl} -methanol; {1 -[2-(2-Naphthalen- 1 -yl-ethyl)-benzyl]-piperidin-2-yl} -methanol; [3-(2-Methyl-piperidin- 1 -yl)-propyl]-[2-(2-naphthalen- 1 -yl-ethyl)-benzyl]-amine; 1-[2-(2-Naphthalen- 1 -yl-ethyl)-benzyl]-pyrrolidin-3-ylamine; 5 1 -Phenyl-3-piperazin- 1 -yl-5,6,7,8-tetrahydro-isoquinoline-4-carbonitrile; 2- [2-(5 -Bromo-2-methoxy-benzylsulfanyl)-phenyl]-6-ethyl- 1,4,5,6-tetrahydro pyrimidine; 2-[2-(4-Methoxy-biphenyl-3 -ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Methoxy-5-phenylethynyl-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro 10 pyrimidine; 2-[2-(2-Naphthalen- 1 -yl-ethyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[3-(2-Methoxy-naphthalen- 1 -ylsulfanylmethyl)-thiophen-2-yl]-1,4,5,6-tetrahydro pyrimidine; 2-[2-(2,5-Dimethoxy-phenylsulfanylmethyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 15 2-[2-(4-Methyl-naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-fluoro-phenyl]-4,4-dimethyl-4,5-dihydro I H-imidazole; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-fluoro-phenyl]-5,5-dimethyl- 1,4,5,6 tetrahydro-pyrimidine; 20 2-[3-(Naphthalen- 1 -ylsulfanylmethyl)-thiophen-2-yl]-1,4,5,6-tetrahydro-pyrimidine; 2- {2-[2-(5-Bromo-2-methoxy-phenyl)-ethyl]-phenyl } -1,4,5,6-tetrahydro-pyrimidine; 2-[3-Chloro-2-(2-naphthalen- 1 -yl-ethyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2- {2- [2-(5-Bromo-2-methoxy-phenyl)-ethyl]-3-fluoro-phenyl} -1,4,5,6-tetrahydro pyrimidine; 25 2-[2-(5-Bromo-2-methoxy-phenylsulfanylmethyl)-3-fluoro-phenyl]-1,4,5,6-tetrahydro pyrimidine; 2-[2-(Naphthalen- 1 -ylsulfanylmethyl)-phenyl]-4,5-dihydro- 1 H-imidazole; 2- [3-Fluoro-2-(naphthalen- 1 -ylsulfanylmethyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[3-Bromo-2-(naphthalen- 1 -ylsulfanylmethyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 30 2- {2-[2-(5-Bromo-2-methoxy-phenyl)-ethyl]-3 -chloro-phenyl} -1,4,5,6-tetrahydro pyrimidine; 2-[2-(2-Methoxy-5-trifluoromethyl-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro pyrimidine; WO 01/10842 PCT/USOO/21327 -175 2-[4-(Naphthalen- I -ylsulfanylmethyl)-thiophen-3-yl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(Naphthalen- 1 -ylsulfanylmethyl)-thiophen-3 -yl]-1,4,5,6-tetrahydro-pyrimidine; 2- (2-[2-(5-Bromo-2-methoxy-phenyl)-ethyl]-3-trifluoromethyl-phenyl }-1,4,5,6 tetrahydro-pyrimidine; 5 2-[2-(2-Naphthalen- 1 -yl-ethyl)-3-trifluoromethyl-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(6-Fluoro-naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; { 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-piperidin-2-yl} -methanol; 2-[3-Fluoro-2-(2-naphthalen- 1 -yl-ethyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; [2-(5-Bromo-2-methoxy-benzylsulfanyl)-3 -chloro-benzyl]-[3-(2-methyl-piperidin- 1-yl) 10 propyl]-amine; 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-pyrrolidin-3-ylamine; 1- [2-(5 -Bromo-2-methoxy-benzylsulfanyl)-3 -chloro-benzyl]-piperazine; 5,5-Dimethyl-2-[2-(2-naphthalen- I -yl-ethyl)-phenyl]-4,5-dihydro-1 H-imidazole; 2-[3-Fluoro-2-(2-naphthalen- 1 -yl-ethyl)-phenyl]-5,5-dimethyl-4,5-dihydro- 1 H 15 imidazole; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3,5-difluoro-phenyl]- 1,4,5,6-tetrahydro pyrimidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3,5-difluoro-phenyl]-5,5-dimethyl-4,5 dihydro- 1 H-imidazole; 20 3-(2-Naphthalen- 1 -yl-ethyl)-2-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-phenylamine; Amino- [2-(2-naphthalen- 1 -yl-ethyl)-phenyl]-acetonitrile; 1- [2-(2-Naphthalen- I -yl-ethyl)-phenyl]-ethane- 1,2-diamine; 2- [2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl] -4-methyl-4,5 -dihydro- 1 H imidazole; 25 2- [2-(5-Bromo-2-methoxy-benzylsulfanyl)-3 -fluoro-phenyl]-4-methyl-4,5-dihydro- 1 H imidazole; 2- [2-(5 -Bromo-2-methoxy-benzylsulfanyl)-3 -chloro-phenyl]-4-methyl-4,5 -dihydro- 1 H imidazole; 2- [2-(5 -Bromo-2-methoxy-benzylsulfanyl)-3,4-difluoro-phenyl]- 1,4,5,6-tetrahydro 30 pyrimidine; 2-[3 -Fluoro-2-(naphthalen- I -ylsulfanylmethyl)-phenyl]-5,5-dimethyl-4,5 -dihydro- 1 H imidazole; WO 01/10842 PCT/USOO/21327 -176 2- {2-[2-(5-Bromo-2-methoxy-phenyl)- 1 -methyl-ethyl]-phenyl }-1,4,5,6-tetrahydro pyrimidine; 2-[2-(5-Bromo-2-methoxy benzyl sulfanyl)-3-fluoro-4-trifluoromethyl-phenyl]-4,4 dimethyl-4,5-dihydro- 1 H-imidazole; 5 2-[2-(5-Bromo-2-methoxy-benzyl sulfanyl)-3-fluoro-4-trifluoromethyl-phenyl]-5,5 dimethyl- 1,4,5,6-tetrahydro-pyrimidine; 2- [3 -Methoxy-2-(2-naphthalen- 1 -yl-ethyl)-phenyl] -1,4,5,6-tetrahydro-pyrimidine; 2- [2-(5 -Bromo-2-methoxy-benzylsulfanyl)-3 -chloro-phenyl]- 1,4,5,6-tetrahydro pyrimidin-5-ol; 10 2- {2- [2-(5 -Bromo-2-methoxy-phenyl)-ethyl] -3 -methoxy-phenyl }-1,4,5,6-tetrahydro pyrimidine; 2- [2-(5 -Bromo-2-methoxy-benzylsulfanyl)-phenyl]-6-ethyl- 1,4,5,6-tetrahydro pyrimidine, and pharmaceutically acceptable salts thereof. 15
86. The method of any one of claims 56-85, wherein said compound binds to the MC4-R with an IC 50 of about 5 ptM or less.
87. The method of claims 86, wherein said compound binds to the MC4-R with an IC 5 0 of about 1 ptM or less. 20
88. The method of claim 87, wherein said compound binds to the MC4-R with an IC 50 of about 0.5 ptM or less.
89. The method of claim 88, wherein said compound binds to the MC4-R with an 25 IC 50 of about 0.1 pM or less.
90. The method of claim 89, wherein said compound binds to the MC4-R with an IC 50 of about 0.05 pM or less. 30
91. The method of claim 90, wherein said compound binds to the MC4-R with an IC 50 of about 0.03 piM or less. WO 01/10842 PCT/USOO/21327 -177
92. The method of any one of claims 56-85, wherein said compound is an antagonist of the MC4-R.
93. The method of any one of claims 56-85, wherein said compound is an agonist of 5 the MC4-R.
94. The method of any one of claims 1, 2, 3, 56, 66, 77, 138 or 139 wherein said MC4-R binding compound is not 2-[2-(2,5-dichlorothiophen-3-ylmethylsulfanyl) phenyl]-1, 4, 5, 6- tetrahydropyrimidine. 10
95. The method of any one of claims 1, 2, 3, 56, 66, 77, 138 or 139 wherein said MC4-R binding compound is not 2[2-(2-chloro- 6-fluoro-benzylsulfanyl)-phenyl]-1, 4, 5, 6-tetrahydropyrimidine. 15
96. The method of any one of claims 1, 2, 3, 56, 66, 77, 138 or 139 wherein said MC4-R binding compound is not 1-(6-bromo-2-chloro-quinolin-4-yl)-3-(2 diethylaminoethyl)-urea.
97. The method of any one of claims 1, 2, 3, 56, 66, 77, 138 or 139 wherein said 20 MC4-R binding compound is not 2-[2-(2,6-difluorobenzylsulfanyl)-phenyl]-1, 4, 5, 6 tetrahydropyrimidine.
98. The method of any one of claims 1, 2, 3, 56, 66, 77, 138 or 139 wherein said MC4-R binding compound is not 10-[2-(1-methyl-piperadin-2-yl)-ethyl]-2 25 methylsulfanyl-1 OH-phenothiazine.
99. The method of any one of claims 1, 2, 3, 56, 66, 77, 138 or 139 wherein said MC4-R binding compound is not 1-(4-hydroxy-1, 3, 5-trimethyl-piperadin-4-yl) ethanone. 30
100. The method of any one of claims 1, 2, 3, 56, 66, 77, 138 or 139 wherein said MC4-R binding compound is not 2-naphthalen- 1 -ylmethyl-4,5 -dihydro- 1 H-imidazole. WO 01/10842 PCT/USOO/21327 -178
101. The method of any one of claims 1, 2, 3, 56, 66, 77, 138 or 139 wherein said MC4-R binding compound is not (2,6-dichloro-phenyl)-imidazolidin-2-ylidene-amine.
102. The method of any one of claims 1, 2, 3, 56, 66, 77, 138 or 139 wherein said 5 MC4-R binding compound is not 2-benzyl-4,5-dihydro- I H-imidazole.
103. The method of any one of claims 1-93 or 138-199 wherein said MC4-R binding compound is not 5-(4-chloro-phenyl)-2,5-dihydro-3H-imidazo[2, 1-a]-isoindol-5-ol. 10
104. The method of any one of claims 1, 2, 3, 56, 66, 77, 138 or 139 wherein said MC4-R binding compound is not 4,6-dimethyl2-piperazin-1-yl-pyrimidine.
105. The method of any one of claims 1, 2, 3, 56, 66, 77, 138 or 139 wherein said MC4-R binding compound is not 2-piperazin-1-yl-pyrimidine. 15
106. The method of any one of claims 1, 2, 3, 56, 66, 77, 138 or 139 wherein said MC4-R binding compound is not 1-pyridin-2-yl-piperazine.
107. The method of any one of claims 1, 2, 3, 56, 66, 77, 138 or 139 wherein said 20 MC4-R binding compound is not 2-piperazin-1-yl-4-trifluoromethyl pyrimidine.
108. The method of any one of claims 1, 2, 3, 56, 66, 77, 138 or 139 wherein said MC4-R binding compound is not 6-piperazin-1-yl-7-trifluoromethyl-thieno[3,2 b]pyridine-3-carboxylic acid methyl ester. 25
109. The method of any one of claims 1, 2, 3, 56, 66, 77, 138 or 139 wherein said MC4-R binding compound is not 5-bromo-2-piperazin-1-yl)-pyrimidine.
110. The method of any one of claims 1, 2, 3, 56, 66, 77, 138 or 139 wherein said 30 MC4-R binding compound is not 1-(3-trifluoromethyl-pyridin-2-yl)-piperazine.
111. The method of any one of claims 1, 2, 3, 56, 66, 77, 138 or 139 wherein said MC4-R binding compound is not 1-(5-trifluoromethyl-pyridin-2-yl)-piperazine. WO 01/10842 PCT/USOO/21327 -179
112. The method of any one of claims 1, 2, 3, 56, 66, 77, 138 or 139 wherein said MC4-R binding compound is not piperazine. 5
113. The method of any one of claims 1, 2, 3, 56, 66, 77, 138 or 139 wherein said MC4-R binding compound is not (2-Hexyloxy-phenyl)-carbamic acid 2-piperidin-1-yl I -piperidin- 1 -ylmethyl-ethyl ester.
114. An MC4-R binding compound of the formula (IX): N s I I P2 N t P G G2 5 10 z z (IX) wherein: p 2 is CH, CF, CCl, CBr, C-alkyl, C-alkoxy, C-CN, C-OH, or CI; P 3 is CH, CF, CCl, CBr, C-alkyl, C-alkoxy, C-CN, C-OH, or CI; 15 P 4 is CH, CCl, CBr, CF, C-alkyl, C-alkoxy, C-CN, C-OH, or CI; G' and G 2 are each independently CH 2 , S, or 0; r is a covalent bond or CH 2 ; t is CH 2 , CR 3 , or CR 3 R 4 ; s is CH 2 , CHR5 or CR5R6 20 R is hydrogen or alkyl; Z' is CH, or covalently linked to Z2 to form a naphthyl ring; Z 2 is CH, C-(C=CH), CCl, CBr, CI, CF, or covalently linked to Z' to form a naphthyl ring; Z 5 is CH, or C-OMe; 25 R 3 , R 4 , R', and R' are methyl or ethyl, or pharmaceutically acceptable salts thereof. WO 01/10842 PCT/USOO/21327 -180
115. The compound of claim 94, wherein ZI is CH, Z 2 is CBr and Z 5 is C-OMe.
116. The compound of claim 114-115, wherein P 2 is CH. 5
117. The compound of claim 114-116, wherein P 4 is CCl or CF.
118. The compound of claim 114-117, wherein G and G 2 are each CH 2 . 10
119. The compound of claim 114-117, wherein G1 and G 2 together are -CH 2 -S- or -S CH 2 -.
120. The compound of claim 114-119, wherein Z' and Z 2 are linked to form a naphthyl ring. 15
121. An MC4-R binding compound, wherein said compound is selected from the group consisting of: NHBr N ~- N 0 NH -N NN02 NO* 2 NH NH NH NH Br CI ~- NH 0 I 0~~ WO 01/10842 PCT/USOO/21327 NB N '-. 0" F B, N 0 'B Br N B N ND N~N N / NH Brr CBr NN N" <NN BBr Br N N'N N-, 11) HN BXN H I <vs '- N'S -' 0s F-'s o Br Br N'-' SN- WO 01/10842 PCT/USOO/21327 -182 N N in N ' NH N'NH NH~ Br' NHN N a a Sa Br Br N' N 7 N" 'N NH F Qa Br Br NH N HN S 0 07N~ " F( "~ ) ' I BrS7 , Br "' BrI NH N N 7~ '-r'H HN H /~ Sy'., a 7~" 7 ~ ""S 0 BBr OHr NII"N N NNI H H N BrrB Brr WO 01/10842 PCT/USOO/21327 -183
122. The MC4-R binding compound of any one of claims 114-121, wherein said compound is not 2-[2-(2,5-dichlorothiophen-3-ylmethylsulfanyl)-phenyl]-1, 4, 5, 6 tetrahydropyrimidine. 5
123. The MC4-R binding compound of any one of claims 114-121, wherein said compound is not 2-[2-(2,6-difluorobenzylsulfanyl)-phenyl]-1, 4, 5, 6 tetrahydropyrimidine.
124. A pharmaceutical composition for the treatment of a MC4-R associated state in a 10 mammal comprising a pharmaceutically acceptable carrier and an effective amount of an MC4-R binding compound of the formula (I): B-Z-E (I) wherein B is an anchor moiety; 15 Z is a central moiety; E is a MC4-R interacting moiety; and pharmaceutically acceptable salts thereof.
125. A pharmaceutical composition for the treatment of a MC4-R associated state in a 20 mammal comprising a pharmaceutically acceptable carrier and an effective amount of an MC4-R binding compound of the formula (III): B-L1-A-L 2 -E (III) wherein: B is an anchor moiety; 25 Li and L 2 are linking moieties; A is a cyclic moiety; and E is a MC4-R interacting moiety.
126. A pharmaceutical composition for the treatment of a MC4-R associated state in a 30 mammal comprising a pharmaceutically acceptable carrier and an effective amount of an MC4-R binding compound of the formula (III): B-L 1 -A-L 2 -E (III) wherein WO 01/10842 PCT/USOO/21327 -184 B is substituted or unsubstituted biaryl, unsubstituted or substituted heterocyclic, or unsubstituted or substituted phenyl, wherein one or more of said substituents are halogens, alkyl, alkynyl, alkoxy, aryl, amino, cyano, or nitro; LI i s a covalent bond, CI-C 6 branched or unbranched alkyl, wherein one or two 5 of the carbons are optionally replaced with oxygen, sulfur or nitrogen atoms; L 2 is a covalent bond, substituted or unsubstituted amino, ether, thioether, or alkyl; E is substituted or unsubstituted alkyl, amino, amidino, guanidino, heterocyclic, or aryl, wherein said substituents are amino, arylalkyl, aminoalkyl, alkyl, aryl, alkenyl, 10 or alkynyl; and A is a substituted or unsubstituted phenyl, heteroaryl, cycloalkyl, or biaryl, and pharmaceutically acceptable salts thereof.
127. The pharmaceutical composition of claim 124-126, wherein said MC4-R binding 15 compound is an MC4-R antagonist.
128. The pharmaceutical composition of any one of claims 124-127, wherein said MC4-R associated state is associated with pigmentation. 20
129. The pharmaceutical composition of any one of claims 124-127, wherein said MC4-R associated state is associated with weight loss.
130. The pharmaceutical composition of claim 129, wherein said weight loss is a result of old age, anorexia nervosa, HIV cachexia or cancer cachexia. 25
131. The pharmaceutical composition of any one of claims 124-130, wherein said mammal is a human.
132. The pharmaceutical composition of any one of claims 124-131, wherein said 30 MC4-R binding compound is of the formula (IX): WO 01/10842 PCT/USOO/21327 -185 N S I I P 2 N t P4 G z Iz ' (IX) wherein: p2 is CH, CF, CCl, CBr, C-alkyl, C-alkoxy, C-CN, or CI; P3 is CH, CF, CCl, CBr, C-alkyl, C-alkoxy, C-CN, or CI; 5 P4 is CH, CC, Clr, CF, C-alkyl, C-alkoxy, C-CN, or CI; G' and G2 are each independently CH 2 , S, or 0; r is a covalent bond or CH 2 ; t is CH 2 , CR 3 , or CR 3 R 4 ; s is CH 2 , CHR 5 or CR 5 R 6 ; 10 R is hydrogen or alkyl; Z' is CH, or covalently linked to Z2 to form a naphthyl ring; Z 2 is CH, C-(C=CH), CCl, CBr, CI, CF, or covalently linked to Z' to form a naphthyl ring; Z 5 is CH, or C-OMe; 15 R 3 , R', R', and R 6 are methyl or ethyl, or pharmaceutically acceptable salts thereof.
133. The pharmaceutical composition of claim 133, wherein said MC4-R binding compound is selected from the group consisting of: 2-[2-(4-benzyloxy-benzylsulfanyl) 20 phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-iodo-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-methoxy-5-nitro-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(naphthalen-1 -ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(3-chloro-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 25 2-[2-(2,5-dimethoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(3-bromo-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; WO 01/10842 PCT/USOO/21327 -186 2-[2-(2-iodo-benzylsulfanyl)-phenyl]-4,5-dihydro- 1 H-imidazole; 2-[2-(2-methoxy-5-nitro-benzylsulfanyl)-phenyl]-4,5-dihydro- 1 H-imidazole; 2- [2-(2-methoxy-5-nitro-benzyloxy)-phenyl] -1,4,5,6-tetrahydropyrimidine; 2-[2-(2-bromo-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 5 2-[2-(3-iodo-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-methoxy-5-nitro-benzylsulfanyl)-phenyl]-3a,4,5,6,7,7a-hexahydro- 1 H benzoimidazole; 2- {2-[2-(2-methoxy-naphthalen- 1 -yl)-ethyl]-phenyl }-1,4,5,6-tetrahydropyrimidine; 2-[2-(5-bromo-2-methoxy-benzylsulfanyl)-phenyl]- 1,4,5,6,-tetrahydropyrimidine; 10 2- { 2-[2-(2-methyl-naphthalen- 1 -yl)-ethyl]-phenyl } -1,4,5,6-tetrahydropyrimidine; 2- {2-[2-(2,3-dihydro-benzo[ 1,4]dioxin-5-yl) -ethyl]-phenyl} -1,4,5,6 tetrahydropyrimidine; 2-[2-(2-methoxy-napthalen-1-ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydropyrimidine; 2-(2-Benzylsulfanyl-phenyl)- 1,4,5,6-tetrahydro-pyrimidine; 15 2-(2-Pentadecylsulfanyl-phenyl)- 1,4,5,6-tetrahydro-pyrimidine; 2-(2-Cyclohexylmethylsulfanyl-phenyl)- 1,4,5,6-tetrahydro-pyrimidine; 2- [2-(2-Methyl-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2- [2-(3 -Nitro-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2- [2-(3,5 -Dimethoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 20 2- [2-(4-Fluoro-benzylsulfanyl)-phenyl] -1,4,5,6-tetrahydro-pyrimidine; 2- [2-(2-Chloro-benzylsulfanyl)-phenyl] -1,4,5,6-tetrahydro-pyrimidine; 2- [2-(2-Fluoro-benzylsulfanyl)-phenyl] -1,4,5,6-tetrahydro-pyrimidine; 2- [2-(2,4-Bis-trifluoromethyl-benzylsulfanyl)-phenyl] -1,4,5,6-tetrahydro-pyrimidine; 2- [2-(3 -Methoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 25 2- [2-(3,5 -Bis-trifluoromethyl-benzylsulfanyl)-phenyl] -1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Methoxy-5-nitro-benzyloxy)-phenyl] -1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Chloro-6-fluoro-benzylsulfanyl)-phenyl]-4,5-dihydro- 1 H-imidazole; 2-(2-Benzylsulfanyl-phenyl)-4,5-dihydro- 1 H-imidazole; 2-[2-(2,6-Difluoro-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 30 2-[2-(Naphthalen- 1 -ylmethoxy)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Methyl-naphthalen- 1 -ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 1- (2-[2-(2-Chloro-6-fluoro-benzylsulfanyl)-phenyl]-5,6-dihydro-4H-pyrimidin- 1-yl} ethanone; WO 01/10842 PCT/USOO/21327 -187 2-[2-(2-Chloro-6-fluoro-benzylsulfanyl)-phenyl]-3a,4,5,6,7,7a-hexahydro- 1 H benzoimidazole; 2-[2-(2-Iodo-benzylsulfanyl)-phenyl]-3a,4,5,6,7,7a-hexahydro- I H-benzoimidazole; 2-[2-(2,5-Dimethyl-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 5 4-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-yl)-phenylsulfanylmethyl]-quinoline; 2-[2-(2-Methoxy-5 -nitro-benzylsulfanyl)-pyridin-3 -yl] -1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Methoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Cyclopentyloxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2,3-Dihydro-benzo[1,4]dioxin-5-ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro 10 pyrimidine; 2-[2-(6-Methoxy-2,3-dihydro-benzo[1,4]dioxin-5-ylmethylsulfanyl)-phenyl]- 1,4,5,6 tetrahydro-pyrimidine; 2-[2-(5-fluoro-2-methoxy-benzylsulfanyl)-phenyl]-4,5-dihydro- 1 H-imidazole; 1 -Methyl-2-[2-(naphthalen- 1 -ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 15 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-4,5-dihydro- 1 H-imidazole; 2-[2-(5-Bromo-2-methoxy-benzyloxy)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(Naphthalen- 1 -yloxymethyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-5,5-dimethyl-1,4,5,6-tetrahydro pyrimidine; 20 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-5,5-dimethyl-4,5-dihydro- 1 H imidazole; 2-[2-(2,6-Dimethoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Bromo-6-methoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[5-Bromo-2-(5-bromo-2-methoxy-benzylsulfanyl)-phenyl]-4,5-dihydro-I H-imidazole; 25 2-[5-Bromo-2-(5-bromo-2-methoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro pyrimidine; 2-[4-Bromo-2-(5-bromo-2-methoxy-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro pyrimidine; 2-[2-(2-Bromo-5-methoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 30 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-5-methyl-phenyl]- 1,4,5,6-tetrahydro pyrimidine; 2-[2-(Biphenyl-3-ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Chloro-2-methoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; WO 01/10842 PCT/USOO/21327 -188 2-[2-(2-Methoxy-5-thiophen-3-yl-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro pyrimidine; 2-[2-(Biphenyl-2-ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2- [2-(5-Iodo-2-methoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 5 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-5-fluoro-phenyl]- 1,4,5,6-tetrahydro pyrimidine; 2- [2-(5 -Bromo-2-methoxy-benzylsulfanyl)-3 -fluoro-phenyl]- 1,4,5,6-tetrahydro pyrimidine; 2-[2-(4,4'-Dimethoxy-biphenyl-3-ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro 10 pyrimidine; 2-[2-(9H-Fluoren-9-ylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(3'-Chloro-4'-fluoro-4-methoxy-biphenyl-3-ylmethylsulfanyl)-phenyl]- 1,4,5,6 tetrahydro-pyrimidine; 2-[2-(1 -Naphthalen- 1 -yl-ethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 15 2- [2-(5-Bromo-2-methoxy-benzylsulfanyl)-5-fluoro-phenyl]-4,5-dihydro- 1 H-imidazole; 2-(2-Benzhydrylsulfanyl-phenyl)- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2'-Fluoro-4"-methoxy-[ 1,1 ';4', 1 "]terphenyl-3"-ylmethylsulfanyl)-phenyl]- 1,4,5,6 tetrahydro-pyrimidine; 2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzamidine; 20 2-[4-(Naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2- [2-(5 -Ethynyl-2-methoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-1,4,5,6-tetrahydro-pyrimidine; 2- [2-(5 -Bromo-2-cyclopentyloxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro pyrimidine; 25 2-[2-(5-Bromo-2-ethoxy-benzylsulfanyl)-phenyl] -1,4,5,6-tetrahydro-pyrimidine; 2- [2-(5 -Bromo-2-propoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; [2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-diethyl-amine; 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-piperazine; C- {4- [3 -(5-Bromo-2-methoxy-benzylsulfanyl)-quinoxalin-2-yl]-morpholin-2-y} 30 methylamine; 2- [2-(2-Methoxy-5-methyl-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2- [2-(5 -Bromo-2-methoxy-benzyloxymethyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; [2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-dimethyl-amine; WO 01/10842 PCT/USOO/21327 -189 2-[2-(5-Bromo-2-isopropoxy-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Ethoxy-naphthalen- I -ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Propoxy-naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 4-Methoxy-3-[2-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-phenylsulfanylmethyl] 5 benzonitrile; 1- {4-Methoxy-3-[2-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-phenylsulfanylmethyl]-phenyl} ethanone; 2-[2-(Naphthalen- 1 -ylsulfanylmethyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-piperidine; 10 C- {4-[2-(2-Methoxy-naphthalen- 1 -ylmethylsulfanyl)-benzyl]-morpholin-2-yl} methylamine; 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-pyrrolidin-3-ylamine; 1-[2-(2-Methoxy-naphthalen- 1 -ylmethylsulfanyl)-benzyl]-pyrrolidin-3-ylamine; 3-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3 -fluoro-phenyl]- 1,5,6,7,8,8a-hexahydro 15 imidazo[1,5-a]pyridine; 3-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-fluoro-phenyl]-5,6,7,7a-tetrahydro- 1 H pyrrolo[l,2-c]imidazole; 2- [2-(Benzo [b]thiophen-3-ylmethylsulfanyl)-phenyl] -1,4,5,6-tetrahydro-pyrimidine; 2-[3-Fluoro-2-(naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 20 2-(Naphthalen- 1 -ylmethylsulfanyl)-3-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-phenylamine; 2- [2-(5 -Bromo-2-methoxy-benzylsulfanyl)-3 -chloro-phenyl]- 1,4,5,6-tetrahydro pyrimidine; 2-[2-(2-Methoxy-phenylsulfanylmethyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 1- {2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-5,6-dihydro-4H-pyrimidin- 1-yl} 25 3-methyl-butan- 1-one; 1- {2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-5,6-dihydro-4H-pyrimidin- 1-yl } 2-phenyl-ethanone; 2-[3-(5-Bromo-2-methoxy-benzylsulfanyl)-pyridin-2-yl]- 1,4,5,6-tetrahydro-pyrimidine; N-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-guanidine; 30 2- [2-(2-Isopropoxy-naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro pyrimidine; 2-[2-(2-Cyclopentyloxy-naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro pyrimidine; WO 01/10842 PCT/USOO/21327 -190 (5-Bromo-2-methoxy-benzyl)-[2-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-phenyl]-amine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanylmethyl)-phenyl]- 1,4,5,6-tetrahydro pyrimidine; 2-[2-(2-Methoxy-naphthalen- 1 -ylsulfanylmethyl)-phenyl]- 1,4,5,6-tetrahydro 5 pyrimidine; 2-[3-(5-Bromo-2-methoxy-benzylsulfanyl)-pyrazin-2-yl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[3-Chloro-2-(naphthalen- 1 -ylsulfanylmethyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(6-Bromo-2-methoxy-naphthalen- 1 -ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro pyrimidine; 10 2-[3-Chloro-2-(2-methoxy-naphthalen- I -ylsulfanylmethyl)-phenyl]-1,4,5,6-tetrahydro pyrimidine; 2-[2-(5-Bromo-2-methoxy-phenylsulfanylmethyl)-phenyl]-1,4,5,6-tetrahydro pyrimidine; 2-[2-(5-Bromo-2-methoxy-phenylsulfanylmethyl)-3-chloro-phenyl]- 1,4,5,6-tetrahydro 15 pyrimidine; 2-[1-(2-Naphthalen- 1 -yl-ethyl)- I H-pyrrol-2-yl]-1,4,5,6-tetrahydro-pyrimidine; (5-Bromo-2-methoxy-benzyl)-methyl-[2-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-phenyl] amine; 2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzylamine; 20 2-[2-(2-Chloro-phenylsulfanylmethyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2-Bromo-phenylsulfanylmethyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-(2-o-Tolylsulfanylmethyl-phenyl)- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(2,5-Dichloro-phenylsulfanylmethyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-(3-Amino-propylamino)-6-(5-bromo-2-methoxy-benzylsulfanyl)-benzonitrile; 25 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-1,4,5,6-tetrahydro-pyrimidine; [2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-diethyl-amine; 4-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-morpholine; 3'-(5-Bromo-2-methoxy-benzylsulfanyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl; 2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-piperazin- 1 -yl-6,7-dihydro-quinoxaline; 30 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-piperidine; C- {4-[2-(2-Methoxy-naphthalen- I -ylmethylsulfanyl)-benzyl]-morpholin-2-yl} methylamine; 1-[3-(5-Bromo-2-methoxy-benzylsulfanyl)-pyrazin-2-yl]-pyrrolidin-3-ylamine; WO 01/10842 PCT/USOO/21327 -191 1-[3-(5-Bromo-2-methoxy-benzylsulfanyl)-quinoxalin-2-yl]-pyrrolidin-3-ylamine; 1-[2-(2-Methoxy-naphthalen- 1 -ylmethylsulfanyl)-benzyl]-pyrrolidin-3-ylamine; C- {4-[3-(5-Bromo-2-methoxy-benzylsulfanyl)-pyrazin-2-yl]-morpholin-3-yl} methylamine; 5 1-[3-Fluoro-2-(2-naphthalen- 1 -yl-ethyl)-benzyl]-piperazine; 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-azetidine; 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-pyrrolidin-3-ol; [2-(Naphthalen-1-ylmethylsulfanyl)-phenyl]-carbamic acid 1-aza-bicyclo[2.2.2]oct-3-yl ester; 10 [2-(2-Methyl-naphthalen-1-ylmethylsulfanyl)-phenyl]-carbamic acid 1 -aza bicyclo[2.2.2]oct-3-yl ester; [2-(2-Methyl-naphthalen- 1 -ylmethylsulfanyl)-phenyl]-carbamic acid 2-piperidin- 1-yl ethyl ester; {1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-pyrrolidin-2-yl} 15 methanol; 4-tert-Butyl-N-naphthalen- 1 -ylmethyl-N-(2-piperidin- 1 -yl-ethyl)-benzamide; N,N-Dimethyl-N'-naphthalen-2-ylmethyl-N'-naphthalen- 1 -ylmethyl-propane- 1,3 diamine; N-(5-Bromo-2-methoxy-benzyl)-N',N'-dimethyl-N-naphthalen- 1 -ylmethyl-propane- 1,3 20 diamine; I -Naphthalen- 1 -ylmethyl-3 -phenethyl- 1 -(2-piperidin- 1 -yl-ethyl)-thiourea; 3 -(4-Dimethylamino-phenyl)- 1 -(3 -dimethylamino-propyl)- 1 -naphthalen- 1 -ylmethyl thiourea; 4- [2-(5 -Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzylamino] -piperidine- 1 25 carboxylic acid ethyl ester; 2- [2-(2-Naphthalen- 1 -yl-ethyl)-phenyl]-ethylamine; Naphthalene-2-sulfonic acid (2-dimethylamino-ethyl)-naphthalen-1-ylmethyl-amide; 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-2-methoxymethyl pyrrolidine; 30 (2-Hexyloxy-phenyl)-carbamic acid 2-piperidin- 1-yl-1 -piperidin- 1 -ylmethyl-ethyl ester; 3-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyloxy]-pyrrolidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyloxymethyl]-pyrrolidine; 2- [2-(Naphthalen- 1 -ylsulfanylmethyl)-phenyl] -piperidine; WO 01/10842 PCT/USOO/21327 -192 3-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzylamino]-propan- 1 -ol; 3-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzylamino]-3-methyl-butan- 1-ol; 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-pyrrolidin-3-ol; { 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-pyrrolidin-2-yl} -methanol; 5 {1-[2-(Naphthalen-1 -ylsulfanylmethyl)-benzyl]-piperidin-2-yl} -methanol; 2-[2-(Naphthalen- 1 -ylsulfanylmethyl)-pyrrolidin- 1 -yl]-ethyl-N-pyrrolidine; N-pyrrolyl- [1 -(2-naphthalen- 1 -yl-ethyl)-pyrrolidin-2-ylmethyl]-amine; 1-(2-Naphthalen- 1 -yl-ethyl)-piperidine-2-carboxylic acid methyl ester; (3-Bromo-benzyl)-(1 -ethyl-pyrrolidin-2-ylmethyl)-naphthalen- 1 -ylmethyl-amine; 10 3-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyloxy]-piperidine; (5-Bromo-2-methoxy-benzyl)-(1 -ethyl-pyrrolidin-2-ylmethyl)-naphthalen- 1 -ylmethyl amine; (1 -Ethyl-pyrrolidin-2-ylmethyl)-naphthalen-2-ylmethyl-naphthalen- 1 -ylmethyl-amine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyloxymethyl]-pyrrolidine; 15 (3 -Bromo-benzyl)-(3 -imidazol- 1 -yl-propyl)-naphthalen- 1 -ylmethyl-amine; (3 -Imidazol- 1 -yl-propyl)-naphthalen-2-ylmethyl-naphthalen- I -ylmethyl-amine; [2-(Naphthalen1-ylmethylsulfanyl)-phenyl]-carbamic acid 2-piperidin-1-yl-l-piperidin 1-ylmethyl-ethyl ester; [2-(Naphthalen-1-ylmethylsulfanyl)-phenyl]-carbamic acid 2-dimethylamino-ethyl ester; 20 1-[2-(Naphthalen-1-ylsulfanylmethyl)-benzyl]-piperazine; [3-(2-Methyl-piperidin-1-yl)-propyl]-[2-(naphthalen-1-ylsulfanylmethyl)-benzyl] amine; 1-[3-Chloro-2-(naphthalen-1-ylsulfanylmethyl)-benzyl]-piperazine; N,N-Dimethyl-N'-(2-naphthalen- 1 -yl-ethyl)-N'-naphthalen- 1 -ylmethyl-ethane- 1,2 25 diamine; { 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-piperidin-2-yl } -methanol; 1- [2-(2-Naphthalen- 1 -yl-ethyl)-benzyl] -piperazine; [3 -(2-Methyl-piperidin- I -yl)-propyl]- [2-(2-naphthalen- 1 -yl-ethyl)-benzyl]-amine; 1- [3 -Fluoro-2-(2-naphthalen- 1 -yl-ethyl)-benzyl]-piperazine; 30 { 1-[3-Chloro-2-(naphthalen-1 -ylsulfanylmethyl)-benzyl]-piperidin-2-yl} -methanol; { 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-piperidin-2-yl} -methanol; { 1-[2-(2-Naphthalen-1 -yl-ethyl)-benzyl]-piperidin-2-yl} -methanol; [3-(2-Methyl-piperidin-1-yl)-propyl]-[2-(2-naphthalen-1-yl-ethyl)-benzyl]-amine; WO 01/10842 PCT/USOO/21327 -193 1-[2-(2-Naphthalen- 1 -yl-ethyl)-benzyl]-pyrrolidin-3-ylamine; 1 -Phenyl-3-piperazin- 1-yl-5,6,7,8-tetrahydro-isoquinoline-4-carbonitrile; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-6-ethyl- 1,4,5,6-tetrahydro pyrimidine; 5 2-[2-(4-Methoxy-biphenyl-3-ylmethylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2- [2-(2-Methoxy-5-phenylethynyl-benzylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro pyrimidine; 2-[2-(2-Naphthalen- 1 -yl-ethyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[3-(2-Methoxy-naphthalen- 1 -ylsulfanylmethyl)-thiophen-2-yl]- 1,4,5,6-tetrahydro 10 pyrimidine; 2-[2-(2,5-Dimethoxy-phenylsulfanylmethyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(4-Methyl-naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-fluoro-phenyl]-4,4-dimethyl-4,5-dihydro 1H-imidazole; 15 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-fluoro-phenyl]-5,5-dimethyl-1,4,5,6 tetrahydro-pyrimidine; 2-[3-(Naphthalen- 1 -ylsulfanylmethyl)-thiophen-2-yl]- 1,4,5,6-tetrahydro-pyrimidine; 2-{2-[2-(5-Bromo-2-methoxy-phenyl)-ethyl]-phenyl } -1,4,5,6-tetrahydro-pyrimidine; 2-[3-Chloro-2-(2-naphthalen- 1 -yl-ethyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 20 2-{ 2-[2-(5-Bromo-2-methoxy-phenyl)-ethyl]-3-fluoro-phenyl}-1,4,5,6-tetrahydro pyrimidine; 2-[2-(5-Bromo-2-methoxy-phenylsulfanylmethyl)-3-fluoro-phenyl]-1,4,5,6-tetrahydro pyrimidine; 2-[2-(Naphthalen-1-ylsulfanylmethyl)-phenyl]-4,5-dihydro-1H-imidazole; 25 2-[3-Fluoro-2-(naphthalen-1-ylsulfanylmethyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-[3-Bromo-2-(naphthalen-1-ylsulfanylmethyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; 2-{2-[2-(5-Bromo-2-methoxy-phenyl)-ethyl]-3-chloro-phenyl}-1,4,5,6-tetrahydro pyrimidine; 2-[2-(2-Methoxy-5-trifluoromethyl-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro 30 pyrimidine; 2-[4-(Naphthalen-1 -ylsulfanylmethyl)-thiophen-3-yl]-1,4,5,6-tetrahydro-pyrimidine; 2-[2-(Naphthalen-1-ylsulfanylmethyl)-thiophen-3-yl]-1,4,5,6-tetrahydro-pyrimidine; WO 01/10842 PCT/USOO/21327 -194 2-{2-[2-(5-Bromo-2-methoxy-phenyl)-ethyl]-3-trifluoromethyl-phenyl} -1,4,5,6 tetrahydro-pyrimidine; 2-[2-(2-Naphthalen- 1 -yl-ethyl)-3-trifluoromethyl-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2-[2-(6-Fluoro-naphthalen- 1 -ylmethylsulfanyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 5 {1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-benzyl]-piperidin-2-yl} -methanol; 2-[3-Fluoro-2-(2-naphthalen- 1 -yl-ethyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; [2-(5-Bromo-2-methoxy-benzylsulfanyl)-3 -chloro-benzyl]-[3-(2-methyl-piperidin- 1-yl) propyl]-amine; 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-pyrrolidin-3-ylamine; 10 1-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3-chloro-benzyl]-piperazine; 5,5-Dimethyl-2-[2-(2-naphthalen- 1 -yl-ethyl)-phenyl]-4,5-dihydro- 1 H-imidazole; 2-[3-Fluoro-2-(2-naphthalen- 1 -yl-ethyl)-phenyl]-5,5-dimethyl-4,5-dihydro- I H imidazole; 2-[2-(5 -Bromo-2-methoxy-benzylsulfanyl)-3,5-difluoro-phenyl]- 1,4,5,6-tetrahydro 15 pyrimidine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-3,5-difluoro-phenyl]-5,5-dimethyl-4,5 dihydro-I H-imidazole; 3 -(2-Naphthalen- 1 -yl-ethyl)-2-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-phenylamine; Amino-[2-(2-naphthalen- 1 -yl-ethyl)-phenyl]-acetonitrile; 20 1-[2-(2-Naphthalen- I -yl-ethyl)-phenyl]-ethane- 1,2-diamine; 2-[2-(5-Bromo-2-methoxy-benzylsulfanyl)-phenyl]-4-methyl-4,5-dihydro-1H imidazole; 2-[2-(5 -Bromo-2-methoxy-benzylsulfanyl)-3-fluoro-phenyl] -4-methyl-4,5-dihydro- 1 H imidazole; 25 2-[2-(5 -Bromo-2-methoxy-benzylsulfanyl)-3 -chloro-phenyl]-4-methyl-4,5-dihydro- I H imidazole; 2- [2-(5 -Bromo-2-methoxy-benzylsulfanyl)-3,4-difluoro-phenyl]- 1,4,5,6-tetrahydro pyrimidine; 2- [3 -Fluoro-2-(naphthalen- 1 -ylsulfanylmethyl)-phenyl]-5,5 -dimethyl-4,5 -dihydro- 1 H 30 imidazole; 2- (2- [2-(5 -Bromo-2-methoxy-phenyl)- 1 -methyl-ethyl]-phenyl } -1,4,5,6-tetrahydro pyrimidine; WO 01/10842 PCT/USOO/21327 -195 2-[2-(5-Bromo-2-methoxy benzyl sulfanyl)-3-fluoro-4-trifluoromethyl-phenyl]-4,4 dimethyl-4,5-dihydro- 1 H-imidazole; 2-[2-(5-Bromo-2-methoxy-benzyl sulfanyl)-3-fluoro-4-trifluoromethyl-phenyl]-5,5 dimethyl- 1,4,5,6-tetrahydro-pyrimidine; 5 2- [3-Methoxy-2-(2-naphthalen- 1 -yl-ethyl)-phenyl]- 1,4,5,6-tetrahydro-pyrimidine; 2- [2-(5 -Bromo-2-methoxy-benzylsulfanyl)-3 -chloro-phenyl]- 1,4,5,6-tetrahydro pyrimidin-5-ol; 2- {2- [2-(5 -Bromo-2-methoxy-phenyl)-ethyl]-3 -methoxy-phenyl }-1,4,5,6-tetrahydro pyrimidine; 10 2- [2-(5 -Bromo-2-methoxy-benzylsulfanyl)-phenyl]-6-ethyl- 1,4,5,6-tetrahydro pyrimidine, and pharmaceutically acceptable salts thereof. 132. The pharmaceutical composition of any one of claims 124-131, wherein said MC4-R binding compound is not 10- [2-(1 -methyl-piperadin-2-yl)-ethyl] -2 15 methylsulfanyl- 1 OH-phenothiazine. 133. The pharmaceutical composition of any one of claims 124-131, wherein said MC4-R binding compound is not 2-naphthalen- 1 -ylmethyl-4,5 -dihydro- I H-imidazole. 20
134. The pharmaceutical composition of any one of claims 124-131, wherein said MC4-R binding compound is not (2,6-dichloro-phenyl)-imidazolidin-2-ylidene-amine.
135. The pharmaceutical composition of any one of claims 124-131, wherein said MC4-R binding compound is not 2-benzyl-4,5-dihydro- I H-imidazole. 25
136. The pharmaceutical composition of any one of claims 124-131, wherein said MC4-R binding compound is not 5-(4-chloro-phenyl)-2,5-dihydro-3H-imidazo[2,1-a] isoindol-5-ol. 30
137. The pharmaceutical composition of claim 124-136, wherein said pharmaceutical composition is suitable for oral administration. WO 01/10842 PCT/USOO/21327 -196
138. A method for treating an MC4-R associated state in a mammal comprising administering an effective amount of a MC4-R binding compound to a mammal such that the MC4-R associated state is treated, wherein said compound is of the formula (X): N (CR 16 R1 6 ). R1 Ar 13 R 1 (CH)e X-(CH)f Ar - R 1 2 R 4 RN(X) 5 wherein Ar and Ar' are aromatic groups; R 1 is selected independently for each position capable of substitution from the group hydrogen, cyano, halogen, alkyl, amino, or aryloxy; R1 2 is selected for each position capable of substitution from the group 10 consisting of hydrogen, halogen, alkoxy, acetylenic, nitro, aryl, alkyl, alkenyl, alkynyl, cyano, acyl, or carbonyl; R 3 is hydrogen, alkenyl, alkynyl, aralkyl, nitro, cyano, alkyl, acyl, carbonyl, or SO 2 CH 3 , and may optionally be linked to an R or an Ri1' group; R1 6 and Ri1' are each independently selected for each position capable of 15 substitution from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heterocyclic, carbonyl, or acyl, and may optionally be connected through an alkyl chain to R or another R16 or Ri1' group, to form a fused or spiro ring system; X is NR 7 , S, 0 or a covalent bond; R' 7 is hydrogen, alkyl, alkenyl, alkynyl, acyl, heterocyclic, or carbonyl; 20 R1 4 and R 5 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, heteroaromatic, halogen, nitro, cyano, amino, or aryl, for each occurrence; w is 0, 1, 2, 3, or 4; e is 0, 1, 2, or 3; 25 f is 0, 1, 2, or 3, and pharmaceutically acceptable salts thereof. WO 01/10842 PCT/USOO/21327 -197
139. A method for treating an MC4-R associated state in a mammal comprising administering an effective amount of a MC4-R binding compound to a mammal such that the MC4-R associated state is treated, wherein said compound is of the formula (XI): R 2 (CH 2 )v R 11 - A r (CH)e / x-(cH)f R 14 Ar' R 12 5 (XI) wherein Ar and Ar' are aromatic groups, as described above; R' 1 is selected independently for each position capable of substitution from the group hydrogen, halogen, alkyl, amino, cyano, or aryloxy. 10 R1 2 is selected for each position capable of substitution from the group consisting of hydrogen, halogen, alkoxy, acetylenic, nitro, aryl, alkyl, alkenyl, alkynyl, cyano, acyl, or carbonyl; X is NR 7 , S, 0 or a covalent bond; R 7 is hydrogen, alkyl, acyl, heterocyclic, or carbonyl; 15 R1 4 and R'1 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, or aryl, for each occurrence; R20 and R 2 1 are each independently selected from the group consisting of substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, hydrogen, or carbonyl, and may optionally be linked to form a heterocycle; 20 vis0,1,2,3,4,5,or6; e is 0, 1, 2, or 3; f is 0, 1, 2, or 3, and pharmaceutically acceptable salts thereof.
140. The method according to claim 138 or 139, wherein Ar is selected from the 25 group consisting of: WO 01/10842 PCT/USOO/21327 -198 R11 RR RN Ri Ri R R 18 R N NN N
141. The method of claim 140, wherein Ar isR or R Il s . 5
142. The method of claim 141, wherein Ar is: RA
143. The method of claim 141, wherein Ar is: RA WO 01/10842 PCT/USOO/21327 -199
144. The method of claim 141, wherein Ar is ts/ 5
145. The method of claim 138-144, wherein R" is selected independently for each aromatic position capable of substitution from the group consisting of hydrogen, halogen, alkyl, amino, and benzyloxy.
146. The method according to claim 145, wherein each R" is independently hydrogen 10 or halogen.
147. The method according to claim 146, wherein said halogen is fluorine, chlorine, or bromine. 15
148. The method according to claim 147, wherein said halogen is fluorine.
149. The method according to claim 147, wherein said halogen is chlorine.
150. The method according to claim 147, wherein said halogen is bromine. 20
151. The method according to claim 146, wherein each R" is hydrogen.
152. The method according to claim 138-15 1, wherein Ar' is selected from the group consisting of: c 1i - _ / I C2 NS WO 01/10842 PCT/USOO/21327 -200 R 1 R 12____ R RN wherein R1 9 is hydrogen, alkyl, acyl, aryl, alkenyl, or alkynyl. 2 3 - R 1 2 6
153. The method of claim 152, wherein Ar' is 5 R 1 2 5
154. The method of claim 152, wherein Ar' is
155. The method of claim 153, wherein R12 is in the 3 position.
156. The method of claim 153, wherein R is in the 6 position. 10
157. The method according to claims 138-156, wherein each R1 2 is selected independently for each aromatic position capable of being substituted from the group consisting of hydrogen, alkoxy, halogen, or cyano. 15
158. The method according to claim 157, wherein each R1 2 is hydrogen, halogen, or alkoxy.
159. The method according to claim 158, wherein said alkoxy is Ci-CIo alkoxy. 20
160. The method according to claim 159, wherein said Ci-Cio alkoxy is is selected from the group consisting of methoxy, ethoxy, n-propoxy, i-propoxy, and cyclopentoxy.
161. The method according to claim 160, wherein said CI-C 10 alkoxy is methoxy. WO 01/10842 PCT/USOO/21327 -201
162. The method according to claim 158, wherein said halogen is bromine, fluorine, iodine or chlorine. 5
163. The method according to claim 162, wherein said halogen is bromine.
164. The method according to claim 162, wherein said halogen is fluorine.
165. The method according to claim 162, wherein said halogen is chlorine. 10
166. The method according to any one of claims 138-165 wherein X is a covalent bond.
167. The method according to any one of claims 138-165 wherein X is S. 15
168. The method according to any one of claims 138 -165 wherein X is 0.
169. The method according to any one of claims 138-165 wherein X is NR 7 . 20
170. The method of claim 169, wherein R 7 is hydrogen, alkyl, or acyl.
171. The method of claim 170, wherein said alkyl is Ci-Cio alkyl.
172. The method of claim 171, wherein said alkyl is methyl. 25
173. The method of claim 170, wherein R 7 is hydrogen.
174. The method of any one of claims 138, or 140-173, wherein R1 6 and R6' are independently selected for each position from the group consisting of hydrogen and 30 alkyl.
175. The method of claim 174, wherein at least one of R1 6 and R 16 ' is hydrogen. WO 01/10842 PCT/USOO/21327 -202
176. The method of claim 174, wherein at least one of R1 6 and R6' is at least once C 1 C 1 0 alkyl. 5
177. The method of claim 176, wherein said C 1 -C 10 alkyl is methyl.
178. The method of claim 176, wherein said CI-C 10 alkyl is ethyl.
179. The method of any one of claims 138, or 140-173, wherein at least two of the R1 6 10 and R16' are linked to form a ring.
180. The method of any one of claims 138-179, wherein R1 4 and R"' are each independently selected from the group consisting of hydrogen, alkyl and phenyl for each occurence. 15
181. The method of claim 180, wherein R' 4 and R"1 are hydrogen for each occurence.
182. The method of claim 180 wherein said alkyl is CI-C 10 . 20
183. The method of claim 182, wherein said alkyl is methyl.
184. The method of any one of claims 138, or 140-183, wherein said R' 3 group is hydrogen, acyl, alkyl, acyl, carboxy, or SO 2 CH 3 . 25
185. The method of claim 184, wherein R 3 is hydrogen.
186. The method of claim 184, wherein said R1 3 group is optionally substituted Ci C 10 alkyl or acyl. 30
187. The method of claim 186, wherein said acyl group is i-propylcarbonyl, benzylcarbonyl.
188. The method of claim 186, wherein said alkyl group is CI-C 1 o alkyl. WO 01/10842 PCT/USOO/21327 -203
189. The method of claim 188, wherein said alkyl group is methyl.
190. The method of any one of claims 138, or 140-189, wherein w is 2. 5
191. The method of any one of claims 138, or 140-189, wherein w is 3.
192. The method of any one of claims 138-191, wherein e is 0. 10
193. The method of any one of claims 138-191, wherein e is 1.
194. The method of any one of claims 138-193, wherein f is 0.
195. The method of any one of claims 138-193, wherein f is 1. 15
196. The method of any one of claims 138-193 wherein f is 2.
197. The method of any one of claims 139-173, wherein R 20 and R2 are each independently selected from the group consisting of substituted or unsubstituted alkyl, 20 carbonyl, and may optionally be linked to form a heterocycle.
198. The method of claim 197, wherein said heterocycle is piperazinyl or morpholinyl. 25
199. The method of any one of claims 139-173, 197 or 198, wherein v is 1, 2, or 3.
200. The method of any one of claims 1-113 or 138-199, wherein the MC4-R associated state is not weight loss. 30
201. A pharmaceutical composition for the treatment of an MC4-R associated state in a mammal comprising a pharmaceutically acceptable carrier and an MC4-R binding compound such as those shown in any one of the methods claims 1-113 or 138-199. WO 01/10842 PCT/USOO/21327 -204
202. A pharmaceutical composition for the treatment of a MC4-R associated state in a mammal comprising a pharmaceutically acceptable carrier and an effective amount of an MC4-R binding compound of the formula (X): N (CR 1 6 R 16 ) 11 113 R11 Ar R R 15 (CH)e x- (CH)f Ar R4 R- 12 R(X ) 5 wherein Ar and Ar' are aromatic groups; R" is selected independently for each position capable of substitution from the group hydrogen, cyano, halogen, alkyl, amino, or aryloxy; R 2 is selected for each position capable of substitution from the group 10 consisting of hydrogen, halogen, alkoxy, acetylenic, nitro, aryl, alkyl, alkenyl, alkynyl, cyano, acyl, or carbonyl; R1 3 is hydrogen, alkenyl, alkynyl, aralkyl, nitro, cyano, alkyl, acyl, carbonyl, or SO 2 CH 3 , and may optionally be linked to an R16 or an Ri1' group; R16 and Ri1' are each independently selected for each position capable of 15 substitution from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heterocyclic, carbonyl, or acyl, and may optionally be connected through an alkyl chain to R or another R or R 1' group, to form a fused or spiro ring system; X is NR", S, 0 or a covalent bond; R 7 is hydrogen, alkyl, alkenyl, alkynyl, acyl, heterocyclic, or carbonyl; 20 R1 4 and R' 5 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, heteroaromatic, halogen, nitro, cyano, amino, or aryl, for each occurrence; w is 0, 1, 2, 3, or 4; e is 0, 1, 2, or 3; 25 f is 0, 1, 2, or 3, and pharmaceutically acceptable salts thereof. WO 01/10842 PCT/USOO/21327 -205
203. A pharmaceutical composition for the treatment of a MC4-R associated state in a mammal comprising a pharmaceutically acceptable carrier and an effective amount of an MC4-R binding compound of the formula (XI): R 2 N R1 (CH 2 )v Ar R 15 (CH)e / / x--(CH) Ar' - R 12 R44 RE(XI) 5 wherein Ar and Ar' are aromatic groups, as described above; R" is selected independently for each position capable of substitution from the group hydrogen, halogen, alkyl, amino, cyano, or aryloxy. R 2 is selected for each position capable of substitution from the group 10 consisting of hydrogen, halogen, alkoxy, acetylenic, nitro, aryl, alkyl, alkenyl, alkynyl, cyano, acyl, or carbonyl; X is NR' 7 , S, 0 or a covalent bond; R 7 is hydrogen, alkyl, acyl, heterocyclic, or carbonyl; R 4 and R 5 are each independently selected from the group consisting of 15 hydrogen, alkyl, alkenyl, or aryl, for each occurrence; R20 and R 2 1 are each independently selected from the group consisting of substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, hydrogen, or carbonyl, and may optionally be linked to form a heterocycle; v is 0, 1, 2, 3, 4, 5, or 6; 20 eis0,1,2,or3; f is 0, 1, 2, or 3, and pharmaceutically acceptable salts thereof.
204. The MC4-R binding compound of the formula (VII): WO 01/10842 PCT/USOO/21327 -206 p11 P4 z z (VII) wherein ZI, Z 2 , Z 3 , Z 4 , and Z 5 are CH, N, or substituted carbon; pI, p2 p3, and P 4 are CH, N or substituted carbon; and 5 P 5 is C-J, wherein J is a moiety of the formula (XIII): N rs N 1t R (XIII) wherein r is a covalent bond, CH, CH 2 , CR', CR R2, or H; t is CH, CH 2 , CR 3 , CR 3 R 4 , or H; 5 5 6 10 s is CH, CH 2 , CHR , CR R , or absent; R is hydrogen, alkyl, alkenyl, arylalkyl, benzocarbonyl, arylalkylcarbonyl, alkylcarbonyl, optionally linked to R', R 2 , R 3 , R 4 , R 5 , or R 6 to form one or more rings; and R', R 2 , R 3 , R 4 , R 5 and R 6 are each halogen, thiol, alkoxy, alkyl, alkenyl, 15 alkynyl, heterocyclic, hydroxyl, nitro, amino, cyano,aryl, optionally linked to form a 2 3 4 5 6 ring with R, R', R , R , R4, R', or R.
205. The MC4-R binding compound of the formula (VIII): WO 01/10842 PCT/USOO/21327 -207 zz (VIII) wherein ZI, Z2, Z3, Z4, and Z5 are CH, N, or substituted carbon; P I, P2, P3, and P 4 are CH, N or substituted carbon; and 5 P 5 is C-J, wherein J is a moiety of the formula (XIII): R (XIII) wherein r is a covalent bond, CH, CH 2 , CR', CR'R 2 , or H; t is CH, CH 2 , CR 3 , CR 3 R 4 , or H; 10 s is CH, CH 2 , CHR 5 , CR R 6 , or absent; R is hydrogen, alkyl, alkenyl, arylalkyl, benzocarbonyl, arylalkylcarbonyl, alkylcarbonyl, optionally linked to R', R 2 , R 3 , R 4 , R, or R 6 to form one or more rings; and R', R2, R , R4, R', and R 6 are each halogen, thiol, alkoxy, alkyl, alkenyl, 15 alkynyl, heterocyclic, hydroxyl, nitro, amino, cyano,aryl, optionally linked to form a ring with R, R', R2, R3, R4, R5, or R.
206. The MC4-R binding compound of the formula (XV): WO 01/10842 PCT/USOO/21327 -208 P2 s z z 1 3 z "Z (XV) wherein ZI, Z 2 , Z 3 , Z 4 , and Z 5 are CH, N, or substituted carbon; P I, P2 p3 , and P 4 are CH, N or substituted carbon; and 5 P 5 is C-J, wherein J is a moiety of the formula (XIII): R (XIII) wherein 1 2 r is a covalent bond, CH, CH 2 , CR', CR R2, or H; t is CH, CH 2 ,CR 3 , CRR 4 , or H; 10 s is CH, CH 2 , CHR , CR R 6 , or absent; R is hydrogen, alkyl, alkenyl, arylalkyl, benzocarbonyl, arylalkylcarbonyl, alkylcarbonyl, optionally linked to R', R 2 , R 3 , R 4 , R', or R 6 to form one or more rings; and R', R2, R', R 4 , R', and R 6 are each halogen, thiol, alkoxy, alkyl, alkenyl, 15 alkynyl, heterocyclic, hydroxyl, nitro, amino, cyano,aryl, optionally linked to form a ring I 2 3 5 6 with R, R', R, R, R 4 , R 5 , or R.
207. The MC4-R binding compound of the formula (XVI): WO 01/10842 PCT/USOO/21327 -209 P 0 z 5 z2 z(XVI) wherein Z I, Z2, Z 3 , Z, and Z' are CH, N, or substituted carbon; P I, P2, p 3 , and p4 are CH, N or substituted carbon; and 5 P 5 is C-J, wherein J is a moiety of the formula (XIII): N r s R (XIII) wherein 1 2 r is a covalent bond, CH, CH 2 , CR', CR R , or H; t is CH, CH 2 , CR 3 , CR 3 R 4 , or H; 10 s is CH, CH 2 , CHR 5 , CR R 6 , or absent; R is hydrogen, alkyl, alkenyl, arylalkyl, benzocarbonyl, arylalkylcarbonyl, alkylcarbonyl, optionally linked to R , R2, R , R4, R or R 6 to form one or more rings; and R', R 2, R', R4, R and R6 are each halogen, thiol, alkoxy, alkyl, alkenyl, 15 alkynyl, heterocyclic, hydroxyl, nitro, amino, cyano,aryl, optionally linked to form a ring with R, R', R2, R', R, R or R.
208. The compound of any one of claims 204-207, wherein P, p 2 P 3 , and P 4 are each substituted or unsubstituted carbon. 20
209. The compound of claim 208, wherein P' is CH.
210. The compound of claims 204-207, wherein at least one of P 2 , p 3 and P 4 is substituted carbon. WO 01/10842 PCT/USOO/21327 -210
211. The compound of any one of claims 204-207, wherein P 2 , p 3 and P 4 are selected from the group consisting of CH, CF, Cl, CBr, C-alkyl, C-alkyoxy, or CI. 5
212. The compound of any one of claims 204-207, wherein Z 3 and Z 4 are each CH.
213. The compound of any one of claims 204-207, wherein Z' is CH.
214. The compound of any one of claims 204-207, wherein Z' is covalently linked to 10 Z 2 to form a naphthyl ring.
215. The compound of any one of claims 204-207, wherein Z 2 is CH, C-(C=CH), CCl, CBr, CI, and CF. 15
216. The compound of any one of claims 204-207, wherein L 2 is a covalent bond.
217. The compound of any one of claims 204-207, wherein R is H, alkyl, benzocarboxy, alkylcarboxy, or arylalkylcarboxy. 20
218. The compound of any one of claims 204-207, wherein s is CRR6 and R 5 and R 6 are each methyl.
219. The compound of any one of claims 204-207, wherein r is a covalent bond. 25
220. The compound of any one of claims 204-207, wherein t, r and s are CH 2 .
221. An MC4-R binding compound of the formula (XVIII): WO 01/10842 PCT/USOO/21327 -211 N (CR1 6 R 16) R A r RI1 (CH)e / ( ) X- (CH), R14 Ar' R' 2 (XVIII) wherein Ar and Ar' are aromatic groups; R" is selected independently for each position capable of substitution 5 from the group hydrogen, cyano, alkoxy, nitro, halogen, alkyl, amino, or aryloxy; R 2 is selected for each position capable of substitution from the group consisting of hydrogen, halogen, alkoxy, acetylenic, nitro, aryl, alkyl, alkenyl, alkynyl, cyano, acyl, or carbonyl; R1 3 is hydrogen, alkenyl, alkynyl, aralkyl, nitro, cyano, alkyl, acyl, 10 carbonyl, or SO 2 CH 3 , and may optionally be linked to an R or an R 1' group; R1 6 and R16' are each independently selected for each position capable of substitution from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, hydroxyl, cyano, aryl, heterocyclic, carbonyl, or acyl, and may optionally be connected through an alkyl chain to R 13 or another Ri 6 or R 1' group, to form a fused or spiro ring system; 15 X is NR ', S, 0 or a covalent bond; R1 7 is hydrogen, alkyl, or carbonyl; R1 4 and R1 5 are each independently hydrogen, halogen, or alkyl; w is 1, 2, 3, or 4; e is 0 or 1; 20 f is 0 or 1, wherein both e and f are not both 0 if X is a covalent bond, and pharmaceutically acceptable salts thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004202804A AU2004202804B2 (en) | 1999-08-04 | 2004-06-24 | Melanocortin-4 Receptor Binding Compounds and Methods of use thereof |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14728899P | 1999-08-04 | 1999-08-04 | |
US60147288 | 1999-08-04 | ||
US22327700P | 2000-08-03 | 2000-08-03 | |
US60223277 | 2000-08-03 | ||
PCT/US2000/021327 WO2001010842A2 (en) | 1999-08-04 | 2000-08-04 | Melanocortin-4 receptor binding compounds and methods of use thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2004202804A Division AU2004202804B2 (en) | 1999-08-04 | 2004-06-24 | Melanocortin-4 Receptor Binding Compounds and Methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6621600A true AU6621600A (en) | 2001-03-05 |
Family
ID=26844785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU66216/00A Abandoned AU6621600A (en) | 1999-08-04 | 2000-08-04 | Melanocortin-4 receptor binding compounds and methods of use thereof |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1204645A2 (en) |
JP (1) | JP2003528810A (en) |
AU (1) | AU6621600A (en) |
BR (1) | BR0012984A (en) |
CA (1) | CA2381008A1 (en) |
MX (1) | MXPA02001160A (en) |
WO (1) | WO2001010842A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001288604B2 (en) * | 2000-08-31 | 2005-02-24 | Novartis Vaccines And Diagnostic Inc. | Guanidinobenzamides as MC4-R agonists |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002064091A2 (en) | 2001-02-13 | 2002-08-22 | Palatin Technologies, Inc. | Melanocortin metallopeptides for treatment of sexual dysfunction |
US6465467B1 (en) | 1999-05-21 | 2002-10-15 | Biovitrum Ab | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
CA2377369A1 (en) | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
US7176279B2 (en) | 2000-06-28 | 2007-02-13 | Palatin Technologies, Inc. | Cyclic peptide compositions and methods for treatment of sexual dysfunction |
US7375125B2 (en) * | 1999-08-04 | 2008-05-20 | Ore Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
US6699873B1 (en) | 1999-08-04 | 2004-03-02 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
EP1273571A4 (en) | 2000-04-14 | 2003-05-02 | Kureha Chemical Ind Co Ltd | Nitrogenous compounds and antiviral drugs containing the same |
ES2251514T3 (en) * | 2000-10-30 | 2006-05-01 | Warner-Lambert Company Llc | LIGANDS OF THE SEROTONINE RECEIVER OF AMINOALQUILPIRROLIDINA AND COMPOSITIONS, ITS PHARMACEUTICAL USES AND METHODS FOR SYNTHESIS. |
EP1341773A2 (en) * | 2000-12-07 | 2003-09-10 | Cv Therapeutics, Inc. | Substituted 1,3,5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis |
WO2002062766A2 (en) * | 2001-02-07 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
ES2278016T3 (en) | 2001-04-09 | 2007-08-01 | Novartis Vaccines And Diagnostics, Inc. | GUANIDINE COMPOUNDS AS AGONISTS OF THE RECEIVER OF MELANOCORTINA 4 (MC4-R). |
US7115607B2 (en) | 2001-07-25 | 2006-10-03 | Amgen Inc. | Substituted piperazinyl amides and methods of use |
US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
UA81749C2 (en) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Derivated of phenylpiperazine as serotonin reuptake inhibitorS |
US7064139B2 (en) * | 2001-10-29 | 2006-06-20 | Uniroyal Chemical Company, Inc. | Method for treating retroviral infections |
CA2468015A1 (en) * | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 2-aminoquinoline compounds |
AU2002351747B2 (en) | 2001-12-21 | 2008-06-05 | H. Lundbeck A/S | Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors |
US20030195187A1 (en) * | 2002-02-04 | 2003-10-16 | Chiron Corporation | Guanidino compounds |
AU2003216274A1 (en) * | 2002-02-11 | 2003-09-04 | Neurocrine Biosciences, Inc. | Pyrrole derivatives as ligands of melanocortin receptors |
BR0308451A (en) | 2002-03-13 | 2005-01-11 | Euro Celtique Sa | Compound, pharmaceutical composition, methods for treating, preventing or ameliorating dysfunction, and compound manufacturing method |
EP1551834B1 (en) | 2002-05-23 | 2010-08-25 | Novartis Vaccines and Diagnostics, Inc. | Substituted quinazolinone compounds |
WO2003104240A1 (en) * | 2002-06-11 | 2003-12-18 | 三共株式会社 | Process for producing cyclic thioether and synthetic intermediate thereof |
US7396930B2 (en) | 2002-06-11 | 2008-07-08 | Sankyo Company, Limited | Process for producing cyclic thioether and synthetic intermediate thereof |
JP2004067673A (en) * | 2002-06-11 | 2004-03-04 | Sankyo Co Ltd | Method for producing cyclic thioether and synthetic intermediate of the same |
GB2389581A (en) * | 2002-06-12 | 2003-12-17 | Viaxxel Biotech Gmbh | Hydrogenated pyrimidines and their use as inhibitors of deoxyhypusine-synthase or hypusination of eIF-5A |
BR0305628A (en) | 2002-07-09 | 2004-09-08 | Palatin Technologies Inc | Pharmaceutical composition for treating sexual dysfunction in a mammal comprising peptide and its use |
JP3714948B2 (en) | 2002-09-11 | 2005-11-09 | 呉羽化学工業株式会社 | Amine compounds and uses thereof |
AU2003284165B2 (en) * | 2002-10-30 | 2008-12-11 | Merck Sharp & Dohme Corp. | Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity |
CA2508914A1 (en) | 2002-12-04 | 2004-06-17 | Gene Logic Inc. | Modulators of melanocortin receptor |
FR2852957B1 (en) * | 2003-03-31 | 2005-06-10 | Sod Conseils Rech Applic | NOVEL IMIDAZO-PYRIDINE DERIVATIVES AND THEIR USE AS A MEDICINAL PRODUCT |
SI1626720T1 (en) | 2003-04-04 | 2008-12-31 | Lundbeck & Co As H | 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors |
DE10316081A1 (en) * | 2003-04-08 | 2004-10-21 | Morphochem AG Aktiengesellschaft für kombinatorische Chemie | New compounds with antibacterial activity |
AU2004249120B2 (en) | 2003-05-23 | 2008-07-24 | Glaxosmithkline | Guanidino-substituted quinazolinone compounds as MC4-R agonists |
MXPA06005736A (en) | 2003-11-19 | 2006-12-14 | Chiron Corp | Quinazolinone compounds with reduced bioaccumulation. |
FR2862971B1 (en) | 2003-11-28 | 2006-03-24 | Sod Conseils Rech Applic | NOVEL BENZIMIDAZOLE AND IMIDAZO-PYRIDINE DERIVATIVES AND THEIR USE AS A MEDICINAL PRODUCT |
BRPI0417858B1 (en) | 2003-12-23 | 2017-10-10 | H. Lundbeck A/S | DERIVATIVE COMPOUNDS OF ANILINE AND PHARMACEUTICAL COMPOSITION THAT UNDERSTAND IT |
CA2558600C (en) | 2004-03-10 | 2013-07-09 | Kureha Corporation | A substituted-trialkyl amine compound with anti-viral activity based on antagonism against a chemokine receptor cxcr4 |
AR052308A1 (en) | 2004-07-16 | 2007-03-14 | Lundbeck & Co As H | DERIVATIVES OF 2- (1H-INDOLILSULFANIL) -ARILAMINE AND A PHARMACEUTICAL COMPOSITION CONTAINING THE COMPOUND |
US20070021433A1 (en) * | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
AR054393A1 (en) | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | DERIVATIVES OF BENZO (B) FURANO AND BENZO (B) THIOPHEN, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF THE REINFORCEMENT OF AMINA BOSS NEUTRANTS. |
US7629473B2 (en) | 2005-06-17 | 2009-12-08 | H. Lundbeck A/S | 2-(1H-indolylsulfanyl)-aryl amine derivatives |
TW200819426A (en) | 2006-08-31 | 2008-05-01 | Lundbeck & Co As H | Novel indane compounds |
EP2103614A1 (en) * | 2008-03-18 | 2009-09-23 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as melanocortin-4 receptor modulators |
AU2009307884B2 (en) | 2008-10-22 | 2014-07-31 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
ES2458872T3 (en) | 2009-04-30 | 2014-05-07 | Novartis Ag | Imidazole derivatives and their use as cyclin-dependent kinase modulators |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8796258B2 (en) | 2011-02-25 | 2014-08-05 | Merck Sharp & Dohme Corp. | Cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US10059671B2 (en) | 2013-02-04 | 2018-08-28 | Prexton Therapeutics Sa | Positive allosteric modulators of mGluR3 |
JP2016516004A (en) | 2013-02-22 | 2016-06-02 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Antidiabetic bicyclic compound |
EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2016056606A1 (en) * | 2014-10-07 | 2016-04-14 | 国立大学法人京都大学 | Benzoisothiazolopyrimidine derivative and salt thereof,and viral infection inhibitor and drug |
EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
AU2018240172C1 (en) | 2017-03-20 | 2019-10-24 | Novo Nordisk Health Care Ag | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators |
CN108084109A (en) * | 2017-12-21 | 2018-05-29 | 南京工业大学 | Synthesis method of 2, 5-disubstituted-1, 3, 4-oxadiazole |
EP3749697A4 (en) | 2018-02-05 | 2021-11-03 | Bio-Rad Laboratories, Inc. | Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand |
EP3853234A1 (en) | 2018-09-18 | 2021-07-28 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
US10675274B2 (en) | 2018-09-19 | 2020-06-09 | Forma Therapeutics, Inc. | Activating pyruvate kinase R |
CN113226356A (en) | 2018-09-19 | 2021-08-06 | 福马治疗股份有限公司 | Activating pyruvate kinase R |
US11098056B2 (en) * | 2018-10-01 | 2021-08-24 | Genzyme Corporation | UDP glycosyltransferase inhibitors and methods of use |
TWI794742B (en) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | Antiviral compounds |
EP4106876A1 (en) | 2020-02-18 | 2022-12-28 | Gilead Sciences, Inc. | Antiviral compounds |
KR20230170745A (en) | 2021-04-16 | 2023-12-19 | 길리애드 사이언시즈, 인코포레이티드 | Method for producing carbanucleosides using amides |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3594380A (en) * | 1969-02-18 | 1971-07-20 | American Home Prod | Isoquinolin-1(2h)-ones |
DE2219841A1 (en) * | 1972-04-22 | 1973-10-25 | Basf Ag | PROCESS FOR THE PREPARATION OF 2- (OALKYLTHIOPHENYL) -1,3-DIAZACYCLOALKENHYDROHALOGENIDES |
US4122263A (en) * | 1973-04-11 | 1978-10-24 | Basf Aktiengesellschaft | Production of 2-(o-alkylthiophenyl)-1,3-diazocycloalkene hydrohalides |
DE3046366A1 (en) * | 1980-12-09 | 1982-07-08 | Bayer Ag, 5090 Leverkusen | TRICYCLIC CYTOSINE DERIVATIVES FOR USE IN MEDICINAL PRODUCTS AND METHOD FOR THE PRODUCTION THEREOF |
GB8619971D0 (en) * | 1986-08-15 | 1986-09-24 | Fujisawa Pharmaceutical Co | Imidazole compounds |
JPS63253073A (en) * | 1987-04-08 | 1988-10-20 | Taisho Pharmaceut Co Ltd | 2-phenylbenzimidazole derivative |
ZA923283B (en) * | 1991-05-29 | 1993-01-27 | Akzo Nv | Phenoxyphenyl derivatives |
US5731408A (en) * | 1995-04-10 | 1998-03-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Peptides having potent antagonist and agonist bioactivities at melanocortin receptors |
JPH09176871A (en) * | 1995-12-25 | 1997-07-08 | Tamura Kaken Kk | Water soluble pre-flux, printed circuit board and surface treatment of metal of circuit board |
US5932779A (en) * | 1996-06-10 | 1999-08-03 | Millennium Pharmaceuticals, Inc. | Screening methods for compounds useful in the regulation of body weight |
JP3553086B2 (en) * | 1997-04-15 | 2004-08-11 | シーエスアイアール | Pharmaceutical composition having appetite suppressing activity |
ZA9811672B (en) * | 1997-12-19 | 2000-06-19 | Lilly Co Eli | Hypoglycemic imidazoline compounds. |
AU742425B2 (en) * | 1998-06-11 | 2002-01-03 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
-
2000
- 2000-08-04 EP EP00953837A patent/EP1204645A2/en not_active Withdrawn
- 2000-08-04 WO PCT/US2000/021327 patent/WO2001010842A2/en active Application Filing
- 2000-08-04 MX MXPA02001160A patent/MXPA02001160A/en active IP Right Grant
- 2000-08-04 BR BR0012984-4A patent/BR0012984A/en not_active Application Discontinuation
- 2000-08-04 AU AU66216/00A patent/AU6621600A/en not_active Abandoned
- 2000-08-04 JP JP2001515309A patent/JP2003528810A/en active Pending
- 2000-08-04 CA CA002381008A patent/CA2381008A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001288604B2 (en) * | 2000-08-31 | 2005-02-24 | Novartis Vaccines And Diagnostic Inc. | Guanidinobenzamides as MC4-R agonists |
Also Published As
Publication number | Publication date |
---|---|
JP2003528810A (en) | 2003-09-30 |
CA2381008A1 (en) | 2001-02-15 |
WO2001010842A3 (en) | 2001-08-16 |
MXPA02001160A (en) | 2002-07-02 |
BR0012984A (en) | 2002-07-16 |
WO2001010842A2 (en) | 2001-02-15 |
EP1204645A2 (en) | 2002-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU6621600A (en) | Melanocortin-4 receptor binding compounds and methods of use thereof | |
US6699873B1 (en) | Melanocortin-4 receptor binding compounds and methods of use thereof | |
EP1644337B1 (en) | Melanocortin-4 receptor binding compounds and methods of use thereof | |
EP1363890A2 (en) | Melanocortin-4 receptor binding compounds and methods of use thereof | |
US6090807A (en) | Use of heterocyclic compounds | |
EP1218352B1 (en) | Benzimidazolone derivatives having mixed serotonine and dopamine receptors affinity | |
EP1300398B1 (en) | Propane-1,3-dione derivatives | |
US6399631B1 (en) | Carbazole neuropeptide Y5 antagonists | |
US20030105147A1 (en) | Benzimidazoles and benzothiazoles and uses thereof | |
WO1997020823A2 (en) | 2-amino quinazoline derivatives as npy receptor antagonists | |
US8101619B2 (en) | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | |
CA2543707A1 (en) | Nitrogen-containing fused heterocyclic compounds | |
HUT70195A (en) | Process for producing benzimidazolone derivatives and pharmaceutical preparations containing them | |
JP2002519412A (en) | Potassium channel blocker | |
JP2006509015A (en) | Spirocyclic urea, compositions containing such compounds, and methods of use | |
CA2319824A1 (en) | Phenylpiperazine derivatives as integrin .alpha.v.beta.3 antagonists | |
SK7792000A3 (en) | 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as alpha-adrenoceptor agonists with improved metabolic stability | |
US6306859B1 (en) | N-substituted imide derivatives with serotonergic activity | |
US6878701B2 (en) | Potassium channel blocking agents | |
US4588725A (en) | 2-piperazinyl-quinazoline derivatives and pharmaceutical compositions containing them | |
DE69824722T2 (en) | Benzimidazole derivative | |
AU2004202804B2 (en) | Melanocortin-4 Receptor Binding Compounds and Methods of use thereof | |
EP1019050A1 (en) | Use of somatostatin agonists and antagonists for treating diseases related to the eye | |
JP2002538154A (en) | N-substituted imide derivatives having serotonin agonist activity | |
MXPA00005120A (en) | 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha. -adrenoceptor agonists with improved metabolic stability |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |